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ABSTRACT 
 
Cystic Fibrosis (CF) is the most common life-shortening autosomal recessive 
disorder. Those patients who have CF suffer from multiple comorbidities. Nearly 85% of 
the deaths related to CF are caused by lung disease. CF lung disease begins early in life 
with inflammation, impaired mucociliary clearance, and initial airway colonization by 
pathogens; it then progresses to chronic infection of the airways. To treat the continuous 
deterioration of lung function, CF patients need to use lung maintenance therapies 
continuously. These treatments are applied to patients for more than 30 years on average. 
However, the majority of evidence was identified using short-term follow-ups (less than 
1 year). Moreover, no guidelines suggest when a treatment change is needed, nor do they 
suggest the order of prescribing those treatments.  
Therefore, a retrospective observational study was conducted using a national 
patient registry, the Cystic Fibrosis Foundation Patient Registry (CFFPR). By emulating 
randomized clinical trials (RCTs), this study investigated the treatment change pattern 
and the causality between suboptimal treatment status and the time to delay in acquisition 
of mucoid Pseudomonas aeruginosa pulmonary infection (mucoid PaPI). 
A cohort of pediatric CF patients (n=4,970) who were diagnosed with nonmucoid 
PaPI before mucoid PaPI during 2006-2011 was identified. Those patients were young, 
healthy, and received multiple chronic treatments only at the baseline. An instrument that 
indicated when the suboptimal treatment status has been achieved and a 
 iv  
rational treatment change is needed was successfully generated by including demographic 
characteristics, comorbidities, clinical signals, and treatment histories. According to 
various thresholds of the instrument, which steered the decision of treatment change, 25 
regimes were built. Each patient was hypothetically randomized to follow each one of 25 
regimes independently. A fixed parameterization of the dynamic logistic marginal 
structural model with the constant-time hazard was applied to investigate the 
effectiveness of following each one of the 25 regimes. Using the effect of following one 
regime as the reference, if a physician changed treatment and was not following any 
regime, it would cause 17% more hazard of developing mucoid PaPI in his/her patient, 
during the 6-year follow-up. The hazard ratio ranged from 0.98 to 1.07 for other regimes.  
To summarize, for a physician, changing treatment without following any regime 
caused the worst outcome. The differences of treatment effect were trivial for the same 
patient who followed varied regimes to receive treatment. To achieve a better outcome, a 
physician should follow a regime, which is, perhaps, the optimal one, to change lung 
maintenance therapies, prudently prescribing an additional treatment from one of the 
three treatment classes: inhaled antibiotic, mucolytic, or anti-inflammatory. 
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Cystic Fibrosis (CF) is the most common life-shortening autosomal recessive 
disorder, which causes mutations in the CF gene on the long arm of chromosome 7 that 
encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein.1-4 
Those mutations on the CF gene can disrupt CFTR function within epithelial cells in 
various ways, ranging from completely losing protein to surface expression with poor 
chloride conductance.5 In the United States, there are approximately 30,000 individuals 
suffering from CF and around 1,000 new cases are diagnosed each year; worldwide, there 
are approximately 60,000 sufferers.6,7  
Currently, having made great strides in health technology and understanding this 
disease, CF patients born today have a median survival of nearly 40 years.8 This is a 
significant improvement, compared to the 6 months expected survival time in 1938, when 
CF was first identified. Given the longer survival time for patients with CF, many 
comorbidities have emerged, such as chronic pulmonary infection, gastrointestinal 
symptoms,9 and metabolic bone disease. Nearly 85% of the deaths related to CF are 
caused by lung disease.10 CF lung disease begins early in life with inflammation, 
impaired mucociliary clearance, and initial airway colonization by pathogens, then 
progresses to chronic infection of the airways. For CF patients, those pulmonary 
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infections cause progressive decline of their lung functions, with episodes of acute 
worsening of respiratory symptoms, which are defined as pulmonary exacerbations (PEx). 
By deteriorating the lung functions from two trajectories, those pulmonary infections, 
especially the chronic pulmonary infections, can significantly shorten overall survival.11  
Pseudomonas aeruginosa is the most common12 and significant life-threatening 
pathogen13 that causes pulmonary infection in pediatric patients. There are two colony 
phenotypes of P. aeruginosa: nonmucoid P. aeruginosa (nonmucoid Pa) and mucoid P. 
aeruginosa (mucoid Pa). Generally speaking, the median age of developing nonmucoid 
Pa and mucoid Pa is 1 and 13 years old, respectively.14 Compared with nonmucoid Pa, 
mucoid Pa has much stronger virulence traits. These traits are associated with irreversible 
damage of lung function,14,15 and quicker and more frequent pulmonary exacerbation. 
Unlike nonmucoid Pa, which may be eradicated by aggressive antibiotics for P. 
aeruginosa, mucoid Pa is much more difficult to treat or eradicate with current 
antibiotics, due to the pathogen’s ability to form a biofilm. Mucoid Pa’s ability to 
produce a biofilm allows for persistent infection, and renders itself resistant to various 
antibiotics,16-19 which results in a poor prognosis for patients.14 Because of this, mucoid 
Pa caused pulmonary infection (mucoid PaPI) is always applied as an indicator of 
disease progression. 
During a CF patient’s life, multiple treatments are needed to maintain health and 
improve survival. Basically, those treatments aid a CF patient in three areas: lung health, 
nutrition, and gene expression. Among them, the maintenance treatments for lung health 
are the most vital and are classified as short-term treatments, chronic treatments, and 
airway-clearance techniques. Short-term treatment includes all treatments that use 
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medication to temporarily treat PEx, such as intravenous (i.v.) antibiotics and oral 
antibiotics. Chronic treatment covers mucolytics, inhaled antibiotics, specific oral 
antibiotics, anti-inflammatory medication, and bronchodilators. The airway clearance 
techniques (ACT) involve cough, percussion, or vibration to loosen mucus from airway 
walls. On average, patients receive one or several of those treatments for 35 years.  
Benefiting from the closer monitoring and innovative therapies, the double-edged 
sword, health resource utilization has increased dramatically, which enhances the clinical 
outcome and healthcare expenditure at the same time. For CF patients over 30 years of 
age, total medical costs per year have more than doubled from $20,536 in 2001 to 
$56,116 in 2007, using 2007 dollars. The increase is even more dramatic, from $3,060 to 
$31,723, for patients under the age of 11.20 A large amount of CF-related spending is 
prescription costs, especially for treating chronic pulmonary infection. Ouyang et al.,21 
using insurance claims from 2004–2006, found that, compared to a matched sample 
without CF, medical expenditures were nearly $50,000 per year using 2006 dollars, more 
than 22 times greater than the matched sample. More than a third of these expenditures 
were for prescription drugs. Another study22 reported that for inhaled antibiotics and 
mucolytics, which are used to maintain lung function, each one class costs more than a 
quarter of the overall annual health expenditure for treating CF. More importantly, even 
though the annual cost varies according to age or disease severity, the percentage of 
inhaled antibiotics and mucolytics taken by the patients remains the same. This indicates 
that no matter how sickly or healthy the CF patient is, on average, they are taking inhaled 
antibiotics and mucus active drugs with the same frequency. Making things even worse, 
after including two expensive, gene-based therapies, which were launched after 2012, the 
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prescription cost is expected to increase dramatically. Even though these treatments are 
very effective, considering the long-term utilization and high price, $312,000 and 
$259,000 for ivacaftor (Kalydeco®, Vertex Pharmaceuticals) and lumacaftor/ivacaftor 
(Orkambi™, Vertex Pharmaceuticals), respectively,23 the barriers for patient access to 
these treatments are nearly insurmountable. 
Given the huge economic burden and enormous spending on lung health 
maintenance medications, the evidence to differentiate suboptimal from optimal 
treatment status for each patient is urgently needed. However, the evidence has not 
existed either in any publication or in the guidelines. Rather than suggesting when a 
suboptimal treatment status has been achieved and a treatment change is needed, the 
guidelines only categorize all treatments by the certainty of net benefits. Additionally, 
those certainties were summarized by existing RCTs, which had small sample size and 
extremely narrow characteristics to represent the whole patient population. In contrast, 
during clinical practice, healthcare providers are facing varied patients case-by-case; each 
individual has unique characteristics ranging from demographic characteristics, disease 
severity, and treatment pattern to personal preference. The causality between suboptimal 
treatment status, which indicates by a treatment change, and time to delay in acquisition 
of mucoid PaPI must be investigated. 
Ideally, an RCT is supposed to identify causal effect by analogously gathering 
data through a randomized assignment of treatment, perfect compliance, and no-right 
censoring. However, the enormous time and monetary cost for an RCT, together with 
long-term follow-up and the tremendous sample size, makes the idea of conducting an 
RCT to capture the causal effect with dynamic treatment regimes impossible. A 
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longitudinal, retrospective observational database is the most appropriate source of data 
for constructing dynamic treatment regimes (DTRs) as complicated as the one in this 
study. Combined with the design of DTRs and methods from causal inference, an 
observational database is able to account for the above issues perfectly. Moreover, an 
observational database reduces the chance of violating unmeasured confounder 
(conditional exchangeability) assumption compared with an RCT, since it captures all of 
the information that exists in physicians’ hands, when a decision to change treatment is 
about to be made.  Last but not least, the observational database captures many useful 
variables, which may include innovative variables to aid decision-making for achieving 
optimal treatment effects. 
To summarize, there are several unsolved issues for steering the utilization of 
chronic treatments: 1) guidelines were generated according to the net benefits of each 
individual treatment, which were investigated in RCTs with short-term follow-ups and a 
small sample size; 2) no study investigated the treatment change pattern; 3) lack of 
evidence-based direction on when and how to make treatment change; 4) the economic 
burden was huge; 5) preliminary results were needed before conducting an RCT. Given 
the above issues, a retrospective observational study, which emulated RCT to investigate 
the treatment change pattern and the causality between suboptimal treatment status and 
time to delay in acquisition of mucoid PaPI, was conducted using a national patient 
registry, the Cystic Fibrosis Foundation Patient Registry (CFFPR). 
The primary objective of this study was to examine the treatment initiation and 
change in patients diagnosed with new or continuing nonmucoid PaPI. The second 
objective was to investigate the optimal treatment regime to delay the acquisition of 
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mucoid PaPI for pediatric CF patients. Those two objectives were investigated 
considering three aims: 1) to analyze the treatment change pattern in the current database 
for CF patients diagnosed with nonmucoid PaPI; 2) to predict the probability of having a 
rational treatment change given patients’ demographic characteristics, comorbidities, 
clinical signals, and treatment histories; 3) to investigate the strategy for rational lung 
treatment change, which maximized the delay in acquisition of mucoid PaPI, specifically 
in patients diagnosed with nonmucoid PaPI. 
A large cohort of CF patients, who were diagnosed with nonmucoid PaPI and had 
not developed mucoid PaPI from 2006 to 2011 in the United States, was identified. 
Those patients were young, healthy, and only received minimal multiple chronic 
treatments at the baseline. Regardless of whether physician only consider the first 
treatment change or all treatment changes in the cohort, they were prone to change 
treatment prudently by only prescribing one additional treatment from one of the three 
treatment classes, inhaled antibiotic, mucolytic, and anti-inflammatory. An instrument 
that indicated when the suboptimal treatment status has been achieved, and a rational 
treatment is needed, was successfully generated by including demographic characteristics, 
comorbidities, clinical signals, and treatment histories. Given various thresholds of 
predicted probability of having rational treatment change and relative change of predicted 
probability of having rational treatment change between the current and previous visit, 
which was predicted using the instrument, 25 DTRs for making rational treatment change 
were generated. Patients who did not follow any regime to receive treatment changes 
encountered the worst outcomes than those following any regime. Among the patients 
who followed different DTRs, with the increase of threshold of relative change of 
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predicted probability, the hazard ratio of developing mucoid PaPI increased first, then 
decreased. The regime, in which the threshold of relative change of predicted probability 
equaled 1.831%, always caused the worst outcome among the regimes that shared the 
same threshold of predicted probability. An optimal strategy was identified (among 25 
strategies) that maximized the time to infection with mucoid PaPI.     
With the results of this study, healthcare providers could switch from experience-
based to evidence-based decision-making. The probability of having rational treatment 
change and DTR strategy aids in identifying suboptimal treatment status, and supports 
the personalized decision-making of treatment change to maintain optimal treatment 
effects. At the same time, the study results could also assist value-based insurance design 
by optimizing traditional treatment utilization prior to reimbursement for extremely 
expensive medications, through step therapy, tiered formulary, prior authorization, and 
other tools of managed care pharmacy. The results of this study provide preliminary 
evidence of when and how to make a change to chronic lung treatments for pediatric CF 
patients using retrospective observational study to emulate RCT. Further analyses are 





BACKGROUND AND SIGNIFICANCE 
 
2.1 Cystic Fibrosis and Clinical Issues in its Management 
2.1.1 Pathophysiology and Incidence Rate 
Cystic Fibrosis (CF) is the most common life-shortening autosomal recessive 
disorder, which causes mutations in the CF gene on the long arm of chromosome 7 that 
encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein.1-3 
Those mutations on the CF gene can disrupt CFTR function within epithelial cells in 
different ways, ranging from completely losing protein to surface expression with poor 
chloride conductance.5 In the United States, there are approximately 30,000 individuals 
suffering from CF and around 1,000 new cases diagnosed each year; worldwide, there are 
approximately 60,000 sufferers.6,7  
The majority of CF patients are Caucasian. The incidence rates range from 
1/3,700 to 1/1,900 in the U.S. Caucasian population,2,24 while rates reduce to 1/9,000, 
1/15,000, and 1/32,000 for Hispanic,25 African American,24,26 and Asian27 populations, 
respectively. In Europe, the overall incidence rate for the entire population is about 
1/3,500.28,29  
Currently, having made great strides in health technology and understanding this 
disease, CF patients born today have a median survival of nearly 40 years.8 This is a 
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significant improvement compared to the 6 months’ expected survival in 1938, when CF 
was first identified. Given the longer survival time for patients with CF, many co-
morbidities have emerged such as chronic pulmonary infection, gastrointestinal 
symptoms,9 and metabolic bone disease. Among them, chronic pulmonary infection is the 
main cause of pulmonary exacerbation (PEx), episodes of acute worsening of respiratory 
symptoms, and can significantly shorten overall survival.11  
 
2.1.2 Diagnosis and Symptoms 
Prior to the development of a newborn screening (NBS) test in 1990s, patients 
were diagnosed with CF using classic signs and symptoms of the disease alone (Table 
2.130). The CF NBS is a screening test, broadly utilized in the U.S., which quantifies the 
immunoreactive trypsinogen (IRT) value, a pancreatic enzyme precursor in a newborn’s 
blood. The concentration is elevated in majority of infants with CF, since pancreatic 
ducts are blocked and damaged by a flow of secretions with a high protein 
concentration.31 However, for those people who do not have a CFTR mutation, the IRT 
value varies only slightly. Whenever there is an abnormal IRT value, the infant either 
undergoes DNA testing to identify known CFTR mutations (IRT/DNA strategy), or a 
second blood sample to measure IRT is collected when the infant is about 2 weeks old.32 
Of all the screening tests, even those with 90% to 95% of sensitivity,33,34 NBS alone only 
identifies newborns at risk for CF, not performing as an ultimate gold standard diagnosis 
tool.  
The sweat chloride test, which measures sweat electrolyte concentrations using 
the Gibson-Cooke35 method, is still the gold standard on which a diagnosis of CF should 
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be made. Considering how the sweat chloride values for a newborn decline gradually,36 
this test should only be measured after the infant is 2 weeks old. Sweat chloride values 
are universally categorized into three groups: normal (<=39 mmol/L), intermediate (40-
59 mmol/L), and abnormal (>=60 mmol/L). These categories do not take age into 
consideration, which may cause uncertainty due to the increase on sweat chloride, when 
an individual ages from infant to teenager. Given the uncertainty of the sweat test, 
together with the fact that genotype analysis can identify mutations on the CFTR gene 
that do not cause CF, the Cystic Fibrosis Foundation (CFF) has suggested that doctors 
arrive at a diagnosis of CF through combined strategies.37 If infants have a positive NBS, 
and have sweat chloride values equal to or greater than 60 mmol/L, then a CF diagnosis 
is confirmed. If an infant has a sweat chloride value equal to or less than 29 mmol/L, a 
diagnosis of CF is very unlikely, unless it arises from a rare phenotype. Infants with a 
positive NBS test result and with a sweat chloride value within the intermediate range 
should be given an extra CFTR mutation assessment. The diagnosis can be confirmed 
with the presence of two CF causing mutations. With no, or only one, CF mutation, no 
finalized diagnosis should be made until after a follow-up clinical assessment and another 
sweat chloride test conducted after the infant is 2 months old.37 With these advanced 
tools, the diagnosis of an infant is close to reality, but still with a measure of uncertainty.  
 
2.1.3 Current Treatments 
During a CF patient’s life, multiple treatments are needed to maintain health and 
improve survival. Basically, those treatments aid a CF patient in three areas: lung health, 




The maintenance treatments for lung health are classified as short-term treatments, 
chronic treatments, and airway clearance techniques. Short-term treatment includes all 
treatments that use medication to temporarily treat PEx, such as intravenous (i.v.) 
antibiotics and oral antibiotics. Chronic treatment covers mucolytics, inhaled antibiotics, 
specific oral antibiotics, anti-inflammatory medication, and bronchodilators. The airway 
clearance techniques (ACT) involve cough, percussion, or vibration to loosen mucus 
from airway walls. A better treatment effect may be achieved when treating a patient with 
bronchodilators and inhaled antibiotics before and after ACT.  
Nutrition is a major component in maintaining health for CF patients. Maintaining 
optimal nutrition involves taking minerals, vitamins, and pancreatic enzymes. As with the 
lungs, CF causes the pancreas to produce thick mucus that blocks the release of enzymes 
needed for proper digestion. Benefiting from enteric coating, pancreatic enzyme 
supplements could be released in the small intestine directly enhancing the patient’s 
digestion ability.  
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are 
gene-based therapies, which were designed to correct the function of the defective protein 
directly. This allows chloride and sodium to move properly in and out of lung and organ 
cells. Gene-based therapies are treatments that address the cause of CF rather than simply 
modifying symptoms. Ivacaftor and lumacaftor are two compounds that belong to this 
therapeutic class. Kalydeco® (ivacaftor) and Orkambi™ (lumacaftor and ivacaftor) were 
approved by FDA on Jan 31st, 2012, and July 2nd, 2015, respectively, and have already 
been released into the market.  
12  
  
2.1.4 Health Resource Utilization and Cost 
Benefiting from the closer monitoring and innovative therapies, the double-edged 
sword, health resource utilization has increased dramatically, which enhances the clinical 
outcome and healthcare expenditure at the same time. The economic burden of CF is 
substantial. Briesacher et al.20 show that the improved outcomes of CF patients are linked 
to closer monitoring of patients. For example, annual pulmonary function testing 
increased 53% from 2001 to 2007. The use of respiratory cultures more than doubled 
over the same time period; utilization of lung maintenance therapy, such as dornase alfa 
and oral antibiotics, also increased. With additional utilization on testing and therapy, 
both short-term clinical outcomes and survival saw marked improvement, while at the 
same time, the cost of treating the disease also saw marked increases. For CF patients 
over 30 years of age, total medical costs per year have more than doubled from $20,536 
in 2001 to $56,116 in 2007 using 2007 dollars. The increase is even more dramatic, from 
$3,060 to $31,723, for patients under the age of 11.20 
A large amount of CF-related spending is prescription cost, especially for treating 
chronic pulmonary infection. Ouyang et al.,21 using insurance claims from 2004–2006, 
found that compared to a matched sample without CF, medical expenditures were nearly 
$50,000 per year using 2006 dollars, more than 22 times greater than the matched sample. 
More than a third of these expenditures were for prescription drugs. Another study22 
reported that for inhaled antibiotics and mucolytics, which are used to maintain lung 
function, each one class costs more than a quarter of the overall annual health 
expenditure of treating CF. More importantly, even though the annual cost varies 
according to age or disease severity, the percentage of inhaled antibiotics and mucolytics 
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taken by the patients remains the same. This indicates that no matter how sickly or 
healthy the CF patient is, on average they are taking inhaled antibiotics and mucus active 
drugs with the same frequency. O’Sullivan et al.38 also found that CF patients who 
experienced pulmonary infections spent $20,000 for medication, more than 40% of the 
overall annual spending. Since two expensive, gene-based therapies were launched after 
2012, the prescription cost is expected to increase dramatically. Even though these 
treatments are very effective, considering the long-term utilization and a price, of 
$312,000 and $259,000 for ivacaftor (Kalydeco®, Vertex Pharmaceuticals) and 
lumacaftor/ivacaftor (Orkambi™, Vertex Pharmaceuticals), respectively,23 the barrier for 
patient access to treatment may be significant. Given the huge economic burden and 
enormous spending on lung health maintenance medication, a way to differentiate 
suboptimal from optimal treatment status for each patient is urgently needed. With such 
an ability to differentiate, treatment changes could be made to maintain optimal treatment 
effects for CF patients before considering expensive drugs, and the value-based pharmacy 
formulary could be optimized, steering society to spend limited health resources more 
efficiently. 
 
2.2 Pulmonary Infection 
Nearly 85% of the deaths related to CF are caused by lung disease.10 CF lung 
disease begins early in life with inflammation, impaired mucociliary clearance, and initial 
airway colonization by pathogens, then progresses to chronic infection of the airways. 
For CF patients, those pulmonary infections cause progressive decline of their lung 
function, with episodes of acute worsening of respiratory symptoms, PEx.  
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2.2.1 Pseudomonas aeruginosa 
Pseudomonas aeruginosa is the most common12 and significant life-threatening 
pathogen13 that causes pulmonary infection for pediatric patients. There are two colony 
phenotypes of P. aeruginosa: nonmucoid P. aeruginosa (nonmucoid Pa) and mucoid P. 
aeruginosa (mucoid Pa). Generally speaking, the median age of developing nonmucoid 
Pa and mucoid Pa is 1 and 13 years old, respectively.14 Compared with nonmucoid Pa, 
mucoid Pa has much stronger virulence traits. These traits are associated with irreversible 
damage of lung function,14,15 and quicker and more frequent pulmonary exacerbation. 
Unlike nonmucoid Pa, which may be eradicated by aggressive antibiotics for P. 
aeruginosa, mucoid Pa is much more difficult to treat or eradicate with current 
antibiotics due to the pathogen’s ability to form of a biofilm. Mucoid Pa’s ability to 
produce a biofilm allows for persistent infection, and renders it resistant to various 
antibiotics,16-19 which results in a poor prognosis for patients.14 What causes nonmucoid 
Pa to transition to mucoid Pa has not been comprehensively studied, but current evidence 
supports the theory that the conversion is driven by the unique CF microenvironment39,40 
which provides the pathogen some protection from dehydration.41,42 
 
2.2.1.1 Intermittent Pseudomonas aeruginosa Pulmonary Infection 
Pseudomonas aeruginosa can exist in a CF patient from an early age. When 
testing patients for Pa, children younger than 1 have tested positive when testing for the 
Pa antibody. However, patients don’t usually test positive for Pa through cultures of the 
upper or lower airway for Pa until they’re older.43 Initially, Pa pulmonary infection 
(PaPI) occurs transiently, so it named either intermittent PaPI or initial PaPI. Several risk 
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factors are associated with the occurrence of intermittent PaPI, such as female, 
homozygous F508 genotype, and Staphylococcus aureus isolation.44 It is possible to treat 
intermittent PaPI through aggressive therapy, but as time passes, the pathogen adapts to 
the airway by developing a mucoid phenotype, which is difficult to eradicate. That is 
when PaPI progresses to a chronic condition in CF patients’ lower and upper airways.45 
Therefore, current guidelines recommend early treatment of initial PaPI,46 so as to reduce 
the prevalence of this pathogen within the body and delay the progression to chronic 
PaPI in order to improve prognosis. 
 
2.2.1.2 Chronic Pseudomonas aeruginosa Pulmonary Infection 
Chronic infection can be defined as an infection that persists despite appropriate 
treatment, immune, and inflammatory response from the host. Moreover, in contrast to 
bacterial colonization, chronic infection is characterized by persistent pathology and 
immune responses.47 Currently there is no universally accepted definition of chronic P. 
aeruginosa infection. Most of the currently used definitions are based on frequency and 
the results of microbiological assessment of secretions from the respiratory tract of CF 
patients. Several definitions of chronic PaPI in CF that have been published or used 
either in clinical settings or for research purposes are listed in Table 2.2.  
 
2.2.2 Other Infections 
Other than P. aeruginosa, several pathogens can also cause pulmonary infection. 
Staphylococcus aureus and Haemophilus influenza are the most frequent causes of early 
infection in airways of CF patients. As time passes and the disease progresses, more 
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pathogens may occur, from P. aeruginosa to late emerging pathogens such as 
Burkerholderia cepacia, fungi, which include Aspergillus species and nontuberculous 
mycobacteria. The most commonly found form of nontuberculous mycobacteria, 
mycobacterium avium complex, causes mycobacterium avium-intracellulare infection 
(MAI), which is also a chronic infection.12 
 
2.3 Chronic Medications for Maintaining Lung Health 
Based on Cystic Fibrosis Pulmonary Treatment Guidelines,48 there are several 
treatment classes available for patients 6 years of age and older with moderate to severe 
disease. These medications include mucolytics, bronchodilators, inhaled antibiotics, and 
anti-inflammatory medications. Among these drugs, with sufficient evidence, current 
guidelines highly recommend the utilization of dornase alfa and inhaled antibiotics for 
patients with P. aeruginosa.  
 
2.3.1 Inhaled Antibiotics 
In the U.S., two inhaled antibiotics, inhaled tobramycin and inhaled aztreonam, 
have been approved by the FDA. Tobramycin is an aminoglycoside antibiotic, used to 
treat Gram-negative infections particularly and especially effective against Pseudomonas 
species. Aztreonam is a monobactam antibiotic under β–lactam class, also used primarily 
to treat infections caused by Gram-negative bacteria. Generally speaking, the inhalation 
route is a fast and effective way of delivering medication locally to the lungs together 
with attractive characteristics compared with traditional route, such as painless and 
flexible administration, rapid onset of action, lower dosing, avoidance of first pass 
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metabolism, and potentially fewer side-effects.49,50 Nebulizer and metered dose inhaler is 
the device to supply the medication as an aerosol created from solution or suspension 
formulation.49,50 Dry-powder inhaler, a simple, fast, and convenient delivery system, 
releases powdered medication directly to the lungs.49,50 Colistin, as a polypeptide 
antibiotic, is effective against most Gram-negative bacteria and has been used as a first 
line approach to suppress chronic P. aeruginosa in the UK and Europe. Even though not 
approved in the U.S., inhaled colistin may still be given to CF patient as off-label 
treatment in U.S. 
Several randomized clinical trials have shown that due to the ability to deliver 
high concentration of drug into the lungs directly, inhaled antibiotics, especially 
tobramycin and aztreonam for P. aeruginosa, have a stronger treatment effect51-65 than 
oral antibiotics, even if pathogens have already developed drug resistance. Other than one 
study,58 which had 56 weeks follow-up, most of these studies had less than 6 months of 
follow-up.  
 
2.3.2 Other Lung Health Maintenance Medication 
Dornase alfa, hypertonic saline, azithromycin, and high dose ibuprofen are four 
other medications that deliver moderate to substantial treatment effects and are 
recommended by the guidelines.48 Dornase alfa has been developed to cleave high 
molecular weight DNA which, when released by dead neutrophils, contributes to the 
tenacity of airway phlegm.66,67 Hypertonic saline directly delivers salt and water to the 
lungs, restoring airway surface hydration to improve mucociliary clearance in vivo.68 
Azithromycin is a macrolide that is most frequently prescribed as an oral antibiotic for 
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patients with CF. A significant part of the treatment effects of this medication are due to 
its function as an anti-inflammatory medication—decreasing the number of neutrophils at 
the site of infection69,70 and reducing the pro-inflammatory cytokines that recruit more 
neutrophils.71,72 Unlike the above three medications, which are suggested for broad 
utilization, high dose ibuprofen, given the rare, but serious adverse events associated with 
it,73 together with the scant data on use in adults, is only suggested for children. 
 
2.3.3 Other Medications 
Aside from those medications recommended by the current guidelines, several 
other chronic medications are also prescribed to treat CF related lung disease. These 
include corticosteroids, 𝛽𝛽2-adrenergic receptor agonists, antifungals, clarithromycin, and 
inhaled colistin. As anti-inflammatory medications, corticosteroids have conflicting 
treatment effects on reducing the rates of pulmonary function decline.74-76 Because of 
these, they are only suggested for CF patients with asthma. Due to insufficient evidence 
on their efficacy, inhaled 𝛽𝛽 2-adrenergic receptor agonists are also not suggested for 
chronic use. Antifungals and a combined therapy that includes clarithromycin, rifampin, 
and ethambutol used to treat Aspergillosis species and MAI, respectively, are rarely 
prescribed chronically because of the relative low incidence of those pathogens.  
 
2.3.4 The Dilemma of Maintaining Lung Health 
Therefore, from a short-term perspective, maintaining current inhaled antibiotics 
for patients infected by chronic P. aeruginosa, regardless of drug resistance, seems to be 
the best choice. However, unlike initial colonization of nonmucoid P. aeruginosa, which 
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is more easily eradicated, chronic P. aeruginosa is difficult to cure and long-term drug 
suppression is the only option. With inhaled antibiotics suppression that lasts longer than 
1 year, drug resistance may easily occur. Without appropriate treatment, increasing drug 
resistance may decrease the time of the transition from nonmucoid PaPI to chronic 
mucoid PaPI.77 Given the consistency of the microbial community structure before and 
after treatment with antibiotics for pulmonary exacerbation, the progression from 
nonmucoid PaPI to chronic mucoid PaPI could be the main reason for decreasing lung 
function and increasing incidence rate of pulmonary exacerbation. The dilemma then 
becomes how to obtain optimal treatment effects over the long term considering lung 
function deterioration, the existence of drug resistance, and other clinical variables.   
 
2.3.5 Treatment Classifications 
All treatments will be classified into five classes according to current guidelines48 
and their functions as per Table 2.3. Theses classes are: mucolytics, inhaled antibiotics, 
anti-inflammatories, bronchodilators, and other chronic treatments. Mucolytics aim to 
alter the properties of lung phlegm to make it easier to clear from the airways. Inhaled 
antibiotics directly fight against and suppress bacterial pathogens isolated from the 
respiratory tract. In order to reduce neutrophils in the lungs, which increase the viscosity 
of the CF spectrum and damage lung structure,78 anti-inflammatories are prescribed. 
Bronchodilators dilate bronchi and bronchioles, decrease resistance in the respiratory 
airway, and increase the airflow to the lungs. Other chronic treatments are used against 
various pathogens or comorbidities that may accompany Pa. Since treatments in the same 
class have similar treatment effects and improve the lung function from the same 
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mechanism, physicians could prescribe them interchangeably in clinical practice. If 
additional treatment effects are needed from a specific mechanism, then additional 
treatments in that class should be prescribed.  
 
2.4 Signals for Clinical Decisions 
In clinical practice, FEV1%, which measures the proportion of a patient’s forced 
expiratory volume in 1 second (FEV1) against the predicted forced expiratory volume in 
1 second for a hypothetical healthy person sharing the same demographic characteristics 
as the patient, is the gold standard for measuring disease severity.11,48,79 The relative 
change between FEV1% at the current visit and the optimal FEV1% in the past year is 
the measure that healthcare providers use to steer treatment change ( ∆𝐹𝐹𝐹𝐹𝐹𝐹1% =
𝐹𝐹𝐹𝐹𝐹𝐹1%−𝐹𝐹𝐹𝐹𝐹𝐹1𝑜𝑜𝑜𝑜𝑜𝑜%
𝐹𝐹𝐹𝐹𝐹𝐹1𝑜𝑜𝑜𝑜𝑜𝑜% ). The number of PEx that occurred in the previous year also informs 
decisions on treatment change. A decreasing FEV1% or more PEx reflects a decline in 
lung function, which may be caused by new infections, a failure to respond to current 
treatment, or other CF related comorbidities. If evidence supports a conclusion that a 
specific treatment is having a poor response, then healthcare providers should adjust the 
treatment accordingly by switching or adding on one or more new treatments, or stopping 
the current treatment. Hypothetically, drug resistance should also work as a signal for 
treatment change. However, that is not always the case for patients with CF because, as 
mentioned previously, unlike intravenous antibiotics, inhaled antibiotics deliver a high 
concentration of medicine directly to the lungs, providing far more medicine than needed. 
Together with the reality that the arsenal of applicable inhaled antibiotics is limited, 
healthcare providers may ignore drug resistance as a signal for treatment change. 
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2.4.1 Predicted Normal FEV1% 
Forced expiratory volume in 1 second (FEV1), together with its derivatives, is the 
most widely employed clinical measurement for lung disease progression in CF.80 
Compared to other spirometric variables that are applied to guide and monitor treatment 
such as forced vital capacity (FVC) and forced expiratory flow at mid-vital capacity 
(FEV25-75), FEV1 also serves as the key short-term endpoint in most clinical trials. In 
clinical practice, the relative change between predicted FEV1% in the current visit and 
the maximum value of predicted FEV1% among all visits that occurred in the past 1 year 
(ΔFEV1%) is always used as a key clinical signal to eliminate short-term fluctuation of 
FEV1. In order to calculate the relative change of predicted FEV1%, the provider first 
measures FEV1% in each encounter visit, using the equation 𝐹𝐹𝐹𝐹𝐹𝐹1% = 𝐹𝐹𝐹𝐹𝐹𝐹1𝑜𝑜𝑜𝑜𝑜𝑜
𝐹𝐹𝐹𝐹𝐹𝐹1𝑜𝑜𝑝𝑝𝑝𝑝𝑝𝑝
, where 
observed FEV1 at that visit is the numerator, and predicted FEV1 for a hypothetical 
healthy person given the same characteristics the observed patient had at that visit is the 
denominator.  
Since the 1980s, several algorithms to predict FEV1 for a hypothetical healthy 
person have been created, but currently, the majority of accredited hospitals follow the 
latest model, the NHANES prediction algorithm, which can predict a normal FEV1 or 
reference value given a person’s age, height, gender, race, and ethnicity. Among all 
traditional prediction algorithms that assumed a fixed distribution for each parameter in 
advance with constant variability across the lifespan, the NHANES81 algorithm is the 
most complex one, with highly accurate predictions. However, since two algorithms are 
applied independently for adolescents and adults, when a patient is transitioning from an 
adolescent to an adult, the prediction of a reference FEV1 is not smooth. Besides the 
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NHANES algorithm, several hospitals apply the Crapo82-84 method to predict reference 
FEV1 values for young adults, but there are no guidelines to suggest which prediction 
algorithm is optimal for which age. Table 2.4 lists several well-accepted algorithms for 
predicting reference FEV1.  
In 2012, an innovative spirometry prediction algorithm was published. Over 
160,000 records from 72 centers in 33 countries were shared with the European 
Respiratory Society Global Lung Function Initiative (GLI). After excluding records that 
had missing and outlying data, 97,759 records of healthy nonsmokers aged from 2.5 to 95 
years were fed into the prediction model. Besides the inclusion of the pediatric population 
and a huge sample size, the prediction algorithm also applied an innovative parametric 
method, the Lambda-Mu-Sigma (LMS), which allows simultaneous modeling of the 
median (mu), the coefficient of variation (sigma), and the skewness (lambda) of a 
distribution family.85 Benefiting from uniqueness, the LMS method is able to convert 
individual’s measurement into a Z score, normally distributed with a mean of 0 and a 
standard deviation of 1. Specifically, the lower limit of normal for all spirometric values 
will be calculated as the 5th percentile of the distribution of Z scores.86 Compared to the 
traditional algorithm, it simultaneously incorporates the relationship between height and 
age into the prediction and provides smoothly changing curves for the transition from 
childhood to adulthood.  
In order to appropriately predict normal lung function as a reference value for 
prediceted FEV1%, in addition to the coefficients for age, height, and race, an age-
varying coefficient for the median spline is also needed. A cross-sectional analysis using 
data from the UK Cystic Fibrosis Trust Registry demonstrated significant differences in 
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interpretation of spirometry results between the GLI algorithm and other traditional 
algorithms. Differences on population level for each age are limited, while individual 
patient results are quite discrepant, especially in young children, adolescents, or patients 
older than 50 years. 
 
2.4.2 Pulmonary Exacerbation 
CF lung disease is characterized by intermittent episodes of acute worsening of 
respiratory symptoms such as cough, sputum production, hemoptysis, often manifesting 
together with systemic symptoms such as weight loss and fatigue. These changes in 
respiratory signs and symptoms, which also necessitate additional treatments, are termed 
pulmonary exacerbation (PEx). PEx also has a significant impact on short-term 
mortality,11 quality of life,87-89 and healthcare expenditure and serves as an indicator in 
the acquisition of new pathogens. While PEx equals FEV1% in clinical importance, there 
is no standard definition for PEx. In fact, PEx has several nonvalidated definitions. The 
components among those definitions are varied, basically consisting of a constellation of 
symptoms, physician examination, and lab test results. Table 2.5 contains components of 
several well-accepted definitions. Three studies have examined components of these 
definitions in order to create a model for perfect prediction of PEx using either clinical 
data90,91 or patients’ and healthcare providers’ opinions.92 Each of those studies indicates 
that symptoms, rather than physician examinations or laboratory values, were found to be 
more predictive for PEx. The only drawback of these studies is that the analyses90,92 
failed to measure the severity of PEx as an outcome. In order to create a unified 
definition for PEx in the future, appropriate identification on the severity of PEx, as well 
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as including the variables of physician examination, laboratory values, and symptoms are 
needed. For my dissertation, PEx is captured by a question, which is self-assessed 
exacerbation with four levels, absent, mild, moderate, and severe using Cystic Fibrosis 
Foundation Patient Registry Questionnaire.  
 
2.5 Prescribing Decisions 
Prescribing decisions are a series of complex composite decisions, which are 
affected by both internal and external factors. The prescribing decision-making is 
definitely dominated by the internal factors that a physician has, but it is also influenced 
by external factors, such as the impact and pressure from senior physicians, 
pharmaceutical representatives, and patients. The first two sections use primary care 
physicians as an example, exploring the internal and external factors that influence 
prescribing decision-making. Then, it focuses on the unique issues on prescribing 
antibiotics and treating chronic lung diseases. At the end, the treatment change, especially 
rational treatment change, will be explained.  
 
2.5.1 Internal Factors that Influence Prescribing Decision-making 
Internal factors include two perspectives: from the physician himself such as 
personality traits, medical training, and clinical experiences, and from therapy such as the 
effectiveness, efficacy, and safety. Among them, clinical effectiveness and safety of a 
therapy is the most important one,93 since the first step of a prescribing decision-making 
is to decide whether a treatment is required, by weighing the trade-off between benefit 
and risk. The trade-off is determined by clinical effectiveness, and safety together with 
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physician-perceived medical needs from a patient.94 Once physicians have decided to 
prescribe, they will then decide whether to choose a drug which they know well, or adopt 
a new therapy. 
Each doctor has a personal set of drugs with which he/she is familiar and always 
chooses from it when confronting a patient.94,95 Other than balancing the benefits and 
risks through the above process, three different decision strategies could be applied as 
shortcuts to prescribe from the set directly: pragmatic, intuitive, and emotional 
strategies.94 Internal factors are involved in the above strategies, but not all of them are 
scientifically reasonable: personal experiences and emotions are examples. The pragmatic 
approach recognizes that physicians do not continually consider the same trade-offs, so 
for repetitive situations, or routine visits without any change of symptoms, they will 
adopt the previous treatments according to their clinical experiences. The intuitive 
approach indicates that the decision may sometimes be based on intuition and personal 
experience. For example, a physician prescribes a specific treatment to a patient because 
it worked well in previous cases, which ignores the difference of clinical signals between 
current and previous patients. The emotional approach highlights that other than 
cognitive factors, emotional factors may also drive prescribing behavior, even though 
they may conflict with physicians’ judgment. For example, a patient requests a specific 
treatment, which he saw on advertisements. The physician may feel the required 
treatment is inferior to another one, but the patient is being forceful as he believes what 
he saw. Therefore, the physician may follow the patient’s request. 
Several internal factors are highly involved in the decision of initiating new 
therapies. When physicians personally make the decision to initiate a new therapy, they 
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are influenced by its perceived economic or pharmacological advantages over 
alternatives.96 Internally, physicians accumulate the economic and pharmacological 
knowledge of new therapies through a series of pathways, including peer-reviewed 
medical journals, guidelines, medical textbooks, and proceedings of conferences.93 
Personality traits, especially the variety of attitudes to innovation, risk perception, and 
benefit, significantly differentiate physicians’ behavior on prescribing new therapies. 
Prosser et al.96 ranked physicians as low, medium, and high prescribers of new therapies, 
according to the local health authority prescribing data. All groups felt they would only 
prescribe a new therapy when they believe it offered a relative advantage over current 
therapy. Compared with low prescribers who treated risks with a ‘wait and see’ policy, 
high prescribers either accepted the risks and uncertainty, or considered risks had been 
minimized by the licensing authority when approving the therapy.   
 
2.5.2 External Factors that Influence Prescribing Decision-making 
In the modern healthcare environment, especially in the hospital setting, external 
factors are also highly involved in the prescribing decision-making, other than internal 
factors which affect physicians’ prescribing behavior directly. For example, the 
medication policies are often steered by the pharmacy and therapeutics (P&T) committee, 
and clinical pharmacists always play key roles in suggesting or even automatically 
switching medications.97 Even though the internal factors that create to analyze 
physicians’ prescribing behavior could be generalized to other behaviors, the influence of 
the P&T committee and clinical pharmacists is unique for determining prescription.  
Basically, there are three sources of external factors: colleagues in the hospital, 
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pharmaceutical representatives, and patients. Colleagues and representatives are cited as 
the most common reasons for prescribing a new therapy after failure of current therapy or 
adverse events.96  
According to diverse functions, the colleagues in the hospital could be classified 
into three groups: senior physicians or specialists, P&T committee members, or clinical 
pharmacists. Each of them affects the process of decision-making on prescriptions 
uniquely. Senior physicians or specialists are important influences on physicians’ 
prescribing decision-making,96,98 which is caused by physicians either worrying about the 
change or that refusal to prescribe may jeopardize their professional relationships,99,100 or 
believing they are knowledgeable about the new therapies.98 P&T committee members 
and clinical pharmacists indirectly affect the prescribing decision-making by introducing 
the importance of cost comparison and peer-reviewed prescribing patterns.101 
Pharmaceutical representatives are employed by pharmaceutical companies to 
promote their products. The majority of the time, they deliver new therapy information 
packed in ‘bite-size’ pieces, which is marketed well, easy to remember, targeted to 
physicians, and is often accompanied with a free lunch and/or small gifts that relate to 
therapy. Their impacts on prescribing a new therapy are tremendous, almost the same as 
clinical experiences of new therapy, which are accumulated internally, from self-learning 
guidelines, and externally, from colleague endorsements.96 Aside from the huge 
influences on promoting therapies, negative influences are always associated with 
pharmaceutical representatives, including inappropriate prescribing,102 increasing 
medication cost,103,104 and specifically, prescribing earlier, if physicians have accepted 
samples and gifts.105  
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Patients’ socioeconomic status, preferences, and expectations, at the moment of 
prescribing, also impact physicians’ prescribing decisions. Among them, patient 
preference is the most significant one. The whole healthcare field is transitioning from 
making decisions by physicians alone to patient-involved decision-making, which 
integrates the evidence-based medicine with patient preference.106 For example, patients 
with cancer may decline chemotherapy and trade potential survival benefit for living with 
current quality of life, after collecting treatment and survival information from physicians, 
and assessing personal preferences. Patient preference could also affect trivial decision-
making on prescriptions, such as choosing cream rather than lotion for treating dermatitis. 
If a patient has low socioeconomics status, a physician may change his prescribing 
decision, shifting to a cheaper therapy within a therapeutic class or shifting to another 
therapy covered by the insurance plan.107 Patient expectations also contribute much to the 
decision-making. Patients who expect medication are about three times more likely to 
receive a therapy, and the odds ratio even goes up to 10, if a physician thinks that the 
patients expect getting medications.108 This partially attributes to patient preference, 
which may differentiate patient’s adherence, and thus treatment effect. The phenomenon 
is mainly affected by physicians’ wish to maintain the ‘doctor-patient’ relationship,109 
even though some of the expectations could go against physicians’ judgment, such as 
prescribing antibiotics in unnecessary cases.110 Considering the large amount of factors to 
into take account, an appropriate prescribing decision that requires the balance between 
patient-centered and evidence-based care is hard to achieve.111 The foundation is 
maintaining a good relationship and trust between physician and patient. 
In conclusion, a couple of internal and external factors tangling together 
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complicates the sophisticated decision-making process. In order to prescribe rationally, 
weighing the trade-off between benefit and risk, physicians have to fight against the 
attraction of using short-cuts and handle the pressure from colleagues, pharmaceutical 
representatives, and patients. 
 
2.5.3 Uniqueness on Antibiotics and Lung Treatment 
Only one study112 specifically investigated the decision-making of antibiotic 
prescribing among primary care physicians. Ten Icelandic primary care physicians were 
involved in the qualitative, semistructured in-depth interviews. Three paths led to 
prescribing antibiotics. In the first path, physicians believed that the infection can/will 
interfere with the patient’s planned activities, and antibiotics could help. For the second 
path, the physicians failed to handle patients’ pressure, either due to lack of time or 
because they were too tired to explain that the infection is viral and that antibiotics will 
not help. The physicians had a neutral attitude in the last path, where they valued the 
patients’ autonomy higher than welfare, and letting the patients make the decision by 
himself. The above three paths are consistent with the results of studies that did not focus 
on any therapeutic area. However, the main difference is on the concern of internal and 
external factors for prescribing decision-making, which is intensively affected by internal 
factors for prescribing antibiotics. A physician’s attitude, restrictive, neutral, or liberal, 
differentiates the prescribing behavior. Being a restrictive prescriber was influenced by 
ecological considerations and concerns for producing resistance, while a liberal 
prescriber was worried about the possible consequences of withholding a necessary 
antibiotic. A patient’s occupation also has a huge impact on prescribing decision-making 
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regardless of their attitudes to the antibiotic. Physicians were quite concerned about the 
effect of illness on the patient’s daily work and life, such as farmers, people in danger of 
losing their jobs, students during exams periods, and children. When treating a farmer, 
the physician knows perfectly well that an antibiotic does not cure the common cold, but 
he may prescribe it as a prophylaxis to protect patient from becoming more ill under 
exposure to wild nature.  
Unlike antibiotics being prescribed periodically for general patients, inhaled 
antibiotics are supposed to be prescribed chronically for patients with CF along with 
chronic lung health maintenance medications. Therefore, it is more valuable to 
investigate treatment changes that could optimize long-term outcomes than to come to a 
better understanding of initiating a treatment. Consider the uniqueness of antibiotics: lung 
health maintenance medications have to be prescribed chronically, the majority of 
prescribers are specialists, and alternative treatments are limited; the influence of external 
factors would therefore be minimized. Internal factors from both physicians’ and 
treatments’ perspective dominate the prescribing decision-making for chronic lung health 
maintenance medications.  
 
2.5.4 Treatment Change 
Generally speaking, there are two different choices regarding prescriptions: 
maintaining the previous treatment or making a treatment change. Treatment change can 
be defined as including one or more of the following events: prescribing a new therapy, 
making any adjustments to dose and/or frequency, switching to another treatment within 
the same treatment class or from a different treatment class, or stopping one or more 
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medications. Depending on whether any evidence is associated with it, treatment changes 
can be categorized into two types: rational and irrational. Before the difference between 
rational and irrational treatment changes is explained, the concept of rational treatment 
will be introduced. 
According to WHO’s definition,113 prescribing rational treatments consists of six 
steps: defining the patient’s problem; specifying the therapeutic objective; verifying 
whether the personal treatment is suitable for this patient; starting the treatment; giving 
information, instructions, and warnings; monitoring the treatment.  
We have to believe that physicians try their best to make rational prescribing 
decisions and feel confident about them; this has been verified by several studies.98,112 In 
Jacoby et al.,98 physicians are classified as low, medium, and high prescribers according 
to the likelihood of their prescribing new therapies. When making prescribing decisions, 
all physicians believe that they themselves are “conservative” and “cautious” based on 
their personality traits, medical training, and clinical experiences, regardless of the 
likelihood of prescribing new therapy. 
While health technology develops fast, rational treatment according to the current 
evidence may be untenable in future after disease becomes better understood through a 
comprehensive perspective. For decades, physicians and patients treated as common 
sense for the notion that higher salt intake is associated with higher blood pressure, a risk 
factor of heart attack. However, several studies114,115 that have been published recently 
indicate a tenuous association or even a reverse association. A meta-analysis,115 which 
combined results from seven RCTs involving a total of 6,250 subjects, found no strong 
evidence that cutting salt intake reduces the risk of mortality or cardiovascular morbidity. 
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However, another study,114 which included 28,880 subjects from two prospective cohorts, 
reported that the less sodium the subjects excreted in urine within 24 hours, the greater 
their risk of cardiovascular-caused mortality. Therefore, reducing salt intake may increase 
rather than diminish the risk of cardiovascular morbidity. It is definitely hard to achieve 
rational treatment, even when prescribing lung health maintenance medications to 
patients with CF. The behavior of prescribing rationally is mainly dominated not by 
external factors but by internal factors. To achieve rational treatment, physicians have to 
keep updating their treatment knowledge from the right sources. Even so, in future, when 
they look back, it is possible that the past decisions on treatments from decades ago are 
untenable.  
Rational treatment change functions as a subcategory of rational treatment. 
Basically, all treatment changes that are supported by evidence in up-to-date studies 
could be defined as rational treatment changes. All other treatment changes are defined as 
irrational treatment changes.  
Irrational treatment changes could be caused by both internal factors and external 
factors. Compared with the impact from therapy, the characteristics of a physician have 
more chance to induce irrational treatment change, especially through personality traits, 
and emotion. For example, if a physician has negative attitudes toward innovation, he 
may be less likely to prescribe a new therapy even if it has been well investigated and has 
produced tremendous treatment effects. In contrast, it is easy for him to prescribe a 
treatment that a patient asked for, even without a good reason, if he is an emotional 
prescriber. External factors, from colleagues in the hospital to patients to pharmaceutical 
representatives, could also lead to irrational treatment changes without a scientific 
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rationale. The scientific rationale does not need to be well understood; it can even be a 
patient preference. However, to quantify the rationale, it has to be a measureable variable. 
For example, if a patient wants to switch from treatment A to treatment B because of side 
effects, this change definitely is rational. However, it would be irrational if the patient 
tried to switch only because of hating treatment A’s brand name.  
In conclusion, only treatment changes supported by evidence would be defined as 
rational treatment changes. Some of the rationales for treatment change are hard to 
identify given the sparse applicable information in databases, such as using a patient 
registry to identify physicians’ attitudes to an innovative treatment. Therefore, the 
definition of rational treatment change would be diverse and unique according to the 
research question and the database that is available for each study. Further information 
about how to identify the rational treatment change in this study will be explained in the 
method section.  
 
2.6 Dynamic Treatment Regimes and Common Applications 
Dynamic treatment regimes (DTRs) are personalized treatment plans. Formally, a 
dynamic treatment regime is a sequence of decision-making that specifies how the 
intensity, frequency, and type of treatments should change to maximize treatment effects 
depending on a patient’s characteristics and needs. It includes two components.116 First, 
rules for how the treatment level and type should vary with disease progression, which 
were identified prior to change any treatment. Second, all of those rules are based on 
time-varying measurements of each individual’s specific needs for the treatment. Thus, 
the rules for a dynamic treatment regime have to be a measure of each individual need, 
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together with decisions on treatment type and level that mirror subject-specific need.117 
The definitions of these needs are varied; they could be severe adverse effects, clinical 
signals that indicate disease progression, or patient preference.  
DTRs are routinely implemented when there is a danger of serious side effect or 
when the necessary dose varies across subjects.117 Whenever the clinical signals/risk 
indicators, such as CD4 count for HIV, move beyond a specific rule-defined threshold, 
then the treatment is changed.118 If the rules are already known, it is simple to identify 
those adjustments, especially if the gold standard, randomized control trials exist. Not 
surprisingly, sometimes the doses, or classes of available drugs are fixed, and the 
thresholds of those needs or rules are made relying on healthcare providers’ experiences 
or unknown reasons. Under those situations, with the access to a reasonable database, 
DTRs can be used as an experimental method to identify those potential thresholds. 
DTRs perfectly fit into the concept of precision medicine and are attractive not 
only to patients, but also to formulary and public policy decision makers. DTRs 
particularly apply well to those patients who show needs for treatment adjustments: 
allowing intensive treatments for better control of the disease, switching treatment 
entirely to prevent severe adverse effects, or delaying the application of expensive 
therapies. The above advantages are exactly the characteristics that a cost-effective test or 
treatment has to acquire summarized in a McKinsey&Company report.119 Therefore, if 
identified appropriately, DTRs are very likely to save money and time by avoiding 
unnecessary treatment.  
At the same time, with scrupulous definition of a priori rule, the use of DTR in a 
study can estimate the treatment effect more precisely than use nondynamic treatment 
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regime. For example, in an RCT that follows nondynamic treatment regime, the protocol 
does not allow any change in treatment, regardless of the disease progression or severe 
side effects. Yet those patients are subjects whose needs occasionally change. They are 
very likely to require treatment adjustments, which are defined as noncompliance by the 
protocol. In contrast, studies utilizing DTRs can explicitly provide treatment adjustments, 
switching, adding, or discontinuing treatment if and when those needs reach a 
predetermined level.116,120  
DTRs can be applied to both RCTs and observational studies. For example, 
Sequential Multiple Assignment Randomized Trial (SMART) is an innovative RCT 
design, which combines a unique characteristic—a decision point—into the traditional 
RCT.121 At each decision point, subjects are re-randomized to one of the available 
treatment options at that stage. The research plan can contain N+1 stages, given the 
number of decision points, N, during the overall follow-up time. In the trial, each subject 
can proceed through stages of treatment as they reach the predetermined level at related 
decision point.  
In a two-stage SMART, there is only one decision point: for instance, whether 
patients get drug resistance after 3 years. To create an example involving CF patients, a 
two-stage SMART study is created. The responder at decision point is defined as “patient 
who develops drug resistance after using first stage treatment for 3 years.” During the 
first stage, all participants are randomized to inhaled antibiotics alone or inhaled 
antibiotic together with preliminary treatments. As the disease progresses, some 
participants may meet the requirement of the decision point. In the second stage, only 
responders to the first stage treatment are re-randomized into two groups: adjust (switch 
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or stop) previous treatment or stay on the same treatment. The optimal treatment 
regimens would identify treatment strategies considering both the baseline characteristics 
at first stage and second stage. In this case, hypothetically, for a male younger than 20 
years old, inhaled antibiotics alone is the optimal treatment, while inhaled antibiotics 
together with preliminary treatment is the optimal treatment for the rest of the 
participants. And for female responders or male responders who are older than 20 years 
old, if they were assigned to inhaled antibiotics alone group, then adjust treatment is the 
optimal strategy in second stage; if they were assigned to inhaled antibiotics together 
with preliminary treatment arm, then keeping the same treatment is the optimal strategy. 
The combination of all the optimal treatment strategies, given the baseline characteristics, 
and history of treatment is the dynamic treatment regimes. 
DTRs can be identified within observational databases. The two main issues that a 
researcher must take into account are 1) the definition of rules or protocols and 2) 
randomization at each decision point. The importance of the first issue is obvious. DTRs 
capture the treatment effects on only those patients who follow the rules exactly. 
Therefore, the definition of the rules is as vital as the identification of exposure, which 
significantly affects the result. Any blur or inappropriate definition of the rules will 
definitely bias the parameter estimation. Failure to randomly assign patients into each 
treatment arm is another issue in observational studies. Several reasons are to blame for 
this issue: baseline covariates such as gender, race, and genetic information; time-varying 
covariates such as weight, disease severity, and clinical variables; and time-varying 
exposures, such as previous treatments. Without appropriately adjusting those 
associations between different reasons and random treatment assignments, the estimation 
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of causality would be biased. It is because the probability of counterfactually having 
different treatments would not be even in each time point, and patients using different 
treatments would not have the same treatment effects as a counterfactual population 
would get if they received the same treatment. Indeed, it is the core of why (sequentially) 
randomized treatments are preferred, when applicable, for making inferences concerning 
DTRs. In conclusion, being able to solve the above two issues is the foundation of 
appropriately identifying DTR using observational databases.116 Unlike the judge for 
properly defining the rules, which is obscure, randomization can be identified 
transparently. Traditional statistical methods, such as stratification and matching, are 
feasible to investigate the optimal treatment effects of DTRs, as long as the data are of 
good quality. Those data can be collected from either an RCT or a cohort with an explicit 
study design that very likely satisfies the sequential randomization assumption. However, 
if there was no explicit study design when data were collected, which may jeopardize the 
assumption of sequential randomization, it is necessary to use advanced statistical 
methods such as a series of methods under causal inference. 
 
2.7 Causal Inference 
Armed with more advanced study designs and statistical methods, researchers are 
not satisfied with merely figuring out the association between exposure and outcome. 
They are eager to investigate the causality, which boosts the development of causal 
inference theory. Unlike common study designs that mainly focus on the observed 
exposures and outcomes, the focus of causal inference is on the unobserved values. For 
example, in order to investigate the causal effect between treatment A and death in 5 
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years, the researcher needs to compare the difference of survival of the same patient with 
and without using treatment A during those 5 years, given other circumstances remain 
exactly same. While it is impossible to go back in time to follow the same patient taking a 
different treatment choice, we can use counterfactual outcomes to estimate what could 
have happened instead.  
Let us assume, after treating with A, Zeus survived for 10 years. At the same time, 
let us assume that somehow we know without treatment A, Zeus would die in 5 years. 
This is then identified as a counterfactual outcome for Zeus given the reality. Consider a 
dichotomous treatment variable A (1: treated, 0: untreated), and a dichotomous outcome 
variable Y (1:death, 0: survival). Here we shall refer to variables such as A and Y that 
have different values for different individuals or subjects as random variables. Let Ya=1 
represent the outcome variable that would have been observed under the treatment value 
a=1, while Ya=0 denotes the outcome variable that would have been observed if a patient 
didn’t get treatment. If we measure the outcome at the fifth year after the treatment 
decision was made, then Zeus has Ya=1=0 and Ya=0=1, because he survived when treated, 
and would have died if untreated. The variables Ya=1 and Ya=0 are referred to as 
counterfactual outcomes or potential outcomes. In order to identify an individual causal 
effect, three components are needed: an outcome of interest; the action, such as treatment, 
a=1 or 0 to be compared here; and individual counterfactual outcomes, Ya=1 and Ya=0. 
Considering the diversity of each individual causal effect within the population, and the 
impossibility of knowing all the counterfactual outcomes for each individual, we mainly 
focus on investigating the average causal effect of a population.122  
The ability to handle time-dependent confounders is another advantage of the 
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causal inference related method. A covariate is a time-dependent confounder for the 
effect of exposure on outcome where the past covariate values predict current exposure 
and current covariate value predicts outcome. In addition, a time-dependent confounder 
may simultaneously be an intermediate variable if past exposure predicts the current 
covariate value.122 The investigation of causality between treatment change and delay of 
time to mucoid PaPI gives a perfect example, shown in Figure 2.1 as a directed acyclic 
graph (DAG). ΔTx(t-1) marks the treatment change, compared to the previous observed 
treatment, at t-1. ΔFEV1%(t-1) marks the predicted FEV1% change, compared to optimal 
predicted FEV1% in previous year, at time t-1. Y(t) represents the outcome at t. In 
clinical practice, the decision of current treatment change, ΔTx(t), is determined by the 
current change of predicted FEV1% (ΔFEV1%(t)), the previous change of FEV1% 
(ΔFEV1%(t-1)), together with the previous treatment adjustment (ΔTx(t-1)), assuming 
the rest of the clinical variables do not impact the decision. For example, if a patient 
received a short-term additional treatment X to treat pulmonary exacerbation, and the 
treatment was effective, then the physician will be likely to prescribe it again if the 
patient experiences the same symptoms.  
At the same time, the current change of FEV1% is determined by the previous 
change of FEV1% (ΔFEV1%(t-1)) and the previous treatment change (ΔTx(t-1)). Under 
this situation, ΔFEV1%(t) is definitely a time-dependent confounder, since ΔFEV1%(t-1) 
predicts current exposure, ΔTx(t), and ΔFEV1%(t) also predicts outcome, Y(t). Because 
previous exposure, ΔTx(t-1) could predict ΔFEV1%(t), ΔFEV1%(t) is also an 
intermediate variable. The challenge of using a standard method is that to estimate the 
joint effects of ΔTx(t) and ΔTx(t-1), we must adjust for the confounding effect of 
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ΔFEV1%(t) to consistently estimate the effect of ΔTx(t) on Y(t), but the moment we 
adjust for the confounding by stratification, regression, or matching on ΔFEV1%(t), we 
cannot consistently estimate the effect of ΔTx(t-1) because the association between 
ΔFEV1%(t) and ΔTx(t-1) results in selection bias, even under the null hypothesis of no 
causal effect (direct, indirect or net) of ΔTx(t-1) on Y. The adjustment of intermediate 
variable ΔFEV1%(t) blocks the potential pathway from ΔTx(t-1), ΔFEV1%(t), to Y(t), 
which increases the effect of ΔTx(t-1) on Y(t). A series of methods under causal 
inference can adjust time-dependent confounders perfectly, which I will concisely 
describe in the method section. 
In order to provide consistent estimates for counterfactual quantities, E(Ya�), at 
least three assumptions have to be met: consistency, conditional exchangeability, and 
positivity.  
1. Consistency: If ?̅?𝐴=𝑎𝑎� for a given subject, then 𝑌𝑌𝑎𝑎�=Y for that subject. 
2. Conditional exchangeability:  
𝑌𝑌𝑎𝑎�∐ A(t)| ?̅?𝐴(𝑡𝑡 − 1)=𝑎𝑎�(𝑡𝑡 − 1), 𝐿𝐿�(t)=𝑙𝑙(̅t)         (2.1) 
for all regimes a�.    
3. Positivity: If  P(?̅?𝐴(𝑡𝑡 − 1) = 𝑎𝑎�(𝑡𝑡 − 1), 𝐿𝐿�(𝑡𝑡) = 𝑙𝑙 ̅(𝑡𝑡)) ≠ 0          (2.2), 
then P(𝐴𝐴(𝑡𝑡)|?̅?𝐴(𝑡𝑡 − 1) = 𝑎𝑎�(𝑡𝑡 − 1), 𝐿𝐿�(𝑡𝑡) = 𝑙𝑙 ̅(𝑡𝑡)) > 0          (2.3) 
for all 𝑎𝑎�(𝑘𝑘) ∈ 𝐴𝐴(𝐾𝐾), and 𝑡𝑡 = 0, …, K. 
The consistency assumption simply means that the outcome for every treated 
patient equals the outcome that would have occurred if he had counterfactually received 
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treatment, and the outcome for every untreated patient equals the outcome that would 
have occurred if the patient had remained counterfactually untreated. Intervention and its 
contrast absolutely have to be well defined. Conditional exchangeability reflects the 
assumption that the value of counterfactual outcomes is independent of the current 
observed treatment and is conditional on treatment history and time-varying covariates. 
In other words, no unmeasured confounder is unevenly distributed between treated and 
untreated groups to bias the estimation. Positivity indicates that the probability of being 
assigned to each treatment level is more than zero. This assumption ensures that any 
patient may experience any level of the treatment at any point of time regardless of his 
covariate history.116,122,123 With the consistency assumption, the observed outcome 
connects to the counterfactual outcome; with the conditional exchangeability assumption, 
the observational database has RCT features: (sequential) randomization at each decision 
point. According to the positivity assumption, patients exist in each treatment level at any 
point of time. Together, the assumptions of causal inference make the association 
between exposure and outcome in observational database as an unbiased estimation of the 
causality between that exposure and outcome in a counterfactual population. Therefore, 




Several guidelines for chronic lung health maintenance treatments exist, which 
somehow steer the prescribing practice. However, rather than suggesting the order of 
prescription, the guidelines only categorize all treatments by the certainty of net benefits. 
42  
  
Additionally, those certainties are summarized by existing RCTs, which have small 
sample size and extremely narrow characteristics to represent the whole patient 
population. In contrast, during clinical practice, healthcare providers are facing patients 
case by case; each individual has unique characteristics ranging from demographic 
characteristics, disease severity, and treatment pattern to personal preference. When and 
how does treatment initiate and change in patients diagnosed with new or continuing 
nonmucoid PaPI? How is it determined if the current treatments are providing optimal 
treatment effects? How can demographic and clinical variables create a score to identify 
suboptimal treatment? What are the cutoffs of the score that indicate a treatment change 
is needed? If a treatment change is needed, what should the healthcare providers do? 
Should they stop a specific medication, switch to another medication, or add on another 
medication to current treatment? Given the above sophisticated questions, no doubt, the 
decisions around treatment adjustment are difficult to make. To make things worse, none 
of the current guidelines in the CF field provides a comprehensive suggestion for rules or 
composite clinical signals that a healthcare provider could follow to deliver the optimal 
treatment effects with appropriate treatment change. Finally, the rarity and complicated 
nature of CF itself reduces the accuracy of decision-making based on routine clinical 
practice. A comprehensive study with a sophisticated design and a broad scope of 
longitudinal data, which reflects real-world practice questions to support the utilization of 
dynamic treatment regimes for CF patients, is lacking. 
Ideally, an RCT is supposed to identify causal effect by analogously gathering 
data through a randomized assignment of treatment, with perfect compliance, and without 
right censoring. However, the cost of conducting a new RCT with a small sample size 
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and a 1-year follow-up is exhaustive in terms of time and money. Furthermore, CF is a 
chronic disease. In order to capture intermediate outcomes such as the length of time it 
takes to develop mucoid PaPI, an RCT with a minimum of follow-up of 5 years is needed. 
Last but not least, treatment change could be determined by a combination of 
demographic variables, clinical signals, and treatment histories, which includes a 
tremendous number of scenarios. To ensure that results are not examined by chance, 
there should be a sufficient sample size for each scenario, enlarging the overall sample 
size and increasing the cost dramatically. For example, let us assume that only ΔFEV1%, 
PEx, and drug resistance determine the treatment change decision. Each additional unit 
change is clinically meaningful, which represents by one or several of the following 
clinical variables: additional 1% change of ΔFEV1%, additional one PEx, additional 
specific drug resistance. In order to measure the causality, I have assigned patients to all 
scenarios. According to the results of a survival analysis,11 we can assume that the 
clinically meaningful range for ΔFEV1% is 6% to 15%; the additional effect of having 
more than five PExs in a year is trivial; and only drug resistance that relates to 
aminoglycoside, beta-lactam, or macrolide affects the treatment change decision. Overall, 
there are 240 potential scenarios. Obviously, the sample size should be huge to 
appropriately capture the causality. In conclusion, the enormous time and monetary cost 
for an RCT, together with long-term follow-up and tremendous sample size, makes the 
thought of conducting an RCT to capture causal effect within dynamic treatment regimes 
an illusion. 
A longitudinal retrospective observational database is the most appropriate source 
of data for constructing DTRs as complicated as the one in this study. This is because that 
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observational database is not only cheaper than conducting an RCT, but also it comes 
with a huge sample size and hypothetically collects patient information in all scenarios. 
However, a traditional retrospective observational database contains none of the 
advantages of an RCT. For example, the treatment that a patient received would have 
been based on treatment history and clinical symptoms rather than being randomly 
assigned; a patient may or may not take the drug; and some patients may be lost to 
follow-up before the targeted outcome/symptom occurs. However, with appropriate 
adjustment those challenges could become strengths. This is because, unlike an RCT, an 
observational database represents specific features of daily clinical practice. As discussed 
previously, combined with the design of a dynamic treatment regime and methods from 
causal inference, an observational database will be able to account for those issues 
perfectly. Moreover, using an observational database reduces the chance of violating the 
unmeasured confounder (conditional exchangeability) assumption compared with using 
an RCT since the observational database captures all the information a physician has 
when a treatment decision is about to be made. Last but not least, the observational 
database provides the chance to identify a score, which may include innovative variables 
to aid decision-making for achieving optimal treatment effects. 
This research was conducted using the U.S. Cystic Fibrosis Foundation Patient 
Registry (CFFPR), which is a nationwide patient registry aiming at tracking treatment 
effects and disease transitions for CF patients. Since 1986, it has tracked over 300 
clinically relevant variables, from demographic characteristics, clinical characteristics, 
and lab test results to treatments used.124 Considering the longitudinal and national 
characteristics of CFFPR, together with the abundant variables that are measured in the 
45  
  
database, there is no doubt that with correct measurement, this study was the most 
appropriate estimation of DTRs for nationwide CF patients. 
Armed with the dynamic treatment regime design, causal inference methods made 
the measurement of causation between rational treatment change and treatment effect a 
reality. With the identification of several potential treatment change rules for DTRs, the 
study provided the optimal treatment pattern for a specific patient given his current 
characteristics. 
In this study, the focus was on identifying optimal dynamic treatment effects by 
treatment class level rather than by each individual treatment. The current guidelines only 
suggest which treatments should be considered for patients older than 6 years old with 
mild to severe lung functions. However, the guidelines lack any information on when to 
initiate which class of treatment and in which order, let alone the timeframe for treatment 
changes and guidelines for providing personalized medicine for each patient based on 
individual characteristics. 
Ideally, optimal dynamic treatment effects for each individual treatment should be 
identified, but considering the extremely large number of treatment combinations and the 
number of patients in the U.S. Cystic Fibrosis Foundation Patient Registry (CFFPR), the 
ambitious aim is difficult to achieve. Moreover, it is complicated to differentiate the 
rationale of treatment change within a class; the change may have nothing to do with 
treatment effects but instead be related to cost, consumer-directed advertising, or 
patient/parent preference for time spent on treatment. For these reasons, this study did not 
take into consideration medication change within a treatment class unless the number of 
treatments in any certain class had changed. For example, if a patient switched from 
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using dornase alfa to hypertonic saline with all other individual treatments remaining the 
same, this switch was not considered a treatment change. However, if a patient previously 
received only dornase alfa and was given an additional hypertonic saline prescription 
during a visit, then a rational treatment change occurred in this visit. The assumption is 
that the physician believed additional treatment was needed in order to change the 
properties of lung phlegm given the patient’s health status. 
The first goal of this study was to better understand the treatment pattern in the 
current database for CF patients diagnosed with nonmucoid PaPI. The second goal was to 
identify the lung treatment score, which affected the decisions of treatment change for 
achieving optimal treatment effects given patients’ demographic characteristics, 
comorbidities, and clinical outcomes. Compared to a composite clinical signal, a score is 
more flexible in assigning weights for each variable. Finally, the study investigated the 
comparative effectiveness of different strategies for lung treatment scores in delaying the 
acquisition of mucoid PaPI, specifically in patients diagnosed with nonmucoid PaPI. In 
addition to these goals, the study also investigated the DTR rule that optimized treatment 
effects. The rules for DTRs, here, included measurement of needs, which are summarized 
by the lung treatment score, together with general decisions of whether to provide 
treatment changes to address subject-specific needs. 
With the results of this study, healthcare providers could switch from experience-
based to evidence-based decision-making. The lung treatment score and DTR strategy 
aided in identifying suboptimal treatment, and aided in making personalized decision on 
treatment change to maintain optimal treatment effects. At the same time, the study 
results could also support value-based insurance design by optimizing traditional 
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treatment utilization prior to reimbursement of extremely expensive medications through 
step therapy, tiered formulary, prior authorization, and other tools for managed care 
pharmacy. 
The balance between healthcare expenditure and effectiveness will be a 
permanent and tough topic for each individual with CF. Since CF is a genetic disorder, 
despite breakthroughs in treating patients, a permanent cure is unlikely. The latest 
treatment for CF, ivacaftor, cannot fully cure the genetic disorder, but can significantly 
increase lung function, weight, and decrease the probability of developing pulmonary 
exacerbations for those patients who have the specific genetic mutation that ivacaftor 
targets for. Especially from the perspective of relative improvement of lung function, 
after being on the treatment for 2 weeks, the treatment effects are sustained around 17% 
regardless of baseline age, lung function, or length of treatment with ivacaftor.125-129 The 
effects are also not permanent; after the treatment of ivacaftor is stopped, patients’ lung 
function decreases to its prior level. In order to maintain the benefits of ivacaftor, the 
patient must remain on the medication permanently. Considering there are only 4%-5% 
of CF patients who can benefit from using ivacaftor, the cost of the drug shouldn’t be a 
huge burden for an insurance company. The issue that insurances should be looking at 
isn’t whether to reimburse ivacaftor, but how to maintain patients’ lung function so as to 
avoid or delay the need for ivacaftor. This is exactly the type of decision-making that the 
results of this study supported. With the study results, insurance companies will be able 
to create a value-based pharmacy formulary in order to help control rapidly increasing 
medication expenditures while providing optimal health outcomes through cost-effective 
treatments. In such a value-based strategy, extremely expensive treatments, such as 
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ivacaftor, will be avoided unless the healthcare provider has already prescribed all other 
treatments step by step (step therapy), and the scenario of suboptimal treatment effect has 
already occurred (prior authorization). 
Last but not at least, even though the study design was rigorous and causal 
inference methodology was applied to adjust for the biases in the observational database, 
considering the huge reliance on treatment pattern that existed in the database (positivity 
assumption of causal inference), and assumptions of routine visits and continuing 
treatment utilizations, the result of this study should be considered exploratory. A gold 
standard RCT should be performed to get solid confirmation of the results for more 
confident application in future. 
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Table 2.2. Definitions of CF patients with chronic PaPI  
Method Length of persistence with P. aeruginosa Frequency of tests (sputum sample or 
deep throat swabs) 
Copenhagen, 1977130 >= 6 consecutive months, or less when combined with the 
presence of two or more P. aeruginosa precipitating 
antibodies 
In study, patients had an average of 10 
sputum cultures per year 
Ballmann, 1988131 more than 50% of cultures in 12 months had to be + 1-4 times a year 
Lee, 2003132 50% of months, when samples had been taken, were + every 3 months 
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Table 2.4. Current existing parametric algorithms for predicted normal FEV1 
  Applied age Intercept Age Age2 Height Height2 Height2 * 





  Male 
       Caucasian & <20 yr 
 
-0.7453 -0.04106 0.004477 NA 0.00014098 0.00011607 
Caucasian & >=20 yr 
 
0.5536 -0.01303 -0.000172 NA 0.00014098 0.00011607 
African-American & <20 yr 
 
-0.7048 -0.05711 0.004316 NA 0.00013194 0.00010561 
African-American & >=20 yr 
 
0.3411 -0.02309 NA NA 0.00013194 0.00010561 
Mexican-American & <20 yr 
 
-0.8218 -0.04248 0.004291 NA 0.00015104 0.0001267 
Mexican-American & >=20 yr 
 
0.6306 -0.02928 NA NA 0.00015104 0.0001267 
Female 
       Caucasian & <18 yr 
 
-0.871 0.06537 NA NA 0.00011496 0.00009283 
Caucasian & >=18 yr 
 
0.4333 -0.00361 -0.000194 NA 0.00011496 0.00009283 
African-American & <18 yr 
 
-0.963 0.05799 NA NA 0.00010846 0.00008546 
African-American & >=18 yr 
 
0.3433 -0.01283 -0.000097 NA 0.00010846 0.00008546 
Mexican-American & <18 yr 
 
-0.9641 0.0649 NA NA 0.00012154 0.0000989 
Mexican-American & >=18 yr   0.4529 -0.01178 -0.000113 NA 0.00012154 0.0000989 
  





  Male 
 
-2.19 -0.0244 NA 0.1052 NA NA 
Female   -1.578 -0.0255 NA 0.0869 NA NA 
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Table 2.4. (continued) 
  Applied age Intercept Age Age2 Height Height2 Height2 * 





  Male 
       <=24 yr 
 
-4.808 0.045 NA 0.1168 NA NA 
>24 yr 
 
-4.203 -0.027 NA 0.1321 NA NA 
Female 
       <=19 yr 
 
-2.703 0.085 NA 0.0686 NA NA 
>19 yr   -0.794 -0.021 NA 0.0686 NA NA 
  





  Male 
 
-2.59946 -0.03509 NA 0.1149 NA NA 
Female   -2.56958 -0.02147 NA 0.1034 NA NA 
  





  Male  
 
-1.26 -0.032 NA 0.0919 NA NA 
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Table 2.5. Clinical symptoms and signs used to define PEx or improvement from PEx in RCTs 
  Articles 
Item Fuch et al137. Ramsey et al65. Dakin et al92. Rosenfield et al91. Rabin et al90. 
Change in sputum production: 
volume, appearance or color 
✔ ✔ ✔ ✔ ✔ 
New or increased hemoptysis ✔   ✔   ✔ 
Increased cough ✔ ✔ ✔ ✔ ✔ 
Decreased activity     ✔ ✔   
Malaise, fatigue, or lethargy ✔         
Absent from school/work due 
to illness 
  ✔   ✔   
Decreased exercise tolerance     ✔ ✔   
Increased dyspnea ✔         
Increased chest discomfort          
Increasing respiratoryrate   ✔ ✔ ✔   
Work of breathing           
Fever>38 °C orally ✔ ✔ ✔ ✔   
Anorexia or weight loss ✔ ✔ ✔ ✔ ✔ 
Changes in chestsounds ✔   ✔ ✔ ✔ 
Decrease in FEV1 or FVC ✔ ✔ ✔ ✔ ✔ 
Radiographic changes 
indicative of an exacerbation 
✔  ✔   
Sinus pain or tenderness ✔         
Change in sinus discharge ✔         




   
 55 
Table 2.5. (continued) 
  Articles 
Item Fuch et al137. Ramsey et al65. Dakin et al92. Rosenfield et al91. Rabin et al90. 
ESR, CRP, WCC, NC*   ✔       
Retractionsor use of accessory 
muscles  
    ✔   
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 OBJECTIVES AND SPECIFIC AIMS 
 
3.1 Objectives 
The primary objective of this study was to examine the treatment initiation and 
change in patients diagnosed with new or continuing nonmucoid PaPI. The second 
objective was to investigate the optimal treatment regime to delay the acquisition of 
mucoid PaPI for pediatric CF patients.   
3.2 Specific Aims 
1. To describe treatment use patterns and changes in pediatric CF patients 
diagnosed with nonmucoid PaPI in the CFFPR from 2006 to 2011.  
2. To create a lung treatment score that indicates suboptimal lung health 
management by when rational treatment changes occur. 
3. To investigate the comparative effectiveness of different treatment regimes, 
which is determined by the threshold of the predicted probability of lung treatment 







4.1 Data Sources 
All of the aims in this dissertation were conducted using data from the Cystic 
Fibrosis Foundation’s Patient Registry (CFFPR). The CFFPR was created in 19668 to 
collect and track information on demographic characteristics, genetic and microbiological 
information, diagnoses, clinical outcomes, self-reported therapies, and hospitalization 
variables of patients with CF who receive care at Cystic Fibrosis Foundation (CFF) 
accredited care centers in the U.S. This information was used to create CF care guidelines, 
assist clinical practice, guide quality improvement on health services, and boost the 
research with complex questions, all of which eventually optimizes survival time and 
quality of life for the entire CF population.  
The CFFPR has set international standards for gathering patient data and has 
served as a model for other nonprofit health organizations all around the world.8 
To better supervise data collection and confirm the quality of the database, in 
2013, the CFF began conducting an external audit of the data entered into the CFFPR 
each calendar year. In 2013, 28 centers of varying size and geographic location 
participated, which included 1,606 patients. Data from 8,247 encounters and 1,471 care 
episodes were audited. All the key information, such as demographic, microbiological, 
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treatment, and hospitalization variables, were compared with the data in the electronic 
medical record (EMR) for completeness and accuracy. Overall, the CFFPR contained 
96.5% of the encounters and 89.7% of the hospitalizations that were recorded in the EMR. 
Among the key variables examined, the accuracy of the data in the registry was over 95% 
accurate for date of birth, sex, and CFTR mutations. Microbiology were recorded 
accurately for 93.1 % of cultures, and medications were recorded accurately with some 
variability by type—over 95% for dornase alfa and azithromycin, over 90% for 
hypertonic saline and aztreonam, and over 85% for inhaled tobramycin.124 According to 
the above result, CFFPR has collected information with similar accuracy as EMR since 
2012. The CFFPR can be applied to mimic EMR data even as early as 2006, since the 
quality of data is similar between 2006-2012 and after 2012. In the assumption section, I 
will concisely describe the results of several preliminary analyses, which have 
investigated the quality of data in the CFFPR from various perspectives. 
All of the data are captured through questionnaires during the inpatient or 
outpatient visit. Data are entered into a secure Web-based portal by trained staff at each 
CFF accredited care center.138 Four databases, an annualized database, an encounter 
database, a care episode database, and a demographic and diagnosis database, are used to 
save the information. The annualized database is the summary of all the events and 
disease deteriorations that were recorded on each visit for the same patient during the full 
calendar year. The care episode database includes information during the same care 
episode, which could be either hospitalization or home care. In order to handle all of the 




4.2 Study Design and Population 
A cohort of de-identified patients diagnosed with nonmucoid PaPI existing in the 
CFFPR from Jan 1, 2006 to Dec 31, 2011 was identified. The main hypotheses and aims 
of this study were addressed using the retrospective cohort design. Patients were 
identified based on exposure to different treatment strategies, and were followed forward 
until diagnosed with mucoid PaPI, death, the end of the study, or did not match the 
treatment strategy, whichever occured first. Considering the long span of time for disease 
progression from nonmucoid PaPI to mucoid PaPI, together with the high cost of 
conducting a prospective cohort study, a retrospective study design is the perfect match 
for the hypotheses. 
 
4.2.1 Study Design 
Armed with the causal inference method, after identifying the potential treatment 
strategies from the cohort and expert opinions, the data were able to emulate an RCT with 
DTR design. For each patient, 25 replicates were created from the index date. At the 
index date, each one of the patients (replicates) was assigned into one of the 25 related 
treatment strategy groups, respectively, given the threshold of lung treatment score when 
a treatment change was received. Those patients were followed until the occurrence of 
outcome, censoring, or failing to match the treatment strategy. With that design and 
method, the study can deliver better causality estimations with fewer biases than a study 





4.2.2 Inclusion and Exclusion Criteria 
Inclusion criteria: 
• Diagnosed with nonmucoid PaPI; 
o More than 1 year history OR 
o More than 1 negative culture test before positive 
• Patient has demographic information and existed in CFFPR from 2006-
2011; 
• Patient has moderately or severely impaired lung function. 
Exclusion criteria: 
• Patients born before 1988 or after 2006; 
• Patients didn’t have any visit after 2006; 
• Diagnosed with mucoid PaPI before nonmucoid PaPI; 
• Patients had lung transplant before index date. 
In order to be qualified as diagnosed with nonmucoid PaPI, patients must have at 
least 1 year of prior history or have at least one negative culture test before the diagnosis. 
With this restriction, only patients initially diagnosed with nonmucoid PaPI were 
identified. Because of the way culture test results are collected and the uniqueness of the 
research question, this study focused on identifying the date of patients’ initial diagnosis 
with nonmucoid PaPI, bypassing the ambiguity of identifying chronic nonmucoid PaPI 
diagnosis using CFFPR. To better aid decision-making about chronic medications for 
maintaining lung health, both treatment-naïve and nonnaïve patients were included, as 
long as the diagnosis date of nonmucoid PaPI was somehow identifiable. 
Following the inhaled antibiotics’ label approved by the FDA, all patients, who 
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were treated with inhaled antibiotics, should be older than 6 years old with moderately to 
severely impaired lung function, indicated by the predicted FEV1% that was less than or 
equaled to 70%. Considering that the prospective RCTs that demonstrated the efficacy of 
inhaled dornase alfa, tobramycin, and oral azithromycin was published in 1994,137 
1999,65 and 2003,139 respectively, all patients for inclusion in the study should have been 
initially diagnosed or initially treated for chronic nonmucoid PaPI after 2004. This is to 
account for the fact that prior to those approvals and publications, physicians may not 
have been prescribing those medications due to the lack of published evidence of efficacy.  
Moreover, before 2006, the richness of data on patient-reported treatment of 
encounter for the CFFPR was suboptimal. An exploratory analysis (Appendix A) was 
conducted to investigate the quality of CFFPR data and whether patient-reported 
treatments can be used as a proxy for prescription or refill records. Because of the 
features of lung health maintaining treatments, chronic utilization, and the results an 
external 2012 CFFPR audit showing that patient-reported treatment appropriately 
reflected prescription information in EMR, the annual inconsistency rate was identified. 
The rate was defined by the proportion of visits in which a patient did not report on a 
specific treatment that was initiated within the calendar year. At the same time, in order 
to investigate whether patient-reported treatments can be used as proxy for refill records, 
the discordance between self-reported treatments and refills in a commercial claims 
database was tested. Generally speaking, self-reported treatment has been captured 
appropriately and consistently since 2006 and is eligible to represent prescriptions since 
the inconsistency rate was about half after 2006. Before 2006, the inconsistency rate was 
about 80%; since 2006, it has decreased to 30% and maintained around 20% at the end 
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(Appendix A, Table A.3). Even though the data in CFFPR are appropriate for indicating 
prescribing patterns, they do not qualified as proxy for refill records, considering the 
discordance between self-reported treatments and refills in a commercial claims database. 
As shown in Appendix A, Table A.4, patients were reported on treatment in many 
records from the CFFPR, but about only half of those records also had claims indicated 
that the same patient had refilled the treatment at related encounter date in the claims 
database. The discordance could be caused by the reality that there are fewer claim 
records in the database than encounter records in the CFFPR. Other than dornase alfa, 
which has a high concordance, when patients reported on treatment and had refilled 
claims, the rest of the concordances came from that both claims database and CFFPR did 
not collect enough information about prescriptions, such as for inhaled aztreonam, 
TOBI® Podhaler, and ivacaftor. The concordance for above treatments is probably 
caused by the small number of patients who have access to the treatment, by the short 
time period since drug approval, or by the extremely high price of the treatment. Without 
further information, it is not possible to draw the conclusion that self-reported treatment 
in the CFFPR can be used as a proxy for refills. However, some patients lied about the 
treatment they received: about 1% to 6% of patients claimed that they were not on 
treatment but actually had refill claims as shown in Appendix A, Table A.8. This result 
definitely supports the previous assumption that patient-reported treatment in the CFFPR 
indicates the prescribing treatment pattern. Detailed descriptions of discordance tests are 
mentioned in the assumption section.  
With these qualifications in place, only patients who were listed in the CFFPR 
from January 1, 2006, to December 31, 2011, were included in the study. Another 
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criterion for patient selection was age. The median ages of those who develop nonmucoid 
Pa and mucoid Pa are 1 and 13 years old,14 respectively, and the majority of patients 
suffering from chronic PaPI are adolescent;140 for inclusion in the study, patients had to 
be younger than 18 years old at the index date. Index date was identified as the date when 
the patient had the first encounter visit after January 1, 2006, if he/she had been 
diagnosed with nonmucoid PaPI previously, or the date of encounter visit when patient 
initially diagnosed with nonmucoid PaPI after January 1, 2006.  
As an antibiotic for treating chronic PaPI, inhaled aztreonam was approved by the 
FDA on February 21, 2010; this recent approval could affect the rationale of treatment 
change given physicians’ belief that newer is better. Another exploratory analysis was 
conducted both in order to understand how the drug approval date or the date when a 
treatment’s efficacy was demonstrated may influence irrational treatment changes and 
also in order to estimate the potential presence of channeling bias in the specific aims. 
The result (Appendix B) supports part of the hypothesis: drug approval date, or the date 
when the efficacy of a treatment was demonstrated, affects treatment change. Before the 
date, the mean number of targeted treatment-associated treatment changes was lower than 
the mean number measured after the date. For instance, 1 year before the approval date, 
the mean number of treatment changes associated with azithromycin was 0.22, while the 
number went up to 0.56 during the first year after the approval date. Hypothetically, 
before the date, the mean number for targeted treatment-associated treatment changes 
should be zero since the drug either hadn’t been approved yet or did not receive enough 
attention about treatment effects in publications. In reality, both off-label use and RCTs 
provide access to targeted treatment before it was approved, which explains the nonzero 
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value of mean number of treatment change that associated with targeted treatment. In 
azithromycin case, the off-label use was probably the dominant reason for the positive 
value. Even though the results already partially support the hypothesis, it is still difficult 
to investigate the association between the approval date and irrational treatment change in 
the preliminary analysis. Further analysis is needed, considering the challenge of 
differentiating rational changes from irrational changes and failing to adjust for other 
issues that may confound the influence of drug approval date on irrational treatment 
changes in the current exploratory analysis. Fortunately, inhaled aztreonam is the only CF 
treatment-related to this research that received approval between 2006 and 2011. More 
importantly, this study focused on investigating treatment changes among treatment class 
levels. The approval of a new drug within a preexisting class has little actual impact in 
related treatment class levels unless there was no alternative in that treatment class. Given 
the results of the exploratory analysis together with a general understanding of the 
treatment and with comprehensive procedures to capture and adjust influence, drug 
approval date does not significantly impact irrational treatment change.  
Patients with a lung transplant before the index date or under 6 years old were 
excluded, since in those situations participants may already be using other treatments, and 
antagonism between pathogens may exist, which complicates the identification of 
treatment effects for current dynamic treatment regimes. 
 
4.3 Exposure, Covariate, and Outcome Assessment 
The core concept of this study is rational treatment change. This indicates whether 
to switch to, add on, or stop one or multiple classes of chronic treatments compared to the 
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treatment received in the previous visit. The treatment mainly consist of two categories: 
inhaled antibiotics and lung health maintenance medications. Moreover, the pulmonary 
guidelines48 for CF separate the suggested treatments by the estimation of net benefit: 
positive, neutral or uncertain, and negative. In this study, I assigned all the related 
medications into five classes regardless of the net benefit, as shown in Table 2.5. The 
utilization of medications that were not included in this table was not considered, since 
either those treatments were only prescribed for short-term use, i.v. antibiotics, or they 
only received approval recently (beyond the time constraints of this study). However, 
some excluded medications may influence the clinical outcome indirectly, with 
appropriate adjustment for those demographic, clinical, and treatment-related variables 
(Figure 4.1), the influence can be mitigated. For example, pancreatic enzyme 
replacements help with digesting and absorbing food, which increases lung function of a 
pediatric patient indirectly by enhancing his weight and height. In this section, I will 
describe the identification and assessment for exposure, covariate, and outcome, 
respectively. Since rational treatment change directly acts as the outcome for Aim 2, and 
it is also included in the lung treatment score, which functions as an exposure for Aim 3, 
I will define it first.  
 
4.3.1 Rational Treatment Change 
As defined in the background section, any treatment change steered by evidence 
is a rational treatment change. Since the main focus of this study is to investigate optimal 
timing of rational treatment change on a class level, the appropriate identification of the 
exposure, rational treatment change, is vital. In my study, treatment information, 
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including both type and quantity, was specifically captured from the class level. Initial 
treatment was defined as the first class of treatment that a patient received after index 
date from 2006 to 2011. For instance, if a patient received both dornase alfa and 
hypertonic saline on the index date, the initial treatment for this patient would be two 
mucolytics. Rational treatment change was defined as a dichotomous variable and was 
measured at each visit. It occurred at a visit only when either a different class or a 
different number of treatments within a class was prescribed according to clinical 
evidence. The clinical evidence had to include at least one change to a clinical variable, 
such as FEV1%, PEx, pathogens, adverse effects, drug resistance, etc.  
In order to investigate how much clinical evidence is needed to define a rational 
treatment change and in order to determine the impact of different definitions on the time 
to acquire mucoid PaPI, rational treatment changes are defined under three assumptions: 
loose, neutral, and strict. For the loose assumption, all treatment changes are rational 
treatment changes regardless of whether clinical evidence exists. A treatment change is 
defined as strict if it is associated with related clinical evidence. For the neutral 
assumption, whenever a physician stops prescribing a treatment, the change can be 
identified as a rational treatment change only if the change in clinical variables is 
consistent with suspending prescription. Consistency means that the change of treatment 
and change of clinical status have an identical direction. For instance, the initiation of one 
treatment causes AE, or drug resistance. If the physician stops prescribing this medication 
accordingly, then it is a rational treatment change. The rest of the decisions to terminate a 
prescription are defined as irrational treatment changes that did not have clinical status 
change in the same direction. Moreover, under the neutral assumption, adding on and 
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switching both between and within treatment class levels are rational treatment changes 
regardless of the existing evidence. Since all treatments were prescribed chronically, I 
anticipated that under the neutral assumption, the probability of a physician’s randomly 
prescribing a treatment without any reason would be low. More clinical evidence is 
needed to define rational treatment change for the loose, neutral, and strict assumptions. 
Results in Aim 1 used the neutral assumption to present the existing treatment 
change pattern. For the following aims, the strict assumption was applied. A sensitivity 
analysis was also conducted to investigate the influence of different rational treatment 
change assumptions on investigating the optimal lung treatment maintenance strategy. 
Table 4.1 lists specific scenarios to illustrate the neutral assumption of treatment 
change. To simplify the scenario, only mucolytics and inhaled antibiotics are taken into 
consideration. All other individual treatments/treatment classes are assumed to remain the 
same between two consecutive visits. After the first of the two consecutive visits, a 
rational treatment change would be confirmed as long as the number of treatments 
prescribed in the second visit increased, regardless of whether the change occurred within 
or between classes. As shown in scenario 2, the minute that inhaled tobramycin is 
initiated in the second visit, the change is considered a rational treatment change because 
the patient has been taking only hypertonic saline but not any other treatment since the 
last visit. Taking treatments every other month is common for patients using lung 
maintenance treatments such as inhaled antibiotics. According to the preliminary analysis, 
patients sometimes fail to report on treatment when the visit occurred in a break month. 
In order to prevent failure to capture treatment caused by the frequency of taking a 
treatment, all treatment frequencies were captured, adjusting incorrect reports during the 
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break month. For terminating a medication, the definition of rational treatment change 
relies on whether clinical variables change in the same direction as treatments reported by 
patients. In scenario 6, a patient stops taking inhaled tobramycin in current visit. This 
would be confirmed as a rational treatment change if the change of clinical status 
increased lung function, yielded a negative culture test result, or caused resistance to 
aminoglycoside to disappear.   
At the beginning, the first four classes were the main focus in defining rational 
treatment change. However, according to the chronic treatment guideline, which 
determined that the chronic use of bronchodilators was associated with uncertain or 
negative benefits, only three treatment classes—inhaled antibiotics, mucolytics, and anti-
inflammatories—were considered to define the rational treatment change. Each 
individual treatment in the last class—other chronic treatments—was treated as a 
confounder in the study since all of them can not only treat specific pathogens or 
comorbidities, but also improve patient’s lung function indirectly, which complicates the 
treatment effects of the other three treatment classes. 
 
4.3.2 Exposure Assessment 
Aim 1 was the descriptive analysis, so there was no exposure. All of the variables 
were described in the outcome assessment section. Aim 2, a prediction model, also did 
not have any exposure.  
In Aim 3, each unique threshold of the lung treatment score was defined as one 
exposure, which indicated whether or not there should be a lung health maintenance 
treatment change in the current encounter visit according to the treatment score threshold. 
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At the end of Aim 2, a lung treatment score was created that predicted the probability of a 
rational treatment change in current visit. Furthermore, the score thresholds were 
determined by clinical experience, score distribution, and variations in disease severity. 
Whenever a treatment was not consistent with the lung treatment score threshold, the 
patient was artificially censored at the visit given the related threshold. Given the various 
treatment score thresholds, each one of the relative observed cohorts was unique, from 
the number of patients to the number of visits for each patient in the cohort. 
 
4.3.3 Outcome Assessment 
Aim 1: Patient demographic characteristics, including but not limited to age, 
gender, race, ethnicity, smoking status, second hand smoking status, pregnancy, 
transplant status, height, and weight, were measured. Clinical variables, such as FEV1, 
predicted current FEV1%, relative change of predicted FEV1% compared to the optimal 
value from the previous year, and number of PEx in the previous year, were also 
measured. The variations of clinical variables by demographic characteristics or other 
clinical variables were measured as well. Treatment patterns, treatment change, and time 
of change were captured, together with other treatment-related variables. More 
importantly, considering the time-varying issue, time-varying covariates, such as FEV1, 
predicted current FEV1%, and PEx were measured at three temporal points for each visit: 
current visit, last visit, and when optimal value was measured among all the visits in the 
previous year. The relationship between clinical variables and changes in lung health 




Aim 2: The main result of Aim 2, the lung treatment score, is a probability of 
getting rational treatment change, which also indicates the probability of having 
suboptimal lung health management.  
Aim 3: Ideally, time from the date of being initially diagnosed with nonmucoid 
PaPI to mucoid PaPI should be identified as the primary outcome. However, with the 
developing technology and early detection leading to better understanding of the disease, 
the age of being initially diagnosed with nonmucoid PaPI is decreasing. At the same time, 
CF patients may receive treatment after 6 years of age. Therefore, the time from the index 
date to being initially diagnosed with mucoid PaPI was applied as the primary outcome 
instead. Patients were censored based on the earliest development of mucoid PaPI, death, 
or the end of the study (Dec 31, 2011), whichever occurred first.  
 
4.3.4 Covariate Assessment 
Aim 2: All variables that are mentioned in Table 4.2, ranging from demographic 
characteristics, clinical variables, and comorbidities to treatment-related variables, were 
considered to enhance the accuracy of prediction, even though demographic 
characteristics and CFRD status are not treated as confounders in the DAG (Figure 4.1). 
All the clinical variables, treatment-related variables, comorbidities, and weight for age Z 
score were treated as time-varying variables. The rest of the demographic characteristics 
were handled as baseline variables in the score prediction model.  
Aim 3: In Figure 4.1, variables in current visit were denoted with t, and (t-1) 
represents the value that occurred in previous encounter visit. To simplify the DAG 
figure, other than ΔFEV1% and ΔTx, the rest of the time-varying covariates were not 
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denoted with t or (t-1) in the figure, such as age, height, weight for age Z score, CFRD, 
and drug resistance. They were taken into consideration as time-varying covariates in the 
analysis. All treatment information was self-reported, which reflected what treatment 
they were on previously, so treatment information of current encounter visit only 
represents the prescribing behavior of the last encounter visit. Other than exposure and 
outcome, which is represented by the green and blue nodes, respectively, the figure 
consists of four groups of independent variables. All the variables of demographic 
characteristics are located in the top-left corner. The top-right corner belongs to 
comorbidity variables. Clinical variables, such as predicted FEV1%, are located in the 
center, and the treatment/pathogen-related variables stand at the bottom. 
Treatment/pathogen-related variables include pulmonary infection and drug resistance 
caused by pathogens other than P. aeruginosa.  
To simplify the figure, I have only included ΔFEV1%; it represents the 
combination or the matrix of all the clinical time-varying covariates, such as ΔFEV1%, 
FEV1%, and PEx. All variables of demographic characteristics, comorbidity variables, 
clinical variables, and treatment/pathogen-related variables were treated as covariates in 
Aim 3. As long as antifungals and clarithromycin were used for more than 1 month, those 
two treatments were considered as covariates. Table 4.3 (a-d) shows the resource, 
original type, descriptions, together with aiming type or class of those covariates in the 
study. The majority of the covariates from the group of clinical variables and 
treatment/pathogen-related variables were adjusted as the confounders, which is 





As mentioned previously, only applying a series of methods under causal 
inference could use an observational database to emulate an RCT. Thereafter, the DTR of 
optimal treatment change strategy can be identified. In order to use an observational 
database to provide consistent estimates of counterfactual quantities, E(𝑌𝑌𝑎𝑎�), at least three 
assumptions have to be met: consistency, conditional exchangeability, and positivity.  
With the satisfaction of the above assumptions, several methods are available to 
handle time-dependent confounders, such as inverse probability weighted (IPW) 
estimation of marginal structural models (MSMs),141 g-estimation of structural nested 
models (SNMs),142 and g-computation.143 Compared with the other two methods, MSMs 
require less computational ability, are more precise to explain, and—most importantly—
have less potential of being misspecified. The major drawback of these models is that, 
compared to SNMs, MSMs fail to explore the potential interactions between exposure 
(treatment) and time-dependent confounders.  
Specifically for Aim 3, I applied IPW estimation to the dynamic MSMs since 
failing to explore the potential interaction between treatment and time-dependent 
confounders was not a major issue in this study. The simplest indication of the interaction 
was mentioned in Robins et al.:144 if there exists a value of 𝑙𝑙𝑗𝑗, say 𝑙𝑙𝑗𝑗 = 0, for all but one 
𝑎𝑎𝑗𝑗∈𝐴𝐴𝑗𝑗,  
𝑓𝑓�𝑎𝑎𝑗𝑗�𝑙𝑙?̅?𝑗−1, 𝑙𝑙𝑗𝑗 = 0,𝑎𝑎�𝑗𝑗−1� = 0.          (4.1) 
Therefore, an MSM is not applicable since the probability of having artificial 
censoring is 0. For example, a study investigating the effect of occupational exposure on 
mortality falls exactly into this scenario: if a subject is off work at time j, and 𝑙𝑙𝑗𝑗 = 0, then 
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that subject could not have occupational exposure 𝑎𝑎𝑗𝑗 = 0. Such a scenario definitely did 
not occur in this study. As mentioned in the background, clinical time-dependent 
confounders are the core clinical signals affecting treatment-change decision-making. 
However, the clinical time-dependent confounders were also included in the exposure, 
different treatment score thresholds, in Aim 3. Therefore, there was an association 
between time-dependent confounders and exposure, but the chance of having an 
interaction was trivial. Even though treatment change scores were determined by clinical 
variables and demographic characteristics (𝐿𝐿�𝑗𝑗 ,𝐹𝐹), the occurrence of exposure depends on 
having a treatment change when the treatment change score was beyond specific 
thresholds,  
𝑓𝑓�𝑎𝑎𝑗𝑗 = 𝑑𝑑𝜃𝜃(𝑙𝑙?̅?𝑗)�𝑙𝑙?̅?𝑗−1, 𝑙𝑙𝑗𝑗 ,𝑎𝑎�𝑗𝑗−1 = 𝑑𝑑𝜃𝜃(𝑙𝑙?̅?𝑗−1), 𝑣𝑣� ≠ 0          (4.2) 
for any 𝑙𝑙𝑗𝑗 ∈ 𝐿𝐿𝑗𝑗. Moreover, unless a traditional method has a fixed exposure, the exposure 
in my study is dynamic—a treatment change strategy. Counterfactually, the same patient 
(replicate) was assigned to each strategy at the index date; whenever the observed 
treatment change did not match the treatment change strategy, the patient was artificially 
censored. Since the treatment change strategy was indirectly determined by those time-
dependent confounders, the probability of interaction between exposure and time-
dependent confounders would be quite low after censoring the patient, whose treatment 
pattern did not match the treatment strategy. 
MSMs are a class of causal models for estimating the causal effects of time-
varying exposure in the presence of time-varying covariates that may be simultaneously 
time-dependent confounders and intermediate variables in the observational data.141,144 
The term marginal comes from the focus of these models—marginal distribution with the 
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counterfactual exposure—rather than the joint distribution. MSMs are structural models, 
since in the econometric and social science fields, anything that models the probabilities 
of counterfactual exposure is often referred to as structural.145 The parameters of an MSM 
can be consistently estimated using IPW estimators. Calculating the IPW estimation is a 
core procedure when conducting MSMs. IPW estimation provides an innovative way to 
adjust both confounders, especially time-dependent confounders, as well as selection 
biases through creating a pseudopopulation within which the confounders and selection 
biases no longer exist. Therefore, the unbiased estimation of a parameter in 
pseudopopulation is consistently equal to the unbiased estimation of the counterfactual 
parameter.141 IPW estimation is the product of inverse probability of treatment weighting 
(IPTW) and inverse probability of censoring weighting (IPCW). IPTW is used to adjust 
the confounders, especially time-dependent confounders, between exposure (treatment) 
and outcome. IPCW is applied to adjust selection bias. Using IPTW as an example, 
which is the inverse probability that a patient will have specific treatment or treatment 
patterns, let us assume that the treatment here is a dichotomous variable—that is, the 
patient is either treated or not treated. If the IPTW=wi, then the subject contributes wi 
copies of him/herself to the pseudopopulation. After the IPTW for each patient in the 
original cohort is calculated and all patients are allowed to contribute multiple copies of 
themselves according to the value of IPTW, the pseudopopulation is created. Within this 
pseudopopulation, the probability of having treatment or not is even for each individual 
patient. Therefore, the association between exposure and confounders is blocked. 
Similarly, IPCW can block the association between selection bias and exposure. Under 
this situation, both confounders and selection biases are only associated with outcome but 
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exposure. In a word, if the assumptions for causal inference are satisfied, the causality 
can be measured in the pseudopopulation since the confounders and selection biases have 
been adjusted.  
There are two methods to calculate the IPW: stabilized weights and unstabilized 
weights. All of the weights comprise a denominator and a numerator. The denominator 
remains the same between stabilized weights and unstabilized weights. The denominator 
estimates the probability of remaining off treatment for IPTW, or the probability of 
remaining uncensored for IPCW independently, by including a time-dependent intercept, 
baseline covariates V, and time-dependent covariates L. Actually, baseline covariates V 
are part of the time-dependent covariates. The numerator of the unstabilized weight 
calculation is more straightforward than for the stabilized weight, using 1 rather than 
estimating the probability of remaining off treatment for IPTW, or the probability of 
remaining uncensored for IPCW, by including a time-dependent intercept and baseline 
covariates V. Since time-dependent covariates (L) are captured only in the denominator 
after weighting in the pseudo-population, the time-dependent covariates are eliminated by 
blocking the association between exposure and time-dependent covariates, regardless of 
applying unstabilized or stabilized weight. The rest, baseline confounders, will be 
adjusted by the outcome model. Below are expressions for stabilized IPTW and IPCW. A 
patient may be right-censored because of failing to following the specific treatment 
protocol, the administrative end of the study, disenrollment from the patient registry, or 
death. Therefore, the indicator of right-censoring 𝐶𝐶𝑗𝑗 can be recorded by the joint function 
of three indicators, 𝐶𝐶𝑗𝑗𝑝𝑝𝑑𝑑𝑜𝑜, 𝐶𝐶𝑗𝑗𝑝𝑝𝑝𝑝𝑎𝑎𝑜𝑜ℎ , and 𝐶𝐶𝑗𝑗𝑝𝑝𝑒𝑒𝑝𝑝 ; each one of them represents one potential 
reason for right-censoring. It can be broken down into three parts:   
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∏ P(𝐶𝐶𝑗𝑗𝑝𝑝𝑑𝑑𝑜𝑜 = 0|𝑌𝑌𝑗𝑗 = 0, ?̅?𝐴𝑗𝑗−1, 𝐿𝐿�𝑗𝑗)𝑑𝑑𝑒𝑒𝑜𝑜(𝑜𝑜)𝑗𝑗=0           (4.3) 
∏ P(𝐶𝐶𝑗𝑗𝑝𝑝𝑝𝑝𝑎𝑎𝑜𝑜ℎ = 0|𝑌𝑌𝑗𝑗 = 0, ?̅?𝐴𝑗𝑗−1, 𝐿𝐿�𝑗𝑗 ,𝐶𝐶𝑗𝑗𝑝𝑝𝑑𝑑𝑜𝑜 = 0)𝑑𝑑𝑒𝑒𝑜𝑜(𝑜𝑜)𝑗𝑗=0          (4.4) 
∏ P(𝐶𝐶𝑗𝑗𝑝𝑝𝑒𝑒𝑝𝑝 = 0|𝑌𝑌𝑗𝑗 = 0, ?̅?𝐴𝑗𝑗−1, 𝐿𝐿�𝑗𝑗 ,𝐶𝐶𝑗𝑗𝑝𝑝𝑑𝑑𝑜𝑜 = 0,𝐶𝐶𝑗𝑗𝑝𝑝𝑝𝑝𝑎𝑎𝑜𝑜ℎ = 0)𝑑𝑑𝑒𝑒𝑜𝑜(𝑜𝑜)𝑗𝑗=0           (4.5) 
• 𝑆𝑆𝑡𝑡𝑎𝑎𝑆𝑆𝑙𝑙𝑆𝑆𝑆𝑆𝑆𝑆𝑑𝑑 𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑑𝑑(𝑡𝑡)=∏ P(𝐴𝐴𝑗𝑗=𝑎𝑎𝑖𝑖,𝑗𝑗|?̅?𝐴𝑗𝑗−1=𝑎𝑎�𝑖𝑖,𝑗𝑗−1,𝐹𝐹=𝑣𝑣𝑖𝑖)P(𝐴𝐴𝑗𝑗=𝑎𝑎𝑖𝑖,𝑗𝑗|?̅?𝐴𝑗𝑗−1=𝑎𝑎�𝑖𝑖,𝑗𝑗−1,𝐿𝐿�𝑗𝑗=𝑙𝑙?̅?𝑖,𝑗𝑗)𝑑𝑑𝑒𝑒𝑜𝑜(𝑜𝑜)𝑗𝑗=0           (4.6) 
• 𝑆𝑆𝑡𝑡𝑎𝑎𝑆𝑆𝑙𝑙𝑆𝑆𝑆𝑆𝑆𝑆𝑑𝑑 𝐼𝐼𝐼𝐼𝐶𝐶𝐼𝐼𝑑𝑑(𝑡𝑡)=∏ P(𝐶𝐶𝑗𝑗=𝑐𝑐𝑖𝑖,𝑗𝑗|𝐶𝐶?̅?𝑗−1=𝐶𝐶?̅?𝑖.𝑗𝑗−1,?̅?𝐴𝑗𝑗−1=𝑎𝑎�𝑖𝑖,𝑗𝑗−1,𝐹𝐹=𝑣𝑣𝑖𝑖)P(𝐶𝐶𝑗𝑗=𝑐𝑐𝑖𝑖,𝑗𝑗|𝐶𝐶?̅?𝑗−1=𝐶𝐶?̅?𝑖.𝑗𝑗−1,?̅?𝐴𝑗𝑗−1=𝑎𝑎�𝑖𝑖,𝑗𝑗−1,𝐿𝐿�𝑗𝑗=𝑙𝑙?̅?𝑖,𝑗𝑗)𝑑𝑑𝑒𝑒𝑜𝑜(𝑜𝑜)𝑗𝑗=0           (4.7) 
Even though both methods are consistent on causal estimation, stabilized weights 
are preferred when calculating IPTW and IPCW since stabilized weights provide a 
narrow 95% CI, together with actual coverage rates that are closer to 95% compared to 
unstabilized weights.146 The statistical superiority of the stabilized weights could occur 
only when the outcome model is not saturated.122 Since the outcome models that have 
time-varying exposures are barely saturated, the stabilized weight was applied in this 
study. Last but not least, with baseline confounders (V) in the conditioning event for both 
the numerator and the denominator, the numerical values of numerator and denominator 
get closer, which results in added stabilization of (less variability in) IPW, further 
narrowing 95% confidence intervals.122 
Initially, MSMs are proposed to estimate static treatment regimes. They are 
increasingly being applied to estimate optimal DTRs. Compared with estimating static 
treatment regimes, the most crucial part of an MSM is the estimation of the value 
function for a targeted regime d. Let’s assume that a group of n subjects are sampled at 
random according to a fixed distribution denoted by 𝐼𝐼𝜋𝜋. The distribution is composed of 
the unknown distribution of each 𝐿𝐿𝑗𝑗  conditional on (𝐿𝐿�𝑗𝑗−1, ?̅?𝐴𝑗𝑗−1), together with a fixed 
exploration strategy for generating the actions. Let the forgoing unknown conditional 
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densities as [𝑓𝑓0,𝑓𝑓1, 𝑓𝑓2, … 𝑓𝑓𝐾𝐾] , and denote the exploratory strategy by 𝜋𝜋 =(𝜋𝜋0,𝜋𝜋1,𝜋𝜋2, … ,𝜋𝜋𝐾𝐾), where each one of 𝜋𝜋 represents an exploratory DTR at time 𝑘𝑘. The 
probability that treatment 𝑎𝑎𝑗𝑗  is taken given history of ?̅?𝐴𝑗𝑗−1  and 𝐿𝐿�𝑗𝑗−1  is 𝜋𝜋𝑗𝑗(𝑎𝑎𝑗𝑗|𝑎𝑎�𝑗𝑗−1 , 
𝑙𝑙?̅?𝑗) (𝑗𝑗 = 1, 2, 3, … , 𝑘𝑘) (𝜋𝜋0(𝑎𝑎0|𝑙𝑙0)  for 𝑗𝑗 = 0) . Therefore, the likelihood under 𝐼𝐼𝜋𝜋  of the 
trajectory [𝑙𝑙0,𝑎𝑎0, 𝑙𝑙1,𝑎𝑎1, … , 𝑙𝑙𝑘𝑘, 𝑎𝑎𝑘𝑘, 𝑙𝑙𝑘𝑘+1] is  
𝑓𝑓0(𝑙𝑙0)𝜋𝜋0(𝑎𝑎0|𝑙𝑙0)∏ 𝑓𝑓𝑗𝑗𝐾𝐾𝑗𝑗=1 (𝑙𝑙𝑗𝑗|𝑙𝑙?̅?𝑗−1, 𝑎𝑎�𝑗𝑗−1)𝜋𝜋𝑗𝑗(𝑎𝑎𝑗𝑗|𝑙𝑙?̅?𝑗 ,𝑎𝑎�𝑗𝑗−1)𝑓𝑓𝐾𝐾+1(𝑙𝑙𝐾𝐾+1|𝑙𝑙?̅?𝐾, 𝑎𝑎�𝐾𝐾). 
Similarly, let the 𝐼𝐼𝑝𝑝 denote the distribution of a trajectory where a targeted regime 
𝑑𝑑 = (𝑑𝑑0,𝑑𝑑1,𝑑𝑑2, … ,𝑑𝑑𝐾𝐾) is used to generate actions. If 𝑑𝑑 is a deterministic strategy, where 0 ≤ 𝑗𝑗 ≤ 𝐾𝐾, 𝑑𝑑𝑗𝑗: (ℒ𝑗𝑗 ,𝒜𝒜𝑗𝑗−1) → 𝒜𝒜𝑗𝑗 is a mapping from the previous history space (ℒ𝑗𝑗 ,𝒜𝒜𝑗𝑗−1) 
to the action space 𝒜𝒜𝑗𝑗, then the likelihood under 𝐼𝐼𝑝𝑝 of the trajectory 
[𝑙𝑙0,𝑎𝑎0, 𝑙𝑙1, 𝑎𝑎1, … , 𝑙𝑙𝑘𝑘 ,𝑎𝑎𝑘𝑘 , 𝑙𝑙𝑘𝑘+1] is  
𝑓𝑓0(𝑙𝑙0)𝕀𝕀[𝑎𝑎0 = 𝑑𝑑0(𝑙𝑙0)]∏ 𝑓𝑓𝑗𝑗𝐾𝐾𝑗𝑗=1 (𝑙𝑙𝑗𝑗|𝑙𝑙?̅?𝑗−1,𝑎𝑎�𝑗𝑗−1)𝕀𝕀[𝑎𝑎𝑗𝑗 = 𝑑𝑑𝑗𝑗(𝑙𝑙?̅?𝑗 ,𝑎𝑎�𝑗𝑗−1)]𝑓𝑓𝐾𝐾+1(𝑙𝑙𝐾𝐾+1|𝑙𝑙?̅?𝐾,𝑎𝑎�𝐾𝐾).  
In other words, the distribution of a dataset represents a sample of 𝐼𝐼𝜋𝜋, and the 
distribution of 𝐼𝐼𝑝𝑝 is the one with targeted estimand. Since the value function (𝐹𝐹𝑓𝑓𝑝𝑝) of 
DTRs is estimated by 
𝐹𝐹𝑓𝑓
𝑝𝑝 = 𝐹𝐹𝑝𝑝𝑌𝑌 = ∫𝑌𝑌𝑑𝑑𝐼𝐼𝑝𝑝 = ∫𝑌𝑌 �𝑝𝑝𝑃𝑃𝑑𝑑𝑝𝑝𝑃𝑃𝜋𝜋� 𝑑𝑑𝐼𝐼𝜋𝜋,          (4.8) 
where  𝑝𝑝𝑃𝑃𝑑𝑑
𝑝𝑝𝑃𝑃𝜋𝜋
 is a version of the Radon-Nikodym derivative and is given by the ratio of the 
two likelihoods mentioned above, the ratio simplifies to  
𝑤𝑤𝑝𝑝,𝜋𝜋 = ∏ Ι�𝐴𝐴𝑗𝑗=𝑝𝑝𝑗𝑗�𝐿𝐿�𝑗𝑗, ?̅?𝐴𝑗𝑗−1��
𝜋𝜋𝑗𝑗�𝐴𝐴𝑗𝑗�𝐿𝐿�𝑗𝑗 ,  ?̅?𝐴𝑗𝑗−1�𝑘𝑘𝑗𝑗=1 .          (4.9) 
It is a weight function depending on the entire data trajectory, as long as it 
matches the regimen 𝑑𝑑 from the beginning till time 𝑗𝑗.120 
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If the data are collected from an RCT and 𝑑𝑑 is one of the investigated regimes, the 
only procedure needed is identifying the subjects who follow regime 𝑑𝑑 exactly. Therefore, 
the estimation of optimal DTRs in an RCT is the same as a censoring question under 
causal inference, as long as the targeted regime is embedded in the trial. Both stabilized 
and unstabilized IPCW, which estimate the probability of a subject that keeps following 
regime 𝑑𝑑 from the index date till current visits, are able to handle selection bias. 
However, if the data are collected from an observational dataset or are not 
sequentially randomized, the 𝐼𝐼𝑝𝑝  is difficult to estimate. Several articles147-150 have 
generated and proved that the above weight is able to estimate the 𝐼𝐼𝑝𝑝 depending on the 
entire observed data trajectory. The numerator is a dummy variable, which indicates that 
the subject was still following regime 𝑑𝑑 at visit 𝑗𝑗. Furthermore, the denominator is the 
probability that a subject received observed treatment in the 𝐼𝐼𝜋𝜋. Whenever the subject’s 
observed treatment 𝐴𝐴𝑗𝑗 does not match the regime at time 𝑗𝑗, the probability is equal to 0. 
Thus, the numerator censors subjects that did not follow regime 𝑑𝑑. The censorship when 
the subject does not follow the regime is defined as artificial censoring to differentiate its 
mechanism with traditional censoring (disenrollment, end of study, or death). In fact, the 
weight effectively produces a stratified redistribution to the correct operation in which 
noncompliers to regime 𝑑𝑑  are censored the first time they do not comply and their 
contributions are redistributed among those who have the same variables and treatment 
history and who remain compliant. This redistribution produces the right estimand, 
because according to the sequential randomization assumption, compliance status at a 
given time among those with the same past is the result of a random mechanism that is 
independent of the future health outcomes that the subjects would experience if they were 
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to comply with regime 𝑑𝑑.120 
 Alternatively, the weight can also be treated as an unstabilized IPCW. The 
numerator is an indicator in which only subjects who kept following regime 𝑑𝑑 would be 
retained. The denominator is the probability of subjects who counterfactually followed 
regime 𝑑𝑑 in the observed dataset until time, k’, when the patient fails to follow the related 
DTR. To simplify the notation, the 𝐶𝐶𝑗𝑗 here includes both traditional and artificial 
censoring �𝐶𝐶𝑗𝑗𝑜𝑜𝑝𝑝𝑎𝑎𝑒𝑒,𝐶𝐶𝑗𝑗𝑎𝑎𝑝𝑝𝑜𝑜�. 
𝑤𝑤𝑝𝑝,𝜋𝜋 = ∏ 1𝜋𝜋𝑗𝑗(𝐴𝐴𝑗𝑗,𝐶𝐶?̅?𝑗=0|𝐿𝐿�𝑗𝑗,?̅?𝐴𝑗𝑗−1,𝑝𝑝�𝑗𝑗)𝑘𝑘′𝑗𝑗=1  s.t. 𝑘𝑘′ = argmin𝑘𝑘 𝐶𝐶𝑘𝑘 = 1          (4.10)  
As mentioned previously, DTRs can be identified within observational databases. 
The two main issues a researcher must take into account are 1) defining the rules or 
protocols and 2) randomization at each decision point. In causal inference, the IPW 
estimation of MSMs is the best solution for the above issues. After applying the IPW, a 
pseudopopulation can be created from the data at each decision point. Following the rules, 
the probability of assigning a patient to different treatment groups is exactly the same. In 
the previous notation, the regime 𝑑𝑑𝑗𝑗 was applied, which emphasized that the same regime 
could be varied at different times. To simplify the notation and emphasize the 
characteristics of each rule rather than the variation of the same regime at different time 
points, I use 𝑑𝑑𝜃𝜃 to represent the rule, which could be varied at different time points. The 
notation matches current treatments given the past observed characteristics or covariates 
𝐿𝐿�𝑗𝑗; for any treatments at time 𝑗𝑗, if it follows the rule, then 𝐴𝐴𝑗𝑗 = 𝑑𝑑𝜃𝜃�𝐿𝐿�𝑗𝑗�. Alternatively, it 
denotes as 𝐶𝐶𝑗𝑗𝑎𝑎𝑝𝑝𝑜𝑜 = 0, which indicates that the patient was not artificially censored at time 
𝑗𝑗  given the DTR 𝜃𝜃 . The variation of 𝜃𝜃  represents different rules. Since 𝑑𝑑𝜃𝜃  is a 
deterministic strategy, given the regime and whether the subject is censored in the current 
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visit, the treatment pattern in the current visit is fixed as long as the traditional censoring 
has been adjusted. Using my research question as an example, let 𝑆𝑆𝑗𝑗 ⊆ 𝐿𝐿𝑗𝑗 , 𝑚𝑚𝜃𝜃 is the 
threshold for the regime 𝑑𝑑𝜃𝜃 , define following 𝑑𝑑𝜃𝜃  (?̅?𝐶𝑗𝑗𝑎𝑎𝑝𝑝𝑜𝑜 = 0) as if 𝑆𝑆𝑗𝑗 > 𝑚𝑚𝜃𝜃 , then 𝐴𝐴𝑗𝑗 =
𝑎𝑎𝑗𝑗−1; if 𝑆𝑆𝑗𝑗 ≤ 𝑚𝑚𝜃𝜃, then 𝐴𝐴𝑗𝑗 ≠ 𝑎𝑎𝑗𝑗−1. Therefore, the weight for dynamic MSMs equals the 
censoring weight, which includes both traditional and artificial censoring parts.  
𝐼𝐼𝑃𝑃𝑃𝑃𝑃𝑃𝑓𝑓: 
𝐼𝐼�𝐴𝐴𝑗𝑗 = 𝑎𝑎𝑗𝑗−1, ?̅?𝐶𝑗𝑗 = 0�𝐿𝐿�𝑗𝑗 ,  ?̅?𝐴𝑗𝑗−1,𝜃𝜃� = 𝐼𝐼�𝐴𝐴𝑗𝑗 = 𝑎𝑎𝑗𝑗−1�?̅?𝐶𝑗𝑗 = 0, 𝐿𝐿�𝑗𝑗 ,  ?̅?𝐴𝑗𝑗−1,𝜃𝜃� ∗ 
𝐼𝐼(?̅?𝐶𝑗𝑗 = 0|𝐿𝐿�𝑗𝑗 ,  ?̅?𝐴𝑗𝑗−1, 𝜃𝜃); 
𝐼𝐼�𝐴𝐴𝑗𝑗 ≠ 𝑎𝑎𝑗𝑗−1, ?̅?𝐶𝑗𝑗 = 0�𝐿𝐿�𝑗𝑗 ,  ?̅?𝐴𝑗𝑗−1,𝜃𝜃� = 𝐼𝐼�𝐴𝐴𝑗𝑗 ≠ 𝑎𝑎𝑗𝑗−1�?̅?𝐶𝑗𝑗 = 0, 𝐿𝐿�𝑗𝑗 ,  ?̅?𝐴𝑗𝑗−1,𝜃𝜃� ∗ 
𝐼𝐼(?̅?𝐶𝑗𝑗 = 0|𝐿𝐿�𝑗𝑗 ,  ?̅?𝐴𝑗𝑗−1, 𝜃𝜃). 
Assuming that traditional censoring has been adjusted (?̅?𝐶𝑗𝑗𝑜𝑜𝑝𝑝𝑎𝑎𝑒𝑒 = 0), if ?̅?𝐶𝑗𝑗𝑎𝑎𝑝𝑝𝑜𝑜 = 0 
and 𝑆𝑆𝑗𝑗 > 𝜃𝜃, then 𝐼𝐼�𝐴𝐴𝑗𝑗 = 𝑎𝑎𝑗𝑗−1�?̅?𝐶𝑗𝑗 = 0, 𝐿𝐿�𝑗𝑗 ,  ?̅?𝐴𝑗𝑗−1,𝜃𝜃� = 1. Similarly, if ?̅?𝐶𝑗𝑗𝑎𝑎𝑝𝑝𝑜𝑜 = 0 and 𝑆𝑆𝑗𝑗 ≤ 𝜃𝜃, 
then 𝐼𝐼�𝐴𝐴𝑗𝑗 ≠ 𝑎𝑎𝑗𝑗−1�?̅?𝐶𝑗𝑗 = 0, 𝐿𝐿�𝑗𝑗 ,  ?̅?𝐴𝑗𝑗−1, 𝜃𝜃� = 1. Therefore, 
𝐼𝐼�𝐴𝐴𝑗𝑗 , ?̅?𝐶𝑗𝑗 = 0�𝐿𝐿�𝑗𝑗 ,  ?̅?𝐴𝑗𝑗−1,𝜃𝜃� = 𝐼𝐼�?̅?𝐶𝑗𝑗 = 0�𝐿𝐿�𝑗𝑗 ,  ?̅?𝐴𝑗𝑗−1,𝜃𝜃� = 𝐼𝐼�?̅?𝐶𝑗𝑗 = 0�𝐿𝐿�𝑗𝑗 ,  ?̅?𝐶𝑗𝑗−1 = 0,𝜃𝜃�. 
Given the change of treatment denoted on DTRs, the previous stabilized weights 
for IPTW and IPCW can be adjusted as below:  
• 𝑆𝑆𝐼𝐼𝐼𝐼𝑑𝑑(𝑡𝑡)=∏ P(𝐴𝐴𝑗𝑗=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗)|𝐶𝐶̅̅𝑗𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,?̅?𝐴𝑗𝑗−1=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗−1),𝐹𝐹=𝑣𝑣𝑖𝑖)P(𝐴𝐴𝑗𝑗=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗)|𝐶𝐶?̅?𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,?̅?𝐴𝑗𝑗−1=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗−1),𝐿𝐿�𝑗𝑗=𝑙𝑙?̅?𝑖,𝑗𝑗)𝑑𝑑𝑒𝑒𝑜𝑜(𝑜𝑜)𝑗𝑗=0           (4.11) 
• 𝑆𝑆𝐶𝐶𝐼𝐼𝑑𝑑(𝑡𝑡)=∏ 𝑃𝑃𝑝𝑝(𝐶𝐶𝑗𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0|𝐶𝐶̅̅𝑗𝑗−1𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,,?̅?𝐴𝑗𝑗−1=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗−1),𝐹𝐹=𝑣𝑣𝑖𝑖)𝑃𝑃𝑝𝑝(𝐶𝐶𝑗𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0|𝐶𝐶?̅?𝑗−1𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,?̅?𝐴𝑗𝑗−1=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗−1),𝐿𝐿�𝑗𝑗=𝑙𝑙?̅?𝑖,𝑗𝑗)𝑑𝑑𝑒𝑒𝑜𝑜(𝑜𝑜)𝑘𝑘=0 .          (4.12) 
More generally, the weights could also represent in the following format: 
• 𝑆𝑆𝐼𝐼𝐼𝐼𝑑𝑑(𝑡𝑡)=∏ P(𝐶𝐶?̅?𝑗𝑡𝑡𝑡𝑡𝑡𝑡=0|𝐶𝐶?̅?𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,𝐶𝐶̅̅𝑗𝑗−1𝑡𝑡𝑡𝑡𝑡𝑡=0,𝐹𝐹=𝑣𝑣𝑖𝑖)P(𝐶𝐶𝑗𝑗𝑡𝑡𝑡𝑡𝑡𝑡=0|𝐶𝐶?̅?𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,𝐶𝐶̅̅𝑗𝑗−1𝑡𝑡𝑡𝑡𝑡𝑡=0,𝐿𝐿�𝑗𝑗=𝑙𝑙?̅?𝑖,𝑗𝑗)𝑑𝑑𝑒𝑒𝑜𝑜(𝑜𝑜)𝑗𝑗=0           (4.13) 
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• 𝑆𝑆𝐶𝐶𝐼𝐼𝑑𝑑(𝑡𝑡)=∏ 𝑃𝑃𝑝𝑝(𝐶𝐶𝑗𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0|𝐶𝐶?̅?𝑗−1𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,𝐶𝐶̅̅𝑗𝑗−1𝑡𝑡𝑡𝑡𝑡𝑡=0,𝐹𝐹=𝑣𝑣𝑖𝑖)𝑃𝑃𝑝𝑝(𝐶𝐶𝑗𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0|𝐶𝐶?̅?𝑗−1𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,𝐶𝐶̅̅𝑗𝑗−1𝑡𝑡𝑡𝑡𝑡𝑡=0,𝐿𝐿�𝑗𝑗=𝑙𝑙?̅?𝑖,𝑗𝑗)𝑑𝑑𝑒𝑒𝑜𝑜(𝑜𝑜)𝑘𝑘=0 .          (4.14) 
In summary, the weight for dynamic MSMs could be investigated by the 
censoring weight.  
Whenever time-dependent confounders are contained in the model, it is difficult 
to use the standard Cox model in any software to compute IPTW estimator β1�. All the 
subject-specific weights, 𝑆𝑆𝐼𝐼𝑑𝑑𝑗𝑗 , vary over time, and most standard Cox models in any 
software programs, even those that allow for subject-specific weights, have a hard time 
handling subject-specific, time-varying weights. The best approach to overcome this 
software problem is to fit a weighted pooled logistic regression, assuming each 
participant has a repetitive routine observation for every fixed time period. The model is P�𝑌𝑌𝑝𝑝,𝑗𝑗+1 = 1�𝑌𝑌𝑝𝑝,𝑗𝑗 = 0,𝐹𝐹,𝜃𝜃� =𝛽𝛽0 + 𝛽𝛽1𝐹𝐹 + 𝛽𝛽2𝜃𝜃,          (4.15)  
where j is an integer that denotes each fixed time period since the start of follow-up. 
 
4.5 Variable Selection 
According to the situation, the evaluation criteria for a prediction model’s 
performance can differ. However, two aspects are always key: 1) the accuracy of 
predictions about future data and 2) the difficulty of interpreting the model. Obviously, a 
model that has limited external validity lacks persuasiveness. At the same time, the 
chance of being inappropriately applied is high if the model includes numerous 
parameters. Therefore, parsimony is an important virtue in the model-selection field.  
In order to balance the accuracy and interpretability of a model, penalization 
techniques, also called shrinkage or regularization methods, have been developed to 
improve models. Although shrinking parts of the regression coefficients toward zero may 
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bias the estimates, these coefficient estimates have smaller variances, enhancing the 
accuracy of prediction by reducing the mean squared error.151 Regression coefficients are 
shrunk by imposing a penalty on their size; this is achieved by adding a penalty function 
to the ordinary linear square (OLS) model. Several regularization methods exist, which 
are classified according to the structure of the penalty function. Some of them enable 
variable selection, which filters unimportant parameters out of the model. 
Ridge regression152 estimates regression coefficients through an L2-norm 
penalized least-squares criteria. As a continuous shrinkage method, ridge regression 
achieves its better predicting performance through a bias-variance trade-off. It not only 
shrinks the coefficient of each variable independently but also shrinks the coefficients of 
correlated variables toward each other.153 However, ridge regression cannot produce a 
parsimonious model by shrinking the coefficients to zero. Therefore, ridge regression is 
ideal if there are many predictors and all of them have enough influence on the dependent 





||𝑦𝑦 − 𝑋𝑋𝛽𝛽||2 + 𝜆𝜆||𝛽𝛽||2]. 
To identify a parsimonious model given many predictors, the least absolute 
shrinkage and selection operator (LASSO) was proposed by Tibshirani.154 Unlike ridge 
regression, the LASSO imposes an L1-penalty on the regression coefficient, possessing 
the characters, continuous shrinkage, and automatic variable selection simultaneously. 
The LASSO does not outperform ridge regression in prediction performance.154,155 
However, as variable selection becomes increasingly important in data analysis, the 
LASSO is much more appealing owing to its sparse representation.156  
Although the LASSO has shown its superiority in many situations, it has some 
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limitations: 1) If the number of variable (p) is larger than the number of observation (n), 
the LASSO at most selects n variables before it saturates. At the same time, the LASSO 
is not well defined unless the bound on the L1-norm of the coefficients is smaller than a 
certain value. 2) If n>p, as long as there are high correlations among variables, it has been 
empirically observed that the ridge regression dominates the LASSO in prediction 
performances. 3) If the pairwise correlations are very high among a group of variables, 
then the LASSO tends to select only one variable from the group and does not care which 





||𝑦𝑦 − 𝑋𝑋𝛽𝛽||2 + 𝜆𝜆||𝛽𝛽||1]. 
Elastic net is an alternative regularization method that avoids the above 
limitations. It inherits the advantages of ridge regression and LASSO by imposing both 
the L1-norm and L2-norm penalties on the regression coefficient through balance factor 𝛼𝛼. 
The factor ranges from 0 to 1, which balances the characters between ridge regression 
and LASSO. The larger the factor is, the more it performs as a LASSO. In the most 
extreme situation, when 𝛼𝛼 equals 1, the factor loses the function of the L2-norm penalty 
and performs the same as LASSO. Conversely, if the factor equals 0, then it performs as 
a ridge regression. Since the probability of having highly correlated variables is high, the 





||𝑦𝑦 − 𝑋𝑋𝛽𝛽||2 + 𝜆𝜆[(1 − 𝛼𝛼)�|𝛽𝛽|�22 + 𝛼𝛼�|𝛽𝛽|�1]], 
was chosen to conduct variable selection. 
In order to apply elastic net successfully, the following four issues have to be 
solved: 1) Should mixed effects be taken into consideration? 2) Does the choice of 
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measurement for cross-validation affect the results and the number of variables that 
would be selected? If so, which measurement is associated with the optimal result? 3) 
Could the outcome be narrowed down? 4) What is the optimal combination of 𝛼𝛼 and 𝛽𝛽 
for each outcome?  
1) Should mixed effects be taken into consideration? 
In this study, only fixed effects were investigated for variable selection and 
finalized predictive score model. Obviously, mixed effects existed: the fixed effects were 
represented in patients’ levels, and random effects were captured by multiple routine 
visits of the same patient. However, the decision of investigating only fixed effects was 
supported by two rationales. First, with the assistance of elastic net, p-value was not 
required for selecting variables. Moreover, in order to create a score that predicts the 
chance of having a rational treatment change, only the coefficients are needed for those 
variables that have been selected in the predictive model. However, the difference 
between the fixed and mixed effects models is trivial in terms of investigating the 
coefficients if there is no interaction between fixed-effects parameters and random-effects 
parameters, which is very likely the case in this study. The best example would be a 
patient with various values of clinical variables and treatment combinations among 
different visits. Last, the number of category for random effects is gigantic, which 
increase the computational burden. Each patient in the cohort of 4,760 represents one 
category of random effects. Currently, only one program is able to cross-validate mixed-
effect models. For each imputed dataset with given 𝛼𝛼, it took about 6 hours to achieve the 
regression. However, 10 imputed datasets, 10 predetermined 𝛼𝛼, and 6 outcomes would be 
investigated. The overall computational time could be more than 3,600 hours (150 days). 
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Therefore, only fixed effects were investigated. Specifically, logistic regression with 
elastic net was applied on variable selection:  min
𝛽𝛽0,𝛽𝛽 −[1𝑁𝑁 ∑ 𝑦𝑦𝑑𝑑(𝛽𝛽0 + 𝑥𝑥𝑑𝑑𝑇𝑇𝛽𝛽) − log (1 + 𝑆𝑆�𝛽𝛽0+𝑥𝑥𝑖𝑖𝑇𝑇𝛽𝛽�𝑁𝑁𝑑𝑑=1 )] + 𝜆𝜆 �(1−𝛼𝛼)2 ‖𝛽𝛽‖22 + 𝛼𝛼‖𝛽𝛽‖1�.  
The predictive score was calculated according to the coefficients of those selected 
variables in the logistic regression.  
Even though random effect was not investigated, its influence could still bias the 
cross-validation results. Traditional cross-validation programs only partition each 
observation without clustering it on patient level. When applying such a program, it is 
very likely that same patient’s visits would be partitioned into different subsamples, 
which definitely biases the cross-validation results. A new cross-validation program was 
coded to partition all visits belonging to the same patient into the same subsamples to 
avoid this issue.  
2) Does the choice of measurement for cross-validation affect the results and the number 
of variables that would be selected? If so, which measurement is associated with the 
optimal result? 
The choice of measurement for cross-validation definitely affects the number of 
variables to be selected. According to both expert opinion and the results of an 
exploratory analysis, the deviance was used as the measurement for cross-validation. 
Cross-validation is a practical way of using computation in place of mathematical 
analysis to investigate how a predictive model performs on a validation set. K-fold 
validation is one way of conducting cross-validation. It automatically partitions the 
original dataset into k subsamples, using the k-1 subsamples as training data and the rest 
one subsample as the validation data. In order to identify the optimal penalty factor, 
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lambda, in the elastic net, k-fold cross-validations were conducted on each potential value 
of lambda. After conducting the cross-validation, the relationship between each lambda 
and the performance of its related model were generated. Then the lambda associated 
with the optimal performance was selected.  
However, several measurements could be applied to capture the performance of 
cross-validation. An exploratory analysis (Appendix C) was conducted to explore the 
impact of different measurements on the number of variables that would be selected 
using the 10 imputed datasets. Four measurements were chosen: deviance, 
misclassification error, ROC, and mean squared error. All results indicated that the 
number of variables selected would vary according to measurement type. To simplify the 
presentation, the result of only one outcome was presented in Appendix C, Figure C.1: 
rational treatment change under strict definition and not including bronchodilators (BD) 
use as a treatment class in imputed dataset 1, in which alpha equaled 0.7. 
Other than type of measurement for cross-validation, the choice of targeted 
lambda could also affect the result. Among several ways of investigating the targeted 
lambda, two methods are common and well identified: lambda.min and lambda.1se. 
Lambda.min is the value associated with minimum mean cross-validated error. 
Lambda.1se gives the most regularized model, such that error is within one standard error 
of the minimum mean cross-validated error. Compared with lambda.min, the value of 
lambda.1se is less likely to overfit the data. Therefore, lambda.min was initially applied 
to investigate the optimal alpha associated with the minimum mean cross-validated error 
among 10 imputed datasets. Then lambda.1se was applied to identify the optimal lambda 
given optimal alpha.  
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Each of the four figures in Appendix C, Figure C.1, represents a cross-validation 
figure given different types of measurements. Each figure has two dotted lines; the left 
and right ones represent how many variables would be chosen if lambda.1min and 
lambda.1se were applied, respectively. The reason the left dotted line always belonged to 
lambda.min is that it overfits the data compared to lambda.1se. If the AUC curve was the 
measurement, it would select the largest number of variables: 92 and 55 for lambda.min 
and lambda.1se, respectively. The numbers decreased to 83 and around 34 if deviance 
was applied, and 83 and 22 if MSE was used. The misclassification error would select 
even fewer variables: around 68 for lambda.min and no variable for lambda.1se. 
However, considering the trend of the misclassification error, which was consistent 
regardless of the number of variables chosen, it was not a qualified measurement for this 
model. Similarly, AUC had a fragmented trend, when the number of selected variables 
decreased to specific values. The difference between deviance and MSE was trivial; 
however, considering expert opinion, the deviance was chosen.  
3) Could the outcome be narrowed down? 
There were six ways of identifying the outcomes, rational treatment change, 
according to whether considers BD use as one treatment class, and different assumptions. 
The three assumptions were defined according to the strictness of identifying rational 
treatment change. In the loose assumption, all treatment changes were treated as rational 
treatment changes regardless of the changes on clinical signals. In the neutral assumption, 
the termination of any treatment class had to match the changes on clinical signals, which 
indicate that a patient’s health improved since previous visit. For the strict assumption, all 
rational treatment changes had to comply with the changes on clinical signals. More 
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specifically under the strict assumption, a rational treatment would occur only in the 
following two scenarios: 1) a patient received more treatments or more treatment classes 
when he had worse clinical signals compared with a previous visit; 2) a patient received 
fewer treatments or fewer treatment classes when he had better clinical signals compared 
with a previous visit. The worse clinical signals could be one of the following three: 
lower predicted FEV1%, more PExs, or more drug resistance. Similarly, the better 
clinical signals were identified in the reverse. If the treatment change did not match the 
related assumption, no rational treatment change would be marked under that assumption. 
Previously, an example was given to illustrate the definition of rational treatment change 
under the neutral assumption. Appendix C, Table C.1, gives an example of the variation 
of defining the rational treatment change under different assumptions. To simply the 
example, predicted FEV1% was assumed to be the only clinical signal that would affect 
the decision of rational treatment change. Because of the unique data that were collected, 
when a patient reported his treatment in a current visit, it reflected only the treatment he 
had received up until the visit. In order to identify the rational treatment change occurring 
in a current visit, a comparison between treatment combinations that a patient receives in 
a current visit and a subsequent visit is needed. However, the change of clinical signals in 
a current visit is determined by the difference of values between a previous visit and the 
current visit. For example, in visit 1, a patient reported that he had previously received 
only one mucolytic and had 52% of predicted FEV1. According to the treatment 
information in visit 2—one mucolytic, one inhaled antibiotic, and two BDs—he had a 
treatment change in visit 1. Compared with the clinical signals in visit 0, 75% of 
predicted FEV1, he had a huge decrease on clinical signals in visit 1. The hypothetical 
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scenario of disease progression matched all assumptions at visit 1; therefore, all rational 
treatment changes were marked as taking place in visit 1. In visit 2, he stopped using one 
BD with improved clinical signal, which still matched all assumptions of rational 
treatment change when taking BD use into consideration. Therefore, three assumptions, 
which included BD use as a treatment class, had rational treatment changes in visit 2. The 
clinical signal kept increasing, and the patient received an additional anti-inflammatory at 
visit 3, which conflicted with the strict assumption. When it came to visit 4, the patient 
had a slightly decreased clinical signal and terminated BD use, which conflicted with the 
neutral and strict assumptions. Moreover, the treatment change occurred only for BD use; 
therefore, other than the loose assumption that included BD use as a treatment class, the 
rest of the assumptions were marked as 0—no related rational treatment change. 
Regardless of assumptions, the rational treatment change was always missing at the first 
and last visit because neither the clinical signal that occurred before the first visit nor the 
future treatment information that occurred after the last visit was measureable. In other 
words, the more strict an assumption is, the more clinical signals are required to match 
the treatment change. The main purpose of this section is to investigate the chance of not 
considering BD use as a treatment class.  
Although the chronic use of BDs is associated with uncertain or negative benefits 
according to guidelines, a comparison of mean cross-validated error using deviance as the 
measurement has been conducted between treatment change that includes BD use and 
treatment change that does not include BD use under the strict assumption (compare 
Appendix C, Tables C.2 and C.3). The comparison was conducted in all 10 imputed 
datasets given deciles of alpha from 0 to 1. In each cell, the number represents the 
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minimum of mean cross-validated error given related alpha in the dataset. If including the 
BD use, the mean of deviance ranged from 0.880462 to 0.851288 on average, conditional 
on related alpha among 10 imputed datasets. With the increase in alpha, the mean of 
deviance decreased. The yellow cell indicated the minimum of deviance in each imputed 
dataset. Compared with other alphas, alpha equaled to 1 was always associated with the 
minimum of deviance. Excluding BD use, the mean of deviance ranged from 0.513688 to 
0.506297 on average given related alpha among 10 imputed datasets. The trend between 
alphas and deviances was similar to the one including BD use. Alpha equaled to 1 was 
also associated with the minimum of deviance. Therefore, those two models shared 
several characteristics in terms of the balance between ridge regression and the LASSO. 
However, compared with excluding BD use, the deviances in another model were almost 
double, indicating a higher chance of inaccurately identifying the rational treatment 
change. Therefore, Appendix C, Tables C.2 and C.3, support the conclusion that BD use 
is associated with more irrational treatment change. According to the above reasons, 
together with the guideline marking BD as a treatment with low certainty of net benefit, 
only three treatment classes were considered in this study: inhaled antibiotics, mucolytics, 
and anti-inflammatories.  
4) What is the optimal combination of α and β for each outcome? 
According to a series of decisions in the above sections, BD use was not 
considered as a treatment class to define rational treatment change, deviance was applied 
as the measurement of cross-validated error, and only fixed effects were estimated in 
objective 2. 
More specifically, the elastic net was applied to select variables in three steps, 
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identifying the optimal 𝛼𝛼� and optimal ?̂?𝜆 and choosing the variables given the optimal 𝛼𝛼� 





||𝑦𝑦 − 𝑋𝑋𝛽𝛽||2 + 𝜆𝜆[(1 − 𝛼𝛼)�|𝛽𝛽|�22 + 𝛼𝛼�|𝛽𝛽|�1]]. 
First, the optimal 𝛼𝛼 was identified, which was associated with the minimum mean 
cross-validated error using deviance as the measurement in each imputed dataset 𝑆𝑆 (𝑆𝑆=1, 
2, …, 10). The 𝜆𝜆𝑑𝑑∗ represents the 𝜆𝜆 associated with the minimum mean cross-validated 
error, 𝜀𝜀?̅?𝑐𝑣𝑣,𝑑𝑑, in the imputed dataset 𝑆𝑆. For each imputed dataset, a 10-fold cross-validation 
was conducted. Therefore, 𝛽𝛽𝜆𝜆𝑖𝑖∗  is a vector of 𝛽𝛽 given 𝜆𝜆𝑑𝑑
∗. The 𝛼𝛼�  was determined by the 
median of 𝛼𝛼�𝑑𝑑 among the imputed datasets, arg min
𝛼𝛼𝑖𝑖
𝜀𝜀?̅?𝑐𝑣𝑣,𝑑𝑑 = arg min𝛼𝛼𝑖𝑖 (𝑦𝑦 − 𝑋𝑋?̂?𝛽𝜆𝜆𝚤𝚤∗)𝑐𝑐𝑣𝑣,𝚤𝚤�����������������. 
In order to prevent overfitting, 𝜆𝜆𝑑𝑑′, which gives the most regularized model such 
that error is within one standard error of the minimum mean cross-validated error given 𝛼𝛼�, 
was identified among each imputed dataset 𝑆𝑆. Similarly, ?̂?𝜆 was determined by the median 
of ?̂?𝜆𝑑𝑑′ among the imputed datasets. Therefore, the optimal 𝛼𝛼� and ?̂?𝜆 were generated, which 
balanced the relationship between minimizing the mean cross-validated error and 
overfitting the data.  
Given the 𝛼𝛼� and ?̂?𝜆, the ?̂?𝛽𝑙𝑙 was calculated for each imputed dataset 𝑆𝑆. The ?̂?𝛽𝑙𝑙 is a 
vector that includes the coefficients of all independent variables to predict rational 
treatment change. Variables were selected in the predictive model as long as the related 
element in ?̂?𝛽𝑙𝑙 was not equal to 0 in any imputed dataset 𝑆𝑆. A set included all variables that 
were selected by the elastic net is denoted by 𝑆𝑆 . The 𝑋𝑋𝑜𝑜𝑑𝑑  is a vector of individuals’ 
variables that are included in 𝑆𝑆, which were measured at all visits in the imputed dataset 𝑆𝑆. 
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The rational treatment change among all visits in each imputed dataset 𝑆𝑆 is marked as 𝑌𝑌𝑜𝑜𝑥𝑥,𝑑𝑑.  
The generalized linear model with log link function was applied to predict the probability 
of having rational treatment change in each imputed dataset 𝑆𝑆. Following Rubin’s rule,157 
the ?̂?𝛽𝑜𝑜𝑙𝑙 were combined as ?̂?𝛽𝑜𝑜. log Pr�𝑌𝑌𝑜𝑜𝑥𝑥,𝑑𝑑 = 1| 𝑋𝑋𝑜𝑜𝑑𝑑� = 𝛽𝛽𝑜𝑜𝑑𝑑 𝑋𝑋𝑜𝑜𝑑𝑑 + 𝜉𝜉𝑑𝑑 
?̂?𝑝𝑜𝑜𝑥𝑥,𝑙𝑙 = log Pr�𝑌𝑌𝑜𝑜𝑥𝑥,𝑑𝑑 = 1| 𝑋𝑋𝑜𝑜𝑑𝑑� = ?̂?𝛽𝑜𝑜 𝑋𝑋𝑜𝑜𝑑𝑑 
In order to closely mimic the strategy of rational treatment change, the predicted 
probability of rational treatment change, ?̂?𝑝𝑜𝑜𝑥𝑥,𝑙𝑙, and the relative change of the predicted 
probability of rational treatment change between the current and previous visits, 𝑃𝑃𝑟𝑟� 𝑜𝑜𝑥𝑥,𝑙𝑙, 
for all visits in each imputed dataset 𝑆𝑆 were calculated. The 𝑝𝑝∗ and 𝑝𝑝∗∗ left corner of the 
ROC curve were chosen as the cutoff for ?̂?𝑝𝑜𝑜𝑥𝑥,𝑙𝑙  and 𝑃𝑃𝑟𝑟� 𝑜𝑜𝑥𝑥,𝑙𝑙 , respectively, in all imputed 
datasets. The confidence interval of 𝑝𝑝∗ and 𝑝𝑝∗∗ were estimated using the nonparametric 
bootstrapping method. The quintile of 95% CI of 𝑝𝑝∗∗ was used to generate cutoffs of 𝑝𝑝∗∗, 
represented by 𝑝𝑝𝑒𝑒∗∗ (n = 1, 2, … , 5). In order to have a larger range of 𝑝𝑝𝑚𝑚∗  (m=1, 2,…, 5), 
the distance between the lower boundary of 95% CI of 𝑝𝑝∗ and 𝑝𝑝∗ was applied to calculate 
𝑝𝑝𝑚𝑚
∗ , and 𝑝𝑝∗  was set as 𝑝𝑝3∗ . Therefore, from 𝑝𝑝1∗  to 𝑝𝑝5∗ , the value increases; 𝑝𝑝2∗  and 𝑝𝑝4∗ 
represent the lower and upper boundary of the 95% CI of 𝑝𝑝∗. 
 
4.6 Statistical Analyses 
To simplify the description, demographic characteristics, clinical variables, 
comorbidities, and treatment/pathogen-related variables denote the feature of a group of 
variables, respectively (Table 4.2). The feature, especially for clinical variables and 
treatment/pathogen-related variables, not only includes the value itself, but also includes 
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the time since index date or other clinical meaningful point, such as the occurrence of 
PEx or drug resistance. For instance, clinical variables denote predicted FEV1%, relative 
change of predicted FEV1% compared with the optimal value in the last year, and 
number of PEx in the previous year since current visit. Comorbidities include CFRD, 
pancreatic insufficiency, gastrointestinal symptoms, asthma, liver disease, etc. 
Treatment/pathogen-related variables indicate the previous treatment 
combinations/patterns, number of treatment change and type of treatment change in the 
previous year, time and result of culture test for airway infection, which was not caused 
by P. aeruginosa, and drug resistance. 
Aim 1. To describe treatment patterns and changes in the original cohort 
a) Described the characteristics of the cohort  
I. Investigated the FEV1% trajectory caused by different reasons during the 
hospitalization for patients in each calendar year using original database.  
II. Summarized patient’s baseline demographic characteristics and clinical 
variables in the cohort and subgroups, which are categorized by mutation classes 
and initial treatments, respectively.  
III. Summarized the prevalence and incidence of death by different reasons in 
each calendar year.  
b) Described initial treatment, probability of transitioning to specific treatment 
combinations, and length of having specific treatment combinations.  
I. Identified treatment change by comparing each patient’s treatment classes in 
current outpatient visit with the previous one. 
II. Identified treatment length for each patient and each treatment combination by 
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using the gap between when a patient changes to a specific treatment combination 
and the time the next treatment change occurs.  
III. Described the treatment combination at the baseline.  
IV. Investigated the relationship between the 1st treatment change and the 
potential treatment combinations that a patient could switch to by summarizing 
the length on current treatment, and the probability of transitioning to potential 
treatment combinations.  
V. Investigated the relationship between all treatment changes and the potential 
treatment combinations that a patient could switch to by summarizing the length 
on current treatment, and the probability of transitioning to potential treatment 
combinations. 
Aim 2. To create a lung treatment score that indicates suboptimal lung health 
management by when rational treatment changes occur. 
a) Predicted the probability of rational lung health maintenance treatment change 
given demographic characteristics and clinical outcome variables, such as predicted 
FEV1% of current visit, change of predicted FEV1%, additional occurrences of PEx 
in the last year, and additional indicators of drug resistance. 
I. Independent variable identification: 
a. Independent variables were identified by all the variables that existed in 
the cystic fibrosis related literature. 
b. All the unique variables that existed in the CFFPR were taken into 
consideration. 
c. If a variable, other than a pathogen/treatment-related variable, was 
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missing for more than 50% of the patients, then this variable was not included. 
d. If a pathogen/treatment-related variable existed more than once in a 
particular patient’s record, and that patient had a related treatment after being 
diagnosed with that pathogen, as long as the frequency of having this variable 
was consistent with the frequency that the majority of the patients had this 
variable, then the variable was included even if more than half of the time it 
was missing from that patient’s record. 
e. Cubic spline for time was included to fit model to data. 
II. Variable selection by elastic net: 
a. Identified the optimal balance factor, 𝛼𝛼, by investigating the probability 
of specific 𝛼𝛼 that was chosen among 10 imputed datasets according to the 
minimum of mean cross-validated error.  
b. Identified the optimal penalty factor, 𝜆𝜆, by investigating the minimum 
standard deviation of lambda given 𝛼𝛼  among 10 imputed datasets and the 
probability that 𝛼𝛼 had been chosen in step 1. 
c. Selected variables in the model by investigating the proportion of a 
variable that had been selected given 𝛼𝛼  and 𝜆𝜆 that had been chosen in the 
previous steps among 10 imputed datasets. 
d. Calculated the coefficient for each variable by combining the related 
coefficients that were identified among 10 imputed datasets. b) Identified timing strategies for treatment change according to different thresholds 
of predicted probability of having rational treatment change. 
Aim 3. To investigate the comparative effectiveness of different treatment strategies as 
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part of rational treatment changes to delay the acquisition of mucoid PaPI. 
a) Created an augmented dataset, in which each patient had 25 replicates. 
b) Artificially censored patient, if the patient was not following the related strategy, 
dθ (θ=1, 2, … , 25). 
c) Constructed the final stabilized weight (SW) for all visits in each replicate, 
respectively. 
I. Calculated stabilized treatment weight for all visits in the same replicate. 
𝑆𝑆𝐼𝐼𝐼𝐼𝑑𝑑(𝑡𝑡)=∏ P(𝐴𝐴𝑗𝑗=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗)|𝐶𝐶̅̅𝑗𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,?̅?𝐴𝑗𝑗−1=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗−1),𝐹𝐹=𝑣𝑣𝑖𝑖)P(𝐴𝐴𝑗𝑗=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗)|𝐶𝐶?̅?𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,?̅?𝐴𝑗𝑗−1=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗−1),𝐿𝐿�𝑗𝑗=𝑙𝑙?̅?𝑖,𝑗𝑗)𝑑𝑑𝑒𝑒𝑜𝑜(𝑜𝑜)𝑗𝑗=0   
II. Calculated stabilized censoring weight by each visit. 
𝑆𝑆𝐶𝐶𝐼𝐼𝑑𝑑(𝑡𝑡)=∏ 𝑃𝑃𝑝𝑝(𝐶𝐶𝑗𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0|𝐶𝐶̅̅𝑗𝑗−1𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,,?̅?𝐴𝑗𝑗−1=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗−1),𝐹𝐹=𝑣𝑣𝑖𝑖)𝑃𝑃𝑝𝑝(𝐶𝐶𝑗𝑗𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0|𝐶𝐶?̅?𝑗−1𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡=0,?̅?𝐴𝑗𝑗−1=𝑝𝑝𝜃𝜃(𝐿𝐿�𝑗𝑗−1),𝐿𝐿�𝑗𝑗=𝑙𝑙?̅?𝑖,𝑗𝑗)𝑑𝑑𝑒𝑒𝑜𝑜(𝑜𝑜)𝑘𝑘=0  
III. Created the final stabilized weight. 
𝑆𝑆𝐼𝐼𝑑𝑑(𝑡𝑡) =𝑆𝑆𝐼𝐼𝐼𝐼𝑑𝑑(𝑡𝑡)*𝑆𝑆𝐶𝐶𝐼𝐼𝑑𝑑(𝑡𝑡) 
d) Built the regression model and Kaplan-Meier Curve. 
I. Nonparametric Kaplan-Meier Curves. 
II. Fixed parameterization of the dynamic logistic MSMs with the constant-time 
hazards, P�𝑌𝑌𝑝𝑝,𝑗𝑗+1 = 1�𝑌𝑌𝑝𝑝,𝑗𝑗 = 0,𝐹𝐹,𝜃𝜃� =𝛽𝛽0 + 𝛽𝛽1𝐹𝐹 + 𝛽𝛽2𝜃𝜃. 
III. Flexible parameterization of the dynamic logistic MSMs with the discrete-
time hazards, P�𝑌𝑌𝑝𝑝,𝑗𝑗+1 = 1�𝑌𝑌𝑝𝑝,𝑗𝑗 = 0,𝐹𝐹,𝜃𝜃, 𝑡𝑡� =𝛽𝛽0 + 𝛽𝛽1𝐹𝐹 + 𝛽𝛽2𝜃𝜃+𝛽𝛽3𝜃𝜃𝑡𝑡. 
To simplify the figure, I have only included ΔFEV1% in Figure 4.1. It represents 
the combination or the matrix of all the clinical time-varying covariates, such as 
ΔFEV1%, FEV1%, and PEx, which are also the core dependent variables to predict the 
lung treatment score. Since the identification and classification of all those clinical time-
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varying covariates are highly associated with lung function, the casual pathway would be 
same compared with this figure. Therefore, in Aim 3, when I mention ΔFEV1%, it 
represents the matrix of all time-varying covariates that affect decision-making on lung 
health maintenance treatment change, and alternatively the lung treatment score.  
The majority of clinical variables and treatment-related variables are time-varying 
covariates, which could act as time-dependent confounders and intermediate variables 
within different causal pathways. If ignoring the relationship within each group, then both 
demographic characteristics and comorbidity variables are associated with time-varying 
clinical covariates. As mentioned previously, even though time-varying covariates are the 
main issues in this model, they also represent the beauty of this model. Since majority of 
demographic and comorbidity variables influence the exposure and outcome indirectly 
through predicted FEV1% or other clinical time-varying covariates, as shown in Figure 
4.1, after adjusting the time-varying FEV1%, I only need adjust other pathogen caused 
infections and any treatments related to those infections to generate the unbiased 
estimation. It definitely reduces the chance of having inappropriate adjustment and 
enhances the probability of having unbiased estimation at the same time. Age, gender, 
race, ethnicity, and height are variables that affect the predicted normal FEV1, which 
indirectly impact the ΔFEV1%. A study indicates pancreatic insufficiency also affects the 
FEV1 value.158 The genotype of CFTR not only affects the severity of lung function 
deterioration, but also impacts the time to mucoid P. aeruginosa colonization159 for CF 
patients.  
Similar to the prediction model in Aim 2, variables were categorized as two types, 
baseline variables and time-varying variables to calculate the numerator and denominator 
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for IPTW and IPCW. For each visit, there were three values at different time points: 
current visit, last visit, and the visit with an optimal value in the previous year, to 
illustrate time-varying variables.  
To focus on the causation of varied strategies for chronic lung health maintenance 
treatment on delay in acquisition of mucoid PaPI, the scenarios where lung function 
temporally fluctuates steeply was not considered. The majority of those scenarios 
occurred during PEx-caused hospitalizations. Therefore, a pseudo encounter visit was 
generated to represent the recovered lung function and an indicator was created to show a 
PEx was cured right before this visit. In clinical practice, the definition of a cure for PEx 
is to recover the predicted FEV1% back to 90% of the optimal predicted FEV1% in the 
previous year. If the patient is not able to fulfill that goal within 2 weeks, healthcare 
providers usually stop the treatment for that specific PEx, to avoid the drug resistance to 
the related i.v. antibiotic. During the PEx-caused hospitalizations, only the records that 
occurred at the last date were taken into consideration as the candidate of pseudo 
encounter, unless there was a record that indicates all variables were measured right after 
the PEx was cured. Then from demographic characteristics to clinical variables, all of the 
values in that visit was used regardless of whether there was any record that existed after 
it and before the last date of hospitalization. If neither a record of the last date of 
hospitalization nor a record indicating that all variables were measured right after the PEx 
was cured was available, then the last record during that hospitalization was used as the 
pseudo encounter. However, time-varying variables, such as FEV1, height, and weight 
were identified as missing regardless of the value measured at that visit. For all the 
chronic treatments, which should not vary over the short term, if an individual treatment 
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was prescribed in 1 day, then it was assumed that treatment was applying throughout the 
hospitalization. A 6-month follow-up after the PEx was also measured to indicate 
whether the PEx was cured. If disease status was stable: no more than 10% reduction on 
predicted FEV1%, and no moderate or severe PEx in any outpatient visit, then the mean 
value of all the predicted FEV1% during that 6-month period was used to represent the 
predicted FEV1% when the patient was out of hospital. 
Whenever a patient has a positive culture test for a new pathogen, or initially 
resists specific treatment, that visit was identified as the time when a new infection or 
drug resistance happened. Antifungals and clarithromycin could be applied as both short-
term and long-term treatment. Those two treatments were considered when they were 
used chronically to treat Aspergillosis species and MAI, respectively. In order to 
appropriately estimate the treatment effects of chronic lung health maintenance 
medication for PaPI, the above two medications were adjusted as confounders. 
 
4.7 Data Reformatting 
In clinical practice, CF patients should have a routine visit at least every quarter, 
where all the clinical variables, such as FEV1 and FVC, are measured. The data in the 
CFFPR show the evidence that this practice is standard with every patient having, on 
average, a routine visit every 3 months. At the same time, I also conducted an exploratory 
analysis using an independent cohort to investigate the relationship between frequency of 
encounter visit and lung function deterioration using generalized linear model. The 
relative change of mean FEV1% between the first and the last year was applied as the 
dependent variable. Independent variables included mean of number of visits in the 
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cohort, age, length of follow-up since index date, gender, race, ethnicity, height, CFRD 
status, and number of treatments in each one of treatment classes at the first and last year, 
respectively.  Even though the number of visits did affect lung function deterioration, the 
impact was trivial compared to the effect of treatments that a patient received at the first 
and last year in the cohort (Appendix D, Tables D.1 and D.2). More specifically, the 
longer follow-up a patient had in this cohort, the less impact the number of visit had to 
the lung function deterioration (Appendix D, Table D.2). Considering all patients had at 
least 2 years of follow-up in the original cohort, I believe that the data reformatting to 
have a quarterly visit for each patient was reasonable, and should not bias the 
identification of the optimal treatment regime. 
Supported by both data and experience in clinical practice, it is reasonable to 
restructure the database as each patient has a fixed number of outpatient visits per 
calendar year. Following real-world clinical practice, I restructured the data quarterly. 
The index date was identified as t=0, which is the latest date between date of diagnosis 
with nonmucoid PaPI and the first encounter date after Dec 31, 2005. It also acts as the 
first core date for each individual. Then I set up the rest core date for each time interval, 
which is 90 (91.3125) days away from the core date in the previous interval. Each time 
interval started at 60 (61.3125) days before the core date and ended at 30 days after the 
core date (Figure 4.2). If a patient had more than one visit in a quarter, the visit that 
happened in the interval before the core date, closest to the core date, was chosen as E3 
rather than E2 or E4 during the T1 interval. In the figure, Ei denotes the i th encounter 
visit since index date, and Tj represents the j th quarter interval (j=1, 2, 3, …, 24). If there 
was no visit in advance, at most 61.3125 days away from the core date, then the closest 
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encounter visit occurred after the core date, at most 30 days away, was chosen as E5 
rather than E6 during T2. If no encounter visit existed in the time interval, then the 
missing observation was used as the encounter visit of this time interval, and further 
imputation was conducted for this missed observation.  
 
4.8 Missing Data 
Missing data is common for all types of databases in the healthcare field, from 
survey, EMR to claims databases. Generally speaking, there are three steps for analysis 
with missing data: identifying potential reasons for the data to be missing, investigating 
the mechanism of missing data, and applying the optimal method to impute missing 
values. In our study, there are four main reasons for missing data. First of all was attrition 
due to natural processes: these include patient death, loss of follow-up, progression to 
mucoid PaPI, and not following the specific treatment change regime. Data collection 
issues during outpatient visit could also result in missing data: for example, failing to or 
inappropriately measuring the demographic characteristics, clinical variables, or 
treatment-related variables during the encounter visit. Reformatting the data also caused 
missing information for patients, particularly those who visit infrequently or whose visits 
are unevenly distributed in the time intervals. Finally, given that the information in the 
CFFPR was all collected through a patient questionnaire, it is possible that a patient could 
have skipped or refused to answer some questions intentionally. However, the positive 
results from the external audit and the exploratory analysis, which investigated the 
quality of data in the CFFPR, made this final issue unlikely to be a significant problem.  
The mechanisms of missing data are categorized into three groups: missing 
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completely at random (MCAR), missing at random (MAR), and missing not at random 
(MNAR). MCAR means that the probability of having missing data on a variable is 
totally independent of any other variables or the value of itself. A considerably weaker 
assumption is made when the probability of having missing data for one variable is only 
conditional on other variables but the value of itself. MNAR is much harder to handle and 
even though many of models might be applicable, nothing in the data indicates which one 
of those models is correct.160 Considering that this study is an observational study, but a 
randomized clinical trial (RCT), hypothetically, the majority of the missing data should 
be MAR, varies by other variables, rather than MCAR. Moreover, the probability of 
having MNAR should be low, since the data in the patient registry was collected directly 
from patients, used for improving disease monitoring and future treatment. At the same 
time, some of the missing variables could have linear trends with time on patient level—
such as height and other demographic variables that are not fluctuating by time. In order 
to confirm the mechanism of missing data, t-test, correlation, regression, and ANOVA 
tests were conducted.161  
To yield the least biased estimate, three strategies—deletion techniques, single 
imputation techniques, and model-based techniques—are applicable. Likewise deletion 
and pairwise deletion are typical techniques to calculate correlation matrices by 
excluding all cases that have at least one missing value, or to calculate correlation 
matrices for each pair of variables that have valid data, respectively. The single 
imputation technique, which creates only a single dataset with the imputed missing value, 
includes methods such as last observation carried forward, arithmetic mean or median 
imputation, and single regression. Model-based techniques mainly cover multiple 
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imputation and maximum likelihood method.  
At first glance, the single imputation technique is advantageous compared to other 
techniques, since it makes use of data that the deletion technique would otherwise discard 
and it is much more straightforward than the model-based techniques. However, the 
single imputation technique has potentially serious drawbacks, producing biased 
parameter estimates, and attenuating standard errors, because of treating the imputed 
values as real data. The model-based technique can appropriately handle those issues, 
especially multiple imputations, appropriately adjusting the standard errors for missing 
data.162 In specific situations, the maximum likelihood method is superior to the multiple 
imputation method.160 This is because the consistency of having same parameters in both 
imputation model and analysis/outcome model prevents the arbitrary decision-making on 
choosing parameters for imputation model. 
In my imputation, I included both the single imputation and model-based 
technique. There are some drawbacks to using the simple imputation method, including 
the fact that it overfits the data, which leads to less generalizability than the original data 
would be. However, for the majority of the demographic characteristics, which are 
mostly complete with a nearly linear trend, simple imputation is the optimal technique. 
The arithmetic mean was calculated for time-varying demographic variables, such as 
height and weight, using the relative change of those variables among all visits that 
occurred 1 year before and 1 year after the current visit, which may contain missing 
information. For those visits that were completely missing caused by data reformatting, 
comorbidities, treatment-related variables, and fixed demographic characteristics, such as 
race and ethnicity, were captured using the last observation carried forward method. 
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IPCW was applied to measure the influence of censoring from death, loss of follow up, 
progression to outcome, and treatment that conflicted with hypothetical treatment change 
strategy. The model-based technique was applied for lung function imputation, 
considering the fluctuation, the potential for it to be influenced by other variables, and the 
importance of this variable to the result in Aim 3. When information about PEx was 
missing, it was assumed that PEx did not occur. If by any chance an acute pulmonary 
exacerbation had really occurred, there is no doubt that any patient participating in the 
CFFPR would have visited a CF-accredited hospital to get appropriate treatment, and all 
the information during that visit would definitely be recorded. In conclusion, with the 
complex imputation strategy for different variables, the imputed value would be 
reasonable with appropriate generalizability. 
 
4.9 Assumptions 
In order to conduct this research, several assumptions have to be made in advance. 
Basically, they included the assumptions for study design, and for method, specifically 
causal inference. Those assumptions for study design fell into two categories: major and 
minor assumptions. Any assumption that requires internal or external tests is major 
assumption. Without making those prudent assumptions, such as using patients’ self-
reported treatment in the CFFPR as the physicians’ prescribing behavior, the result would 
be biased or even have limited credibility. Other assumptions are minor assumptions. 
These assumptions have limited influence on the main hypothesis, but ignoring them 
could also bias the result. Generally speaking, all the assumptions that were made during 
data cleaning procedures are minor assumptions, such as assuming all the Pa culture tests 
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without clear phenotype results belong to nonmucoid Pa, as long as it occurred between 
positive culture tests of nonmucoid and mucoid Pa; assuming all the patients marked as 
other races have same predicted normal lung function as Caucasian; and assuming all 
treatments that were prescribed during PEx caused hospitalization would only 
temporarily affect lung function within that time interval. In this section, I will mainly 
focus on the major assumptions made in the study design section. Minor assumptions will 
be discussed in the section on data cleaning. Considering other than consistency, and 
conditional exchangeability, positivity is the only assumption that is testable, which was 
investigated by the result in the Aim 1, the assumption of the methodology, causal 
inference, will be only mentioned in the discussion. 
In my study, there are four major assumptions. First, I assume that the patients’ 
self-reported treatment information can be applied as a proxy for physicians’ prescribing 
patterns. Second, after a new drug is approved, there should be some related irrational 
treatment changes. Furthermore, it is appropriate to reformat routine outpatient visit into 
every quarter. Last, patients, who had their FEV1 measured at the index date, and who 
had their FEV1 measured within 6 months since the index date, share the similar baseline 
characteristics, disease progression, and prescription pattern. 
 
4.9.1 Assumption 1 
Since all the treatment information in the CFFPR is self-reported, it may not 
precisely reflect the prescription and treatment that a patient has received. Moreover, the 
way a healthcare provider asked or collected information may vary by the calendar year 
or by changes in the questionnaire used. Furthermore, all treatments on which this study 
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focuses are chronic treatments, which are supposed to be used continuously after 
initialization. However, in the CFFPR, after treatment initiation, there are many ‘not on 
treatment’ or missing responses. Considering that treatment change is a huge component 
of this analysis, two preliminary exploratory analyses were conducted to test the quality 
of the data, and to investigate whether the self-reported treatment could be used as a 
proxy for the prescribing pattern or even refill pattern. I have tested the trends in 
treatment consistency by calendar year (Appendix A.1), as well as investigated the 
discordance between self-reported treatment information and refilled information in the 
CFFPR and the MORE2 claims database (Appendix A.2), independently.  
I have investigated the trends in treatment consistency in the following manner. 
Inconsistency was defined as a proportion, the number of visits during which patients did 
not report using a treatment after the treatment was initiated. In order to compare the 
result with another exploratory study, I included only those 9,958 patients who were 
recorded in both the CFFPR and the claims database. Moreover, I focused only on certain 
lung health maintenance treatments: dornase alfa, ivacaftor, inhaled tobramycin, 
tobramycin powder inhaler, and inhaled aztreonam. These treatments were chosen 
because none of them have OTC alternatives, simplifying the identification of 
medications from the claims database using the National Drug Code (NDC). For each 
treatment, several results were reported: self-reported records in each calendar year 
(Appendix A, Table A.1), proportion of patient inconsistency in each calendar year 
(Appendix A, Table A.2), proportion of patient inconsistency in each calendar year for 
patients had at least two visits that year (Appendix A, Table A.3), and proportion of 
patient inconsistency in each calendar year for patients who had at least two visits in any 
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calendar year (Appendix A, Table A.4). The rationale of adding the last two tables is to 
better estimate the inconsistency of self-reported treatment among target patients who 
have at least two visits per calendar year and are older than 6 years of age.  
The consistency test results supported the hypothesis. The more recent a calendar 
year was, the more consistent the data were, as long as the targeted treatment had been 
initialized. The quality of self-reported treatment significantly improved from 2004 to 
2006 and held steady until 2012. Results in Table A.1.1, especially the results from 
dornase alfa and inhaled tobramycin, support this conclusion. Both drugs had about a  
20% decrease in inconsistency for patients who claimed they were not on the treatment. 
Compared with dornase alfa and inhaled tobramycin, the other medications had later 
approval date as well as higher chances of failing to be collected; therefore, the number 
of patients who took them was not used to support the conclusion. Tables A.1.2, A.1.3, 
and A.1.4 also support the conclusion but from different perspectives. The stricter the 
inclusion criteria, the better the results. Tables A.1.2 through Table A.1.4 show that the 
absolute change in the proportion of inconsistency significantly increased between 2006 
and 2011. For example, for inhaled tobramycin, I compared inconsistency before and 
after 2006. As a result, Table A.1.2 shows an approximate 20% absolute change. The 
number goes up to around 35% and 60% in Tables A.1.3 and A.1.4, respectively. 
Although the proportion of inconsistency for inhaled tobramycin was about double 
compared to that for the dornase alfa, the result makes sense because of the less frequent 
intake of inhaled tobramycin (every other month). The less frequently a patient took 
medication, the more missing or not on treatment responses the CFFPR had. Moreover, 
the distribution of the inconsistency proportion also supported my conclusion. Although 
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the lower quartiles were filled with positive numbers before 2006, they contained no 
other values but zero after 2006. Similar trends also occurred in other quartiles. Therefore, 
from the consistency perspective, self-reported treatment in the CFFPR can be applied as 
the proxy for the prescribing pattern in EMR as long as the self-reporting occurred after 
2006. Additionally, the frequency of taking a treatment also affects patient-reported 
outcomes. For example, a patient may not report that he was on treatment during a break 
month if he was taking inhaled tobramycin every other month. 
In the discordance test, multiple rationales lead to discordance in treatment 
between the CFFPR and the claims database by each individual treatment during each 
calendar year. One of the rationales is that the claims database does not have claims 
records for the entire United States. Additionally, insurance sometimes provides limited 
reimbursement for specific treatments. Therefore, a patient may acquire the treatment 
through an alternative pathway, such as a patient assistance plan, which bypasses 
insurance. In this situation, it is no wonder that the claims database cannot capture all 
claims information for a patient. Without identifying the rationale for discordance, it 
would be arbitrary to use self-reported treatment as a proxy for refill information to 
represent adherence patterns. However, given the limited proportion of discordance when 
a patient does not report a treatment but has the refill information in the claims database, 
together with the result from the previous analysis, it is warranted to use self-reported 
treatment as a proxy for prescribing behavior. 
As mentioned previously, in the discordance test, I focused only on mucolytics, 
inhaled antibiotics, and CFTR modulators; in these categories are included dornase alfa, 
tobramycin, tobramycin powder inhaler, aztreonam, colistin, and ivacaftor. Since I had 
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only partial data for lumacaftor that were collected before the last date of 2014, I did not 
take this treatment into consideration. At the same time, because I focused only on 
investigating the discordance between the self-reporting and the refills information in the 
claims database, only those 9,958 patients who existed both in the claims database and 
the CFFPR were considered. Claims statuses were classified into five categories. Several 
adjustments according to claims status were made, and all claims with unknown statuses 
were also kept.  
Overall, 77,264 claims met my inclusion criteria. About 80% of the refills were 
for dornase alfa; the specific percentage of each drug is represented in Appendix A, Table 
A.5. In Appendix A, Table A.6, the overall number of claims in each calendar year is 
represented. From 2008 to 2013, every year had more than 10% of the total amount of 
refills between 2000 and 2015. The rest of the years had limited refills. Appendix A, 
Table A.7, describes the trend of number of refills per patient per calendar year. The 
trend was straightforward: as time passed, more patients had more annual visits that were 
covered by insurance. Back in 2000, very few patients had more than 10 claims in a year. 
The number jumped to about 17 in 2006. The largest overall number of visits in a year 
came in 2013, with an increase of 29 from 2012. 
One of the main issues is eliminating the influence of multiple visits during the 
same hospitalization. As in previous steps, after excluding the multiple-encounter records, 
I saved either the last encounter date or the one when clinical variables were measured, as 
the visit date during hospitalization. All demographic characteristics and clinical 
variables were collected at that date. For comorbidities and treatment variables, as long as 
they were reported once during the hospitalization, they were captured on that date. After 
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applying the above procedures, 179,078 records were left, which represented 3,736 
unique patients who, according to the CFFPR, had refilled one of the targeted 
medications.  
In order to investigate the discordance between self-reported treatment in the 
CFFPR and refill information in the claims database, those two datasets were linked. For 
each treatment, if the encounter date fell within the range from a refill date to right before 
the patient finished the treatment, then a treatment possession variable was generated. 
Otherwise, a missing value was assigned, which means that according to the claims 
database, the patient did not receive any treatment on that encounter date. In reality, there 
could be a gap between the date when a patient finished treatment and the date of the next 
refill. At the same time, patients seldom have perfect adherence. I, therefore, added grace 
periods to estimate potential dates when patients would run out of treatment. The sum of 
refill date, supply days, and grace periods represent the last date after which a patient 
finished treatment. To better mimic reality, different grace period lengths were assigned, 
ranging from 0, 30, 60, 90 days, to the same length of supply days in the current refill. 
The hypotheses varied according to the lengths of grace periods. For example, if a grace 
period equals 0, it means that a gap between the date of finishing treatment and the next 
refill is unbearable. It also assumes that patients have perfect adherence. Therefore, any 
date that are not in the range of refill date to the refill date plus the supply days means the 
patient is “not on treatment.” If the grace period equals the supply days, this means the 
patient has about 50% adherence for this treatment. Only the date that is not in the range 
from refill date to refill date plus double supply days is defined as “not on treatment” 
according to the claims database. 
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Other than linking those two datasets using the encounter data in the CFFPR and 
refills in the claims database, I also generated several variables indicating whether a 
patient possessed a treatment at a visit given the different lengths of grace periods. 
Moreover, I excluded the encounter visit for each patient if the encounter date did not fall 
within the range from the earliest to the latest date of the patient’s claims. After this 
procedure, 71,019 encounters were left.  
I did not report the proportion of agreement when patients had negative responses 
both in the CFFPR and the claims database. The proportion of agreement on negative 
responses would be 100% minus the proportion of disagreement and the proportion of 
agreement on positive responses. Appendix A, Table A.8, shows that many visits have 
reported on treatment in the CFFPR but that the overall number of positive responses has 
been halved in the claims database. This could be explained by the shorter time intervals 
and fewer records in the claims database compared to the CFFPR;  a patient may have 
switched his insurance a couple of times between 2000 and 2015, which may not be 
captured by the claims database. Moreover, both the CFFPR and the claims database 
have limited records for inhaled aztreonam, TOBI® Podhaler, and ivacaftor. This is 
probably caused by one of the following reasons: the small patient population that 
qualified for these treatments, the short time period since drug approval, or the 
tremendous cost of the treatments.  
Generally speaking, about 75% of all claims records were consistent with the 
encounter data regardless of the length of the grace periods. The longer a grace period, 
the more likely a claim matched the encounter records, and the proportion of agreement 
increased. With the increasing number of visits, when a patient claimed a treatment or 
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refilled a prescription, the proportion of discordance increased. For treatments such as 
TOBI® Podhaler and ivacaftor, which had limited patients who either was on the 
treatment or refilled the prescription, the proportion of agreement was about 99%. 
However, those results could not support our conclusion, since the majority of 
agreements were contributed by negative responses both in the CFFPR and the claims 
database. In order to keep missing and “not on treatment” responses from influencing the 
agreement proportion, I measured the discordance. Specifically, I focused on scenarios in 
which a patient reported he/she was not on treatment, while the claims database indicated 
that he/she had refilled the prescription and the supply days of the treatment were 
sufficient before to last until the encounter visit. The proportion of this specific 
discordance was really low among all encounter visits for each individual treatment 
(Appendix A, Table A.8, yellow section). Therefore, I draw the conclusion that patients 
seldom have a recall bias, or barely intentionally report that they are not on a treatment, 
which conflicts with reality.  
To better investigate the discordance between self-reported treatment in the 
CFFPR and the refill records in the claims database, I have conducted several analyses 
for each individual treatment, measuring different outcomes. Those outcomes include: the 
number of claims that matched the encounter data when the patient reported on the 
treatment in the CFFPR (Appendix A, Table A.9), the proportion of discordance by 
calendar year (Appendix A, Table A.10), and the proportion of discordance by individual 
patient and calendar year (Appendix A, Table A.11). Since each treatment has four tables 
and the trend was similar, I just used aztreonam to illustrate the results. Generally 
speaking, the results of this section support the previous conclusions. With increasing 
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grace periods, the proportion of discordance decreased first, then it increased after hitting 
bottom. After the discordance achieved the lowest proportion with a specific grace period, 
any additional grace period could only link extra claims data with encounter data. 
However, the majority of the time, the patient was not really on treatment. The minimum 
proportion of discordance could be achieved with different grace periods in each 
individual calendar year. For example, the minimum discordance was achieved with a 30-
day grace period in 2010, while the same minimum was achieved with a 90-day grace 
period from 2011 to 2014. 
There is only one issue we need to be aware of. For any medication approved 
between 2003 and 2013, the trend of discordance was close to 0 at 1 or 2 years before the 
approval and kept increasing until 1 or 2 years after approval. After that, discordance was 
fixed if the information was collected appropriately. This phenomenon is presented in 
Appendix A, Tables A.10 and A.11. Before 2010, when aztreonam got FDA approval, 
the discordance rate was low. Starting with 2010, the proportion of discordance went up 
and mostly held steady beginning in 2012. This phenomenon disclosed the rationale 
behind the fake low value of discordance: no patient could get the treatment a couple of 
years before the drug was approved since the medication did not exist in the market. The 
discordance should therefore be 0, which means perfect agreement. However, during that 
time period, some patients may have accessed the drug through RCTs. In that situation, 
utilization was captured by encounter data in the CFFPR but not in the claims database 
since the NDC code was not available and there was no related reimbursement. So, the 
proportion of discordance started to increase. Since only a limited number of patients 
were in the trial, the discordance rate should still have been low; the majority of patients 
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could not get treatment, which is reflected in both the CFFPR and the claims database. 
After the drug was approved, many patients could access the medication. The 
discordance rate, therefore, increased dramatically since some patients were reimbursed 
through patient support groups or other insurance companies. Those patients’ information 
was captured not by the claims database but by the CFFPR. After 1 or 2 years, the patient 
population on this treatment was fixed, and the discordance rate would, therefore, stay the 
same from then on.  
In order to eliminate the influence of the above issues, I measured the proportion 
of discordance resulting from patients who reported in the CFFPR that they were “not on 
treatment” but who had refill information in the claims database during relative time 
intervals. The relative time interval is defined as the range from refill date to the sum of 
refill date, days supplied, and the grace period, which also covers the encounter date. The 
results indicate that the proportion of discordance, specifically for this situation, is 
relatively low, representing less than 10% of overall discordance (Appendix A, Table 
A.12). As can be seen, the discordance of treatment reported by the CFFPR and the 
claims database varied in terms of treatments and calendar years. It would be arbitrary to 
use self-reported treatment as a proxy for refill information in representing an adherence 
pattern. Given the limited proportion of discordance when a patient does not report on 
treatment but has refill information, together with the results from the first analysis, self-






4.9.2 Assumption 2 
After the efficacy of a new drug is demonstrated and published, or is approved, 
there is an increasing trend of prescribing it immediately. As mentioned previously, 
prescribing behaviors are complicated and could be determined by both internal and 
external factors. However, the belief that “newer is better” may still be able to affect 
physicians’ prescribing behaviors both internally and externally, especially for a disease, 
like cystic fibrosis, which has limited tools in a healthcare providers’ arsenal to treat the 
patient. But, if the patient is not severe enough to be qualified for the treatment, or the 
current treatment works better than the new treatment, after a short period of time using 
the new treatment, the patient may switch back to the previous treatment. If the belief 
affects the prescribing behavior in the above manners, tons of treatment changes should 
occur after a new treatment has its efficacy demonstrated and published or received 
approval. A majority of these changes are potentially irrational treatment changes given 
the patients’ disease severity. I identify those important dates as “the composite date” or 
“the approval date”, which represents either when a new treatment efficacy is 
demonstrated and published or when a new treatment is approved, and use the composite 
date or the approval date interchangeably to represent those two scenarios. Therefore, the 
drug approval date indicates the date when evidence was generated either through 
published articles or through drug approval in my dissertation.  
In order to investigate the association between a new treatment approval date and 
related irrational treatment changes, another descriptive exploratory analysis was 
conducted to investigate the difference of treatment changes in the range of 1, 2, or 3 
years before and after the drug approval date. As mentioned previously in the study 
117  
  
design and population section, different methods were applied to adjust the influence of 
approval date of the treatment on irrational treatment changes, according to the degree of 
the influence. In order to achieve the above goal, the following methods were applied 
independently or together: narrowing the time interval to avoid the inclusion of approval 
date for all treatments; rigorously identifying rational treatment changes by excluding 
irrational treatment changes, specifically on ‘stop prescribing one/multiple treatments’ 
when it conflicts with clinical variables; and including the drug approval date in the 
predictive and regression model. The results showed that the time of drug approval, or 
when publication demonstrated the efficacy of a new treatment, did affect physicians’ 
prescribing behaviors, without untangling other confounders. Table B.2 in Appendix B 
supports this conclusion. Using tobramycin as an example, the number of related 
treatment change was almost fixed, 0.5 times per year, regardless of the time length 
before the approval date. However, it increased considerably after the approval date. The 
influence lasted around 1 year, which varied by treatment, and had more impact if no 
alternative treatment existed. However, there was no significant result that indicates to 
what extent the date affects irrational treatment change. Even so, the impact of drug 
approval on irrational treatment change should merely bias the result of those three aims.  
The exploratory analysis will be explained in the following paragraphs. The 
whole CFFPR cohort was applied to conduct this exploratory analysis. Among 1,217,848 
records in the cohort, 124,447 reflect PEx-caused hospitalization. Since the multiple 
visits during a hospitalization were irrelevant to this exploratory analysis, they were 
excluded, and only the last date of the hospitalization or the last measured date during the 
care episode, whichever occurred later in recorded outpatient visits, was kept as the date 
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of the outpatient visit when the patient’s lung function was cured after the hospitalization. 
After applying the above procedures, only 58,421 records were left. Overall, 1,151,822 
records existed in the claims database after including only the last date of hospitalization. 
If lung function was measured on the last date of a care episode and this occurred earlier 
than the last date of the hospitalization, then that value was treated as lung function after 
PEx had been cured. If there was no measurement at the last date of a care episode, then 
the last observed lung function value at the last date of hospitalization was used. If 
neither of the above two scenarios were met, the mean lung function value during the 
next 6 months, when the disease was stabilized, would be applied. Otherwise, a missing 
value would be given; imputations were conducted to handle these missing values. A 
stable situation is defined by composite signals that include 1) not having a PEx-caused 
hospitalization, 2) a relative decrease of no more than 10% in the predicted FEV1% for 
patients with moderately or severely impaired lung function, and 3) not having moderate 
or severe exacerbation during an outpatient visit. Only 2,160 records had unique patient 
and encounter date combinations, which represented 1,770 patients who had stabilized 
situations within 6 months after the PEx and who also had their lung function measured 
during that time. The lung function records for these patients were considered to reflect 
cured lung function after PEx-caused hospitalization. 
For missing FEV1 and height values, the last observed value was carried forward. 
Some FEV1 values were still missing after the adjustment, since they occurred in 
advance of the records reflecting lung function measurement. I, therefore, excluded all 
FEV1 values that were missing at the beginning and were not caused by PEx. With this 
adjustment, only 889,081 records were left. All races recorded as “other” were treated as 
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Caucasian. Additionally, following ATS guidelines, the predicted FEV1 was adjusted for 
Asians, since they have 88% of the lung function compared with Caucasians when other 
variables are constant. A 1-year assumption (1.25 years) and a 6-month assumption were 
independently applied to the latest encounter that occurred before 01/01/2006, and the 
oldest encounter that occurred after 01/01/2006 to handle the misidentified and missing 
prescription issue.  
This study focuses on investigating the treatment effects on treatment class level; 
therefore, only treatment changes on class level have been captured. Treatments were 
categorized within four categories: airway clearance, inhaled antibiotics, anti-
inflammatories, and bronchodilators. Both dornase alfa and hypertonic saline were 
included in the airway clearance group. Three inhaled antibiotics, tobramycin, aztreonam, 
and colistin, were considered. Two medications, high-concentrate ibuprofen and 
azithromycin, belong to the anti-inflammatory group. Beta agonist and anticholinergics 
fit in the bronchodilator group. For each medication, the approval date or the composite 
date was determined by three components: 1) the date when the prospective RCT for the 
medication had demonstrated efficacy and was published, 2) the approval date of the 
medication in United States, and 3) the earliest date when the medication was reported in 
the database. If a treatment had both a published date and an approval date, then the 
earliest one was used. If a treatment did not have an approval date or it was difficult to 
identify the approval date, then the date when the medication was initially reported in the 
CFFPR, plus a 3-month grace period, was applied (Appendix B, Table B.1). To better 
investigate the potential influence that a treatment approval could have on related 
treatment changes, all treatment changes that occurred within 1, 2, or 3 years before and 
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after the date were compared. 
For all patients who had records both before and after the drug approval date, the 
following values were measured for each patient before and after the drug approval date: 
the number of encounter visits per year, the number of visits with treatment changes 
between treatment classes, the number of visits with treatment changes between treatment 
classes and that included the targeted treatment, and the mean length of time from the last 
visit until a change that related to the targeted treatment. 
I have captured the treatment changes between the treatment class levels, and all 
the detailed information is listed in Appendix B, Table B.2, which reflects the following 
trends. First of all, the results indicate that the right year was chosen, since the number of 
treatment changes, related to the targeted treatment rarely increased regardless of the 
length of time before the drug was approved. For example, no matter whether I chose 1, 2, 
or 3 years before tobramycin was approved, the number of treatment changes relative to 
tobramycin varied from only 0.47 to 0.5 times per patient. Moreover, patients tended to 
have more visits as time passed. As the oldest approved treatment, dornase alfa had the 
least number of visits (around 4.9), while azithromycin and hypertonic saline, as the latest 
medications, had a much greater number of visits per patient year (around 6.2) after they 
were approved. Last, the date—approval date, published date, or date when the first 
patient reported on a specific treatment—did affect the treatment change. It was 
supported by the results that the number of treatment changes relative to each targeted 
treatment reached a peak in the first year, decreased thereafter, and was almost fixed 
since the second year after the drug was approved. Consider tobramycin as an example: 
after the drug approval, there were about 0.37, 0.28, and 0.32 treatment changes in the 
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first, second, and third years, respectively, after it was newly approved. Specifically, 
when I reported the number of changes and the number of changes relative to the targeted 
treatment, I reported only by patient, not by calendar year. Therefore, the real numbers 
for the second and third calendar years would be close to the difference between 2 
adjacent years based on the analysis I have conducted. However, because the sample size 
varied each year, this result is just an approximation. Moreover, with the limited 
differences between each year and the general trends of decrease in the number of 
treatment changes relative to the targeted treatment, it is arbitrary to draw the conclusion 
that the drug approval date, actually the composite date, is definitely associated with 
irrational treatment change. Even though the increase of number of treatment changes 
relative to the targeted treatment in the first year after medication approval is much larger 
for the three remaining medications, the results are clouded for the following reasons. 
First, there was no drug officially approved for treat CF specifically before dornase alfa. 
When it received approval, obviously many patients switched to this medication. 
Moreover, the date identifications were artificial for azithromycin, and hypertonic saline, 
respectively, which may influence the number of changes before the relative date and 
amplify the influence of drug approval on treatment change. At the same time, the quality 
of the data improved greatly after 2006, so the dates for azithromycin and hypertonic 
saline, which were defined around the beginning of the 2006 may influence the result. 
Finally, with the existence of patients who have extremely infrequent routine visits, it is 
hard to differentiate rational from irrational treatment changes using mean length from 
the previous visit to the visit in which there was a targeted treatment–related change. To 
summarize, physicians’ prescribing behavior is affected by the date when a drug is 
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approved or when a publication demonstrates the efficacy of a new treatment. This 
influence on prescribing behavior could last about 1 year, which is varied by treatment 
and could have more impact if no alternative treatment exists. No significant results show 
to what extent the date could affect irrational treatment change.  
Fortunately, inhaled aztreonam was the only medication that received approval 
between 2006 and 2011, and it was always prescribed after initialization of inhaled 
tobramycin. Therefore, the additional irrational treatment changes caused by the approval 
of inhaled aztreonam would merely bias the results.  
 
4.9.3 Assumption 3 
For my dissertation, it is appropriate to reformat patient routine visits quarterly. 
According to clinical practice, CF patients should have a routine visit at least every 
quarter when all the clinical variables, such as FEV1 and FVC, are measured. The data in 
the CFFPR support the phenomenon that, on average, patients had a routine visit every 3 
months. At the same time, an exploratory analysis (Appendix D), which investigated the 
relationship between frequency of encounter visit and lung function deterioration, also 
supports this assumption. To simplify the analysis, the focus was on investigating the 
influence of number of visits per year on annual proportion of lung function deterioration, 
conditional on each patient’s demographic characteristics, comorbidities, and treatment-
related variables at the first and the last year when patient existed in the CFFPR. The 
transitions of demographic characteristics, comorbidities, treatment/pathogen-related 
variables were not considered. 
The CFFPR was applied in investigating both assumptions 2 and 3. The data-
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cleaning procedures were also similar between these two assumptions. However, unlike 
assumption 2, which took the full time frame into consideration, assumption 3 included 
existing records only from 2006 to 2011. After excluding multiple visits that occurred 
during the PEx-caused hospitalization and keeping only the last date of hospitalization or 
the last measured date during the care episode, the number of observations dropped from 
31,130 to 14,646. If lung function was measured on the last date of a care episode that 
occurred earlier than the last date of hospitalization, then it was used as the lung function 
after PEx was cured. If there was no measurement on the last date of the care episode, 
then the last observed lung function value on the last date of hospitalization would be 
used. If neither of the above two scenarios was met or the FEV1 value was still missing, 
then the mean lung function value during the next 6 months, when the disease was 
stabilized, would be applied. Otherwise, missing values would be given and future 
imputation would handle these missing values. Finally, 324,815 observations exist in the 
database after including only the last date of hospitalization.  
At the same time, I also tried to eliminate multiple encounter records from the 
same hospitalization, which was caused by reasons other than pulmonary exacerbation. 
Basically, the procedure was similar to excluding the multiple visits during the PEx-
caused hospitalization. However, the mean lung function in the 6 months after the 
hospitalization was not calculated to represent the recovered lung function, even if the 
patient’s disease was stable. Finally, lung function was adjusted for 170, 532, and 1,562 
records, using the relative measurement from the last date of care episode, last encounter 
date, and missing record, respectively. 
To better estimate the assumption, records that inappropriately captured treatment 
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information have to be adjusted. For example, all inhaled antibiotics could be taken 
continuously, every other month, or at another frequency. In the CFFPR, some patients 
reported not being on inhaled antibiotics; in reality, they were on treatment, but the date 
of visits occasionally happened during the gap or break month. In order to better capture 
treatment changes, those reports of “not on treatment” were revised to “on the relative 
treatment”. Previously, there were 60,432; 5,295; and 4,381 records on inhaled 
tobramycin, inhaled colistin, and inhaled aztreonam, respectively; after the adjustment, 
the numbers went up to 62,697; 5,589; and 4,733, respectively—an average increase of 
5%. 
All in all, the number of visits was related to the proportion of lung function 
deterioration—the more visits a patient had on average, the greater a reduction in lung 
function he may suffer—but the contribution was pretty limited. If only considering 
patients that existed in the CFFPR for at least 1 year, for each additional outpatient visit 
that a patient had in a calendar year, his predicted FEV1% relatively decreased an 
additional 0.1% per year (Appendix D, Table D.1). For those patients who have existed in 
the CFFPR for more than 2 years, the impact relatively decreased to 0.08% per year 
(Appendix D, Table D.2). Considering the inclusion criteria for the core aims in this 
study required that the patient be present within the CFFPR for at least 2 years, the 
relation between the frequency of visit and lung function decline should be trivial.  
Treatments had far more impact on the change of lung function than the number 
of visits. At the first year when patient enrolled in the CFFPR, the less treatment a patient 
received, the less lung function deterioration he may suffer during the following years. 
This is especially the case for mucolytics and anti-inflammatories. Using the model, 
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where patients had more than 2 years follow-up, compared to patients who were on two 
anti-inflammatories, patients who did not receive any anti-inflammatory in the first year 
had about 2.6% less lung function deterioration in the future. At the last year, the effects 
of treatments were reversed from the first year. However, the majority of treatment 
effects were not statistical significant, and had much smaller impacts compared with 
related treatment effects in the first year (Appendix D, Table D.2).   
Therefore, even though there is a relationship between number of visits and lung 
function deterioration, it is reasonable to reformat the database as each patient has a fixed 
number of encounter visits per calendar year, given the trivial contribution to lung 
function deterioration. Together with the experience of clinical practice and result that on 
average patients have about 4.7 visits per calendar year in the CFFPR, the decision to 
reformat encounter visit records as occurs quarterly to standardize the capture of lung 
function change between two routine visits is definitely reasonable. 
 
4.9.4 Assumption 4 
The accuracy of prediction decreased dramatically for those patients with 
consecutively missing FEV1s, especially if the consecutive missing occurred after the 
index date. To explore the influence on baseline variables and outcomes of different 
methods of defining the index date, the following study has been conducted. All results in 
Appendix E, Tables E.1, E.2, E.3, and E.4 were summarized using the index date and the 
date when FEV1 was initially measured after the index date, respectively. The majority 
of results were consistent between the two tables, but there were some discrepancies. 
Generally speaking, the later FEV1 was first measured, the worse the patient’s clinical 
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status was and the more likely he/she was on treatments. Compared with using the 
predetermined index date directly, if the date when FEV1 was first measured (Table E.2) 
was applied as the new index date, there were more treatment utilizations and shortened 
lengths of time to event (mucoid PaPI, disenrollment, or death) in the cohort. Therefore, 
the following four methods were proposed to handle missing FEV1s at the index date: 1) 
excluding all patients whose FEV1 did not measure at current index dates; 2) excluding 
all patients who had more than a specific grace period—for example, a 1-year gap 
between the index date and when FEV1 was first measured—and using the first measured 
date as the index date for the remaining patients; 3) using the first measured date after 
2006 as the index date for the whole population; and 4) excluding all patients who had 
more than a specific grace period—for example, a 1-year gap between the index date and 
when FEV1 was first measured—and using the current index date and imputing missing 
FEV1 values for the remaining patients. The following results supported the second 
method with a 6-month grace period as the optimal way of identifying the new index date 
for Aim 2 and 3. 
The first encounter date after 01/01/2006 for patients older than six was identified 
as the index date for Aim 1. The decision seemed appropriate, until the missing values of 
lung function were imputed. Rather the missing value of FEV1 being imputed directly, 
multiple imputations were applied to calculate the change of FEV1 values between the 
current and future visit. The imputing strategy worked well for missing values that 
occurred independently. As long as either previous or future FEV1 was available, 
together with the imputed change of FEV1, the missing value of FEV1 at a current visit 
was imputable. However, with the increased number of consecutive missing values, the 
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accuracy decreased dramatically. This is because each calculation had an error that 
accumulated with the number of calculations needed for imputing FEV1. Without 
appropriate control, those accumulated errors would jeopardize the imputation. 
Fortunately, if the consecutive missing values occurred between two existing FEV1s, the 
error could still be adjusted by calculating those missing values from two directions: 
forward from the earliest measured FEV1 or backward from the latest measured FEV1. 
However, the accuracy of imputation would decrease tremendously if FEV1 were 
measured at only one end, especially at the latest visit. Actually, 769 patients did not have 
FEV1 measured at the index date using the current method. Therefore, the influence of 
using different methods to define the index date on baseline variables was investigated to 
examine whether patients who had FEV1 measured later are significantly different from 
patients who had it measured earlier (at the index date).  
Results were listed in two tables. Appendix E, Tables E.1 and E.2, represent the 
baseline information from using the current method to identify the index date for patients 
older than 6 after 01/01/2006. However, in Appendix E, Tables E.3 and E.4, the baseline 
information is reported on the date when FEV1 was measured, but not index date. In the 
following section, the “index date” specifically indicates the index date that was defined 
by the first method. To better investigate the results of using different methods to identify 
the index date, the cohort was categorized into four groups according to the gap between 
the index date and when FEV1 was first measured after the index date. Group 1 included 
patients whose FEV1 was measured at the index date. The gaps in groups 2, 3, and 4 
were 0–6 months, 6–12 months, and more than a year in length, respectively. In Table 
E.2, patients were classified into the same groups as Table E.1 even though there was no 
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gap in Table E.2. Cells were highlighted in yellow as long as they were significantly 
statistically different for either the chi-square test or ANOVA test. If the number was 
different between Table E.1 and E.2, that result was marked in red. 
In Appendix E, Tables E.1 and E.2, generally speaking, the age distributions are 
different, and younger patients are prone to have later FEV1 measurements. The trend is 
also reflected in the height and weight section; the later FEV1 was first measured, the 
shorter and lighter a patient was (Appendix E, Table E.1) as long as they were younger 
than 14 years old. Hispanics tended to have later FEV1 measurement. Compared with 
patients who had their FEV1 measured at the index date, patients who had later 
measurement were more likely to have GERD, to have PEx in the previous year, and to 
take mycolytics and inhaled antibiotics. Patients who had later measurement were also 
more likely to have drug resistance, but considering the limited number of events, that 
result is not stable. The proportion of patients who would develop mucuoid PaPI or who 
would disenroll was not statistically different from other groups. But patients who did not 
have FEV1 measured for more than 1 year were more likely to die. Finally, time to 
disenrollment was significantly different among those groups. 
On Appendix E, Tables E.3 and E.4, with the delay in choosing the index date, the 
results of height and weight are larger than on Tables E.1 and E.2. Even so, Tables E.3 
and E.4 show results and trends similar to those on Tables E.1 and E.2. However, some 
variables had significantly different results; for example, the later a patient had FEV1 
measured, the worse lung function he had, the more likely he had a lung transplant or be 
on the waiting list, the more likely he was on anti-inflammatories and bronchodilators, 
and the quicker he would develop mucoid PaPI.  
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The difference of results between Tables E.1, E.2, and Tables E.3, E.4 were 
probably caused by the delay in choosing the index date. But three huge issues should not 
be ignored. First, lung function was significantly statistically different among those 
groups represented in Tables E.3 and E.4. Differences in height and weight may 
contribute to the difference in lung function, but it does not account for all differences. 
Therefore, patients in different groups may be fundamentally different even if their lung 
functions were counterfactually measured on the index date in Tables E.1 and E.2. 
Moreover, with the delay in choosing the index date, patients were more likely on 
treatments, which directly affected the exposure, treatment change, of the Aim 3. Finally, 
the delay in choosing the index date affected the time frame of developing the outcome 
(mucoid PaPI, death, disenrollment); the time frame change of developing the outcome 
has already been shown in the comparison between Tables E.1, E.2, and Tables E.3, E.4.  
Moreover, the time interval between the last FEV1 measurement and the index 
date was also investigated, as illustrated in Appendix E, Table E.5. Among the 796 
patients who did not have FEV1 measured on the index date, 396 had FEV1 measured 
before the index date. Furthermore, 320 patients had their FEV1s measured within 6 
months before the index date.  
Therefore, a prudent way of identifying the index date was needed, a way that 
would balance reliability and accuracy in handling those missing FEV1s. As mentioned 
previously, four methods were proposed. Each one had a unique rationale. For the first 
method, the assumption was that the physician should make a decision according to 
clinical variables, especially lung function. Prescribing decisions were different 
compared to targeted prescribing decisions if patients did not measure their FEV1 at the 
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index date. Rather than excluding all patients who did not measure FEV1 at the index 
date, the second method gave a grace period of probably 1 year before FEV1 was 
measured. The second method assumed that the failure of measuring FEV1 was caused 
by physicians’ belief that the accuracy of measurement is low for younger patients. It also 
assumed that the prescribing decision after FEV1 is measured is equivalent regardless of 
the gap between the index date and when FEV1 was first measured. However, if the gap 
was longer than 1 year, it assumed that prescribing decisions were different for the 
remaining population. Unlike the first or second method, the third method just defined 
the index date as the date when FEV1 was first measured, ignoring the effect of the gap. 
The third method assumed that prescribing decisions were exactly the same as long as 
FEV1 was measured. The fourth method applied a statistical approach regardless of the 
different rationales.  
The second method was applied to define the index date, which was supported by 
a few reasons. First, by using this method, the chance of selection bias was much lower 
than using the first method, which directly excluded about one-sixth of all patients. At the 
same time, this method took the gap into consideration, preventing information bias. 
Since some patients had late FEV1 measurements, the time to outcome would be 
shortened if the first measured date was applied as the index date. Finally, compared with 
the fourth method, the second method emphasized rationale rather than relying on the 
power of statistics.  
The decision to accept a gap of at most 1 year was based on the huge change of 
time to death and time to mucoid PaPI shown in Appendix E, Tables E.3 and E.4, 
compared with Tables E.1 and E.2. Other grace periods with shorter lengths may 
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probably be applicable. However, even if the grace period were minimized to 6 months, 
the probability of receiving treatments at baseline was still significantly different between 
the same groups in Tables E.1, E.2 and Tables E.3, E.4. Even so, the 6-month grace 
period for the second method was more reasonable, which balanced the consistency of 
the population’s baseline characteristics with generalizability. More importantly, by 
applying the 6-month grace period for the second method, at least 586 out of 796 patients 
in the cohort would be kept.  
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Demographic Clinical variable Comorbidities Treatment/pathogen relative variables
  Age   FEV1% (ΔFEV1%)   CFRD   Previous tx patterns/combinations
  Gender   # of PEx in previous year   Pancreatic insufficiency   Tx change and time of change in the last 1 year
  Race   Gastrointestinal symptoms
  Ethnicity   Asthma
  Height   Liver disease   Drug resistance
  Weight
  Weight for age Z score
  Lung Transplant status
  Smoking status
  Second hand smoke status
  Pregnancy
  CFTR genotype
  Time and result of culture test for aiway 
infection (other pathogens)
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Table 4.3 Reformatting the demographic characteristics. 
 
 
Variable Name Type Code Meaning Reformat code Meaning Dataset
eDWID Numeric
Unique patient ID 
(encrypted) Demographic data
Encounterdate Numeric Encounter date Encounter data
DOB Numeric Date of birth Demographic data
Deathdate Numeric Date of death Demographic data
Age Numeric
(encounterdate-
DOB)/365.25 Age in years Encounter data





Sex Dichotomous FALSE Male 1 male Demographic data
" " Female 0 female
Height Numeric Height in cm Encounter data
Weight Numeric Weight in kg Encounter data
Race* Categorical 1 White race 1 Caucasian Demographic data
2
Black or African 
American 2 Black
3
American Indian or 
Alaska Native 3 Asian
4 Asian 3 Asian
5
Native Hawaiian or 
Other Pacific Islander 3 Asian
6 Others 4 Others
   
135 
Table 4.3 (continued). 
 
 
Variable Name Type Code Meaning Reformat code Meaning Dataset
Hispanic Categorical 1 Hispanic 1 Yes Demographic data
2 Non hispanic 0 No
Smoking** Categorical 1 No 0 No Annual data
2 Occasionally 1 Yes
3
Yes, Regularly, less than 
1 ppd 1 Yes
4
Yes, Regularly, 1 ppd or 
more 1 Yes
5 Declined to answer 2 Unknown
U Not Known 2 Unknown
W Not Applicable 2 Unknown
Pregnant Categorical 0 No 0 No Annual data
1 Yes 1 Yes
N No 0 No
U Not Known 2 Unknown
W Not Applicable 2 Unknown
Pregnancy_outco
me Categorical 1 Live birth 1 Live birth Annual data
2 Still birth 2 Still birth
3 Spontaneous abortion 3 Spontaneous abortion
4 Therpeutic abortion 4 Therpeutic abortion
5 Undelivered 5 Undelivered 
U Unknown 6 Unknown 
N Not Applicable 0 Not pregnant
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Variable Name Type Code Meaning Reformat code Meaning Dataset
Transplant status Categorical 1 Not pertinent 0 No Annual data




Evaluated, final decision 
pending 0 No
4 Evaluated, rejected 0 No
5 Had transplantation 1 Had transplantation
Mutation 1 Categorical 0
mutation doesn’t belong 
to any class 6
mutation doesn’t belong 
to any class
1 Class I 1 Class I
2 Class II 2 Class II
3 Class III 3 Class III
4 Class IV 4 Class IV
5 Class V 5 Class V
. missing 9 missing
Mutation 2 Categorical 0
mutation doesn’t belong 
to any class 6
mutation doesn’t belong 
to any class
1 Class I 1 Class I
2 Class II 2 Class II
3 Class III 3 Class III
4 Class IV 4 Class IV
5 Class V 5 Class V
. missing 9 missing
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Table 4.3 (continued). 
 
Variable Name Type Code Meaning Reformat code Meaning Dataset
Mutclass Categorical 0
mutation class I-III group 
(both)
1
mutation class IV/V 
group (any)
2
genotyped but not 
identified in mutation 
class I-III or IV-V group 
or misisng (any)
F508 Categorical 1 homozygots 1 homozygots
2 heterozygots 2 heterozygots
3 none 3 none

















* For patients who have multiple races, the one with the lowest reference lung function will be applied. Generally speaking, Asian has worse lung 
function than Black and Caucasian
** Second smoke has same coding system
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Table 4.4 Reformatting the treatment information. 
 
Variable Name Type Code Meaning Reformat code Meaning Dataset
Tobi Dichotomous On inhaled tobramycin Encounter data
Tobifreq Categorical 1
300 mg BID alternate 
month schedule Encounter data
2 300 mg BID continuous
3





gentamicin, amikacin) Encounter data
Aminofreq Categorical 1 Alternate Month Encounter data
2 Continuous
3
Other regimen (different 
dose or freq)
Colistin Dichotomous On colistin Encounter data
Colistinfreq Categorical 1 Alternate Month Encounter data
2 Continuous
3
Other regimen (different 
dose or freq)
Aztreonam Dichotomous On inhaled aztreonam Encounter data
Aztreonamfreq Categorical 2
75 mg TID Alternate 
Month Schedule Encounter data
3 75 mg TID Continuous
4 Other regimen
Azith Dichotomous On azithromycin Encounter data
Clarith Dichotomous On clarithromycin Encounter data
Dornasealfa Dichotomous On dornase alfa Encounter data
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Table 4.4 (continued). 
 
Variable Name Type Code Meaning Reformat code Meaning Dataset
Dornasefreq Categorical 1 2.5 mg QD Encounter data
2 2.5 mg BID
3
Other regimen (different 
dose or freq)
High_ibuprofen Dichotomous On high-dose ibuprofen Encounter data
Hypersaline Dichotomous On hypertonic saline Encounter data
Hyperconc Categorical 1 The concentration is 3% Encounter data
2 The concentration is 4%
3 The concentration is 5%
4 The concentration is 6%
5 The concentration is 7%
6 The concentration is 8%
7 The concentration is 9%
8 The concentration is 10%
Hyperfreq Categorical 1 QD Encounter data
2 BID
3 other
Saba1 Dichotomous Short acting beta agonist Encounter data
Laba Dichotomous Long acting beta agonist Encounter data
Anticholinergics Dichotomous Short acting Encounter data
Anticholinergicl Dichotomous Long acting Encounter data
Combobroncho Dichotomous
Combination beta agonist 
and anticholinergic Encounter data
Corticosteroids1 Dichotomous Oral (e.g. prednisone) Encounter data
Corticosteroids2 Dichotomous
Inhaled (e.g. fluticasone, 
Flovent, budesonide) Encounter data
   
140 
Table 4.4 (continued). 
 
Variable Name Type Code Meaning Reformat code Meaning Dataset
Corticosteroids3 Dichotomous
Inhaled combination wth 
bronchodilator (e.g. 
Advair) Encounter data
Enzymes Dichotomous On any enzymes Encounter data
Antifungals Dichotomous On any antifungals Encounter data
Beta agonist 0
Not on any beta agonist, 
includes saba, laba, 
combobroncho, and 
inhaled combination of 
corticosteroids with BD Encounter data
1 Used beta agonist
Anticholinergic 0
Not on any 
anticholinergic, includes 
short acting, long acting 
anticholinergic and 
inhaled combination of 
corticosteroids with BD Encounter data
1 Used anticholinergic
AC Categorical 0
Not on any AC, includes 
dornase alfa and 
hypertonic saline Encounter data
1 Used 1 AC
2 Used 2 AC
IA Categorical 0
Not on any IA, includes 
tobi, aztreonam, and 
colistin Encounter data
1 Used 1 IA
2 Used 2 IA
3 Used 3 IA
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Variable Name Type Code Meaning Reformat code Meaning Dataset
AI Categorical 0
Not on any AI, includes 
high dose ibuprofen and 
azithromycin Encounter data
1 Used 1 AI
2 Used 2 AI
BD Categorical 0
Not on any BD, beta 
agonist and 
anticholinergic Encounter data
1 Used 1 BD
2 Used 2 BD
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Table 4.5 Reformatting the clinical variables and comorbidities. 
 
 
Variable Name Type Code Meaning
Reformat 
code Meaning Dataset
fvc Continuous Encounter data
fev1 Continuous Encounter data
fev1p fev1 percent predicted 
Using NHANES equation to 
calculate the reference 
fev1pcat Categorical fev1 percent predicted in category 1   fev1p>70%
2   40<fev1p<=70%
3   10<fev1p<=40%
4   <=10%
apesassess Categorical 1 Absent PEx (assessed) Encounter data
2 Mild PEx (assessed)
3 Moderate PEx (assessed)
4 Severe PEx (assessed)
ce_reasons1 Dichotomous
# days/nights with reason pulmonary 
exacerbation Care episode data
ce_reasons2 Dichotomous
# nights with reason pulmonary 
complication Care episode data
ce_reasons3 Dichotomous
# nights with reason GI 
complications Care episode data
ce_reasons4 Dichotomous
# nights with reason transplant 
related Care episode data
ce_reasons5 Dichotomous # nights with reason sinus infection Care episode data
ce_reasons6 Dichotomous
# nights with reason non-transplant 
surgery Care episode data
ce_reasons7 Dichotomous # nights with reason other Care episode data
ce_reasons8 Dichotomous # nights with reason unknown Care episode data
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Table 4.5 (continued). 
 




Has drug intolerance/allergies for 
dornase alfa Encounter data
allertobi Dichotomous
Has drug intolerance/allergies for 
tobramycin Encounter data
allercolistin Dichotomous
Has drug intolerance/allergies for 
colistin Encounter data
allermacro Dichotomous
Has drug intolerance/allergies for 
macrolide antibiotics Encounter data
allerhighibu Dichotomous
Has drug intolerance/allergies for 
high-dose ibuprofen Encounter data
allerhyper Dichotomous
Has drug intolerance/allergies for 
hypertonic saline Encounter data
alleraztreonam Dichotomous
Has drug intolerance/allergies for 
aztreonam Encounter data
arthro Dichotomous Arthritis/Arthropathy Encounter data
abpa Dichotomous
Allergic Bronchial Pulmonary 
Aspergillosis (ABPA) Encounter data
rlresaminoglycosid
es Categorical 1
Resistant to All Aminoglycosides 
Tested (e.g., tobramycin, gentamicin) 1 Resistant Encounter data
2 No 0 No
3 Testing Not done 2 Testing Not done
rlresbetalactams Dichotomous 1
Resistant to All Beta Lactams Tested 
(e.g., ceftazidime, imipenem) 1 Resistant Encounter data
2 No 0 No
3 Testing Not done 2 Testing Not done
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Table 4.5 (continued). 
 




Resistant to All Quinolones Tested 
(e.g., ciprofloxacin, levofloxacin) 1 Resistant Encounter data
2 No 0 No
3 Testing Not done 2 Testing Not done
CFRD_status Categorical 0 No CF related diabetes 0 No CFRD Encounter data
2
Impaired Glucose Tolerance (FBG < 
126, 2-h PG 140-199) 0 No CFRD
3
CFRD with or without fasting 
hyperglycemia 1 CFRD
DIOS Dichotomous
Distal intestinal obstruction 
syndrome (DIOS, Meconium ileus 
equiv.) Encounter data
GERD Dichotomous
GERD (Gastro-Esophageal Reflux 
Disease) Encounter data
hemopt Dichotomous Hemoptysis, massive Encounter data
paninsuf Dichotomous Pancreatic insufficiency Encounter data
pancreatitis Dichotomous
Pancreatitis (defined by mutation 
class<=3) Diagnosis data
ptx Dichotomous Pneumothorax Encounter data
PEx Categorical
Number of PEx in the previous one 
year (ce_reasons1>0) Encounter data
Pexloose Categorical
Number of PEx in the previous one 
year with loose definition 
(ce_reasons1>0 or apesassess>=3) Encounter data
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Figure 4.1: DAG for hypothetical causation between treatment changes and time to mucoid PaPI (after adjusting with the minimal 









TREATMENT CHANGE PATTERN 
 
5.1 Data Management 
The core data were collected from the encounter dataset in CFFPR spanning the 
years from 1988 to the end of 2011. The demographic dataset, care episode dataset, and 
annual dataset were also used to build the cohort. Overall there were 44,541 patients in 
the cohort. Visits that had only a bacteria culture test on Feb 15th of that year, but were 
lacking any other information, were treated as artificial data, since that’s the last date of 
each annual report. So, a visit was excluded if all variables that related to encounter date, 
diagnosis, clinical variables, and prescriptions were missing. After excluding duplicates 
and all culture tests that were tested before birth, there were 2,371,532 visits left in both 
the drug resistance dataset and the encounter dataset. After linking those two datasets, the 
linked dataset was built. 
 
5.1.1 Assumption on Unclear Pseudomonas aeruginosa  
Culture Test Results 
As shown in Figure 5.1, the results of the culture test are inconsistent. The 
inconsistency was generated from two levels: inconsistency between phenotype results 
and culture test results, and inconsistent results of phenotypes in the same visit. For 
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example, there were 90,119 visits with a diagnosis of Pseudomonas aeruginosa 
Pulmonary Infection (PaPI), but which failed to report phenotype—mucoid, nonmucoid, 
or unknown. Overall, 121,179 visits reported the phenotype as mucoid and nonmucoid 
PaPI at the same time. Therefore, two assumptions had to be made to adjust for each 
individual issue. For all positive culture test of pseudomonas aeruginosa that failed to 
report the phenotype, as long as it occurred before diagnosis with mucoid PaPI, it was 
assumed as nonmucoid. Otherwise, it was treated as mucoid PaPI. Moreover, whenever 
the phenotype test results were conflicted in the same visit, they were adjusted under the 
following order: mucoid PaPI, nonmucoid PaPI, unknown PaPI. For example, if a 
patient was diagnosed with a contradictory result, having both mucoid PaPI and 
nonmucoid PaPI, the phenotype result would be adjusted as mucoid. Overall, there were 
263,254, 199,740, and 24,630 visits that were tested with mucoid, nonmucoid, and 
unknown phenotype of pseudomonas aeruginosa results independently. At the same time, 
847 patients, whose phenotype remained unknown in the culture results during all 
encounter visits, were excluded. Another 2,417 patients who received positive mucoid 
PaPI test results earlier than positive nonmucoid PaPI results were also excluded, since 
the results either conflicted with the real world situation, or indicated that those tests were 
conducted too late to identify the true date of developing mucoid PaPI. After excluding 







5.1.2 Assumptions on Race to Predict Normal Lung Function  
Given Other Demographic Characteristics 
In order to capture all information in the dataset, the linked dataset was further 
linked to a demographic dataset and a death dataset. If only Caucasians and Blacks were 
considered, it would affect the calculation of normal FEV1. Moreover, ATS guidelines 
gave an adjustment for Asians, so the original six categories of race were combined into 
four: Caucasian, Black, Asian, and others. When looking at patients who claimed to be of 
multiple races, and considering that Caucasians and Asians would have the highest and 
lowest predicted normal FEV1, respectively (given identical other demographic 
characteristics), the race category with the lowest predicted normal FEV1 was entered for 
those patients. For example, patients who identified as Black Asian or Caucasian Asian 
were simply identified as Asian. Individuals identifying as American Indian or Alaska 
Native, and Native Hawaiian or other Pacific Islander were also identified as Asian, since 
hypothetically their lung functions are lower than either Caucasian or Black. When there 
was conflicted demographic information for the same patient, the order list (Table 5.1) 
was followed to pull out information with a lower number first. For example, if a patient 
reported himself as Caucasian and Black among different visits, he was treated as 
Caucasian.  
 
5.1.3 Other Exclusion Criteria 
After excluding those patients who did not have demographic information in the 
CFFPR, there were 41,043 unique patients left. After excluding those patients who did 
not have at least 1 year of visits before being diagnosed with nonmucoid PaPI, or did not 
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have at least 1 negative culture test result before being diagnosed with any phenotype  of 
PaPI, the number decreased to 17,470, representing 1,217,848 visits. Another 9,429 
patients were excluded according to the birth date, before Jan 1st 1988 or after Dec 31st 
2005. Overall, 2,330 patients were diagnosed with mucoid PaPI before 2004, and an 
additional 29 patients received a transplant before they were initially diagnosed with 
nonmucoid PaPI; both of which conditions conflicted with inclusion criteria, so they 
were also excluded. Other exclusion criteria were:  
• patients who did not have any visits after 01/01/2006, 
• who had less than two visits annually, 
• who did not have FEV1 measured in any visit,  
• and visits when patients were younger than 6 years old. 
After applying all the exclusion criteria, 4,970 unique patients were left, 
encompassing 322,549 observations. This is the final cohort used for the majority of 
Objective 1.  
 
5.1.4 Assumptions on Recovered Lung Function after Hospitalization 
Since this study mainly focuses on investigating dynamic treatment regimes in 
order to optimize treatment effects, short-term lung function deterioration during 
hospitalization was not taken into consideration. To support the decision, a preliminary 
analysis was conducted to investigate the predicted FEV1% trajectory during 
hospitalization for each patient using the cohort. In the analysis, all hospitalizations that 
occurred in each calendar year were captured independently. The number of events, mean 
duration of hospitalization, mean value of predicted FEV1% at the first date and last date 
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of the hospitalization, mean relative change of predicted FEV1% during hospitalization, 
and mean relative change of predicted FEV1% per day during hospitalization for each 
patient were measured according to the different reasons listed for the hospitalization. 
Because a patient’s lung function at initial hospitalization was not reported before 2010, 
only 2010 and 2011 results were used in this preliminary analysis, which investigated the 
predicted FEV1% trajectory during hospitalization for each patient. 
Table 5.2 shows the predicted FEV1% trajectory in 2010. More than a quarter of 
the patients were hospitalized because of pulmonary exacerbation (PEx) annually 
(1338/4970 = 26.92%). On average, this condition caused more hospitalizations than any 
other reasons for each patient (1.61 events). During each hospitalization, the mean 
durations varied from 6.98 to 14.80 days. The top 4 reasons for longer hospitalizations 
were pulmonary complications other than PEx, PEx, others, and sinus infection. 
Hospitalizations on average lasted 18.43, 14.80, 11.99, and 11.96 days, respectively. The 
range of predicted FEV1% at both the first and last date were huge, and PEx-caused 
hospitalizations had the widest range (13.03, 152.43) and (15.09, 161.65) at the first and 
last date, respectively. Generally speaking, patients had worse lung function on the first 
date than the last date regardless of the reason for hospitalization. PEx and non-transplant 
surgery were the only two reasons that had moderate impaired lung function at the index 
date in the median (66.84% and 65.30%). Compared with other reasons, PEx, sinus 
infection, and pulmonary complications other than PEx had more improvement on 
relative change of predicted FEV1% during hospitalization, which on average were 0.22, 
0.15, and 0.14 times higher. The relative change of predicted FEV1% decreased to 0.02 
times higher per day during hospitalization for the above three reasons. Table 5.3 
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indicates similar trends. In summary, the predicted FEV1% trajectory increased during 
the hospitalization. According to different reasons, on average, the improvement ranged 
from 0.01 to 0.22 times. Patients hospitalized for lung-related reasons, such as PEx, 
pulmonary complications other than PEx, and sinus infection, had more severe lung 
function on the first date of the hospitalization. Therefore, the FEV1 value that was 
measured on the last date of hospitalization is more reasonable value to be applied for the 
purposes of the study as the value that the patient would have when not sick enough to 
need hospitalization.  
According to this result, multiple visits that occurred during the same 
hospitalization were combined as one “cured visit,” when the reason that caused 
hospitalization was cured. The rationale was that whenever the hospitalization was 
terminated, the patient’s lung function achieved a peak as the short-term deterioration 
was cured. It was handled in the following manner: 1) excluded the multiple visits during 
the same hospitalization and corrected encounter date to the last hospitalization date 
(when the reason that caused hospitalization was cured), 2) calculated the cured FEV1 
after the related hospitalization, 3) adjusted the chronic treatment that the patient had 
received during the hospitalization.  
Specifically, only the last date of hospitalization, or the last measured date in the 
care episode, was kept; the other visits that occurred during the same hospitalization were 
deleted. A majority of the time, the patient only had one visit at the end of the 
hospitalization, either the last date of hospitalization or the last measured date in the care 
episode, and the last measured date in the care episode always occurred earlier than the 
last date of hospitalization. However, if the patient had visits recorded at both of those 
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two dates, then the last date of hospitalization was kept, unless FEV1 was measured at 
the last measured date in the care episode.  
In order to calculate the cured FEV1, the following procedures were conducted:  
1) If there was a measurement of lung function at the last date of care episode, 
which also occurred earlier than the last date of that hospitalization, then that value was 
used;  
2) If there was no measurement at the last date of the care episode, then the 
last measured lung function at the last date of hospitalization was used;  
3) If none of the above scenarios were met, then the mean FEV1 that 
occurred within the next 6 months, when the disease was stabilized, was applied;  
4) Otherwise, a missing value was assigned.  
Stabilized disease status was defined as not currently experiencing a PEx, or not 
experiencing more than a 10% decrease on predicted FEV1% compared to the maximum 
value in the past year for patients with moderately or severely impaired lung function, or 
not currently assessed with moderate or severe exacerbation. Finally, as long as a patient 
had received their chronic treatments at any visit during the hospitalization, the related 
treatments were marked as occurring during the “cured visit.” Overall, there were 
305,409 visits left. In order to differentiate the influence of PEx and any other reasons 
that caused hospitalizations, the number of changed FEV1 was reported independently. 
For PEx-caused hospitalizations, there were 2,835, 3,804, 1,220, and 6,331 visits that had 
a new FEV1 generated according to the above four scenarios, respectively. The numbers 
were even lower for hospitalizations caused by other reasons: 162, 399, 497, and 1,071 
for each individual scenario, respectively. In a word, only about half of the “cured visits” 
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had a FEV1, the rest of the FEV1s in the “cured visit” category were imputed in Aim 2.  
Lung function values in 349 visits were collected at a consecutive future visit, 
since the last date that lung function was measured during the care episode occurred later 
than the last date of hospitalization and equaled the values in the consecutive visit. 
However, without further information, those values were not adjusted.  
Finally, those visits that inappropriately captured treatment information were 
adjusted. All the inhaled antibiotics can be used continuously, every alternative month, or 
at some other frequency level. In the CFFPR, patients were reported as not on treatment 
when the date of the visit fell within the gap of a break month. In order to better capture 
treatment change patterns, those “not on treatment” were adjusted as “on treatment” as 
long as the encounter date was located in a scheduled gap within the treatment protocol. 
Previously, there were 58,020, 5,189, 4,299 visits on inhaled tobramycin, inhaled colistin, 
and inhaled aztreonam, respectively. After the adjustment, the number went up to 60,233, 
5,480, and 4,646, respectively, which represents a 5% increase on average. All above 
assumptions only affected the number of visit, decreasing from 322,549 to 305,409, but 
not number of unique patients, which were still 4,970 in the cohort. 
 
5.1.5 Assumptions about Imputing Height and Weight 
Generally speaking, the majority of time-independent demographic characteristics 
were imputable without making any assumptions. As long as they were recorded once 
among all the visits for the same patient, variables such as age, gender, race are imputable. 
On the other hand, the majority of time-dependent covariates are not imputable without 
further assumptions. For example, previously, the FEV1 in the “cured visit” was imputed 
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with a composite assumption. However, the more assumptions a study has, the more 
likely it is biased. Therefore, it is important to balance the number of assumptions and the 
number of missing values.  
In order to calculate the predicted FEV1%, a clinical signal for making a 
treatment change decision, height and weight are required. The arithmetic mean was 
calculated for the time-dependent demographic variables, height and weight, using the 
values of those variables that occurred right before and after the missing visit and 
conditional on time. If there were consecutive missing visits, then the fixed changing 
trend was assumed among those visits and those missing values were imputed 
independently. If the missing data happened at the index date, then the value that 
occurred in the original database right before the index date, together with the value that 
occurred right after the index date, were used to calculate the value at the index date. 
Here, the index date was defined as the date of the first visit in the cohort or the initial 
diagnosis with nonmucoid PaPI after the beginning of 2006 for each individual patient. 
Out of 309 patients who didn’t have a measurement of height in the index date, only 11 
of them lacked a prior measured height and only 4 of them did not have a posterior height 
recorded in the entire 3-year interval. All the patients who didn’t have posterior height 
measured were caused by short follow-up time until the development of outcome, or end 
of study, or hypothetically stopped growing, older than 18. For those patients who did not 
have any information on height during the 3-year interval prior to the index date, if they 
were older than 18 years old, and a posterior measurement occurred within 1 year, or the 
posterior height was measured within 6 months after the index date regardless of age, the 
posterior height was used as the height at the index date. If the patient did not have any 
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posterior height measurement in the 3-year interval after index date, and a height was 
measured within 1 year prior to the index date, then the prior height was used. After the 
above procedures, 2 patients still had missing values on height. Since both of them had a 
huge gap of time from a previous measurement, the growing trends of a patient with 
similar disease severity (transplant status and F508) and demographic information (age, 
gender, race) were employed to impute their missed heights. The same procedures were 
also applied on the imputation for weight. After finishing the data management, all visits 
that occurred prior to the index date were excluded.   
 
5.2 Results 
To fulfill Aim 1, this section described the results from four parts. The first part 
described the baseline characteristics of patients in the cohort. Then, the results of 
subgroup analyses were present, which investigated the association between the baseline 
characteristics and the volume of CFTR function that patients had, and the association 
between the baseline characteristics and the number of treatment classes that patients 
received. At the same time, the annual competing risks of death were summarized. Last, 
the medication trends were described by summarized the baseline treatment combinations 
that patients received and the treatment change patterns in the cohort.  
 
5.2.1 Baseline Characteristics of Patients in the Cohort 
Overall, there were 4,970 unique patients. After excluded the visit that occurred 
before index date, the number of visits decreased from 305,409 to 108,567 in the cohort 
(Figure 5.2). Table 5.4 represents the baseline demographic characteristics. More than  
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50% of patients were younger than 8 when enrolled in the cohort. There were 17.95%, 
15.63%, and 10.93% patients in the 9~11, 12~14, and 15~17 age group, respectively. 
Only 120 patients were older than 18 years old at the index date. Slightly more female 
patients, 50.62%, were in the cohort. The dominant race in the patient cohort was 
Caucasian. Black and Asian patients only represented about 5% of all patients. The 
majority of patients were non-Hispanic, 92.66%. Generally speaking, height and weight 
tended to increase consistently in the 6~9, 9~11, 12~14, and 15~18 age groups regardless 
of the measurement, mean, median, or value in the 1st or 3rd quartile. For those age groups 
older than 18 years old, the trend of growing height and gaining weight decreased. Some 
patients in the 9~11 age group had extreme high weight, even higher than the patients in 
the 12~14 age group. However, the CF patients tended to be shorter and slimmer than the 
normal population. For example, the mean height and weight were only 167.95 cm and 
60.33 kg for patients who were older than 18 years old. Less than 1% of patients had ever 
smoked. Only 6 patients were pregnant. Patients had few comorbidities, such as CFRD 
(3.86%), DIOS (1.41%), pancreatitis (0.30%), and ABPA (2.37%) at the baseline. 
Nobody had hemoptysis at the index date. Other than pancreatic insufficiency, which 
bothered 93.54% patients, GERD was the only comorbidity that affected more than 10% 
of the population.  
Table 5.5 indicates the distribution of mutation class. From mutation class I to V, 
both the function of CFTR and patient’s lung function increased, as long as other 
demographic characteristics and clinical values were fixed. For each patient, at most two 
mutations were reported. The majority of patients were classified in mutation class II 
regardless of using the 1st or the 2nd mutation. Compared to the 2nd mutation, the 
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proportion of patients who were classified as class II in the 1st mutation was  
higher (86.50% vs. 56.02%). There were few class IV and V mutations in the 1st mutation. 
In the 2nd mutation, the proportion increased to 1.91% and 1.81% for class IV and V, 
respectively. Unlike the 1st mutation, in the 2nd mutation, more patients’ mutations could 
not be classified in any existing mutation class, because of the uncertain CFTR functions 
that were associated.  
Following Green et al.,163 the mutation classes were further categorized into three 
groups. Specifically, patients with two mutations in class I, II, or III were grouped 
together, because their mutations typically lead to little or no CFTR function. Patients 
with one or two mutations in class IV or V were grouped together because these 
mutations are associated with residual CFTR function. If the class of any mutation was 
unsure or failed to measure, those patients were grouped, which had unsure CFTR 
function. The majority of patients had little or no CFTR function (77.55%); 4.25% and 
18.21% patients had residual and unsure CFTR function, respectively. In the following 
sections, the little or no CFTR function group is abbreviated as the no CFTR function 
group. 
Table 5.6 presents the baseline clinical information of this cohort. About ¾ of 
patients had mild impaired lung functions. Only 55 patients (1.11%) had severely 
impaired lung function at the baseline. Many patients did not have their lung function 
measured at the index date, which caused a higher missing rate (16.02%). In the mildly 
impaired lung function group, the median value is 100.73% with 114.61% as the 3rd 
quartile. For patients who had severely impaired lung function, the median value is  
35.22% with 27.23% as the 1st quartile. More than ¾ patients did not have any PEx in the 
160  
 
previous year before the index date. As the number of PEx episodes increased from 1 to 3, 
the proportion of patients who had specific number of PEx decreased from 15.63% to 
1.33%. There were less than 1% patients who had more than 3 PEx in the previous year. 
The number of PEx with loose definition had more number of PEx. However, similar to 
PEx, with the increase of the number of PEx under loose definition, the proportion 
decreased. Patients who had more than 5 PEx with loose definition represented less than 
1% of patients of the cohort. The proportion of patients who had drug resistance were 
also low, 1.57%, 0.66%, and 0.82% for aminoglycoside, beta-lactum, and quinolone, 
respectively.  
 
5.2.2 Baseline Characteristics of the Subgroup Patients in the Cohort 
Subgroup analyses of the baseline information were conducted conditional on 
mutation class and number of initial treatment class that a patient received. As shown in 
Table 5.7, there were associations between mutation classes and some demographic 
characteristics, such as age, race, ethnicity, and pregnancy, at the index date (chi-square 
p-value < 0.05). If a patient had no CFTR function, that patient was more likely to be 
documented when young (55.27% vs. 46.45% and 45.30% in 6~8 age group). More 
patients identified as Black in the unsure group (9.28% vs. 2.78% and 3.32%). With the 
increase in CFTR function, more patients identified themselves as Hispanic (5.66% vs 
9.95%), and the proportion of Hispanic patients was highest in the unsure group (13.92%). 
Compared with patients in the no CFTR function group, patients who had residual CFTR 
function were more likely to be pregnant (0.47% vs. 0.10%). Other than young adults 
who had similar mean height, the other patient groups had statistically significant 
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differences on means of height and weight (ANOVA p-value < 0.05). Patients who had 
residual CFTR functions on average were taller and heavier, and patients who had no 
CFTR function on average had the slowest physical development. As age increased, the 
difference in weight between patients with no CFTR function and residual CFTR 
function, on average, grew. It reached the peak in the 15~18 year-old group (64.22—
55.33 = 8.89 cm). There was no statistically significant association between the rest of 
the demographic characteristics and the mutation classes in the baseline. Mutation classes 
were also associated with some comorbidities, such as CFRD, GERD, and pancreatitis. 
GERD was one of the most common comorbidities at the index date, which affected 
more than 10% of the patients. Other than pancreatitis and ABPA, the more CFTR 
function a patient had, the less likely they were to suffer from comorbidities at the index 
date.  
Table 5.8 shows similar trends; the more CFTR function a patient had, the 
healthier he was. However, the differences were not statistically significant (Chi-square 
p-value > 0.05). Patients with residual CFTR function had both higher proportions in the 
mildly impaired lung function group (74.88% vs. 73.82% and 72.15%) and higher 
predicted FEV1% on average (107.14% vs. 102.83% and 101.92). However, the missing 
rate was also higher in the residual CFTR function group. Patients with residual CFTR 
function were less likely to have PEx in the past year regardless of which definitions 
were applied (84.36% and 63.03% patients did not have PEx and PEx with loose 
definition). The probabilities of having drug resistance were low in all three groups. 
Other than drug resistance of aminoglycosides, which affected about 1.5% patients, other 
drug resistances affected less than 1% of patients in the related group, respectively. 
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Table 5.9 indicates that there were associations between the number of treatment 
classes that a patient received and some demographic characteristics, such as age, race, 
and ethnicity at the baseline. Only 3 treatment classes were taken into consideration: 
mucolytics (ML), anti-inflammatories (AI), and inhaled antibiotics (IA). Compared with 
the no initial treatment group, the proportions of patients aged 6 to 8 were higher in 
patient groups who received 1, 2, or 3 treatment classes. Conversely, the no initial 
treatment group had higher proportions of patients aged 9 to 11, 12 to 14, and 15 to 17 
compared with the rest of the groups. Adult patients represent a small proportion in each 
group ranging from 1.19% to 4.58%. The majority of patients were Caucasian, 
representing more than 92% of patients in each individual group. However, the 
distributions of other races were not consistent. The proportion of Black patients was the 
lowest (3.07%) for patients who received 2 classes of treatments, and the highest (4.55%) 
for patients who received 1 class treatment. The proportion of Asians doubled in the 3 
classes groups, compared with the rest of the groups (2.94% vs. 1.23%, 1.27%, and 
1.02%). The more treatment classes that a patient received, the more likely the patient 
was Hispanic, increasing from 5.41% to 14.05%. There were associations between the 
number of treatment classes and physical development, such as height and weight, when 
the patient was aged 6~8 or 15~18. The more treatment classes a patient had received, the 
more likely on average they were to have had a slow physical development. The trend 
could be identified even for those age groups which did not have statistically significant 
different means.  There were also associations between the number of treatment classes 
that a patient received and comorbidities such as CFRD, GERD, and ABPA. The more 
treatment classes a patient received, the more likely they were to have had one of the 
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above comorbidities. However, patients who did not receive any treatment had a higher 
chance of suffering from CFRD (4.23% vs. 2.59%) and ABPA (2.14% vs. 1.90%), 
compared to patients who received one class of treatment. 
Table 5.10 shows the associations between the number of treatment classes that a 
patient received and clinical variables such as predicted FEV1%, PEx, and drug 
resistance. From 3 to 1, the fewer treatment classes a patient was receiving, the more 
likely the patient was to have less impaired lung function. No initial treatment group 
shared similar distribution on the severity of impaired lung function with the 1 treatment 
class group, but the 1 treatment class group had a higher proportion of patients who 
suffered from moderately impaired lung function and a lower proportion of missing 
values. Moreover, the more treatment classes that a patient received, the lower the 
predicted FEV1% on average. However, the mean predicted FEV1% was lower for 
patients who did not receive any treatment, compared to patients who received 2 classes 
of treatments if they had mild (100.83% vs. 102.76%) or severely impaired lung function 
(31.91 % vs. 34.23%). Similarly, with the increase of number of treatments, the chance of 
having more PEx also increased regardless of which definitions were applied. However, 
patients in the no initial treatment group had a lower chance of not having any or having 
only one PEx compared to a patient who received 1 class of treatment (80.77% vs. 82.67 
and 13.58% vs. 13.92%). Among each individual drug resistance, the more treatment 






5.2.3 Competing Risks of Death by Calendar Year 
Considering that CF is a progressive, genetic, long-term disorder, other than lung 
function deterioration, several other reasons could also trigger death. Therefore, the 
prevalences and incidences of death that relate to different reasons were investigated. 
Table 5.11 shows that respiratory/cardiorespiratory was the main cause of death, with 
7.64 person/1000 patient-years as the incidence. Among those competing risks, 
transplant-related death was the only one that consistently caused more than 1 
person/1000 patient-years. The other causes of death were lower in prevalence. Because 
of the low incidence rate, there was barely any difference between prevalence and 
incidence rate among all other groups.  
 
5.2.4 Treatment Combinations and Treatment Change Patterns 
Figure 5.3 represents the proportion of patients who were on different treatment 
combinations at the baseline. In order to simplify the tick, a three-digit number was 
created. From the left to the right, the value represents the number of treatments that a 
patient received in the inhaled antibiotics, mucolytics, and anti-inflammatory classes. For 
example, a ‘000’ means the patient didn’t receive any treatment, and ‘111’ means the 
patient received 1 inhaled antibiotics, 1 mucolytics, and 1 anti-inflammatory in the visit. 
Overall, there were 3,702 patients who had at least 1 treatment change. More than 1/3 of 
patients (33.55%) were treatment naïve at the baseline. Other than no treatment, the top 4 
treatment combinations were ‘010’ (24.58%), ‘110’ (12.48%), ‘011’ (6.21%), and ‘111’ 
(5.24%), which overall included 50.01% of patients. There were fewer patients on other 
treatment combinations. Overall, 1,059 patients (28.61%) received one or more inhaled 
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antibiotics in the baseline visit. Given other treatments remained fixed, with the increase 
on the number of inhaled antibiotics a patient received, the proportion decreased. 
Regardless of the number of inhaled antibiotics that a patient received, the top 4 common 
combinations of mucolytics and anti-inflammatories were ‘00’ (38.01%), ‘10’ (37.36%), 
‘11’ (11.83%), ‘20’ (6.56%).  
To better visualize the proportion of switching to other potential treatment 
combinations and the length of using the current treatment, four heat maps were created 
(Figure 5.4, 5.5, 5.6, 5.7). Unlike Figures 5.4 and 5.5, which only capture the 1st switch, 
Figures 5.6 and 5.7 capture all changes during the study. Figure 5.4 and Figure 5.6 
indicate the relationship among current treatment, potential treatment combination that a 
patient could switch to, and the proportion of patients who switched from the current 
treatment to a related targeted treatment combination among all switches. The x-axis 
represents the targeted treatment combination that a patient could switch to, and the y-
axis represents the treatment that a patient was currently on. The color of the square on 
the crossing represents the proportion of patients that would switch from the current 
treatment to the related targeted treatment combination among all the switches. The 
darker a square is, the more likely a patient would follow this switching path, which was 
defined by the combination of a current treatment and related potential treatment 
combination that a patient could switch to. Similarly, in both of Figure 5.5 and Figure 5.7, 
the color indicates the mean length of using the current treatment. The darker a square is, 
the longer a patient used that treatment on average. All the white parts indicate that no 
patient had followed that switching path. Since the treatment that a patient received in the 
last visit could only be identified at a future visit, which was not measurable, treatment 
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change was not considered at the last visit. When the first treatment change occurred, 
there were 24 treatment combinations for the current treatment, and 30 potential 
treatment combinations that a patient could switch to. As shown in Figure 5.4, the darkest 
red occurred when patients switched from ‘000’ to ‘010’, which indicated that about 14% 
(13.56%) of the 1st switch was to initiate 1 mucolytic. Other than this switching path, 
‘010’ to ‘110’, and ‘010’ to ‘020’, were also darker than the rest, which represents  
10.02 % and 8.05% of the 1st switch, respectively.  
The fewer treatment classes a patient received, the more potential treatment 
combinations he could switch to. For example, treatment naïve patients (‘000’) had 22 
combinations they could switch to, which represents 33.55% of the 1st switch. For 
patients who received only 1 mucolytic, there were 9 potential treatment combinations, 
and the overall proportion was 24.58%. The number of potential treatment combination 
decreased to 4, and the overall proportion decreased to only 3.70% for patients who were 
only on 2 mucolytics. Each oblique line represents a specific treatment change pattern 
regardless of what current treatment a patient received. For example, the oblique line that 
includes switching path from ‘000’ to ‘010’ indicating that the physician prescribed an 
additional mucolytic whenever a treatment change decision had been made. The squares 
on 3 oblique lines were more likely to have darker colors, which indicated the potential 
trends on treatment change decisions that a physician was prone to make. In each one of 
the oblique lines, the physician was prone to prescribing an additional treatment from one 
of the three treatment classes, respectively. All those three lines had several squares in 
darker color. However, the color on the oblique line of prescribing one additional 
mucolytic was on average darker than the other two. So, among those 3 treatment change 
167  
 
patterns, physicians were prone to prescribe 1 additional mucolytic. Other than the 
squares that were on those three oblique lines, the other switching paths were less likely 
to be followed. Nobody stopped using a treatment in any treatment class, which was 
indicated by the empty of any square in the left corner of Figure 5.4.  
Figure 5.5 represents the length of using the current treatment. In this study, 
yellow was applied to indicate an extreme length of using the current treatment, more 
than 1,461 days—4 years. One switching path had this color: patients who received 2 
inhaled antiobiotics and 1 mucolytic in the current treatment and were going to receive an 
additional inhaled antibiotics. Other than this path, patients who switched from only 1 
anti-inflammatory to 1 inhaled antibiotic, 1 mucolytic, and 2 anti-inflammatories, had the 
longest length: 1,371 days. Unlike the distribution of darker squares in Figure 5.4, the 
majority of the squares were evenly distributed in Figure 5.5. However, from bottom to 
top, the color became darker. Alternatively, the more treatments that a patient received in 
the current treatment, the longer the patient was likely to stay on it. 
In Figures 5.6 and 5.7, the number of current treatment combinations increased to 
30, and the number of potential treatment combinations increased to 33. The upper range 
of proportion decreased from 14% to 7.5%. So did length of using current treatment, 
which did not have any patient who was on their current treatment for longer than 4 years. 
The switching path from ‘000’ to ‘010’ was still in the top 5 (7.00%), but the path that 
had the highest proportion among all the switches in the cohort was the one in which 
patients used 1 inhaled antibiotic and 1 mucolytic in the current treatment and received an 
additional mucolytic in the future (7.33%). Several other squares also had darker color, 
such as ‘010’ to ‘110’ (7.01%), ‘111’ to ‘121’ (6.62%), and ‘010’ to ‘020’ (6.06%)’. 
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Similar to Figure 5.4, prescribing an additional inhaled antibiotic, or mucolytic, or anti-
inflammatory, were still the top three treatment change decisions that a physician was 
prone to make in Figure 5.6. Furthermore, the chance of prescribing an additional 
mucolytic was still higher than the other two. Unlike Figure 5.5, in Figure 5.7, the 
previous two paths, ‘210’ to ‘310’ and ‘001’ to ‘112’, that were associated with the 
longest length of using the current treatment were much lighter. The number decreased 
from 1,659, and 1,371 to 813 and 994, respectively. The following paths had the darkest 
color in Figure 5.7, ‘100’ to ‘210’, ‘110’ to ‘212’, and ‘012’ to ‘122’, which had 1,274, 
1,281, and 1,296 days, respectively. Figure 5.7 also marked the trend where, as the 
number of treatments that a patient received in their current treatment increased, the 
length of using the current treatment was prolonged.  
 
5.3 Discussions 
The discussion section is organized in the following manner. The first part 
focuses on the discussion of the mechanism, direction and extent of bias that each 
assumption may induce. The second part compares the baseline characteristics of patients 
in this cohort with the related statistics data in the CFF annual report. Then, the 
discussion summarizes the issues around subgroup analyses, especially focused on why 
the clinical information was statistically significant associated with the number of 
treatment that a patient received, but not associated with CFTR function that a patient had. 
After the subgroup analyses section, the reasons of increase in competing risks of 
mortality are analyzed. In the medication trends section, the reasons for not including 
bronchodilator as a treatment class, the indication of treatment combinations that patients 
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received at the baseline, and the issues around the results of treatment change patterns are 
discussed. At the end, advantages and disadvantages of this cohort, together with the 
impact of results in Aim 1 is summarized.  
 
5.3.1 Summary Regarding Assumptions 
In order to better manage the data, several assumptions were made. Generally 
speaking, without appropriate controls, assumptions could induce uncertainty and bias in 
the final result. However, for the results in this study, the chance of being biased by those 
assumptions is low, since the majority of them were determined either based on well-
accepted clinical evidence, or investigated and supported by preliminary tests. At the 
same time, those assumptions were made conservatively. Therefore, even had those 
assumptions biased the results, it only underestimated the result; the real estimate could 
only be larger than the current results. In the following paragraph, three examples of this 
are explained.   
First, whenever the culture test results were conflicted, the more severe results 
were always identified. The rationale is that the time of developing mucoid PaPI is an 
important clinical signal of having severe lung function deterioration, which was well 
captured by the healthcare provider. Therefore, the assumption that all positive culture 
test results were assumed as nonmucoid before diagnosis with mucoid PaPI is reasonable. 
This assumption would not affect the identification of outcome—first date diagnosed 
with mucoid PaPI—unless the chance of misdiagnosed mucoid PaPI as an unknown 
phenotype of PaPI is really high. If by any chance it was misclassified, it only reduced 
the sample size, shortened the length of follow-up until developing mucoid PaPI, the 
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outcome of Aim 3, and underestimated the time to event. Moreover, for a multiracial 
patient, the race that was associated with less lung function was used to calculate the 
reference lung function. Under this situation, the predicted FEV1% would be higher than 
it should be, if the normal multiracial person actually had better lung function than the 
one that was used for them in the analysis. Alternatively, patients were marked healthier 
than they should be, which decreased the potential sample size that followed the 
treatment change strategy in Aim 2 and 3. Last, a series of conservative identifications 
and calculations were conducted to measure the recovered lung function after a 
hospitalization, which decreased the change of predicted FEV1% between ‘cured visit’ 
and follow-up visit. If by any chance there was a rational treatment change in the follow-
up visit, then the estimate, using relative change of predicted FEV1% as a clinical signal, 
would be underestimated. Therefore, the estimates in all 3 objectives were minimum 
values.   
 
5.3.2 Baseline Characteristics of Patients in the Cohort 
As was demonstrated in Table 5.4, young patients constituted the cohort, with less 
comorbidities. Compared with the CFFPR 2011 annual data report, which summarized 
the whole CF patient cohort in the US, that around half of patients were older than 18 
years old, only 2.41% of patients were in the same category in this cohort. Even though, 
majority of patients were extremely young in this cohort, the distribution of gender, race, 
and ethnicity were consistent between patients in the report and in this cohort. The 
majority of patients were Caucasian and non-Hispanic with equal chance of either being a 
male or a female. Because of the younger distribution of age, patients had less 
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comorbidities compared with the report. Using CFRD, GERD, and DIOS as an example, 
only 3.86%, 1.41%, and 13.52% of patients suffered from above comorbidities, 
respectively. The related number went up to 19.0%, 28.9%, and 4.7% in the report. 
However, their physical developments, especially height and weight, were extremely 
slower than that of people without CF. Because of this, the generalizability of Aim 1 and 
the following 2 aims are mainly on the early stage of patients, rather than the entire 
population of CF patients. This scenario and narrower generalizability is caused by the 
inclusion criteria that a patient was either only diagnosed with nonmucoid PaPI but 
mucoid PaPI before 2006 and alive till 2006, or initially diagnosed with nonmucoid PaPI 
after 2006. Regardless of the inclusion criteria that a patient followed, the chance of 
being young was high. At the same time, the results of time irrelevant variables were 
consistent in this cohort and the annual report, which also supported the conclusion that 
the narrower generalizability is acceptable. 
The distribution of patients’ disease severity is consistent between the report and 
this cohort, using the functions of CFTR protein as the measurement. The majority of 
patients had little or no CFTR function, and only about 5% and 20% of patients had 
residual and unsure CFTR function, respectively. Even though the report failed to 
indicate the disease severity by another measurement, the class of mutation on two 
chromosomes, considering the consistency using the functions of CFTR protein as the 
measurement between the report and this cohort, the disease severity in this cohort is 
generalizable and acceptable with a small chance of being biased. Table 5.5 demonstrates 
that compared with 2nd mutation, the 1st mutation had a higher proportion of mutation 
class II (86.50% vs. 56.02%). However, the 1st mutation had lower proportions of 
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mutation class I and unsure class (4.89% vs. 17.83% and 1.85% vs. 13.52%), which 
absorbed the difference on mutation class II. There were 18.21% patients that were 
classified into group of having unsure CFTR function. The majority of them were 
determined by the mutation class on the 2nd mutation. In the 1st mutation, only 6.3% 
mutations belonged to the unsure class; however, the number went up to 17.97% in the 
2nd mutation. This may cause information bias, since some patients who only had one 
mutation within unsure class could be assigned to either no function or residual function 
group. According to current knowledge, without considering the unsure class, a patient 
would be classified as no function if both mutations are in class I, II, or III. As long as 
one mutation belongs to class IV or V, then the patient has residual function. Therefore, a 
patient, who had one mutation in class IV or V and another one in the unsure class, 
should be classified into the group with residual function. A patient who had one 
mutation in class I, II, or III and another one in the unsure class, without further 
information about the unsure mutation, could be either classified as no function or 
residual function. It seems that the creation of the unsure group would bias the result. 
However, the chance is trivial. First, the whole assumption is based on a determination 
that the mutation in the unsure class has a similar function as the one in 1 of the 5 
mutation classes, if it has superior function that class V or inferior function than class I, 
then the assumption is violated, and more classes are needed. Even if the unsure mutation 
belongs to 1 of the 5 classes, according to current information, only 12 patients could be 
reclassified into a group with residual but unsure function, which represents only 1.33% 
patients in the unsure group. Therefore, the disease severity in this cohort is generalizable 
and acceptable with a small chance of being biased.  
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In general, patients were healthy at the baseline. The median of predicted FEV1% 
was higher than 100%. This was probably caused by the following three reasons: 1) the 
low accuracy of lung function measurement had overestimated the FEV1; 2) the 
reference lung function, which was predicted by using NHANES method, had 
underestimated the FEV1; 3) the majority of patients were young, aged 6 to 8, whose 
lung function did not deteriorate too much. Considering the result of lung function was 
similar to the one in the CFFPR annual report, which included all CF patients in the U.S., 
the chance of having biased lung function was decreased. The proportion of missing 
values on predicted FEV1% was high, which was caused by failing to measure FEV1. It 
could be a reflection of not trusting the accuracy of lung function measurement on 
children, together with the reality that those young patients had good lung function.  
The definition of PEx was vague. In order to capture all the events, the categories 
PEx and PEx with loose definition were created. Unlike PEx, which was determined by 
the number of PEx-caused hospitalizations alone, the number of visits when the patient 
reported having moderate to severe PEx was also taken into consideration to define PEx 
with loose definition. Compared with PEx, PEx with loose definition identified more PEx 
incidents. However, the proportion of patients who had less than 2 PEx events were 
similar to patients who had less than 4 PEx events using loose definition (93.98% vs. 
95.98%). 
 
5.3.3 Baseline Characteristics of the Subgroup Patients in the Cohort 
The unsure group was a mixture of patients who had little or no CFTR function 
and who had residual functions, which was supported by several baseline characteristics. 
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The mean of height and weight in Table 5.7 indicated the conclusion. Other than when a 
patient was older than 18 years old, the unsure group always had a mean height and 
weight that was in the middle between the residual function group and the no function 
group. The range of height and weight in the unsure group was even wider than the 
residual CFTR function group. The proportion of patients who had comorbidities such as 
CFRD, DIOS, and GERD also supported this trend. The more CFTR function that a 
group had, the less likely it had specific comorbidities. The proportion of having specific 
comorbidities in the unsure group was located in the middle of the residual function and 
the no function group. 
The associations in Tables 5.7 and 5.9 were consistent in demographic 
characteristics such as age, race, ethnicity, and comorbidities such as CFRD, and GERD. 
They were statistically significantly associated with both mutation class and number of 
treatment class that a patient received at the baseline. Similarly, the less CFTR function 
that a patient had, or the more treatment class a patient received at the baseline, the 
slower physical development the patient had experienced. However, there were some 
differences; several associations were only identified with the mutation class. Patients 
who had residual CFTR function were more likely pregnant or had pancreatitis at the 
baseline. Considering that the probability of having each one of those two events was low, 
it did not affect the conclusion. However, several variables or specific categories were 
conflicted with the trend that the more treatment classes a patient received at the baseline, 
the more likely the patient was to suffer from a specific comorbidity. For example, the 
proportion of having pancreatitis decreased as the number of treatment classes that a 
patient received at the baseline increased. Compared with a patient who received one 
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class of treatment, patients who did not initiate any treatment at baseline had a higher 
probability of being diagnosed with CFRD. 
However, there was a huge difference of associations in Tables 5.8 and 5.10. 
Generally speaking, the clinical information was statistically significant associated with 
the number of treatment that a patient received, but not associated with CFTR function. 
The better clinical outcomes that a patient had, the more likely he would receive less 
class of treatment in related visit. Alternatively, it could be treated as a signal that the 
above clinical information was applied in the decision-making of prescribing, at least the 
number of treatment class that a patient received at the baseline. Even though those were 
associations, not causations, which cannot directly prove the hypothesis, as a descriptive 
objective, the above analyses had already indirectly supported the hypothesis that clinical 
information could be applied to determine rational treatment changes on the treatment 
class level and proved that the study aimed in the right direction. Surprisingly, there were 
fewer younger patients in the no initial treatment group than the other groups, which 
probably indicated that the young patients were overtreated. Considering the effect of 
CFTR function, the mutation class should be considered in treatment decision-making. 
This is explored further in Aim 2.  
 
5.3.4 Competing Risks of Death by Calendar Year 
The majority of deaths were caused by respiratory-related comorbidities; the 
competing risks of death for other comorbidities were low. As shown in Table 5.11, there 
were increasing trends of death in several groups, which could be explained by the 
following reasons. First of all, the quality of data was better after 2006, supported by a 
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preliminary analysis. Given the improvement in collecting information, it was highly 
likely that more deaths and reasons for death would be captured. Moreover, the 
improvements on length of survival also contributed to this trend. The longer a patient 
lives, the more likely he/she would be to die from reasons other than lung function 
deterioration.  
 
5.3.5 Treatment Combinations and Treatment Change Patterns 
At first, bronchodilators were also considered as another treatment class. However, 
considering the result of another preliminary analysis, the unstable, irrational treatment 
change that was caused by including BD as another class, and the limited treatment 
effects of BD, this study focused on only the 3 treatment classes.  
There were 24 treatment combinations in the baseline visit. However, the top 5 
treatment combinations encompassed more than 4/5 (82.06%) of the patient population. 
More than 2/3 (71.39%) of the patients did not receive any inhaled antibiotics at the 
baseline.  More than 80% (81.93%) of the patients did not receive any anti-
inflammatories. Mycolytics is the treatment class that most patients were on (59.32%). 
The above results indicated that patients in the cohort either had acceptable lung function 
or were undertreated. Considering the results of lung function in Tables 5.6, 5.8, and 5.10, 
the results match the results here, which support the former conclusion that patients had 
acceptable lung functions at the baseline. It was rare for a patient to receive more than 1 
anti-inflammatory or more than 1 inhaled antibiotic.  
Several interesting results were identified by heat-maps. First, physicians were 
prone to prescribe an additional inhaled antibiotic, or mucolytic, or anti-inflammatory to 
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maintain patients’ lung functions. However, the chance of prescribing additional 
mucolytics was higher than either of the other two. It was probably caused by the 
certainty and estimate of net benefit together with the more approachable price of 
medications in that class. This result is significant, in terms of supporting the search for 
evidence-based decision-making and precision medicine. The chronic treatment guideline 
only recommends a treatment according to the certainty and estimate of the net benefit, 
but fails to suggest a treatment change pattern and probability of following a specific 
switching path. With the successful identification of the above results, together with the 
optimal rational treatment change strategy that was identified in Aim 3, this gap can be 
bridged. In the future, a physician should be able to determine the optimal treatment 
strategy and the path of treatment change according to the patient’s characteristics, 
clinical values, and treatment history.  
Moreover, the trend of length of time on current treatment was also consistent in 
Figures 5.5 and 5.7. The more treatments that a patient received, the longer the patient 
would keep using the current treatment. The conclusion was supported by the trends in 
those figures, from the bottom to the top, the color of squares got darker on average. This 
pattern was particularly prevalent when the patient was treatment naïve or only receiving 
1 anti-inflammatory. Compared to Figure 5.5, Figure 5.7 is more solid, which was 
supported by the following reasons. First, there were more patients in each square, which 
decreased the chance of having extreme treatment length. As an example, patients who 
had the top 2 longest treatment length in Figure 5.4 had much lighter color in Figure 5.6. 
Previously, there was only one patient in each one of the switching paths ‘210’ to ‘310’ 
and ‘001’ to ‘112’. However, the number of patients increased to 7 and 2, respectively. 
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Therefore, the chance of having an extreme length would be significantly eliminated by 
having more patients in each switching path. This explanation also applies to the squares, 
which had extreme short length but advanced current treatments. Moreover, both figures 
failed to measure treatment change at the last visit. However, considering there were 
more treatment changes in the second figure than the first, the chance of having a biased 
result in Figure 5.7 should be lower than in Figure 5.5. Last but not least, Figure 5.5 only 
measured the 1st treatment change in the cohort, in which patients would definitely be 
healthier than later when declines in health prompted the recorded treatment changes. 
There is no doubt that Figure 5.5 would fail to measure severe situations. For example, 
none of the patients had received more than 2 inhaled antibiotics as the current treatment 
in Figure 5.5. In summary, the more advanced treatments that a patient received, the 
longer he would keep using the current treatment. 
Last but not least, the fewer treatments that a patient received, the more treatment 
combinations were available to switch to. As mentioned previously, as the current 
treatment combination improved from ‘000’, ‘100’, to ‘200’, the potential number of 
treatment combinations that a patient could switch to decreased from 22, 8, to 3, which 
exactly matched current knowledge. There were limited chronic treatments for CF 
patients, three inhaled antibiotics, two mucolytics, and two anti-inflammatories. At the 
beginning, when patients were treatment naive or only received one class of treatment, 
there were plenty of choices. As the disease progresses, after a patient has received 
advanced treatments, say 2 inhaled antibiotics, 1 mucolytic, and 1 anti-inflammatory, 
there are few choices left. Together with the economic burden, a majority of the time a 
patient may keep using the same advanced treatment combination, but having more 
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additional treatments, even the suboptimal status are reached. However, several treatment 
combinations rarely occur. There were only 33 treatment combinations in the cohort, 
other than no treatment, yet nobody reported that he was only on 3 inhaled antibiotics, or 
3 inhaled antibiotics and 2 anti-inflammatories in the potential treatment combination.  
All of the above information portrays a cross-sectional treatment pattern of 
patients who were diagnosed with nonmucoid PaPI. Even though several assumptions 
were made, the chance of the results that was being biased by those assumptions is low, 
since the majority of them were determined either based on well-accepted clinical 
evidence, or investigated and supported by preliminary tests. In the baseline visit, patients 
in this cohort had acceptable generalizability for all CF patients in the U.S., but were 
younger, healthier with less comorbidities. The results from both the baseline visit and 
follow-up visits indicated that the clinical values were applied in the decision-making of 
prescribing. The better clinical outcomes that a patient had, the more likely he would 
receive less class of treatment in related visit. Even though there were 24 treatment 
combinations in the baseline visit, physicians were more likely (82.06%) to prescribe one 
of five treatment combinations. During follow-ups, physicians were prone to prescribe an 
additional inhaled antibiotic, or mucolytic, or anti-inflammatory to maintain patients’ 
lung functions. The chance of prescribing an additional mucolytic was higher than either 
of the other two. At the same time, the more treatments that a patient received, the longer 
the patient would keep using the current treatment. Furthermore, the fewer treatments that 
a patient received, the more treatment combinations were available to switch to in future 
visit.  
This is the largest cohort of United States CF patients who were diagnosed with 
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nonmucoid PaPI and had not developed mucoid PaPI from 2006 to 2011. Because of the 
large sample size, diverse center in U.S., long-term follow-up, and good quality of the 
data, there was an excellent opportunity to comprehensively analyze this subgroup of CF 
patients. These results could not only indicate the variations of disease stage that this 
subpopulation exhibits, but also support the decision-making around having rational 
treatment changes. However, the drawback of this cohort is that because of the composite 
inclusion criteria, the cohort is a mixed population including both newly diagnosed 
patients and patients who had been diagnosed with nonmucoid PaPI for years. Because of 
this, the index date was determined to be either the first date when the patient was 
diagnosed with nonmucoid PaPI, or the first visit in 2006 for those patients who had been 
previously diagnosed with nonmucoid PaPI. Under this situation, the result is more 
generalizable for all patients who had been diagnosed with nonmucoid PaPI. However, 
the stability of the decision support these results provide is lower than one that could be 
identified using the subcohort, in which patients have identical disease stages. Therefore, 
this study is the first step toward analyzing how to make rational treatment change 
decisions, which maximize the delay of developing mucoid PaPI. Further analyses for 
more specific patient populations are needed. 
  
5.4 Conclusions 
Even though several assumptions were made prior to the investigation, the chance 
of the results that was being biased by those assumptions is low, since the majority of 
them were determined either based on well-accepted clinical evidence, or investigated 
and supported by preliminary tests. 
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This is the largest cohort of United States CF patients who were diagnosed with 
nonmucoid PaPI and had not developed mucoid PaPI from 2006 to 2011. Among the 
4,970 unique patients, the majority of them were Caucasian and younger than 12 years 
old. Since the age of this cohort was young, patients were healthy: they were barely 
affected by comorbidities, other than pancreatic insufficiency and GERD, at the baseline; 
majority of patients only had mild impaired lung function, did not have any PEx in the 
previous 1 year, and barely had any drug resistance. However, according to the result of 
genetic testing, more than ¾ of those patients had dysfunction of CFTR protein, which 
indicated more aggressive disease progression. Subgroup analyses indicated that the 
clinical signals were applied in the decision-making of prescribing, at least the number of 
treatment class that a patient received at the baseline.  
Because patients were young and healthy at baseline, they barely received 
advanced treatment combinations: more than half of patients either received no treatment 
or one mucolytic. Regardless of whether only considering the first treatment change or all 
treatment changes in the cohort, physicians were prone to change treatment prudently by 
only prescribing one additional treatment from any one of the three treatment classes. At 
the same time, the fewer treatment classes a patient received, the more potential treatment 
combinations he could switch to. Last but not least, the more treatments that a patient 




Table 5.1. Order list for dealing with variables with conflicted results 
Variable Order 
Race   
 Caucasian  1 
  Black 2 
  Other 3 
Gender   
  Male 1 
  Female 2 
Hispanic   
  Yes 1 
  No 2 
Death date   




































  PEx 1338 1.61 1 1 2 (1, 10) 1338 14.80 10 14 17 (0, 336)
  Pulmonary comlications 
other than PEx 46 1.13 1 1 1 (1, 2) 46 18.43 5 10.5 15 (1, 145)
  GI complications 73 1.07 1 1 1 (1, 2) 73 6.98 2 3 7 (0, 97)
  Transplant related 6 1.00 1 1 1 (1, 1) 6 7.17 1 4.5 10 (1, 22)
  Sinus infection 14 1.21 1 1 1 (1, 2) 14 11.96 9 13 15 (0, 21)
  Non transplant surgery 26 1.00 1 1 1 (1, 1) 26 8.38 0 1 10 (0, 65)
  Other 106 1.15 1 1 1 (1, 5) 106 11.99 2 5.5 14 (0, 243)















  PEx 1137 66.62 51.00 66.84 81.76 (13.03, 152.43) 1213 79.64 64.09 81.14 95.16 (15.09, 161.65)
  Pulmonary comlications 
other than PEx
25 76.09 52.52 82.26 95.77
(33.48, 105.33)
37 81.13 68.37 89.43 94.91 (20.34, 124.57)
  GI complications 25 76.13 61.90 75.47 102.16 (25.91, 119.85) 47 93.74 80.62 95.92 106.73 (33.28, 158.10)
  Transplant related 2 79.78 79.78 79.78 79.78 (79.78, 79.78) 1 83.27 83.27 83.27 83.27
  Sinus infection 7 80.42 62.88 75.90 103.23 (45.26, 121.07) 10 102.88 92.05 102.15 113.16 (72.03, 141.80)
  Non transplant surgery 5 78.05 63.43 65.30 81.56 (62.29, 117.69) 16 98.05 79.83 99.97 118.66 (46.50, 146.92)
  Other 40 84.97 69.34 86.76 99.32 (31.72, 123.99) 81 88.58 76.49 89.63 106.69 (14.15, 144.42)
  Unknown 0 . . . . . 18 100.22 90.57 99.54 113.79 (46.83, 130.50)
 Number of event Mean duration of hospitalization































  PEx 1059 0.22 0.05 0.17 0.33 (-0.37, 1.85) 1054 0.02 0.00 0.01 0.03 (-0.04, 0.32) 
  Pulmonary comlications 
other than PEx
22 0.14 0.02 0.08 0.18
(-0.10, 0.64)
22 0.02 0.00 0.00 0.03
(-0.005, 0.100)
  GI complications 19 0.05 -0.02 0.02 0.09 (-0.16, 0.44) 18 0.01 0.00 0.00 0.02 (-0.08, 0.07)
  Transplant related 1 0.04 0.04 0.04 0.04 1 0.00 0.00 0.00 0.00
  Sinus infection 4 0.15 -0.13 0.11 0.42 (-0.23, 0.60) 4 0.02 -0.01 0.01 0.04 (-0.02, 0.07)
  Non transplant surgery 5 0.01 -0.02 0.00 0.10 (-0.27, 0.25) 4 0.02 -0.02 0.01 0.06 (-0.04, 0.10)
  Other 33 0.03 -0.01 0.05 0.09 (-0.76, 0.43) 32 0.01 0.00 0.00 0.01 (-0.03, 0.09)
  Unknown 0 . . . . . 0 . . . . .























  PEx 1538 1.74 1 1 2 (1, 10) 1538 14.51 10 13 16 (0, 517)
  Pulmonary comlications 
other than PEx 33 1.06 1 1 1 (1, 2) 33 10.12 3 11 14 (0, 29)
  GI complications 76 1.22 1 1 1 (1, 4) 76 4.64 2 2.25 6 (0, 22)
  Transplant related 5 2.00 1 1 2 (1, 5) 5 8.36 1 6 13 (0, 21.80)
  Sinus infection 23 1.09 1 1 1 (1, 2) 23 7.74 1 7 14 (0, 19)
  Non transplant surgery 32 1.06 1 1 1 (1, 2) 32 4.25 0 0 5 (0, 46)
  Other 113 1.28 1 1 1 (1, 18) 113 8.21 2 3 8 (0, 162)















  PEx 1360 66.40 49.59 66.97 82.37 (12.01, 150.56) 1350 79.32 63.78 80.14 96.07 (14.33, 157.11)
  Pulmonary comlications 
other than PEx
25 74.71 63.93 77.91 86.49
(27.36, 117.23)
26 79.24 66.09 83.35 91.73 (23.35, 130.44)
  GI complications 24 81.43 65.70 86.59 98.40 (31.01, 121.08) 52 90.17 83.26 93.68 103.69 (16.81, 126.00)
  Transplant related 2 77.46 66.80 77.46 88.12 (66.80, 88.12) 3 73.57 39.54 88.12 93.06 (39.54, 93.06)
  Sinus infection 13 86.31 61.79 82.50 95.29 (54.05, 162.64) 21 92.69 76.11 89.25 114.67 (43.70, 160.77)
  Non transplant surgery 11 94.52 83.11 99.20 103.95 (36.17, 122.67) 19 92.40 85.73 93.19 103.14 (36.17, 117.56)
  Other 46 73.82 53.38 75.60 90.71 (21.39, 131.75) 78 79.22 69.83 80.73 96.86 (29.13, 128.79)
  Unknown 0 . . . . . 22 95.80 82.05 97.15 107.52 (49.55, 135.41)
 Number of event Mean duration of hospitalization





















  PEx 1218 0.22 0.06 0.17 0.32 (-0.67, 2.07) 1210 0.02 0.00 0.01 0.03 (-0.08, 0.30) 
  Pulmonary comlications 
other than PEx
22 0.13 0.00 0.13 0.25
(-0.13, 0.54)
20 0.03 0.00 0.01 0.05
(-0.03, 0.12)
  GI complications 17 0.05 -0.01 0.07 0.09 (-0.08, 0.22) 17 0.01 0.00 0.01 0.02 (-0.03, 0.09)
  Transplant related 1 0.00 0.00 0.00 0.00 0 . . . . .
  Sinus infection 12 0.07 -0.09 -0.03 0.07 (-0.13, 1.01) 12 0.02 -0.01 -0.01 0.01 (-0.09, 0.34)
  Non transplant surgery 7 0.00 -0.03 0.00 0.01 (-0.10, 0.14) 3 0.05 0.00 0.00 0.14 (0.00, 0.14)
  Other 39 0.03 -0.05 0.03 0.11 (-0.26, 0.46) 37 0.01 -0.01 0.00 0.02 (-0.05, 0.12)
  Unknown 0 . . . . . 0 . . . . .
Mean relative change of FEV1% during hospitalization Mean relative change of FEV1% per day during hospitalization
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Table 5.4. Baseline demographic characteristics 
 
 
N % Mean (range) 1st Quartile Median 3rd Quartile
Age 
  6~8 yrs 2638 53.08% 6.72 (6.00, 9.00) 6.09 6.21 7.23
  9~11yrs 892 17.95% 10.45 (9.00, 12.00) 9.73 10.39 11.22
  12~14yrs 777 15.63% 13.42 (12.00, 14.99) 12.67 13.43 14.13
  15~17yrs 543 10.93% 16.35 (15.00, 17.98) 15.66 16.24 17.04
  >=18yrs 120 2.41% 19.42 (18.00, 22.78) 18.43 19.13 20.12
Total 4970 100.00%
Gender 0.00%
  Male 2454 49.38%
  Female 2516 50.62%
Total 4970 100.00%
Race 
  Caucasian 4685 94.27%
  Black 198 3.98%
  Asian 65 1.31%
  Other 22 0.44%
Total 4970 100.00%
Ethnicity
  Hispanic 365 7.34%
  Non-hispanic 4605 92.66%
  Total 4970 100.00%
Height (cm)
  6~8 yrs 2638 53.08% 116.83 (86.02, 146.00) 111.00 116.00 121.20
  9~11yrs 892 17.95% 136.87 (114.00, 163.00) 131.00 136.00 142.46
  12~14yrs 777 15.63% 153.64 (130.00, 186.00) 147.00 154.00 159.00
  15~18yrs 543 10.93% 164.84 (140.00, 190.00) 158.00 165.00 171.00
  >18yrs 120 2.41% 167.95 (143.93, 188.2) 161.50 168.00 173.00
Total 4970 100.00%
Weight (kg)
  6~8 yrs 2638 53.08% 21.98 (12.30, 50.50) 19.10 21.20 23.80
  9~11yrs 892 17.95% 33.18 (19.90, 100.00) 27.80 31.40 36.40
  12~14yrs 777 15.63% 45.23 (22.70, 84.56) 37.50 44.10 51.10
  15~18yrs 543 10.93% 56.22 (30.80, 105.00) 48.80 55.00 61.70
  >18yrs 120 2.41% 60.33 (39.60, 110.00) 53.51 58.60 65.30
Total 4970 100.00%
Smoking 0.00%
  No 4633 93.22%
  Yes 30 0.60%
  Not known/declined to a 307 6.18%
Total 4970 100.00%
Transplant status
  No 4954 99.68%
  Had transplant 9 0.18%
  Accepted, on waiting list 7 0.14%
Total 4970 100.00%
Pregnancy
  No 4949 99.58%
  Yes 6 0.12%




Table 5.4. (continued) 
 
 
N % Mean (range) 1st Quartile Median 3rd Quartile
Comorbidities
  CFRD 192 3.86%
  Pancreatic insufficiency 4649 93.54%
  Gastrointestinal symptoms
    DIOS 70 1.41%
    GERD 672 13.52%
    Pancreatitis 15 0.30%
  Pulmonary
    ABPA 118 2.37%




Table 5.5. Baseline demographic characteristics 
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Table 5.7. Baseline demographic characteristics by mutation class  
 
 
N % Mean (range) N % Mean (range) N % Mean (range)
Age <0.0001
  6~8 yrs 2130 55.27% 6.72 (6.00, 9.00) 98 46.45% 6.58 (6.00, 9.00) 410 45.30% 6.75 (6.00. 9.00)
  9~11yrs 679 17.62% 10.45 (9.00, 12.00) 39 18.48% 10.43 (9.01, 11.79) 174 19.23% 10.47 (9.02, 11.91)
  12~14yrs 581 15.08% 13.36 (12.00, 14.99) 30 14.22% 13.52 (12.27, 14.85) 166 18.34% 13.57 (12.01, 14.97)
  15~17yrs 383 9.94% 16.35 (15.00, 17.98) 33 15.64% 16.45 (15.03, 17.94) 127 14.03% 16.34 (15.00, 17.96)
  >=18yrs 81 2.10% 19.25 (18.00, 22.25) 11 5.21% 20.18 (18.46, 22.27) 28 3.09% 19.65 (18.01, 22.78)
Total 3854 100.00% 211 100.00% 905 100.00%
Gender 0.6837
  Male 1914 49.66% 105 49.76% 435 48.07%
  Female 1940 50.34% 106 50.24% 470 51.93%
Total 3854 100.00% 211 100.00% 905 100.00%
Race <0.0001
  Caucasian 3690 95.74% 199 94.31% 796 87.96%
  Black 107 2.78% 7 3.32% 84 9.28%
  Asian 47 1.22% 3 1.42% 15 1.66%
  Other 10 0.26% 2 0.95% 10 1.10%
Total 3854 100.00% 211 100.00% 905 100.00%
Ethnicity <0.0001
  Hispanic 218 5.66% 21 9.95% 126 13.92%
  Non-hispanic 3636 94.34% 190 90.05% 779 86.08%
  Total 3854 100.00% 211 100.00% 905 100.00%
Height (cm)
  6~8 yrs 2130 55.27% 116.85 (86.02, 146.00) 98 46.45% 118.27 (105.00, 137.00) 410 45.30% 116.38 (100.00, 141.00) 0.077
  9~11yrs 679 17.62% 136.46 (114.00, 162.00) 39 18.48% 141.09 (125.00. 158.00) 174 19.23% 137.52 (118.00, 163.00) 0.0019
  12~14yrs 581 15.08% 153.29 (132.99, 181.94) 30 14.22% 157.75 (137.00, 186.00) 166 18.34% 154.11 (130.00, 179.00) 0.0226
  15~18yrs 383 9.94% 164.10 (140.00, 190.00) 33 15.64% 170.62 (152.00, 187.00) 127 14.03% 165.57 (147.00, 188.00) 0.0003
  >18yrs 81 2.10% 168.58 (152.00, 188.20) 11 5.21% 169.55 (158.00, 185.00) 28 3.09% 165.52 (143.93, 185.00) 0.2312
Total 3854 100.00% 211 100.00% 905 100.00%
Chisq/  
ANOVA








N % Mean (range) N % Mean (range) N % Mean (range)
Weight (kg)
  6~8 yrs 2130 55.27% 21.90 (12.80, 50.50) 98 46.45% 23.54 (16.00, 41.50) 410 45.30% 21.99 (12.30, 45.00) 0.0008
  9~11yrs 679 17.62% 32.43 (19.90, 75.50) 39 18.48% 39.28 (25.40, 74.70) 174 19.23% 34.75 (20.50, 100.00) <0.0001
  12~14yrs 581 15.08% 44.45 (22.70, 84.56) 30 14.22% 53.57 (34.40, 80. 40) 166 18.34% 46.45 (26.20, 83.89) <0.0001
  15~18yrs 383 9.94% 55.33 (30.80, 100.00) 33 15.64% 64.22 (45.35, 105.00) 127 14.03% 56.80 (34.00, 102.00) <0.0001
  >18yrs 81 2.10% 59.77 (39.60, 78.30) 11 5.21% 68.53 (51.90, 110.00) 28 3.09% 58.71 (43.50, 91.20) 0.0222
Total 3854 100.00% 211 100.00% 905 100.00%
Smoking 0.6408
  No 3593 93.23% 200 94.79% 840 92.82%
  Yes 23 0.60% 2 0.95% 5 0.55%
  Not known/ 
declined to answer/ 
missing
238 6.18% 9 4.27% 60 6.63%
Total 3854 100.00% 211 100.00% 905 100.00%
Transplant status 0.3149
  No 3840 99.64% 210 99.53% 904 99.89%
  Had transplant 9 0.23% 0 0.00% 0 0.00%
  Accepted, on 
waiting list
5 0.13% 1 0.47% 1 0.11%
Total 3854 100.00% 211 100.00% 905 100.00%
Pregnancy 0.0033
  No 3844 99.74% 208 98.58% 897 99.12%
  Yes 4 0.10% 1 0.47% 1 0.11%
  Unknown 6 0.16% 2 0.95% 7 0.77%
Total 3854 100.00% 211 100.00% 905 100.00%
Chisq/  
ANOVA















N % Mean (range) N % Mean (range) N % Mean (range)
Comorbidities
  CFRD 156 4.05% 2 0.95% 34 3.76% 0.046
  Gastrointestinal 
symptoms
    DIOS 59 1.53% 2 0.95% 9 0.99% 0.4564
    GERD 550 14.27% 21 9.95% 101 11.16% 0.0145
    Pancreatitis 5 0.13% 9 4.27% 1 0.11% <0.0001
  Pulmonary
    ABPA 85 2.21% 7 3.32% 26 2.87% 0.3239
Chisq/  
ANOVA




Table 5.8. Baseline clinical information by mutation class 
 
 
N % Mean (range) N % Mean (range) N % Mean (range)
FEV1% 0.7081
  >70% 2845 73.82% 102.83 (70.01, 258.71) 158 74.88% 107.14 (70.65, 187.82) 653 72.15% 101.92 (70.07, 189.05) 0.0095
  40~70% 358 9.29% 59.12 (40.02, 69.93) 15 7.11% 59.71 (45.85 69.46) 90 9.94% 58.78 (40.16, 69.89) 0.901
  10~40% 41 1.06% 32.65 (18.50, 39.90) 1 0.47% 36.20 13 1.44% 32.34 (22.51, 39.21) 0.8609
  missing 610 15.83% 37 17.54% 149 16.46%
Total 3854 100.00% 211 100.00% 905 100.00%
# of Pex 0.5288
0 3014 78.20% 178 84.36% 702 77.57%
1 614 15.93% 24 11.37% 139 15.36%
2 149 3.87% 7 3.32% 43 4.75%
3 52 1.35% 0 0.00% 14 1.55%
4 14 0.36% 1 0.47% 4 0.44%
5+ 11 0.29% 1 0.47% 3 0.33%
Total 3854 100.00% 211 100.00% 905 100.00%
# of Pex (loose) 0.2449
0 2196 56.98% 133 63.03% 531 58.67%
1 943 24.47% 35 16.59% 213 23.54%
2 368 9.55% 24 11.37% 90 9.94%
3 192 4.98% 10 4.74% 35 3.87%
4 84 2.18% 3 1.42% 13 1.44%
5 45 1.17% 5 2.37% 14 1.55%
6 14 0.36% 0 0.00% 5 0.55%
7 4 0.10% 1 0.47% 1 0.11%
8+ 8 0.21% 0 0.00% 3 0.33%
Total 3854 100.00% 211 100.00% 905 100.00%
Drug resistance
  Aminoglycoside 60 1.56% 3 1.42% 15 1.66% 0.8494
  Beta-lactum 26 0.67% 1 0.47% 6 0.66% 0.9358
  Quinolone 32 0.83% 2 0.95% 7 0.77% 0.8494






Table 5.9. Baseline demographic characteristics by initial treatment classes, ML, AI, IA 
 
 
N % Mean (range) N % Mean (range) N % Mean (range) N % Mean (range)
Age <0.0001
  6~8 yrs 934 44.35% 993 62.81% 556 56.91% 155 50.65%
  9~11yrs 460 21.84% 235 14.86% 154 15.76% 43 14.05%
  12~14yrs 389 18.47% 205 12.97% 137 14.02% 46 15.03%
  15~17yrs 298 14.15% 109 6.89% 88 9.01% 48 15.69%
  >=18yrs 25 1.19% 39 2.47% 42 4.30% 14 4.58%
Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
Gender 0.076
  Male 1003 47.63% 782 49.46% 514 52.61% 155 50.65%
  Female 1103 52.37% 799 50.54% 463 47.39% 151 49.35%
Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
Race 0.0372
  Caucasian 1991 94.54% 1483 93.80% 929 95.09% 282 92.16%
  Black 84 3.99% 72 4.55% 30 3.07% 12 3.92%
  Asian 26 1.23% 20 1.27% 10 1.02% 9 2.94%
  Other 5 0.24% 6 0.38% 8 0.82% 3 0.98%
Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
Ethnicity <0.0001
  Hispanic 114 5.41% 104 6.58% 104 10.64% 43 14.05%
  Non-hispanic 1992 94.59% 1477 93.42% 873 89.36% 263 85.95%
  Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
Height (cm)
  6~8 yrs 934 44.35% 118.62 (86.02, 142.00) 993 62.81% 116.02 (91.10, 146.00) 556 56.91% 115.56 (100.00, 138.00) 155 50.65% 115.73 (100.00, 143.00) <0.0001
  9~11yrs 460 21.84% 137.04 (114.00, 163.00) 235 14.86% 137.05 (118.00, 162.00) 154 15.76% 136.52 (118.00, 162.00) 43 14.05% 135.40 (115.00, 157.00) 0.5991
  12~14yrs 389 18.47% 154.46 (133.00, 186.00) 205 12.97% 153.22 (132.99, 176.00) 137 14.02% 152.52 (130.00, 178.00) 46 15.03% 151.94 (133.00, 169.00) 0.0588
  15~18yrs 298 14.15% 164.67 (140.00, 190.00) 109 6.89% 166.69 (147.00, 186.00) 88 9.01% 164.44 (145.00, 188.00) 48 15.69% 162.47 (145.00, 189.00) 0.0473
  >18yrs 25 1.19% 171.49 (157.00, 186.00) 39 2.47% 167.44 (149.00, 188.20) 42 4.30% 167.16 (143.93, 188.00) 14 4.58% 165.43 (152.00, 177.00) 0.1243
Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
Weight (kg)
  6~8 yrs 934 44.35% 22.79 (13.32, 48.70) 993 62.81% 21.64 (12.80, 50.50) 556 56.91% 21.29 (13.40, 40.40) 155 50.65% 21.65 (12.30, 36.10) <0.0001
  9~11yrs 460 21.84% 33.53 (20.50, 100.00) 235 14.86% 32.98 (21.10, 63.70) 154 15.76% 32.87 (21.70, 60.20) 43 14.05% 31.62 (19.90, 52.10) 0.4294
  12~14yrs 389 18.47% 46.17 (25.50, 84.56) 205 12.97% 44.40 (26.23, 83.89) 137 14.02% 44.40 (27.00, 74.90) 46 15.03% 43.50 (22.70, 66.70) 0.0652
  15~18yrs 298 14.15% 56.36 (30.80, 105.00) 109 6.89% 58.33 (38.10, 97.10) 88 9.01% 54.70 (34.00, 102.00) 48 15.69% 53.29 (36.64, 100.00) 0.0242
  >18yrs 25 1.19% 62.93 (43.50, 91.20) 39 2.47% 61.48 (42.80, 110.00) 42 4.30% 60.16 (44.81, 87.50) 14 4.58% 52.98 (39.60, 69.00) 0.0305
Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
Chisq/ 
ANOVA









N % Mean (range) N % Mean (range) N % Mean (range) N % Mean (range)
Smoking 0.2035
  No 1967 93.40% 1479 93.55% 905 92.63% 282 92.16%
  Yes 19 0.90% 6 0.38% 3 0.31% 2 0.65%
  Not known/ 
declined to answer/ 
missing
120 5.70% 96 6.07% 69 7.06% 22 7.19%
Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
Transplant status 0.1711
  No 2098 99.62% 1578 99.81% 974 99.69% 304 99.35%
  Had transplant 5 0.24% 3 0.19% 1 0.10% 0 0.00%
  Accepted, on 
waiting list
3 0.14% 0 0.00% 2 0.20% 2 0.65%
Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
Pregnancy 0.0613
  No 2102 99.81% 1572 99.43% 970 99.28% 305 99.67%
  Yes 3 0.14% 2 0.13% 1 0.10% 0 0.00%
  Unknown 1 0.05% 7 0.44% 6 0.61% 1 0.33%
Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
Comorbidities
  CFRD 89 4.23% 41 2.59% 37 3.79% 25 8.17% <0.0001
   Pancreatic 
insufficiency
1958 92.97% 1491 94.31% 914 93.55% 286 93.46% 0.4459
  Gastrointestinal 
symptoms
    DIOS 30 1.42% 21 1.33% 16 1.64% 3 0.98% 0.8695
    GERD 189 8.97% 258 16.32% 168 17.20% 57 18.63% <0.0001
    Pancreatitis 9 0.43% 5 0.32% 1 0.10% 0 0.00% 0.4681
  Pulmonary
    ABPA 45 2.14% 30 1.90% 29 2.97% 14 4.58% 0.019
Chisq/ 
ANOVA









N % Mean (range) N % Mean (range) N % Mean (range) N % Mean (range)
FEV1% <0.0001
  >70% 1606 76.26% 100.83 (70.04, 181.51) 1207 76.34% 105.83 (70.21, 195.42) 652 66.73% 102.76 (70.01, 258.71) 191 62.42% 101.33 (70.07, 158.98) <0.0001
  40~70% 195 9.26% 59.15 (40.02, 69.89) 100 6.33% 61.20 (40.32, 69.91) 124 12.69% 58.61 (40.37, 69.93) 44 14.38% 55.22 (40.11, 69.36) 0.001
  10~40% 19 0.90% 31.91 (18.58, 39.21) 6 0.38% 34.87 (26.67, 39.72) 18 1.84% 34.23 (21.47, 39.90) 12 3.92% 30.32 (18.50, 39.89) 0.3472
  missing 286 13.58% 268 16.95% 183 18.73% 59 19.28%
Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
# of Pex <0.0001
0 1701 80.77% 1307 82.67% 702 71.85% 184 60.13%
1 286 13.58% 220 13.92% 193 19.75% 78 25.49%
2 82 3.89% 38 2.40% 55 5.63% 24 7.84%
3 24 1.14% 13 0.82% 18 1.84% 11 3.59%
4 9 0.43% 2 0.13% 6 0.61% 2 0.65%
5+ 4 0.19% 1 0.06% 3 0.31% 7 2.29%
Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
# of Pex (loose) <0.0001
0 1452 68.95% 830 52.50% 456 46.67% 122 39.87%
1 441 20.94% 425 26.88% 242 24.77% 83 27.12%
2 139 6.60% 175 11.07% 134 13.72% 34 11.11%
3 49 2.33% 78 4.93% 75 7.68% 35 11.44%
4 15 0.71% 34 2.15% 35 3.58% 16 5.23%
5 6 0.28% 28 1.77% 20 2.05% 10 3.27%
6 3 0.14% 7 0.44% 8 0.82% 1 0.33%
7 1 0.05% 1 0.06% 2 0.20% 2 0.65%
8+ 0 0.00% 3 0.19% 5 0.51% 3 0.98%
Total 2106 100.00% 1581 100.00% 977 100.00% 306 100.00%
Drug resistance
  Aminoglycoside 22 1.04% 20 1.27% 21 2.15% 15 4.90% <0.0001
  Beta-lactum 10 0.47% 8 0.51% 10 1.02% 5 1.63% 0.0134
  Quinolone 9 0.43% 15 0.95% 9 0.92% 8 2.61% 0.0001
Chisq/ 
ANOVA




Table 5.11. Prevalence and incidence of each reason for death by calendar year 
 
 
Prevalence Incidence Prevalence Incidence Prevalence Incidence Prevalence Incidence Prevalence Incidence Prevalence Incidence
Respiratory/cardiorespiratory 7.62 7.64 8.37 8.40 8.38 8.41 9.02 9.06 8.14 8.17 8.42 8.46
Liver disease/liver failure 0.33 0.33 0.27 0.27 0.29 0.29 0.29 0.29 0.31 0.31 0.34 0.34
Trauma 0.15 0.15 0.06 0.06 0.09 0.09 0.14 0.14 0.06 0.06 0.14 0.14
Suicide 0.09 0.09 0.09 0.09 0.00 0.00 0.11 0.11 0.06 0.06 0.06 0.06
Transplant related: 
Bronchiolitis obliterans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.40 0.40 0.54 0.54
Transplant related: Other 1.40 1.40 1.50 1.50 1.66 1.66 1.64 1.64 1.11 1.11 1.42 1.42
Other 0.93 0.93 0.97 0.97 1.13 1.14 1.06 1.06 0.71 0.71 0.85 0.85
Unknown 0.51 0.51 0.47 0.47 0.96 0.96 0.78 0.78 1.05 1.05 0.82 0.82
2009 2010 20112006 2007 2008
  
 
200  Figure 5.2. Flow chart 
  
 
201  Figure 5.3. The proportion of patients who were on different treatment combinations at the baseline. 
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To fulfill Aim 2, a complex strategy of missing value imputation was conducted, 
which was explained in detail in Appendix F. This section described the results using the 
10 imputed datasets from three parts. The first part described how each independent 
variable was identified. Then, the result of variable selection using elastic net was 
described in four procedures: 1) identifying the optimal balance factor, α (by 
investigating the probability of specific α that was chosen among 10 imputed datasets 
according to the minimum of mean cross-validated error); 2) identifying the optimal 
penalty factor, λ (by investigating the minimum standard deviation of lambda given α 
among 10 imputed datasets and the probability that α had been chosen in step 1); 3) 
selecting the variables in the model (by investigating the proportion of a variable that had 
been selected given α and λ that had been chosen in the previous steps among 10 imputed 
datasets); 4) calculating the coefficient for each variable (by combining the related 
coefficients that were identified among 10 imputed datasets). After calculating the overall 
coefficient for each variable among 10 imputed datasets, the predicted probability and 
relative change of predicted probability of having rational treatment change were imputed 
for each visit. Last, given the above predicted probability, relative change of predicted 
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probability of having rational treatment change, together with different thresholds, 25 
varied timing strategies for treatment change were created. 
As mentioned previously, bronchodilator (BD) use was not considered as a 
treatment class. At the same time, from clinical experience, the neutral definition has 
limited generalizability, which assumed the termination of any treatment class had to 
match changes in clinical signals—a sign that a patient’s health is improving. Therefore, 
three treatment classes, inhaled antibiotics (IA), mycolytics (ML), and anti-
inflammatories (AI), were taken into consideration to define the rational treatment change 
under either the loose or strict assumptions. Compared to the loose assumption, in which 
all treatment changes were treated as rational treatment changes regardless of the changes 
in clinical signals, the strict definition is more rigorous in that all rational treatment 
changes had to comply with changes in the clinical signals. Because of the difference in 
identifying rational treatment change, all following results, such as predicting the 
probability of having a rational treatment change, and identifying optimal treatment 
change strategies, would be different. It could be taken as conducting two models with 
the same procedures. To simplify the presentation, in the following section, the main 
focus is on the results of applying the strict definition. The result of applying the loose 
definition is also described with explanation.  
 
6.1.1 Independent Variable Identification 
Independent variables were identified as all the variables that were investigated in 
the related literature. At the same time, all the unique variables that were recorded in the 
CFFPR were taken into consideration. Since no variable had more than 50% missing 
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values for the majority of patients, all variables in the CFFPR were considered for 
variable selection. Cubic spline of time of visit with three knots was also created for each 
visit. 
 
6.1.2 Variable Selection by Elastic Net 
Following the procedures that were mentioned in the section on methods, an 
elastic net was conducted to investigate the model that balanced the accuracy of 
prediction and the parsimoniousness of the variables. First, the optimal 𝛼𝛼� was identified. 
Table 6.1 presents the minimum of the mean cross-validated error using deviance as the 
measurement in each imputed dataset given different 𝛼𝛼� . The minimum deviance, 
regardless of the value of 𝛼𝛼� , was identified in each imputed dataset, and marked as 
yellow. In Table 6.1, other than two imputed datasets where the minimum deviance could 
be reached when 𝛼𝛼 equaled 0.9 or 1, the minimum deviance is only reached when 𝛼𝛼 is 
equal to 1. The difference in minimum deviance between imputed datasets was small. 
According to the result, optimal 𝛼𝛼� is equal to either 0.9 or 1. Unlike Table 6.1, which 
uses the strict definition to capture the rational treatment change, the rational treatment 
change in Table 6.2 is captured by using the loose definition. To identify the unique 
optimal 𝛼𝛼� and prevent overfitting, rather than using 𝜆𝜆𝑑𝑑∗, which was associated with the 
minimum of mean cross-validated error, 𝜆𝜆𝑑𝑑′, which gave the most regularized model such 
that error is within one standard error of the minimum of mean cross-validated error 
given 𝛼𝛼�, was identified among each imputed dataset. The related 𝜆𝜆𝚤𝚤′�  was marked in yellow 
in Table 6.3 for each imputed dataset given different optimal 𝛼𝛼� . The 𝛼𝛼�  that was 
associated with the minimum SD of 𝜆𝜆𝚤𝚤′�  should be the optimal one. Compared with 𝛼𝛼� = 0.9, 
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𝛼𝛼� = 1 was associated with a smaller SD (0.000100 vs. 0.000104) of 𝜆𝜆𝑑𝑑′ across the imputed 
datasets. This indicated less variance of ?̂?𝜆, and less chance of overfitting among imputed 
datasets. Even though when 𝛼𝛼� = 0.8, the SD of 𝜆𝜆𝚤𝚤′�  across the imputed datasets was smaller 
(0.000080), considering that the optimal 𝛼𝛼�  could only equal to 0.9 or 1 as identified 
previously, the result of 0.8 was ignored. Therefore, the optimal 𝛼𝛼� was 1, and the related 
optimal ?̂?𝜆 was 0.002009, the median of 𝜆𝜆𝚤𝚤′�  when 𝛼𝛼� = 1. 
Unlike the strict definition, the optimal 𝛼𝛼� was identified in a more straightforward 
manner using the loose definition. As shown in Table 6.2, using the loose definition, 𝛼𝛼� = 
1 is always associated with the minimum deviance in all imputed datasets. Even though 
the minimum SD of 𝜆𝜆𝚤𝚤′�  was not reached when 𝛼𝛼�  = 1, the difference was trivial 
(4.336809E-19 vs. 0) in Table 6.4. Therefore, the optimal 𝛼𝛼� = 1, and the related optimal ?̂?𝜆 
was 0.002223, the 𝜆𝜆𝚤𝚤′�  in the first imputed dataset when 𝛼𝛼�  = 1. Table 6.5 presents the 
choices of optimal 𝛼𝛼�  and ?̂?𝜆  combinations for different outcomes. The only difference 
between the left and right column is the consideration of the number of PEx as either a 
categorical variable or a continuous variable in the prediction model. The probability 
indicated the chance of identifying the minimum deviance by using the related 𝛼𝛼� among 
imputed datasets. The resource indicated from where the optimal ?̂?𝜆  was identified, it 
could be either from the imputed dataset 1 or the median of 𝜆𝜆𝚤𝚤′� . The optimal ?̂?𝜆 would only 
be identified from the imputed dataset 1, if the related SD of 𝜆𝜆𝚤𝚤′�  was close to 0, otherwise 
the median of 𝜆𝜆𝚤𝚤′�  would be applied. Regardless of the outcome, it was more likely that the 
optimal 𝛼𝛼� = 1. Because of this, in the following analyses, optimal 𝛼𝛼� was always set up as 
1. The related optimal ?̂?𝜆  was identified according to the outcome in each prediction 
model, which was marked in yellow in Table 6.5. 
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After identifying the optimal combination of 𝛼𝛼� and ?̂?𝜆, the proportion of a variable 
that had been selected in each model among 10 imputed datasets was reported in Table 
6.6. Unlike continuous variables, which reported the proportion of being selected directly, 
the categorical variables reported the highest proportion in one of its category in Table 
6.7. The influence of including PEx defined loosely (‘PExloose’) was investigated. The 
left side of Tables 6.6 and 6.7 does not include PExloose while the right side does include 
PExloose in the model. Similar to Table 6.5, the number of PEx in the past year, as either 
a categorical or continuous variable, was assigned in different models to investigate its 
influence on variable selection. The influence of variable selection according to different 
definitions of outcomes were also investigated.  
The result of the influence of including PExloose and whether the number of PEx 
in the past year should be treated as a categorical variable will be analyzed in the 
following two paragraphs. Red font indicates that there was a difference in the proportion 
of a variable that had been selected between the models that did and did not include 
PExloose. However, this difference does not affect the result of the variable selection as 
long as the number was larger than 0, since all variables that were larger than 0 were 
selected into the prediction model. For example, under the loose definition of having a 
rational treatment change, if the number of PEx was treated as a continuous variable, 
compared to the model that did not include PExloose, the chance of selecting predicted 
FEV1 in the previous visit as a predictor for the prediction model decreased from 0.8 to 
0.6 in the model that included PExloose. In other words, the predicted FEV1 in the 
previous visit was selected as the predictor in 6 imputed datasets if PExloose was 
considered and the outcome was defined loosely. Other than predicted FEV1 in the 
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previous visit, after considering PExloose, whether the patient was infected by 
Aspergillus was the only variable that was associated with less chance of being selected. 
Conversely, whether the patient had pancreatic insufficiency, pancreatitis, nonmucoid 
PaPI, or drug resistance to beta lactams in the previous visit were variables that had a 
higher chance of being selected after taking the number of PExloose into consideration. 
However, none of the above changes in proportion affected the variable selection in 
related models. There was only one variable which affected the pattern of selected 
variables after considering PExloose. This is marked in blue in Table 6.6. If the rational 
treatment change was defined loosely or neutrally, after considering PExloose, and 
treating the number of PEx and PExloose as continuous variables, then the chance of 
being selected for the variable that indicated drug resistance to quinolone in the current 
visit decreased from 0.5 to 0. Considering the similarity between the variable of the 
number of PEx and PExloose, together with the limited difference in the pattern of 
selected variables, there was limited difference between including and not including the 
variable of number of PExloose. Therefore, the final model did not include the number of 
PExloose.    
Compared to the model that treated the number of PEx as a continuous variable, 
the pattern of the selected variable is different for three variables if the number of PEx 
was treated as a categorical variable. Whether the patient had hemoptysis, whether the 
patient was infected by aspergillus, and the number of PEx in the past year at the 
previous visit are those three variables; they are marked in orange in Table 6.6. These 
variables could not be selected as predictors if the number of PEx was treated as a 
continuous variable.  Table 6.7 presents more details on several categorical variables. 
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Mutation 1 class was never selected in any model. However, mutation 2 class was 
selected in the majority of categories, even for the one that ‘doesn’t belong to any class.’ 
Three and four numbers were selected for the number of PEx in the past year in previous 
visit and current visit, respectively. Those numbers were 4, 5, 9 for the previous visit, and 
1, 2, 3, 5 for the current visit, which supported the conclusion that the number of PEx 
barely has any influence when it is beyond 5. At the same time, the variable selection, 
more specifically, category selections for the same variable, were consistent among the 
models regardless of including the number of PExloose or not. Considering the ceiling 
effect was reached when number of PEx reached 5, together with the variable of number 
of PEx in the past year at the previous visit, the clinical signal would not be included if 
the number of PEx was treated as a continuous variable; thus there is no doubt that the 
number of PEx in the past year should be treated a categorical variable with the 
maximum of number of PEx in the past year set as 5.  
Given the 𝛼𝛼�  and ?̂?𝜆 , together with 𝑆𝑆 , which included all variables that were 
selected by elastic net, the generalized linear model with log link function was applied to 
predict the probability of having a rational treatment change in each imputed dataset 𝑆𝑆. 
Following “Rubin’s rule,” the coefficients for the same variable, ?̂?𝛽𝑜𝑜𝑑𝑑, among all imputed 
datasets were combined as ?̂?𝛽𝑜𝑜� . Therefore, a combined coefficient for each variable was 
identified, rather than having 10 coefficients for the same variable in each imputed 
dataset. Tables 6.8 and 6.9 represent the combined coefficients, ?̂?𝛽𝑜𝑜� , under strict and loose 
definitions, respectively. Each table includes four parts: coefficient, standard error, 95% 
CI, and proportion of the total variance that is attributable to the missingness (‘percentage 
of missing’). According to the results shown in Table 6.8, for each additional year of age, 
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the chance of receiving a rational treatment change decreased 0.0302. For each additional 
1% of predicted FEV1 in the current visit, the probability of having a rational treatment 
change decreased 0.0285. However, if the 1% increase occurred at a previous visit, then 
the probability increased 0.0170. Compared to class I on mutation 2, a patient was more 
likely to receive a rational treatment change if the class was II or III, but the influence 
was not statistically significant. Conversely, a patient who had class IV or V on mutation 
2 had only 70.35% and 62.43% chance of having a rational treatment change, 
respectively. Those patients identified as Asian were more likely (1.0901) to receive a 
rational treatment change than those identified as Caucasian, which was not statistically 
significant. Compared to patients identified as Caucasian, patients identified as Black 
were 16.52% less likely to receive a rational treatment change. Patients who were 
infected by Aspergillus and B.cepacia were more likely to receive a rational treatment 
change with 13.05% and 105.41% increases, respectively. However, a patient who was 
infected by MSSA had an 18.88% lower chance of being appropriately treated. If the 
patient was diagnosed with nonmucoid PaPI or mucoid PaPI, the probability of receiving 
a rational treatment change increased by 36.30% and 70.78%, respectively. The more 
PEx that a patient had in the past year at the previous visit, the less likely the patient 
would receive a rational treatment change. However, if the number increased in the 
current visit, then the likelihood increased. A patient with drug resistance to 
aminoglycosides or quinolones in the current visit would have an increased chance of 
receiving a rational treatment change, but the chance would decrease if drug resistance to 
beta lactams occurred in the previous visit. Generally speaking, the more treatment that a 
patient received in the current visit, the less likely the patient would receive a rational 
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treatment change, especially for mucolytics and inhaled antibiotics. There is limited 
difference in the chance of having a rational treatment change between patients who 
received 1 or 2 treatments in the anti-inflammatories class or the bronchodilators class. 
Finally, the proportion of the total variance that is attributable to the missingness was low, 
ranging from 0-6% in this model. 
Compared to the strict model, there were several similarities and differences in 
considering the loose model. Several variables in Table 6.9 share influences on the 
probabilities of having rational treatment changes as the related ones in Table 6.8, such as 
age; predicted FEV1 in the current visit; mutation 2 when class is IV or V; being Black; 
whether the patient was infected by Aspergillus, B.cepacia, or MSSA; whether the 
patient was diagnosed with mucoid PaPI; the number of PEx in the past year as recorded 
at the previous and current visit; and drug resistance to quinolones at the current visit. 
However, there were several differences between the two models. First, several variables 
were only selected in one model but not the other, especially in the comorbidities and 
infections category. For example, whether the patient had pancreatic insufficiency, 
pancreatitis, or was diagnosed with nonmucoid PaPI was included in the model that used 
a strict definition of outcome; whether the patient had hemoptysis was only included in 
the model that loosely defined outcome. Moreover, several variables had statistically 
significant effects in one model but not the other, such as predicted FEV1 at the previous 
visit, when the number of PEx in the past year at the previous visit was greater than 2; 
drug resistance to aminoglycosides in the current visit; and the use of mucolytics, inhaled 
antibiotics, anti-inflammatories, and bronchodilators had statistically significant effects in 
the strict model but not the loose model. Similar to the results in Table 6.8, the proportion 
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of the total variance that is attributable to the missingness is also low, ranging from 0 to 
5%. 
 
6.1.3 Calculating the Predicted Probability of Having Rational  
Treatment Change and Identifying Strategies for Treatment  
Change According to Different Thresholds 
In order to closely mimic the strategy of having a rational treatment change, the 
predicted probability of having a rational treatment change, ?̂?𝑝𝑜𝑜𝑥𝑥,𝑑𝑑, and the relative change 
of predicted probability of having a rational treatment change between the current and 
previous visit, 𝑃𝑃𝑟𝑟� 𝑜𝑜𝑥𝑥,𝑑𝑑, for all visits in each imputed dataset 𝑆𝑆 were calculated. The 𝑝𝑝∗, and 
𝑝𝑝∗∗ , left corner of the ROC curve, was chosen as the cut-off for ?̂?𝑝𝑜𝑜𝑥𝑥,𝑑𝑑 and 𝑃𝑃𝑟𝑟� 𝑜𝑜𝑥𝑥,𝑑𝑑 , 
respectively, in all imputed datasets. After 1000 times nonparametric bootstrapping, 
confidence intervals were generated for ?̂?𝑝𝑜𝑜𝑥𝑥,𝑑𝑑 and 𝑃𝑃𝑟𝑟� 𝑜𝑜𝑥𝑥,𝑑𝑑, respectively. Figures 6.1 and 6.2 
present those results in one imputed dataset (imputed1) using the strictly defined outcome 
and the loosely defined outcome, respectively. In the strict model, the point estimate and 
95% CI for ?̂?𝑝𝑜𝑜𝑥𝑥,𝑑𝑑 and 𝑃𝑃𝑟𝑟� 𝑜𝑜𝑥𝑥,𝑑𝑑 were 0.080 (0.076, 0.084) and 1.831% (0.222, 3.440). In the 
loose model, the values changed to 0.090 (0.087, 0.093) and 0.475% (-0.124%, 1.074%) 
for ?̂?𝑝𝑜𝑜𝑥𝑥,𝑑𝑑 and 𝑃𝑃𝑟𝑟� 𝑜𝑜𝑥𝑥,𝑑𝑑, respectively. Compared to ?̂?𝑝𝑜𝑜𝑥𝑥,𝑑𝑑, the 1000 times bootstrapping of 𝑃𝑃𝑟𝑟� 𝑜𝑜𝑥𝑥,𝑑𝑑 
was more normally distributed, which was supported by the normally distributed 
histogram and the location of the majority of the dots on the line in the quantile-quantile 
plot in Figure 6.1. Even though the distribution of ?̂?𝑝𝑜𝑜𝑥𝑥,𝑑𝑑 skewed to the left, according to 
the result in the quantile-quantile plot, this distribution is still acceptable. However, more 
potential cut-offs need to be investigated. Similar trends are shown in Figure 6.2.  
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The quintile of 95% CI of 𝑝𝑝∗∗ was used to generate cut-offs of 𝑝𝑝∗∗, represented by 
𝑝𝑝𝑒𝑒
∗∗ (n = 1, 2, … , 5). In order to have a larger range of 𝑝𝑝𝑚𝑚∗  (m=1, 2, …, 5), the distance 
between the lower boundary of 95% CI of 𝑝𝑝∗ and 𝑝𝑝∗ was applied to calculate the 𝑝𝑝𝑚𝑚∗ , and 
𝑝𝑝∗ was set as 𝑝𝑝3∗ . Therefore, there were five cutoffs for both 𝑝𝑝∗, and 𝑝𝑝∗∗, which were 
0.072, 0.076, 0.080, 0.084, 0.088 and 0.222%, 1.0265%, 1.831% , 2.6355%, 3.440%, 
respectively.  
In the beginning, 5 dynamic treatment strategies were created relying only on the 
5 cut-offs of 𝑝𝑝∗. However, supported by the results shown in Figure 6.3, using 𝑝𝑝∗ alone 
failed to generate an appropriate strategy. Figure 6.3 represents the distribution of 
predicted probability of having a rational treatment change according to the treatment 
change that was actually given. The red and blue histograms represent patients who did 
and did not receive a rational treatment change, respectively. About 50% of the entire 
area overlaps. In other words, it was hard to clearly differentiate the behavior of receiving 
or not receiving a rational treatment change, unless 0.3 was used as the cut-off. However, 
if 0.3 was chosen as the cut-off for the dynamic treatment strategy, then the 
misclassification error is really high, since about 90% of visits would be identified as not 
having a rational treatment change, and around half of these conflict with reality.  
After digging into the data and consulting clinical experts, I included the relative 
change of the predicted probability of having a rational treatment change between the 
previous and current visits, and added a grace period (0.01) for predicted probability. 
From the clinical perspective, the rationale of including relative change was that: 1) there 
was a delay between being sick and having a visit, which delayed the occurrence of a 
rational treatment change; 2) preventing the potential disease deterioration after current 
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visit, even the current disease severity is controlled by the treatments. For the first 
scenario, some patients do not want to take any new medications when they are sick, but 
a couple of weeks later, they gave up and finally had a visit and received treatment. 
Patients in the second scenario are worried about their future health status, since it 
dramatically deteriorates compared with the health status in previous visit; even the 
current health status is controlled by the treatments. Therefore, those patients may discuss 
with their healthcare providers and have a rational treatment change. At the same time, 
the grace period of predicted probability gives some flexibilities to the strategy when the 
evidence of whether a treatment change is needed is uncertain given current knowledge. 
Overall, compared with the strategy that did not take 𝑝𝑝∗∗  into consideration, after 
including the threshold of 𝑝𝑝∗∗  into the strategy, the main difference occurred at two 
scenarios: 1) a patient does not necessarily have a rational treatment change, if the 𝑝𝑝∗ was 
higher than the threshold, but 𝑝𝑝∗∗ was lower than related threshold; 2) a patient either has 
or does not have a rational treatment change was both acceptable, if the 𝑝𝑝∗ was lower 
than the threshold, but 𝑝𝑝∗∗ was higher than related threshold. From the data perspective, it 
looks like the above assumptions were met. Figures 6.4 and 6.5 support the decision to 
include both 𝑝𝑝∗ and 𝑝𝑝∗∗ in generating the dynamic treatment strategy. Figure 6.4 presents 
the proportion of patients following each of the different treatment change strategies over 
time. Three strategies were investigated. At the 1st visit, around 80% patients still 
followed the related strategy. The proportion decreased to around 20% at the 5th visit, and 
to about 0% at the 23rd visit. Compared to the proportion in Figure 6.4, after including 𝑝𝑝∗∗ 
in the dynamic treatment strategy, the proportion has a huge increase among all visits in 
Figure 6.5. The proportion increased to about 100% and 60% at the 1st and 5th visits, 
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respectively. Even though the proportion was around 3% by the 23rd visit, it was still 
high, around 10%, at the 22nd visit. Considering the clinical meaning, together with the 
huge improvements in the proportion of patients who were able to follow the strategy, 𝑝𝑝∗∗ 
should be included in the determination of a dynamic treatment strategy.  
Overall, there were 25 dynamic treatment strategies that consisted of different 
combinations of 𝑝𝑝∗  and 𝑝𝑝∗∗ . Using 𝑝𝑝∗  = 0.080, and 𝑝𝑝∗∗  = 1.831% as an example to 
illustrate how the dynamic treatment strategy works, if in the current visit, a patient has a 
predicted probability for a rational treatment change less than 0.080 and the relative 
change of the predicted probability for a rational treatment change between the previous 
and current visit is smaller than 1.831%, then according to the dynamic treatment strategy, 
counterfactually, the patient should not receive any rational treatment change. If the 
patient did receive a treatment change in the real world, the patient record was treated as 
artificially censored, because of the failure to follow the dynamic treatment strategy. 
Similarly, if the patient’s predicted probability of having a rational treatment change is 
greater than 0.090 (0.080 + 0.010) and the relative change of the predicted probability of 
having a rational treatment change between the previous and current visit is greater than 
1.831%, then the patient should receive a rational treatment change. If the patient did not, 
then the record for the visit was artificially censored. For all other scenarios, artificial 
censoring was not considered. The rationale behind this method is that a patient should 
have a rational treatment change if the health status has worsened, and should not receive 
a rational treatment change if the situation has improved. For uncertain health status, 
either improvement or deterioration, having a rational treatment change or not is 
acceptable. The effects of those 25 dynamic treatment strategies were investigated as part 
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of Aim 3. 
 
6.2 Discussions 
The discussion section is organized in the following manner. The first part 
focuses on the discussion of the advantages and disadvantages of the complex strategy of 
imputing missing values. Then, the strengths of this aim are discussed from different 
perspectives: innovative methodologies are applied; all potential scenarios that would 
shorten the transition from research to real world practice are considered prudently; 
several hidden trends are consistent with our knowledge. After the strengths section, all 
limitations are also discussed.  
 
6.2.1 Data Management of Missing Values 
The model that included preexisting lung function variables and did not include 
the indicator under the neutral assumption using the MCMC method was chosen to 
impute the missing delFEV1. Basically, this was determined by answering four questions: 
which method, MCMC or FCS, should be chosen; whether to include the indicator or not; 
whether to include preexisting lung function variables or not; and which assumption 
(strict, loose, or neutral) to choose.  
First, the MCMC method was chosen for MI. Both MCMC and FCS methods 
have their advantages and disadvantages. MCMC assumes that all variables in the 
imputation model have a joint multivariate normal distribution. Instead of assuming a 
joint distribution, FCS uses a separate conditional distribution for each imputed variable. 
Because of the unique assumption, FCS has more reliable estimates if the value of the 
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imputed variable follows a specific distribution, such as a binary outcome for a logistic 
model or a count variable for a poisson model. In simulation studies,164,165 the FCS has 
been shown to produce estimates that are comparable to the MCMC method if the 
distribution was appropriately specified. Unlike MCMC, which provides reliable 
estimates even if the assumption of multivariate normal distribution is violated, as long as 
the sample size is large enough,164,166 in FCS the chance of providing reliable estimates is 
small if any distribution of imputed variable is misspecified. Considering the chance of 
misspecified a distribution, MCMC is preferred. Moreover, the sample size of this cohort 
is large, and the fraction of missingness is low. Out of 79,724 visits, there were only 
5,001 missing values for FEV1, which increases the chance of acquiring reliable 
estimates by using the MCMC method. Finally, the delFEV1, the change of FEV1 that 
was measured between the current and future visit, is a continuous variable, which fits the 
MCMC method better. 
The answer of whether to include the indicator is negative, which was supported 
by the following reasons. As shown in Figure F.2, Appendix F, after including the 
indicator, the imputation model was not converged, especially under the loose and strict 
assumptions. Under those scenarios, it was highly likely to have autocorrelation between 
the iterations of imputation (Figure F.4, Appendix F), which was indicated by a giant 
magnitude of the observed dependency of imputed delFEV1 across iterations. In other 
words, there was a strong correlation between the imputed values in adjacent imputed 
datasets. Things were even worse if using the differences of imputed delFEV1 between 
the model that included the indicator and the model that did not include the indicator as 
the standard for decision. The results matched the expectation that the differences only 
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existed in the missing value that occurred at an artificial visit (Figure F.7, Appendix F) 
rather than an existing visit (Figure F.8, Appendix F), since the indicator only marked the 
missing delFEV1 that was caused by creating an artificial current visit. However, when 
missing values occurred at artificial visits, the differences were not only huge in some 
models, but also had converse directions under different assumptions (Figure F.7, 
Appendix F). Even though, after including the indicator, the difference of FEV1 between 
forward and backward calculations in the same visit decreased (Table F.2, Appendix F), 
the inclusion of the indicator was still problematic.   
All results supported the inclusion of preexisting lung function variables. After 
including those variables, the range of imputed delFEV1 shrunk. Figures F.5 and F.6 in 
Appendix F show that the upper boundary of percentage increased after including those 
variables; the imputed delFEV1 was more likely to concentrate around 0. Similar results 
are also shown in Figures F.12 and F.13 in Appendix F. At the same time, in Table F.2 in 
Appendix F, after including the preexisting lung function variables, the differences in 
FEV1 between forward and backward calculation in the same visit decreased in all 
models.  
Last, the neutral assumption was chosen, as it was associated with better 
performance from several perspectives. Both Figures F.2 and F.4 in Appendix F show 
that the loose and strict assumptions were not reliable if the indicator was included in the 
model; the model lost convergence and revealed correlations among imputed values in 
adjacent imputed datasets. Even though the neutral assumption was not associated with a 
higher chance of having small values for imputed delFEV1, the distribution of imputed 
delFEV1 was consistent and normally distributed in all models. At the same time, it had 
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fewer differences of FEV1 between forward and backward calculations in the same visit 
in all models (Table F.2 in Appendix F). According to the above results and the rationale 
of this assumption, the neutral assumption was chosen for the MI. Ideally, this MI model 
should be applied on independent data to investigate its external validity. However, 
considering the sample size of the cohort, which included all CF patients that met the 
inclusion criteria in the U.S., the external validity of this model should be acceptable.  
Unlike the traditional method, which has fewer requirements for the missing 
pattern, casual inference has a strong request in terms of the missing pattern. Without 
appropriate adjustment of the missing variables, it could not only jeopardize the 
assumption of conditional exchangeability, but also bias the result by amplifying the 
inappropriate estimates through IPW. Therefore, a complex strategy was conducted to 
impute different types of missing values. According to the mechanism and rationales of 
the missing values, different methods under both the single imputation technique and 
model-based technique were applied. After applying a reasonable, comprehensive, and 
complex strategy to impute the missing values, the imputed datasets should be able to 
provide the same estimates as the ideal data. 
 
6.2.2 Strengths of the Predictive Model 
From the methodology perspective, this objective was conducted innovatively. 
Innovations include the application of the multiple imputation method and the use of the 
elastic net method, conducting cross-validation and bootstrapping on patient level rather 
than by visits, and investigating the dynamic treatment strategy of rational treatment 
changes. As mentioned previously, the application of multiple imputation is able to 
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capture the fluctuation of lung function data. Rather than using the traditional method of 
selecting variables, the elastic net was applied in this study to balance the accuracy of 
prediction and the parsimonious of the model. As more than 60 variables had to be 
selected into the prediction model, the traditional stepwise regression would not only 
consume more time, but also cause biases unless all potential interactions and cubic 
splines were investigated. From a clinical perspective, aside from the accuracy of 
prediction, the parsimonious of a model is also crucial, since the physician may not have 
enough time to measure all patient’s clinical variables comprehensively. To prevent 
random effects for the same patient among different visits, in both cross-validation and 
bootstrapping, all visits were clustered by patient, then related analyses were conducted 
by patients instead of visits. Last but not least, two variables were considered to organize 
the dynamic treatment strategy. There are limited publications on the topic of dynamic 
treatment regimes. Most of these publications investigated only treatment initiation issues. 
This study is the first to investigate the dynamic treatment strategy of having rational 
treatment change. Compared to the initiation question, this research question has more 
hurdles around investigating the causality of the rational changes involved in the dynamic 
treatment strategy, which will be discussed later. At the same time, both predicted 
probability for rational treatment change and relative change of predicted probability 
between current and previous visit were included to build the dynamic treatment strategy, 
which did not force patients with uncertain health status to either have or not have a 
rational treatment change. Two scenarios were included for patients with uncertain health 
status: 1) who had a worse health status (beyond the threshold of predicted probability) in 
current visit, but the health status barely deteriorated compared with previous visit; 2) 
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who had an acceptable health status (below the threshold of predicted probability) in 
current visit, but the health status dramatically deteriorated compared with previous visit 
(beyond the threshold of relative change of predicted probability between current and 
previous visit). 
Other than applying innovative methods, all potential scenarios that would 
shorten the transition from research to real-world practice were considered. Rather than 
fully trusting the multiple imputation, a complex imputation strategy was applied, which 
included both the single imputation techniques such as last observation carried forward, 
arithmetic mean, as well as model-based techniques such as multiple imputation using 
FCS or MCMC. Reformatting the cohort to have a routine visit quarterly is another good 
example. There were limited methods to appropriately investigate the treatment effects 
within visits occurring at an irregular frequency. To apply the most stable method, and 
considering the frequency for routine visits suggested by treatment guidelines and data in 
the cohort, the cohort was reformatted. Moreover, the definition of what constituted a 
rational treatment change was unclear. Rather than make an arbitrary decision, three 
different ways of defining rational treatment change, depending on the strictness of the 
relationship between a treatment change and the clinical signals for a treatment change, 
were investigated. Finally, using predicted probability alone to define a dynamic 
treatment strategy would eliminate many patients. After checking the distribution of the 
estimate through 1000 bootstraps, and consulting with clinical experts, together with the 
proportion of patients following each treatment change strategy over time, the relative 
change of predicted probability of having a rational treatment change between previous 
and current visit was included.  
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The path for selecting the appropriate model and variables to predict the 
probability of having a rational treatment change is fascinating. It also indicates several 
hidden trends. First of all, regardless of which outcome was applied, the elastic net was 
prone to choose a LASSO regression. Alternatively, there were limited strong 
correlations among predictors. At the same time, the optimal combination of 𝛼𝛼� and ?̂?𝜆 was 
the same for both the neutral definition and the loose definition (Table 6.5), which 
supported the similarity between those two outcomes from another perspective. In other 
words, CF patients would rarely terminate the use of one class treatment without 
improving health status. The number of PEx in the past year by the previous visit would 
not be selected when treating the number of PEx as a continuous variable; this is a strong 
sign that indicates that those variables should be treated as categorical variables rather 
than continuous variables. Several interesting effects were identified in the prediction 
model regardless of which outcome was applied. Those clinical signals, predicted FEV1, 
drug resistance, and number of treatments in the related treatment class, do consistently 
affect the probability of having a rational treatment change. If the same variable was 
chosen in both the current visit and the previous visit, then the effect of those two 
variables would be reversed. For example, the greater the number of PEx in the past year 
at the previous visit, the less likely the patient would be received a rational treatment 
change. However, the trend reversed when it considering the current visit. All drug 
resistances were chosen in the model, but the same type of drug resistance would only be 
chosen once, either in the previous visit or the current visit. The majority of the 
coefficients shared the same directions as common knowledge; however, several of them 
were conflicted. For example, patients who identified as Black had lower expected lung 
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functions compared to patients who identified as Caucasian, but their chance of receiving 
a rational treatment change was lower. Similarly, unlike the other two drug resistances, 
which had higher chances of receiving rational treatment changes, having drug resistance 
to beta lactams was associated with a lower chance of receiving a rational treatment 
change. It was hard to judge the performance of the prediction model between using the 
strictly defined outcome and the loosely defined outcome in the current stage. However, 
the strict model may be better according to the direction and significance of the 
coefficients for several variables such as treatment class, and number of PEx in the past 
year as recorded at a previous visit.  
 
6.2.3 Limitations of the Predictive Model 
This analysis has several limitations. First, the reformatting may have biased the 
results. Even though several assumptions were investigated to fulfill the multiple 
imputation of those missing lung functions, and a complex imputation method was 
applied for the rest of the missing values, the real rationales of the patients for not having 
those visits are unknown, which may or may not be consistent with the assumptions made 
in the analysis. Therefore, the ideal situation would be to conduct the analysis again using 
original data. However, until a mature method that is able to handle time-dependent 
confounders in an irregular visit frequency is available, the current method of analysis is 
one of the best for the data that are available. Moreover, in terms of choosing the optimal 
𝛼𝛼�  for the elastic net, the difference of deviance given different 𝛼𝛼  was trivial, which 
indicated a limited difference between 𝛼𝛼s. However, the minimum SD of 𝜆𝜆𝚤𝚤′�  may locate in 
the 𝛼𝛼 that was not chosen. Therefore, there is a small chance that the analysis failed to 
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identify the optimal combination of 𝛼𝛼� and ?̂?𝜆. At the same time, other than time variable, 
which included a cubic spline, the prediction model did not include interactions, squares, 
or cubic splines for the rest of predictors. It seems that the effect estimation would be 
biased without considering those adjustments. However, since the sample size was large, 
including multiple visits, this cohort belonged to big data. Therefore, those adjustments 
on variables were not required to identify a model with better performance. Furthermore, 
from physicians’ perspective, there is limited need of including interactions, squares in 
this analysis; since those adjusted variables are complicated to explain to patients, the 
parsimonious model is preferred. Last, there were two issues associated with including 
two variables for the identification of the dynamic treatment strategy: whether or not 
other variables are needed and whether or not more cut-offs are needed. While after 
including the relative change of predicted probability the proportion of patients following 
each of the different treatment change strategies over time increased, to conclude that 
there are no other variables needed is an arbitrary decision. However, considering the 
limited time that each physician has when treating a patient and the complexity of a 
treatment strategy, using two variables to define a dynamic treatment strategy is 
acceptable. Whether more cut-offs are needed is a difficult question to answer in the 
current stage of research. However, given current available information, the number of 
cut-offs should be reasonable, since for the relative change of predicted probability, those 
five cut-offs cover 95% CI, and for predicted probability, those related cut-offs cover an 






Even though there are several limitations for this analysis, due to the application 
of the innovative methods and comprehensive considerations, the result of this analysis is 
reasonable, accurate, and stable. 
In summary, Aim 2 bridged the gap between Aim 1 and 3. All patients with 
irregular frequency of visit were reformatted into having a routine visit every quarter. At 
the same time, according to the mechanism of missing data, a complex strategy of 
missing value imputation was successfully applied, which generated 10 imputed datasets. 
Under the assistance of machine learning method (elastic net), the prediction model that 
balanced the accuracy and parsimoniousness was generated using the imputed datasets. 
With the support of ‘Rubin’s rule’, the coefficients of each independent variable were 
combined, and the predicted probability of having rational treatment change and relative 
change of predicted probability between previous and current visit were calculated 
accordingly. Given the different thresholds of predicted probability and relative change of 
predicted probability, 25 varied timing strategies for treatment change were created. The 
proportion of patients who followed any one of the strategies was high. In another word, 
in Aim 3, no matter which strategy was identified as the optimal one for treatment change, 
which is associated with the longest time to mucoid PaPI, it will not be difficult to embed 
into clinical practice, since the proportion of patients who followed any one of the 25 
strategies was high. A patient will receive a rational treatment change on treatment class 
level, if and only if his predicted probability and relative change of predicted probability 
between previous and current visit was higher than the threshold of the strategy, and vice 
versa. However, none of the 25 strategies is perfect, since there is a grace period for the 
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predicted probability of having rational treatment change, within which the prescribing 
behavior of either having or not having a rational treatment change is acceptable. Models 
with different lengths of grace period had also investigated. The current grace period was 
chosen after balancing the proportion of patients who followed the strategy and the 
proportion of patients who had uncertainty on the treatment change. Currently, the 
uncertainty of the treatment change was caused by the low accuracy of differentiating the 
observed treatment change from no treatment change within a specific range of the values 
of predicted probability. However, after successfully identifying the optimal strategy and 
that well accepted by healthcare providers in clinical practice, the uncertainty range will 
be shrunk, which shortens the grace period. In other words, the more evidence we have, 
or the more physicians prescribed rationally following the strategy, the less uncertainty is 
left. Ideally, the strategy will be re-estimated using the latest cohort every couple of years. 
After several iterations, at the end, the grace period will disappear and an optimal strategy 
with a clear-cut threshold will be generated. With the identification of an optimal strategy, 
healthcare providers will be able to prescribe rationally without any uncertainty, 
supported by confirmed evidence, rather than guessing whether a treatment change is 
needed when the predicted probability locates within the grace period. At the same time, 
the value-based formulary can be designed on the treatment class level: adding treatment 
or switching treatment will only be reimbursed, if the timing of prescribing matches the 
threshold of dynamic treatment regime. In such a value-based formulary, patients’ lung 
function will be optimized so as to avoid or delay the need for extremely expensive 
treatments, such as ivacaftor and ivacafotr/lumacaftor, unless the healthcare provider has 
already prescribed all the other treatments step by step (step therapy), and the scenario of 
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suboptimal treatment effect has already occurred (prior authorization). Therefore, the 
annual cost of the health plan for CF patients could be well maintained without 
sacrificing the healthcare utilization.  
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1 2 3 4 5 6 7 8 9 10
0 0.513712 0.513815 0.513591 0.514084 0.513882 0.513225 0.513310 0.513633 0.513643 0.513989
0.1 0.506486 0.506602 0.506285 0.506779 0.506607 0.505879 0.506029 0.506293 0.506276 0.506802
0.2 0.506439 0.506565 0.506239 0.506739 0.506555 0.505823 0.505977 0.506249 0.506230 0.506757
0.3 0.506416 0.506545 0.506218 0.506713 0.506529 0.505802 0.505957 0.506227 0.506213 0.506734
0.4 0.506404 0.506534 0.506204 0.506702 0.506511 0.505789 0.505946 0.506215 0.506203 0.506723
0.5 0.506395 0.506526 0.506195 0.506694 0.506501 0.505780 0.505941 0.506208 0.506195 0.506715
0.6 0.506386 0.506521 0.506190 0.506686 0.506496 0.505772 0.505934 0.506200 0.506189 0.506709
0.7 0.506380 0.506517 0.506189 0.506683 0.506492 0.505767 0.505939 0.506196 0.506185 0.506706
0.8 0.506375 0.506514 0.506186 0.506681 0.506489 0.505763 0.505936 0.506193 0.506182 0.506694
0.9 0.506370 0.506511 0.506184 0.506678 0.506485 0.505761 0.505934 0.506191 0.506179 0.506690














1 2 3 4 5 6 7 8 9 10
0 0.576606 0.576576 0.576596 0.576515 0.576621 0.576628 0.576668 0.576594 0.576594 0.576557
0.1 0.570516 0.570483 0.570498 0.570403 0.570550 0.570521 0.570582 0.570485 0.570470 0.570454
0.2 0.570441 0.570408 0.570422 0.570327 0.570472 0.570442 0.570505 0.570407 0.570394 0.570378
0.3 0.570402 0.570368 0.570381 0.570288 0.570432 0.570401 0.570465 0.570367 0.570354 0.570339
0.4 0.570379 0.570349 0.570362 0.570264 0.570409 0.570378 0.570441 0.570347 0.570330 0.570315
0.5 0.570372 0.570333 0.570346 0.570258 0.570402 0.570370 0.570433 0.570331 0.570323 0.570308
0.6 0.570363 0.570330 0.570342 0.570249 0.570393 0.570361 0.570424 0.570327 0.570313 0.570299
0.7 0.570359 0.570326 0.570338 0.570245 0.570389 0.570358 0.570417 0.570323 0.570307 0.570295
0.8 0.570356 0.570323 0.570335 0.570242 0.570386 0.570353 0.570415 0.570320 0.570305 0.570292
0.9 0.570351 0.570317 0.570330 0.570236 0.570380 0.570347 0.570410 0.570314 0.570299 0.570286
















1 2 3 4 5 6 7 8 9 10 Mean SD Min Max Median
One se lambda 
(alfa=0.8)
0.002508 0.002497 0.002516 0.002768 0.002509 0.002503 0.002507 0.002506 0.002508 0.002482 0.002530 0.000080 0.002482 0.002768 0.002507
Best lambda 
(alfa=0.8)
0.000295 0.000244 0.000246 0.000270 0.000269 0.000268 0.000245 0.000269 0.000269 0.000266 0.000264 0.000015 0.000244 0.000295 0.000269
One se lambda 
(alfa=0.9)
0.002447 0.002219 0.002236 0.002461 0.002230 0.002225 0.002228 0.002227 0.002446 0.002206 0.002293 0.000104 0.002206 0.002461 0.002229
Best lambda 
(alfa=0.9)
0.000262 0.000217 0.000240 0.000240 0.000239 0.000239 0.000218 0.000239 0.000239 0.000237 0.000237 0.000012 0.000217 0.000262 0.000239
One se lambda 
(alfa=1.0)
0.002202 0.001997 0.002012 0.002215 0.002203 0.002002 0.002005 0.002005 0.002202 0.001986 0.002083 0.000100 0.001986 0.002215 0.002009
Best lambda 
(alfa=1.0)















1 2 3 4 5 6 7 8 9 10 Mean SD Min Max Median
One se lambda 
(alfa=0.8)
0.002779 0.002779 0.002779 0.002779 0.002779 0.002779 0.002779 0.002779 0.002779 0.002779 0.002779 4.336809E-19 0.002779 0.002779 0.002779
Best lambda 
(alfa=0.8)
0.000521 0.000521 0.000521 0.000521 0.000521 0.000521 0.000521 0.000521 0.000521 0.000521 0.000521 0.000000E+00 0.000521 0.000521 0.000521
One se lambda 
(alfa=0.9)
0.002470 0.002470 0.002470 0.002470 0.002470 0.002470 0.002470 0.002470 0.002470 0.002470 0.002470 0.000000E+00 0.002470 0.002470 0.002470
Best lambda 
(alfa=0.9)
0.000463 0.000463 0.000463 0.000463 0.000463 0.000463 0.000463 0.000463 0.000463 0.000463 0.000463 0.000000E+00 0.000463 0.000463 0.000463
One se lambda 
(alfa=1.0)
0.002223 0.002223 0.002223 0.002223 0.002223 0.002223 0.002223 0.002223 0.002223 0.002223 0.002223 4.336809E-19 0.002223 0.002223 0.002223
Best lambda 
(alfa=1.0)










Alfa Probability Lambda Resource Alfa Probability Lambda Resource 
0.8 / 0.8 0.2 0.003050 imputed 
dataset 1
0.9 / 0.9 0.4 0.002976 imputed 
dataset 1
1 1 0.002223 imputed 
dataset 1
1 0.4 0.002678 imputed 
dataset 1
0.8 / 0.8 0.2 0.003050 imputed 
dataset 1
0.9 / 0.9 0.4 0.002976 imputed 
dataset 1
1 1 0.002223 imputed 
dataset 1
1 0.4 0.002678 imputed 
dataset 1
0.9 0.2 0.002200 median 0.9 /
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Table 6.6. The proportion of a variable that has been selected in each model among 10 imputed datasets 
 
Cat Con Cat Con Cat Con Cat Con Cat Con Cat Con
(Intercept) 1 1 1 1 1 1 1 1 1 1 1 1
Age 1 1 1 1 1 1 1 1 1 1 1 1
Predicted FEV1 in current 
visit
1 1 1 1 1 1 1 1 1 1 1 1
Predicted FEV1 in 
previous visit
0.9 0.8 0.9 0.8 1 1 0.9 0.6 0.9 0.6 1 1
Mutation 1 class 0 0 0 0 0 0 0 0 0 0 0 0
Mutation 2 class 1 1 1 1 1 1 1 1 1 1 1 1
Hispanic 0 0 0 0 0 0 0 0 0 0 0 0
Gender 0 0 0 0 0 0 0 0 0 0 0 0
Race 1 1 1 1 1 0.5 1 1 1 1 1 1
Smoking 1 1 1 1 1 1 1 1 1 1 1 1
Transplant 0 0 0 0 0 0 0 0 0 0 0 0
F508 0 0 0 0 0 0 0 0 0 0 0 0
Arthropathy 0 0 0 0 0 0 0 0 0 0 0 0
CFRD 0 0 0 0 0 0 0 0 0 0 0 0
DIOS 0 0 0 0 0 0 0 0 0 0 0 0
GERD 0 0 0 0 0 0 0 0 0 0 0 0
Pancreatic insufficiency 0 0 0 0 0.3 0.2 0 0 0 0 0.3 0.3
Pancreatitis 0 0 0 0 0.6 0.3 0 0 0 0 0.9 0.3
TB 0 0 0 0 0 0 0 0 0 0 0 0
Pneumothorax 0 0 0 0 0 0 0 0 0 0 0 0
Not include BD (included PExloose)
Loose Neutral StrictVariables




Table 6.6. (continued) 
 
Cat Con Cat Con Cat Con Cat Con Cat Con Cat Con
Hemoptysis 1 0 1 0 0 0 1 0 1 0 0 0
Enzymes 0 0 0 0 0 0 0 0 0 0 0 0
ABPA 0 0 0 0 0 0 0 0 0 0 0 0
Aspergillus 0.8 0 0.8 0 0.9 0.7 0.2 0 0.2 0 1 0.4
B. cepacia 1 1 1 1 1 1 1 1 1 1 1 1
B. cenocepacia 0 0 0 0 0 0 0 0 0 0 0 0
Burkholderia species 0 0 0 0 0 0 0 0 0 0 0 0
Candida 0 0 0 0 0 0 0 0 0 0 0 0
Mycobacterium gordonae 0 0 0 0 0 0 0 0 0 0 0 0
MAI 0 0 0 0 0 0 0 0 0 0 0 0
MRSA 0 0 0 0 0 0 0 0 0 0 0 0
MSSA 1 1 1 1 1 1 1 1 1 1 1 1
Other gram-negative 
microorganisms
0 0 0 0 0 0 0 0 0 0 0 0
Serratia marcescens 0 0 0 0 0 0 0 0 0 0 0 0
Staphylococcus aureus 1 1 1 1 1 1 1 1 1 1 1 1
Stenotrophomonas 
/Maltophilia
0 0 0 0 0 0 0 0 0 0 0 0
Non-mucoid Pa PI 0 0 0 0 1 0.8 0 0 0 0 1 1
Unknown type of mucoid 
Pa PI
0 0 0 0 0 0 0 0 0 0 0 0
Mucoid Pa PI 1 1 1 1 1 1 1 1 1 1 1 1
Not include BD (included PExloose)
Loose Neutral StrictVariables




Table 6.6. (continued) 
 
Cat Con Cat Con Cat Con Cat Con Cat Con Cat Con
Number of PEx in the past 
year in previous visit 
1 0 1 0 1 0 1 0 1 0 1 0
Number of PEx in the past 
year in previous visit 
(loose definition)
/ / / / / / 1 0 1 0 1 0.9
Drug resistance of 
aminoglycosides in 
previous visit
0 0 0 0 0 0 0 0 0 0 0 0
Drug resistance of beta 
lactams in previous visit
0 0 0 0 0.6 0.2 0 0 0 0 0.9 0.5
Drug resistance of 
quinolones in previous 
visit
0 0 0 0 0 0 0 0 0 0 0 0
Number of PEx in the past 
year in current visit 
1 1 1 1 1 1 1 1 1 1 1 1
Number of PEx in the past 
year in current visit (loose 
definition)
/ / / / / / 1 1 1 1 1 1
Drug resistance of 
aminoglycosides in 
current visit
1 1 1 1 1 1 1 1 1 1 1 1
Not include BD (included PExloose)
Loose Neutral StrictVariables




Table 6.6. (continued) 
 








Cat Con Cat Con Cat Con Cat Con Cat Con Cat Con
Drug resistance of beta 
lactams in current visit
1 1 1 1 0 0 1 1 1 1 0 0
Drug resistance of 
quinolones in current visit
1 0.5 1 0.5 1 1 1 0 1 0 1 1
Mucolytics 1 1 1 1 1 1 1 1 1 1 1 1
Inhaled antibiotics 1 1 1 1 1 1 1 1 1 1 1 1
Anti-inflammatories 1 1 1 1 1 1 1 1 1 1 1 1
Bronchodilators 1 1 1 1 1 1 1 1 1 1 1 1
Not include BD (included PExloose)
Loose Neutral StrictVariables




Table 6.7. The proportion of a variable that has been selected in each model among 10 imputed datasets for categorical variables 
 
Cat Con Cat Con Cat Con Cat Con Cat Con Cat Con
Mutation 1 class:
1
2 0 0 0 0 0 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0 0 0 0 0 0
4 0 0 0 0 0 0 0 0 0 0 0 0
5 0 0 0 0 0 0 0 0 0 0 0 0
Doesn’t belong to any 
class
0 0 0 0 0 0 0 0 0 0 0 0
Missing 0 0 0 0 0 0 0 0 0 0 0 0
Mutation 2 class:
1
2 1 1 1 1 1 1 1 1 1 1 1 1
3 0 0 0 0 0 0 0 0 0 0 0 0
4 1 1 1 1 1 1 1 1 1 1 1 1
5 1 1 1 1 1 1 1 1 1 1 1 1
Doesn’t belong to any 
class
1 0 1 0 0 0 1 0 1 0 0 0
Missing 0 0 0 0 0 0 0 0 0 0 0 0
Number of PEx in the past 
year in previous visit:
0
1 0 0 0 0 0 0
2 0 0 0 0 0 0
Not include BD (included PExloose)
Loose Neutral StrictVariables







Table 6.7. (continued) 
 
Cat Con Cat Con Cat Con Cat Con Cat Con Cat Con
Number of PEx in the past 
year in previous visit:
3 0 0 0 0 0 0
4 1 1 0.9 1 1 0.9
5 1 1 0.6 1 1 0.8
6 0 0 0 0 0 0
7 0 0 0 0 0 0
8 0 0 0 0 0 0
9 1 1 1 1 1 1
10 0 0 0 0 0 0
11 0 0 0 0 0 0
12 0 0 0 0 0 0
Number of PEx in the past 
year in previous visit 
(loose definition):
0
1 / / / / / / 0 0 0
2 / / / / / / 0 0 0
3 / / / / / / 0 0 0
4 / / / / / / 0 0 0
5 / / / / / / 0 0 0
6 / / / / / / 0 0 0
7 / / / / / / 0 0 0
Not include BD (included PExloose)
Loose Neutral StrictVariables





Table 6.7. (continued) 
 
Cat Con Cat Con Cat Con Cat Con Cat Con Cat Con
Number of PEx in the past 
year in previous visit 
(loose definition):
8 / / / / / / 0 0 0
9 / / / / / / 0 0 0
10 / / / / / / 0 0 0
11 / / / / / / 0 0 0
12 / / / / / / 0 0 0
13 / / / / / / 0 0 0
14 / / / / / / 1 1 1
15 / / / / / / 0 0 0
16 / / / / / / 0 0 0
Number of PEx in the past 
year in current visit:
0
1 1 1 1 1 1 1
2 1 1 1 1 1 1
3 1 1 1 1 1 1
4 0 0 0 0 0 0
5 0.3 0.3 1 0.5 0.5 1
6 0 0 0 0 0 0
7 0 0 0 0 0 0
8 0 0 0.6 0 0 1
Not include BD (included PExloose)
Loose Neutral StrictVariables





Table 6.7. (continued) 
 
Cat Con Cat Con Cat Con Cat Con Cat Con Cat Con
Number of PEx in the past 
year in current visit:
9 0 0 0 0 0 0
10 0 0 0 0 0 0
11 0 0 0 0 0 0
12 0 0 0 0 0 0
Number of PEx in the past 
year in current visit (loose 
definition):
0
1 / / / / / / 0 0 1
2 / / / / / / 1 1 1
3 / / / / / / 0 0 1
4 / / / / / / 0 0 1
5 / / / / / / 0 0 1
6 / / / / / / 0 0 1
7 / / / / / / 0 0 0
8 / / / / / / 0 0 0
9 / / / / / / 0 0 0
10 / / / / / / 1 1 1
11 / / / / / / 0 0 0
12 / / / / / / 0 0 0
13 / / / / / / 0 0 0
Not include BD (included PExloose)
Loose Neutral StrictVariables





Table 6.7. (continued) 
 









Cat Con Cat Con Cat Con Cat Con Cat Con Cat Con
Number of PEx in the past 
year in current visit (loose 
definition):
14 / / / / / / 0 0 0
15 / / / / / / 0 0 0
16 / / / / / / 1 1 1
Not include BD (included PExloose)
Loose Neutral StrictVariables










(Intercept) 0.077065 0.182932 -0.281499 0.435629 1.080112 2%
Age -0.030657 0.004205 -0.038898 -0.022415 0.969809 1%
Predicted FEV1 in current visit -0.028935 0.001440 -0.031758 -0.026112 0.971480 4%
Predicted FEV1 in previous visit 0.016858 0.001424 0.014067 0.019648 1.017000 2%
Mutation 2 class:
1
2 0.019029 0.039885 -0.059151 0.097209 1.019211 3%
3 0.055319 0.077819 -0.097219 0.207857 1.056878 3%
4 -0.351695 0.136665 -0.619562 -0.083827 0.703495 2%
5 -0.471186 0.142136 -0.749778 -0.192595 0.624261 2%
Doesn’t belong to any class -0.078217 0.055941 -0.187863 0.031429 0.924764 1%
Missing -0.014997 0.149995 -0.308987 0.278994 0.985115 1%
Race
Caucasian
Black -0.180514 0.084421 -0.345979 -0.015049 0.834841 1%
Asian 0.086258 0.141071 -0.190242 0.362758 1.090088 1%
Others 0.156320 0.262386 -0.357947 0.670587 1.169200 0%
Smoking
No
Yes -0.196449 0.151121 -0.492655 0.099758 0.821644 2%
Unknown -0.203701 0.061444 -0.324136 -0.083267 0.815706 2%


















Pancreatitis -0.430184 0.220581 -0.862575 0.002207 0.650390 3%
Aspergillus 0.122658 0.038919 0.046374 0.198942 1.130498 2%
B. cepacia 0.719820 0.171199 0.384277 1.055364 2.054064 0%
MSSA -0.209266 0.046733 -0.300864 -0.117667 0.811180 2%
Staphylococcus aureus -0.067421 0.054585 -0.174410 0.039567 0.934801 2%
Non-mucoid Pa PI 0.309718 0.069905 0.172691 0.446745 1.363041 3%
Mucoid Pa PI 0.535222 0.077365 0.383582 0.686862 1.707827 2%
Number of PEx in the past year 
in previous visit:
0
1 -0.339920 0.059419 -0.456380 -0.223459 0.711828 1%
2 -0.539888 0.094210 -0.724543 -0.355233 0.582813 2%
3 -0.640141 0.140864 -0.916245 -0.364037 0.527218 2%
4 -0.543722 0.208533 -0.952453 -0.134990 0.580584 2%
5 -0.753817 0.299377 -1.340586 -0.167048 0.470567 0%
Drug resistance of beta 
lactams in previous visit:
No
Yes -0.425746 0.143198 -0.706535 -0.144956 0.653282 6%
















Number of PEx in the past year 
in current visit:
0
1 0.795043 0.056136 0.685017 0.905069 2.214536 1%
2 1.185062 0.089067 1.010491 1.359634 3.270891 1%
3 1.421844 0.132873 1.161408 1.682280 4.144757 2%
4 1.074606 0.211695 0.659687 1.489525 2.928839 1%
5 1.430203 0.279524 0.882340 1.978065 4.179546 1%
Drug resistance of 
aminoglycosides in current 
visit:
No
Yes 0.185849 0.074467 0.039897 0.331802 1.204241 0%
Testing not done -0.588553 0.599280 -1.763120 0.586015 0.555130 0%
Drug resistance of quinolones 
in current visit:
No
Yes 0.287911 0.105390 0.081336 0.494485 1.333638 2%
Testing not done 0.099959 0.595046 -1.066309 1.266227 1.105126 0%
Mucolytics
0






















2 -1.240852 0.047396 -1.333747 -1.147958 0.289138 1%
Inhaled antibiotics
0
1 -0.496329 0.033702 -0.562386 -0.430273 0.608761 2%
2 -0.850033 0.075273 -0.997571 -0.702495 0.427401 2%
3 -2.042663 0.287697 -2.606539 -1.478788 0.129683 0%
Anti-inflammatories
0
1 -0.406660 0.034664 -0.474603 -0.338717 0.665871 2%
2 -0.281437 0.104250 -0.485764 -0.077111 0.754698 0%
Bronchodilators
0
1 -0.322451 0.033481 -0.388079 -0.256824 0.724371 2%

















(Intercept) 0.635256 0.108659 0.422284 0.848228 1.887506 1%
Age -0.028081 0.003846 -0.035619 -0.020542 0.972310 0%
Predicted FEV1 in current visit -0.009108 0.001378 -0.011810 -0.006405 0.990934 5%
Predicted FEV1 in previous visit -0.001201 0.001375 -0.003896 0.001495 0.998800 5%
Mutation 2 class:
1
2 0.010826 0.036397 -0.060511 0.082162 1.010884 0%
3 -0.009286 0.072113 -0.150626 0.132054 0.990757 0%
4 -0.418090 0.123116 -0.659393 -0.176787 0.658303 0%
5 -0.382783 0.121941 -0.621783 -0.143783 0.681961 0%
Doesn’t belong to any class -0.121752 0.049907 -0.219568 -0.023936 0.885368 0%
Missing -0.116738 0.071729 -0.257324 0.023848 0.889818 0%
Race
Caucasian
Black -0.211211 0.078868 -0.365789 -0.056633 0.809603 0%
Asian 0.069268 0.130407 -0.186325 0.324861 1.071723 0%
Others 0.136831 0.247878 -0.349000 0.622662 1.146634 0%
Smoking
No
Yes -0.177151 0.137589 -0.446821 0.092519 0.837653 0%
Unknown -0.231731 0.056634 -0.342732 -0.120730 0.793159 0%
















Aspergillus 0.109340 0.035906 0.038965 0.179716 1.115542 0%
B. cepacia 0.660352 0.165355 0.336263 0.984441 1.935473 0%
MSSA -0.214312 0.043306 -0.299191 -0.129434 0.807096 0%
Staphylococcus aureus -0.079446 0.050483 -0.178391 0.019499 0.923628 0%
Mucoid Pa PI 0.242335 0.040280 0.163388 0.321281 1.274220 0%
Number of PEx in the past year 
in previous visit:
0
1 -0.140077 0.055017 -0.247908 -0.032246 0.869291 0%
2 -0.250059 0.087130 -0.420831 -0.079287 0.778755 0%
3 -0.251660 0.130701 -0.507828 0.004509 0.777509 0%
4 -0.033396 0.194640 -0.414885 0.348092 0.967155 0%
5 -0.136775 0.281766 -0.689027 0.415477 0.872166 0%
Number of PEx in the past year 
in current visit:
0
1 0.627469 0.052618 0.524340 0.730599 1.872865 0%
2 0.900488 0.083303 0.737217 1.063758 2.460802 0%
3 1.027431 0.125114 0.782211 1.272651 2.793880 0%
4 0.629146 0.200281 0.236603 1.021689 1.876008 0%
















Drug resistance of 
aminoglycosides in current 
visit:
No
Yes 0.127152 0.070929 -0.011867 0.266171 1.135589 0%
Testing not done 0.094147 0.760673 -1.396746 1.585039 1.098721 0%
Drug resistance of beta 
lactams in current visit:
No
Yes -0.186798 0.119371 -0.420760 0.047164 0.829611 0%
Testing not done -0.683217 0.755187 -2.163356 0.796922 0.504990 0%
Drug resistance of quinolones 
in current visit:
No
Yes 0.242641 0.101375 0.043949 0.441333 1.274611 0%
Testing not done 0.252922 0.552340 -0.829645 1.335488 1.287783 0%
Mucolytics
0
1 -0.755664 0.035636 -0.825509 -0.685819 0.469699 0%



















1 -0.546949 0.030906 -0.607524 -0.486374 0.578713 0%
2 -0.905168 0.070192 -1.042742 -0.767594 0.404474 0%
3 -2.114768 0.276643 -2.656978 -1.572559 0.120661 0%
Anti-inflammatories
0
1 -0.405523 0.031814 -0.467878 -0.343169 0.666628 0%
2 -0.366443 0.099734 -0.561917 -0.170968 0.693196 0%
Bronchodilators
0
1 -0.324555 0.030686 -0.384698 -0.264412 0.722849 0%











Figure 6.1. Histogram and normal quantile-quantile plot of bootstrapping the cutoff of 





Figure 6.2. Histogram and normal quantile-quantile plot of bootstrapping the cutoff of 





Figure 6.3. The histogram of predicted probability of having rational treatment change given observed treatment change pattern (strict 
definition). 






Figure 6.4. Plot of the proportion of patients following each of the different treatment change strategies over time (strict definition, 
only included predicted probability, 𝑝𝑝∗) 






            
  
     





Figure 6.5. Plot of the proportion of patients following each of the different treatment change strategies over time (strict definition, 





 OPTIMAL TREATMENT REGIME 
 
7.1 Results 
To fulfill Aim 3, this section describes the results from four parts. The first part 
described how the augmented datasets were created to investigate the treatment effect of 
following different DTRs. Then, both data-driven and knowledge-driven methods were 
applied to select the variables in the numerator and denominator of IPTW and IPCW 
respectively. After identifying the variables in the numerator and denominator of IPCW 
and IPTW, the related predications were conducted independently in each replicate 
among 10 augmented datasets. Give the coefficients that were identified previously, the 
weight was created for all visits. The influence of applying stabilized inverse probability 
weighting (SIPW) and unstabilized inverse probability weighting (UIPW) was compared 
by using two outcomes: the value distribution of weights, and nonparametric Kaplan 
Meier curve, respectively. At the end, the results of four models were present. Those 
models were, 1) fixed parameterization of the dynamic logistic MSMs with UIPW; 2) 
fixed parameterization of the dynamic logistic MSMs with SIPW; 3) flexible 




7.1.1 Creating the Augmented Datasets 
As mentioned in Aim 2, 25 unique dynamic treatment strategies were taken into 
consideration for Objective 3. Those 25 strategies were marked as two digits. From the 
left to the right, the first digit indicated the value of the predicted probability of having a 
rational treatment change and the second digit indicated the value of the relative change 
of the predicted probability of having rational treatment change between current visit and 
previous visit. For example, strategies 33 and 43 had the same value for the relative 
change of the predicted probability, but had different predicted probabilities. To simplify 
the scenario, in Aim 3, only the strict definition of rational treatment change was 
considered. Therefore 25 replicates were created for each unique visit. Each replicate 
relates to one unique dynamic treatment change strategy. According to the related 
strategy, all visits were investigated in each replicate. If the observed treatment change 
pattern of having a rational treatment change in a visit conflicted with the counterfactual 
treatment pattern that the patient was supposed to follow, as determined by the related 
strategy, then the follow-up visits were artificially censored. In other words, according to 
the patient’s demographic characteristic, clinical variables, and treatment history, if in a 
visit the physician did not make a treatment change decision that followed the related 
dynamic treatment change strategy, the follow-up visits were censored.  An augmented 
dataset, which included 25 replicates, was created, and only those visits where the 
treatment classes that a patient received followed related rational treatment change 
strategies were kept in each replicate. The 10 imputed datasets transited to 10 augmented 




7.1.2 Variable Selection for the Weights 
The selection of variables to predict IPW, which would appropriately adjust 
selection bias and confounder bias in a research question, is a complicated procedure. 
The variables could be selected through either knowledge-driven or data-driven methods. 
The knowledge-driven method is the most common method, and includes all variables 
that were mentioned in the related articles or according to clinical experiences. Those 
variables must have relationships with both exposure and outcome. After identifying 
those variables, given the current understanding of the relationships among those 
variables, a DAG figure is created. Other than intermediators, the other types of variables 
are included in the model. The data-driven method selects only the variables that are 
significantly associated with the predicted outcome. All variable selection methods that 
were mentioned previously could be applied here.  
Both data-driven and knowledge-driven methods were applied in this study. 
Specifically, based on knowledge and clinical experience, all variables in the CFFPR that 
were investigated in the previous two aims were included.  The result in Aim 2 indicated 
that LASSO was more preferable for this dataset, since 𝛼𝛼 always equaled to 1, which 
makes elastic net as same as a LASSO, among all prediction models in each one of the 10 
imputed datasets. Because of this, LASSO was applied to select the variable for 
calculating the weight for the numerator and denominator of inverse probability of 
censoring weighting (IPCW) and inverse probability of treatment weighting (IPTW), 
respectively. After simplification, there was only one outcome for IPTW, rational 
treatment change under strict definition. However, the outcome for IPCW was identified 
jointly by three outcomes: disenrollment, death, or end of study. In another words, IPTW 
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was applied to adjust the time-dependent confounder between the exposure (patient who 
followed a specific strategy to have rational treatment change under strict definition) and 
the outcome (time to mucoid PaPI). Similarly, the selection bias that was caused by loss 
to follow-up, death, and end of study was jointly adjusted by the IPCW.  In order to 
investigate the difference between using one censor indicator that covered all three 
reasons and using three indicators that covered different reasons, independently, to 
predict IPCW, both the numerator and the denominator of IPCW were investigated under 
those scenarios in 10 imputed datasets. Unlike the IPCW, considering the influence of 
different strategies, the variable that was selected in IPTW was also investigated in each 
replicate of the 10 augmented imputed datasets. As long as a variable was selected in the 
same replicate once among 10 augmented datasets, it would be selected for that replicate 
related strategy. Therefore, the proportion of being selected was jointly determined by 
imputed dataset and strategy. If a variable was only chosen once, the proportion of being 
selected in IPTW and IPCW were 0.04 and 0.1, respectively. Table 7.1 presents the 
related results of variable selection. If a variable was selected for less than 50% among all 
augmented imputed datasets in the prediction model either for numerator or denominator 
of IPTW, it was excluded. Considering no variable was selected, if the disenrollment or 
death was applied as the outcome to predict either the numerator or the denominator of 
the IPCW, the joint probability of predicting three indicators equaled to the probability of 
predicting the end of the study alone. Table 7.1 shows that there is barely any difference 
on variable selection between using censor and using the end of study as the outcome on 
either predicting the numerator or the denominator of the IPCW. At the same time, 
considering the importance of simplicity to a model, only one indicator was chosen. 
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Therefore, one indicator, censor, was applied as the outcome to predict both the 
numerator and denominator of IPCW.  
Following Hernan’s method of predicting the IPW with time-dependent 
confounders, both baseline variables (V) and time-dependent variables that were 
measured in the current visit (L) were included in the denominator prediction. For 
numerators, only baseline variables (V) were included. At the same time, in each model, 
the selected baseline variables (V) had to be a subset of the variables that were selected in 
the current visit (L). Moreover, treatment-related variables were included in the IPTW 
but not the IPCW, considering the assumption that treatment-related variables affected 
the censoring indirectly. Last, given the assumption of no unmeasured confounder left 
after adjusting the IPCW and IPTW, other than treatment-related variables, the rest of the 
variables should be included in both IPCW and IPTW at the same time. The only 
exception was censoring indicator, which only existed in the prediction model of IPTW 
as a predictor.  
Following the above procedures, the variables that were finally included in each 
model are also present in Table 7.1. Different color font indicates the rationale of making 
a related decision. For example, variable of drug resistance of beta lactam in baseline 
visit was only selected by LASSO in predicting the denominator of IPTW. Because it 
was a baseline variable, as long as it was chosen in the denominator, it had to be chosen 
in the numerator. Therefore, it was selected in the prediction model of the numerator of 
IPTW, and was marked in pink to indicate the rationale. Since it was selected in IPTW, 
this variable should also be selected in the related model in IPCW, which is marked as 
orange in the decision column of IPCW. Table 7.1 presents all variables that were 
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selected in those four models. The following time-dependent variables (L) were selected: 
height, weight, predicted FEV1 in current visit, number of visit, number of visit (spline), 
smoking status, transplant status, CFRD status, whether the patient had GERD, whether 
the patient had pancreatic insufficiency, whether the patient had pancreatitis, whether the 
patient had hemoptysis, did the patient use any enzymes, whether the patient had ABPA, 
whether the patient was infected by any species of Aspergillus, B. cepacia infection, 
candida infection, MAI infection, MRSA infection, MSSA infection, being infected by 
any other Gram-negative microorganisms, S. aureus infection, whether patient was 
diagnosed with nonmucoid PaPI in the current visit, whether the patient was diagnosed 
with unknown type of mucoid PaPI in the current visit, number of PEx in the past year, 
drug resistance to aminoglycosides, drug resistance to beta lactams, drug resistance to 
quinolones, number of mucolytics that the patient received, and the number of anti-
inflammatories that the patient received. The following baseline variables (V) were also 
selected: mutation 2 class, age, predicted FEV1, height, weight, race, transplant status, 
CFRD status, whether the patient had GERD, B. cepacia infection, MRSA infection, 
being infected by any other Gram-negative microorganisms, whether the patient was 
diagnosed with nonmucoid PaPI, number of PEx in the past year, drug resistance to 
aminoglycosides, drug resistance to beta lactams, drug resistance to quinolones, number 







7.1.3 Calculating the Weights 
After identifying the variables in the numerator and denominator of IPCW and 
IPTW, the related predications were conducted independently in each replicate among 10 
augmented datasets. Tables 7.2 and 7.3, 7.4 and 7.5, 7.6 and 7.7, 7.8 and 7.9 present the 
estimations of the odds ratio for variables in the numerator of IPTW, the denominator of 
IPTW, the numerator of IPCW, and the denominator of IPCW, respectively. To better 
investigate the difference among different imputed datasets, Tables 7.2, 7.4, 7.6, and 7.8, 
and Tables 7.3, 7.5, 7.7, and 7.9 present the results from the 2nd, and 8th imputed dataset, 
respectively. In each table, the results using strategies, 33, 43, and 53 are also present. 
There were few differences among either strategies or imputed datasets. However, the 
differences among the imputed datasets were larger than the differences among the 
strategies. The majority of the variables matched the expectation and understanding, but 
the effects were not statistically significant in predicting the numerator of IPTW (Tables 
7.2 and 7.3). Only some of the variables had statistically significant influences: mutation 
2 class, drug resistance to aminoglycosides, and the number of anti-inflammatories. With 
a decrease in the severity of mutation that a patient had, or an increase in the number of 
anti-inflammatories that a patient received, the chance of having a rational treatment 
change, on the numerator of IPTW, decreased. Compared to predicting the numerator of 
the IPTW, more variables were statistically significant in predicting the denominator of 
the IPTW (Tables 7.4 and 7.5), such as baseline variables (V): age, predicted FEV1, 
height, mutation 2 class, whether the patient had been diagnosed with nonmucoid PaPI, 
number of PEx in the past year, number of mucolytics that the patient received, and time-
dependent variables (L) that were measured at the current visit: predicted FEV1, height, 
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number of visit, number of visit in spline, smoking status, CFRD status, whether the 
patient had pancreatitis, whether the patient had ABPA, B. cepacia infection, MSSA 
infection, whether patient was diagnosed with nonmucoid PaPI, whether the patient was 
diagnosed with an unknown type of mucoid PaPI, number of PEx in the past year, 
number of mucolytics that a patient received, number of inhaled antibiotics that a patient 
received, number of anti-inflammatories that a patient received, and number of 
bronchodilators that a patient received in the current visit. If a variable was chosen both 
at the current visit and baseline visit, the directions of effect were conversed, and the 
direction of effects in the current visit was always consistent with our expectation. For 
example, if, at the baseline visit, the patient had a higher predicted value of FEV1, was 
taller, had fewer PEx, or more mucolytics, then it was more likely that the patient would 
receive a rational treatment change in the current visit. Conversely, if the patient had a 
higher predicted value of FEV1, fewer PEx, more mucolytics, or was taller, then the 
chance of having a rational treatment change decreased. Compared with the related 
reference, the chance of having a rational treatment change was huge, more than 10, for a 
patient who was infected by B. cepacia. The odds ratio was 11.274 under strategy 33 in 
imputed dataset 2. If a patient had pancreatitis or MSSA infection at the current visit, the 
chance of having a rational treatment change decreased; these are the only two variables 
that had a direction of effect different than our expectations. 
Several variables were statistically significant in predicting the numerator of the 
IPCW (Tables 7.6 and 7.7) at the baseline visit, such as predicted FEV1, height, weight, 
GERD, B. cepacia infection, being infected by any other Gram-negative microorganisms, 
and diagnosis with nonmucoid PaPI. The directions of effects were reasonable for the 
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majority of those variables. For example, if a patient had GERD as a comorbidity, was 
infected by B. cepacia, or infected by any other Gram-negative microorganisms at the 
baseline visit, the chance of being censored increased. However, two of their directions 
conflicted with our expectation and knowledge—the better lung function a patient had, or 
the heavier a patient was, the more likely the patient would be censored. At the same time, 
the probability of being censored was dominated by three scenarios: had received a 
transplant, infected by B. cepacia, and infected by other Gram-negative microorganisms 
at the baseline visit. These had large odds ratios of 8.152, 8.082, and 3.759 under strategy 
33 in imputed dataset 2, respectively. The estimates of variables in denominator of IPCW 
shared similar effects to the one in numerator of IPCW. For example, weight, B. cepacia 
infection, MRSA infection, and infection by other Gram-negative microorganisms at the 
baseline visit still had statistically significant effects with the same direction as the one in 
the numerator. Similar to the trends in IPTW, the same variable that was measured in the 
current visit also had a conversed effect compared with the related one that was measured 
in the baseline visit. For example, having had a transplant at the current visit would 
decrease the probability of being censored. However, being infected by B. cepacia, being 
infected by MRSA, or being infected by other Gram-negative microorganisms at the 
current visit would also increase the probability of being censored, especially in the last 
scenario, which still had statistically significant effect. 
 
7.1.4 Influence of Applying Different Methods to Calculate Weights 
Those estimates among the different models gave a general description of each 
variable in the model. The performance of those prediction models, especially the 
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difference between using stabilized weights and unstabilized weights, which would affect 
the result of Aim 3 directly, will be compared in the following section. Figure 7.1 shows 
the distribution of the stabilized inverse censoring weight (SICW) under different 
strategies in different imputed datasets. The left and right columns represent the 
distribution in imputed datasets 2 and 8, respectively. From the top to bottom, those 
figures represent the distribution under strategies 33 and 53, respectively. SICW was 
normally distributed around 0.9 regardless of the strategies and imputed datasets that 
were chosen. Unlike the agreement on using the SIPCW to adjust the selection bias, the 
difference between using the stabilized inverse treatment weighting (SIPTW) and 
unstabilized inverse treatment weighting (UIPTW) to adjust the time-dependent 
confounder was unclear. Therefore, Figure 7.2, 7.3 was compared to Figure 7.4, 7.5 
respectively. While the differences among different strategies and imputed datasets as 
represented in the figures are trivial, there is a huge difference in distribution between 
UIPTW and SIPTW. Unlike SIPTW, which is normally distributed with 1 as the mean in 
Figure 7.3, the UIPTW has an exponential distribution in Figure 7.2. Moreover, 1 is the 
minimum value of UIPTW. Figure 7.4 and Figure 7.5 present the distribution of final 
weights in both UIPW and SIPW, respectively. UIPW and SIPW was the production of 
SIPCW and UIPTW, and SIPCW and SIPTW, respectively. Even though at first glance 
Figure 7.4 seems like a normal distribution, it has an extreme skew to the right. The 
distribution in Figure 7.5 is closer to normal with a mean around 1. More importantly, 
compared to UIPW, the chance of having larger value was much lower in SIPW, which 
are supported by the data in Tables 7.10 and 7.11. Without any further adjustment, from 
the mean, median, upper quartile to maximum, the SIPW is always associated with 
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smaller values. The upper quartile for SIPW and UIPW is around 1 and 3, respectively. 
The skew that is introduced to the data by using UIPW meant that SIPW is preferred in 
this study.  Table 7.12 shows the number of extreme values, larger than 10, in SIPW 
under different strategies in varied imputed datasets. Only 175 out of 28,976 visits were 
associated with extreme values under strategy 33 in imputed dataset 2. The proportion of 
having extreme values in SIPW was consistent, around 0.6%, regardless of the strategy 
and imputed dataset. Under this situation, 10 was set as the maximum value of SIPW. 
Table 7.11 presents the distribution of truncated SIPW, which had around 1.015 as the 
mean. 
Figures 7.6, 7.7, and 7.8 also present the influence of different methods of 
weighting. The left and right columns represent the trends in imputed datasets 2 and 8, 
respectively. From the top to bottom, those figures represent the nonparametric Kaplan 
Meier curve without any adjustment, adjustment by UIPW, and adjustment by SIPW, 
respectively. Without any adjustment or adjusting by SIPW, the difference in results 
between different imputed datasets is trivial. However, there are huge differences 
regarding the method of weighting. Without any adjustment, there are barely any 
differences in the survival curves among five strategies (13, 23, 33, 43, 53) in Figures 7.6, 
7.7, and 7.8. Applying IPW to adjust the results reveals huge differences among the 
strategies and imputed datasets. As shown in Figures 7.6, 7.7, and 7.8, in imputed dataset 
2, after adjusting UIPW, there is a huge decrease of survival in the 5th visit for strategies 
13 and 23, from 1 to 0.91, and another decrease on the 20th visit, from around 0.90 to 
0.88. The other strategies had survival rates around 1 until the 23rd visit. However, in 
imputed dataset 8 for strategies 13 and 23, there was a decrease at the 5th visit, from 1 to 
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0.975 and a decrease to 0.94 at the 20th visit. The other strategies shared trends similar to 
the related ones in imputed dataset 2. When the SIPW was applied, the decrease occurred 
constantly, and the final survival rate was comparable to the one that was adjusted by the 
UIPW under same strategy. At the same time, there remained a difference in survival 
rates between the different strategies until late visits.  
 
7.1.5 Results of Applying Different Models 
As mentioned previously, SIPW is preferred in this study. However, in order to 
investigate the stability of the result, UIPW was also applied to adjust the final model. 
Other than the difference of building weight, unlike using UIPW to adjust bias, which 
does not require any variable adjustment in the regression model, when SIPW was 
applied, the baseline variables in the numerator had to be adjusted in the regression 
model. The following baseline variables were adjusted in the regression model: mutation 
2 class, predicted FEV1, number of PEx in the previous year, number of mucolytics that 
the patient received, number of anti-inflammatories that the patient received, age, gender, 
race, transplant status, drug resistance to aminoglycosides, drug resistance to beta lactams, 
and drug resistance to quinolones. Tables 7.13 and 7.14 present the results of fixed 
parameterization of the dynamic logistic MSMs. Table 7.15 present the results of a 
flexible parameterization of the dynamic logistic MSM. Unstabilized and stabilized 
weighting were applied in Tables 7.13 and 7.14, respectively. The point estimate in each 
table was calculated according to the result in 10 augmented imputed datasets. The 
minimum and maximum of point estimation among those 10 augmented imputed datasets 
were also reported.  
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7.1.5.1 The Fixed Parameterization of the Dynamic Logistic MSM with UIPW 
Table 7.13 shows that without adjusting any baseline variables, and with applied 
UIPW, not following any strategy (strategy 1) was superior to some strategies (strategies 
11-15, 21-25), and worse than other strategies. Figure 7.9 supports the conclusion by 
depicting the survival curves of six strategies (no strategy, 13, 23, 33, 43, and 53).  As 
shown in Figure 7.9, the survival rates are low for strategies 13 and 23, and are high for 
strategies 33, 43, and 53. The survival rate of not following any strategy is located in the 
center, and is surrounded by the survival curves of the other five strategies under 
discussion. Compared to following strategy 55, if a physician did not follow any rational 
treatment change strategy, the odds of developing mucoid PaPI would be 4 times higher. 
If the cut-off of predicted probability was fixed, then the worst outcome was always 
associated with a relative change of predicted probability equal to 1.8310% (strategy 
‘X3’) or 2.6355% (strategy ‘X4’). Among the strategies that were investigated, without 
adjusting variables, strategy 31 was associated with the optimal outcome and strategy 23 
was associated with the worst outcome.  
 
7.1.5.2 The Fixed Parameterization of the Dynamic Logistic MSM with SIPW 
After adjusting the baseline variables and applied SIPW, not following any 
strategy caused the worst outcome (Table 7.14 and Figure 7.10). Given fixed baseline 
variables, compared to following strategy 55, if a physician’s treatment changes did not 
follow any rational treatment change strategy, the odds of developing mucoid PaPI 
would be 1.17 times higher (95%CI (1.13, 1.22)). Similar to the previous model, if the 
cut-off of predicted probability was fixed, then the worst outcome was always reflected 
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by a relative change of predicted probability equal to 1.8310% (strategy ‘X3’). As shown 
in Figure 7.10, other than not following any strategy, the differences of odds ratio among 
different strategies were trivial. Compared to following strategy 55, only following 
strategies 31, 51, or 52 would delay the progression to mucoid PaPI. The optimal 
outcome was achieved if the physician followed strategy 51. Considering the results of 
point estimation and confidence interval, at the baseline visit, with an increase in 
predicted FEV1, a decrease in age, a decrease in severity of mutation class, or a decrease 
in the number of mucolytics a patient received, the odds of developing mucoid PaPI 
decreased. At the same time, Caucasian and Black patients had the lowest and highest 
odds of developing mucoid PaPI, respectively. The number of PEx in the past year had 
an inconsistent effect on the outcome: it increased at the beginning, and decreased when 
the number of PEx was greater than 4. If a patient had drug resistance to aminoglycosides, 
the odds of developing mucoid PaPI increased. Surprisingly, if a patient had not test drug 
resistance of quinolones, the odds of developing mucoid PaPI increased.  
 
7.1.5.3 The Flexible Parameterization of the Dynamic Logistic MSM with SIPW 
The result of flexible model was present in Table 7.15. After adjusting the 
baseline variables and applying the SIPW, the results show that the assumption of 
constant-time hazards was held. Compared to the effects in the 6th year, the effects in the 
first 2 years were not statistically significantly different. Even though the effects from the 
3rd to 5th year were statistically significant, the absolute impacts were trivial compared to 
influences from the other variables. The maximum of the absolute difference of the 
coefficient, 0.4178, occurred at the 5th year. This difference was much smaller than the 
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absolute difference of the coefficient on the interaction between strategy 1X and any year.  
When not considering the effect of strategy on a specific year, not following any 
strategy still caused the worst outcome. Compared to following strategy 55, which was 
the most strict strategy to define rational treatment change, not following any strategy, on 
average, increased the odds ratio of developing mucoid PaPI by 1.4156 times. When 
taking only the interaction between strategy and year into consideration, the treatment 
effect of not following any treatment strategy ranked in the middle among all strategies in 
the same year. At the baseline visit, with an increase in predicted FEV1, a decrease in age, 
a decrease in severity of mutation class, and a decrease in number of mucolytics a patient 
received, the odds of developing mucoid PaPI decreased. At the same time, Caucasian 
and Black patients had the lowest and highest odds of developing the outcome, 
respectively. The number of PEx in the past year had inconsistent effect on the outcome: 
it increased at the beginning, and decreased when the number of PEx was greater than 4. 
Similarly, in mutation 2, compared to the class I, the chance of developing mucoid PaPI 
was higher in the class III. If a patient had drug resistance to aminoglycosides, the odds 
of developing mucoid PaPI increased.  If a patient had not test the drug resistance to beta 
lactams or quinolones, the odds of developing mucoid PaPI was decreased and increased 
respectively.  
 
7.1.5.4 The Time-dependent Cox Regression 
A time-dependent Cox regression was also built to investigate the difference 
between following a strategy when changing treatment (specifically strategy 33, the first 
strategy identified) and changing treatment without following any strategy. The final 
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model was identified based on the AIC value using stepwise regression. As shown in 
Table 7.16, the result of variable selection is consistent among 10 imputed datasets. Table 
7.17 presents the final result after combining the result from 10 imputed datasets. 
Compared with following strategy 33, the chance of developing mucoid PaPI would be 
2.84 times higher if a physician made a treatment change without following any strategy. 
The above result was consistent with the result in the fixed parameterization of the 
dynamic logistic MSMs using the SIPW. Hemoptysis, MAI infection, and bronchodilator 
use were three variables that would significantly shorten the time to mucoid PaPI. 
 
7.2 Discussions 
The discussion section is organized in the following manners. The first part 
focuses on the discussion of the innovations and successes of this objective. Then, all 
limitations are discussed. At the end, a summary of these results and their potential 
applications are summarized from three perspectives: 1) steering the design of RCTs; 2) 
directing the clinical practice; 3) supporting the design of value-based drug formulary. 
 
7.2.1 Strengths 
There are two innovations in the investigation of Aim 3. First, this is the first 
study to investigate the causality of different treatment change strategies. This solves two 
complicated research questions: investigating dynamic treatment regimens and 
investigating treatment change, at the same time. Dynamic MSM is an advanced causal 
method, which was applied to investigate dynamic treatment changes. However, unlike 
traditional questions about dynamic treatment regimens, which investigate initiation, this 
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study was able to investigate the effects of treatment switching by using the predicted 
probability of having a rational treatment change and related strategies. Moreover, this 
study innovatively embedded the regularization method into selecting variables for the 
prediction of IPW. The majority of the time, confounders and intermediate variables have 
to be well identified in order to appropriately investigate the causality between exposure 
and outcome. With the increase of the number of parameters and the sheer volume of data 
available, the chance of fully understanding the function of each variable in the dataset 
was dramatically decreased. This regularization method provides an opportunity to 
investigate causality with a fair amount of knowledge.  
Other than the innovations, one of the key successes was the ability to build the 
SIPW with a narrow range under this complicated scenario. Benefitting from combining 
the data-driven and knowledge-driven method, the prediction models of numerator and 
denominator of IPTW and IPCW balanced the parsimoniousness and accuracy of 
prediction at the same time. After truncating the stabilized weights that were beyond 10, 
the mean of SW decreased from 20.9848 to 1.0177 under strategy 53 in imputed dataset 2. 
At the same time, unlike the traditional prediction model of IPCW, which included the 
indicator of receiving treatment as an independent variable, in this study, IPTW held an 
indicator of being censored. In other words, rather than building IPCWs that were 
conditional on whether a patient received the treatment, in this study, IPTW was 
predicted conditional on whether or not the patient was being censored. This change was 
made to embrace the uniqueness of dynamic treatment regimes, in which the artificially 
censored dataset would be identified after the normal censoring had already been adjusted. 
At the same time, the causation of extreme values of SIPW was investigated. The 
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majority of the time, censoring was caused by the different rationales between predicting 
the probability of having a rational treatment change and predicting the probability of 
being artificially censored for the denominator of the IPTW. The first outcome was 
predicted by the difference of values that were measured between previous and current 
visits for the same variables. However, the denominator of the IPTW may be determined 
by the difference of values that were measured between baseline and current visits. 
Together with the issue that no visit was censored at the 1st visit, extreme values of SW 
could occur. For example, one patient had a higher predicted FEV1 (200%) at the 
baseline visit, the value decreased dramatically to 61.58% at the 1st visit, and maintained 
consistently around 80%, in the following visits. At the first visit, the predicted 
probability of having rational treatment was much higher (0.5141) than the threshold. 
However, because of the missing value for the relative change of predicted probability, 
the visit was not censored. In the following visits, since the lung function barely 
fluctuated, the predicted probability of having rational treatment change was lower than 
the cut-offs for the strategy, so no rational treatment change was needed. However, the 
inflated value of the predicted FEV1 at the baseline visit still affected the prediction of 
the denominator of IPTW. Under that situation, the SIPW kept increasing exponentially 
from the baseline until the last visit. Even though the stabilized weight in each visit 
ranged only from 1.11 to 3.42, the final weight in each visit is a product that includes all 
previous visits, and some patients had as many as 20 visits. There is no doubt that these 
patients have extreme values of SW. Since truncated weights with extreme values can 
decrease the chance that a small number of replicates have undue influence on the result 




At the same time, the varied results among those four models directly present the 
issues of building dynamic MSM, and the fixed parameterization of the dynamic logistic 
MSMs with SIPW should be the final model in this study. As mentioned previously, the 
SIPW is more stable compared with UIPW. Both the fixed parameterized model and 
flexible parameterized model with SIPW indicated similar results: physicians who did not 
prescribe treatment following any strategy would cause the worst outcome. However, 
compared with the fixed parameterized model, which identified an optimal strategy that 
did not associate with time, the identification of optimal strategy is complicated for the 
flexible parameterized model: the optimal strategy is varied in each calendar year. 
Considering the complexity of the optimal strategy, and the marginal benefit of applying 
the flexible parameterized model, the fixed parameterized model is preferred. Last but not 
least, compared with time-dependent cox regression, the fixed parameterized model was 
more likely to comprehensively adjust the time-dependent confounders, which were 
supported by the results. In the time-dependent cox regression, compared with physicians 
who followed strategy 33 to change prescription, the chance of developing mucoid PaPI 
would be 2.84 times higher, if a physician made a treatment change without following 
any strategy. For the same comparison, the number decreased to 1.14 in the fixed 
parameterized model. Therefore, the results in the fixed parameterization of the dynamic 
logistic MSMs with SIPW are the key findings in this objective. 
Specifically, this study suggests that physicians had to make treatment changes 
following rational treatment change strategies. If not, the worse outcome would occur. 
Compared to following a specific strategy, 55, the odds of developing mucoid PaPI 
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would be 1.17 times higher for a patient whose treatment change did not follow any 
strategy. The optimal outcome would be achieved following strategy 51: the physician 
should not provide a treatment change on the treatment class level if the predicted 
probability of having a rational treatment change is lower than 0.088 and the relative 
change of probability is lower than 0.222% between the current and the previous visit; if 
the probability is higher than 0.098 and the relative change of probability is higher than 
0.222%, then the physician should change the treatment on the treatment class level. 
Generally speaking, these results are consistent with the concept of evidence-based 
medicine: treatment has to be changed if and only if it is supported by the clinical signals. 
However, given there have been limited longitudinal studies for CF patients, the accuracy 
of this result is hard to prove directly. Let alone, the treatment effects of following varied 
DTRs to make treatment change were not statistically different given their boot strapped 




The analysis present in this aim relies on the validity of the assumptions outlined 
in the method section of this dissertation. Unlike positivity, which was investigated by 
testing whether there was at least 1 patient in all potential scenarios, the assumptions of 
consistency and no unmeasured confounder are untestable. However, CFF accredited 
clinics and hospitals almost prevented the pathogen transmission, such as Pseudomonsa 
Aeruginosa, among patients by following the Infection Prevention and Control 
Guideline167 and cohort segregation. There was still a small chance that the pathogen 
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transmission existed, 0.018 per year for chronic infection with Pa.168 Under that situation, 
the assumption of consistency may be violated by interferences among patients who 
received chronic treatments and who did not. Fortunatelly, the rate was low and there is 
limited time to have patient-patient interaction for pediatric CF patients. Therefore, the 
chance of violating the assumption of stable unit treatment consistency, thereafter to 
violate the assumption of consistency, would be low. In addition, the assumption that the 
artificial censorship and the censorship models used in the denominator of the weights 
are correctly specified is crucial for consistent estimates. To increase the possibility of 
correctly fitting the probability of artificial censoring and censoring, respectively, very 
rich models with tremendous numbers of variables were applied, and variables that were 
selected in each model were included jointly. However, the direction and consistency of 
effect estimates are conflicted with current knowledge for several variables in the 
prediction model of IPW, which may be problematic. For example, the more PEx that a 
patient had in the baseline visit, the higher chance the patient may receive rational 
treatment change in predicting the numerator of the IPTW. However, when the number 
was greater than 4, the estimate decreased, and even reversed when the number equaled 
or was greater than 5. Similarly, compared to mutation 2 class V, a patient whose 
mutation did not belong to any class or was missed had a higher value in predicting the 
numerator of the IPTW. This scenario could be explained by the tendency for physicians 
to make a rational treatment change according to other clinical signals when faced with 
an uncertain mutation type. However, without further information, the explanation is not 
certain. If a patient had pancreatitis or MSSA infection at the current visit, the chance of 
having a rational treatment change decreased, which was opposite to our expectation.  
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Last but not least, 25 strategies were investigated in this study. According to the 
result in the flexible parameterization of dynamic logistic MSM, which is not smooth, 
perhaps other potential strategies should be investigated. At the same time, the 
identification of those strategies in Objective 2 may also bias the result, if there was any 
unmeasured confounder that confounded any irrational treatment changes as a rational 
treatment change given the clinical signals.  
 
7.3 Applications 
The results of this study are very likely to be generalizable to other samples with 
the same outcomes. The CFFPR is a nationwide patient registry that, since 1986, has 
been aimed at tracking treatment effects on and survival time transitions of CF patients. 
Considering the longitudinal and national characteristics of the CFFPR, the abundant 
variables measured in the database, and the prudent inclusion criteria, this study has good 
generalizability. At the same time, developing mucoid PaPI works as the indicator for 
disease progression, after which the chance of survival decreases dramatically. Using this 
indicator provides an alternative way of identifying treatment effects that doesn’t require 
further adjustment for death. Given the above characteristics, the results of this study are 
stable and generalizable for several potential applications, which are described in the 
following sections. 
 
7.3.1 Steering the Design of RCTs 
In the current study, the observational data were applied to emulate the RCT, 
which investigated the DTR of treatment change that causes the optimal outcome. Even 
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though the advanced method had been applied, those results have to be double-proved 
before being adopted into the guidelines and supporting future decision-making. Unlike 
traditional RCTs, which compare efficacy among two or several interventions, this 
innovative RCT requires comparison of the efficacy of several DTRs. Since all DTRs are 
determined by the threshold of the predicted probability of having rational treatment 
change and the threshold of the relative change of predicted probability of having rational 
treatment change between the current and previous visit, without the results of this study, 
millions of potential DTRs have to be compared in order to identify the optimal one. 
Considering the extreme expense of conducting an RCT and the sample size needed to 
generate enough power, the results of this study are invaluable, specifically for the 
following two conclusions. The patient who did not follow any regime for treatment 
changes had worse outcomes than patients who followed any other regime. With the 
increase of the threshold of relative change of predicted probability, the hazard ratio of 
developing mucoid PaPI increased and then decreased among patients who followed 
related DTRs. The regime in which the threshold of relative change of predicted 
probability equaled 1.831% always caused the worst outcome in regimes with the same 
threshold of predicted probability. Therefore, the main focus of designing an RCT is 
investigating the optimal threshold of the predicted probability of rational treatment 
change. 
If the project were funded with $1 million (probably enough to recruit only 200 
patients), with the study’s results, hypothetically just five DTRs would need to be 
compared to investigate the optimal DTR. Specifically, patients older than 6 years old 
and diagnosed with nonmucoid PaPI but mucoid PaPI are randomized into five DTRs. 
282  
  
For those DTRs, the lower thresholds of predicted probability of having rational 
treatment change are 0.072, 0.076, 0.080, 0.084, and 0.088. The upper thresholds are 0.01 
higher than the related lower thresholds. At the same time, the threshold for the relative 
change of predicted probability of having rational treatment change is consistent among 
those five DTRs: 0.222% and 3.440% for the lower and upper thresholds, respectively. 
Whenever both a patient’s predicted probability and relative change of predicted 
probability of having rational treatment change are higher than the upper threshold, then 
he receives a rational treatment change. If both of those two values are smaller than the 
related lower threshold, then he should not receive any rational treatment change. 
Prescribing an additional treatment from any one of three treatment classes—inhaled 
antibiotics, mucolytics, or anti-inflammatories—can be defined as a rational treatment 
change if it follows the previous rules. For the rest of the scenarios, they follow the rules 
all the time regardless of whether additional treatment is prescribed. If the patient 
develops mucoid PaPI, receives a lung transplant, or dies, he will be censored.  
Generally speaking, this design balances the trade-off between sample size and 
number of DTRs being investigated. The design specifically focuses on investigating the 
causality between using different thresholds of predicted probability to define DTRs and 
time until mucoid PaPI develops. Hypothetically, if all 25 regimes were investigated, 
there would be only eight patients followed each one of the regimes. Obviously, not 
enough power would be generated in this hypothetical trial. Using the same concept of 
DTR design rather than applying a specific threshold of relative change for each regime, 
a relatively broad grace period is given: 0.222% to 3.440%. The determination of whether 
a patient will follow a specific regime depends on whether the observed treatment change 
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pattern is consistent with the threshold of the related regime. Unlike the observational 
study, which created 25 replicates of each individual visit, only five replicates have to be 
created in the RCT since the threshold of predicted probability is fixed among those five 
DTRs. Those five replicates apply only to investigate the optimal thresholds of the 
relative change, assuming the threshold of predicted probability is fixed. With the support 
of this design, even the RCT enrolls only 200 patients, who are randomly assigned into 
one of the five regimes; after five replicates are created, the results can represent 1000 
patients. On average, around 40 patients follow each of the 25 DTRs, which may 
generate enough power. In other words, the results of this study are invaluable, especially 
in the direction of supporting the design of RCTs. 
 
7.3.2 Directing the Clinical Practice 
With the identification of the optimal dynamic treatment regime, using the 
longitudinal data under the causal inference, physicians can use these results in the future 
to make treatment changes at the right time by following the optimal strategy. Using the 
optimal regime 51 as an example, the physician should not provide a treatment change on 
the treatment class level if the predicted probability of having a rational treatment change 
is lower than 0.088 and the relative change of predicted probability is lower than 0.222% 
between the current and previous visits; if the probability is higher than 0.098 and the 
relative change of predicted probability is higher than 0.222%, then the physician should 
change the treatment at the treatment class level. If the predicted probability and relative 
change of predicted probability are in the remaining scenarios, the prescribing behavior is 
acceptable regardless of whether a treatment change is made. At the same time, given 
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unique demographic values, clinical variables, and treatment histories at the baseline visit 
and current visit, the physician can make personalized treatment change decisions for 
each patient confidently, rather than guessing whether the demographic and clinical 
characteristics of each individual patient match the studies’ inclusion criteria, from which 
the guidelines were generated. With the application of the optimal dynamic rational 
treatment change strategy, both healthcare providers and patients are surrounded with 
certain evidences when a treatment change decision has to be made. Therefore, the 
clinical outcome—time to mucoid PaPI—will be extremely delayed at the CF patient 
population level.  
 
7.3.3 Supporting the Design of Value-based Drug Formulary 
At the same time, the study results could also support value-based formulary 
design prior to reimbursement of extremely expensive medications by optimizing 
traditional treatment utilization through step therapy, tiered formulary, prior authorization, 
and other tools for managed care pharmacy. Drug formulary was initially designed in the 
early twentieth century to manage and control inventory, manage costs, and facilitate the 
purchasing process.169,170 As time passed, drug formulary evolved into a negotiating tool 
with drug manufacturers. In order to design a drug formulary, drug review and formulary 
placement decisions have to be made based mainly on clinical safety and efficacy. Other 
than those two components, cost and rebate are other major factors for traditional cost-
based formulary designs.169,170 Cheaper treatments, including the sum of manufacturer 
price and rebate, are always listed in the lower tier with low or no copayments. Rather 
than applying cost as the third component, the value-based formulary ranks individual 
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treatments in therapeutic areas according to comparative drug values171-173 and assigns 
them to related tiers. Compared with traditional cost-based formulary design, the value-
based formulary design reduces the annual cost of the health plan without negatively 
affecting healthcare utilization.173  
With the successful identification of the dynamic treatment regime, the value-
based formulary could be designed on the treatment class level: additional treatment or 
switching treatment will be reimbursed only if the prescription timing matches the 
threshold of the dynamic treatment regime. In such a value-based formulary, patients’ 
lung function would be optimized so as to avoid or delay the need for extremely 
expensive treatments such as ivacaftor and ivacafotr/lumacaftor unless the healthcare 
provider has already prescribed all the other treatments step by step (step therapy) and the 
scenario of suboptimal treatment effects has already occurred (prior authorization). 
Therefore, the annual cost of the health plan for CF patients could be well controlled 
without sacrificing healthcare utilization.  
After several years’ application, with improvements in patients’ health and 
emerging treatments, a better strategy may be identified. At the same time, with an 
increase in the number of patients who follow the optimal strategy, the grace period 
narrows down. Therefore, every couple of years, a new iterative strategy will be 
identified with more certain evidences. After enough iterations, grace periods may 
eventually disappear, and an optimal strategy with a clear-edged threshold could be 
identified. Before the final optimal strategy is identified, insurance companies will 
redesign their formularies whenever the optimal strategy is updated. They will reimburse 
only those treatment changes that match the optimal strategy. In such a situation, this 
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The analysis undertaken in Aim 3 represents the first comparison of dynamic 
rational treatment change strategies for chronic treatment of pediatric CF patients using 
marginal structural models and inverse probability weighting. In summary, patients who 
do not follow a treatment-change regime have worse outcomes than those following any 
regime. Among the patients who followed different DTRs, the hazard ratio of developing 
mucoid PaPI first increased, then decreased, as the threshold of relative change of 
predicted probability increased. The regime in which the threshold of relative change of 
predicted probability equaled 1.831% always caused the worst outcomes compared with 
other regimes that shared the same threshold of predicted probability. An optimal strategy 
was identified among 25 strategies; this optimal strategy maximized the time to infection 
with mucoid PaPI and includes the following guidelines: the physician should not 
provide a treatment change on the treatment class level if the predicted probability of 
having a rational treatment change between the current and previous visit is lower than 
0.088 and the relative change of predicted probability is lower than 0.222%; if the 
probability is higher than 0.098 and the relative change of predicted probability is higher 
than 0.222%, then the physician should change the treatment on the treatment class level. 
If the probability ranges from 0.088 to 0.098, it is acceptable to either implement a 
treatment change or not. Generally speaking, these results are consistent with the concept 
of evidence-based medicine: treatment has to be changed if and only if it is supported by 
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the clinical signals.  
Currently, several guidelines for chronic lung health maintenance treatments exist 
to recommend prescribing practices. However, rather than suggesting the order of 
prescription, the guidelines only categorize all treatments by the certainty of net benefits. 
Additionally, those evidences are generated by existing RCTs with small sample sizes 
and extremely narrow characteristics that don’t represent the whole patient population. 
With the identification of the optimal dynamic treatment regime, using longitudinal data 
under the causal inference, physicians can use the results of this study in the future to 
make treatment changes at the right time by following the optimal strategy. At the same 
time, physicians can make personalized treatment change decisions for each patient 
confidently given the unique demographic values, clinical variables, and treatment 
histories at the baseline visit and current visit, rather than guessing whether the 
demographic and clinical characteristics of each individual patient match the studies’ 
inclusion criteria from which the guidelines were generated. With the application of the 
optimal dynamic rational treatment change strategy, both healthcare providers and 
patients are presented with certain signs when a treatment change decision has to be made. 
Therefore, the clinical outcome—time to mucoid PaPI—will be maximally delayed at the 
CF patient population level. The only drawback is that the current study has generated 
causality by emulating the design of an RCT but conducting a real RCT. However, the 
results of this study will help to design an RCT to investigate the causality between 
following different DTRs and a delay in developing mucoid PaPI. The results of the new 
RCT, in return, can prove the evidence generated by this study.  
At the same time, the study results could also support value-based formulary 
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design by optimizing traditional treatment utilization—step therapy, tiered formulary, 
prior authorization, and other tools for managed care pharmacy—prior to reimbursement 
of extremely expensive medications. After several years’ application, with improvement 
in patient health and emerging treatments, a better strategy may be identified. At the same 
time, with an increase in the number of patients following the optimal strategy, the grace 
period will narrow down. Therefore, every couple of years, a new iterative strategy will 
be identified with more certain evidence. After a number of iterations, grace periods may 
eventually disappear, and an optimal strategy with clear-edged thresholds could be 
identified. Insurance companies will then redesign their formularies whenever the 
optimal strategy is updated. They will reimburse only those treatment changes that match 
the optimal strategy. In this situation, this research can not only deliver the right therapy 
to the right patient at the right time but also at the right cost, indirectly controlling 
healthcare costs by optimizing traditional treatments and delaying the use of innovative 
yet expensive treatments.  
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Variable Numerator Numerator Denominator Denominator Numerator Denominator Numerator Denominator Numerator Denominator
(Intercept) 1 1 1 1 1 1 1 1 1 1
Age (baseline) 0 1 0 1 0 1 1 1 1 1
Predicted FEV1 in current 
visit X X 1 1 X 1 X 1 X 1
Predicted FEV1 in current 
visit (baseline)
0 0 1 1 1 1 1 1 1 1
Height X X 1 1 X 1 X 1 X 1
Weight X X 0 0 X 0 X 1 X 1
Height (baseline) 0 0 0 0 1 0 1 1 1 1
Weight (baseline) 0 0 0 0 1 0 1 1 1 1
Number of visit (spline) X X 1 1 X 1 X 1 X 1
Number of visit X X 0 0 X 1 X 1 X 1
Mutation 1 class 0 0 0 1 0 0.48 0 0 0 0
Mutation 2 class 0 0 0 0 0.28 1 1 1 1 1
F508 0 0 0 0 0 0 0 0 0 0
Disenrollment X 0 X 1 X X X X X X
Death X 0 X 0 X X X X X X
Hispanic 0 0 0 0 0 0 0 0 0 0
Gender 0 0 0 0 0 0.52 0 0 0 0
Race 0 0 0 0 0 1 1 1 1 1
Smoking X X 0 0 X 1 X 1 X 1
Transplant X X 1 0 X 0.16 X 1 X 1
Arthropathy X X 0 0 X 0.44 X 0 X 0
CFRD_status X X 0 0 X 0 X 1 X 1
DIOS X X 0 0 X 0 X 0 X 0
GERD X X 1 1 X 0 X 1 X 1
Pancreatic insufficiency X X 0 0 X 1 X 1 X 1
Pancreatitis X X 0 0 X 1 X 1 X 1
Probability of being selected
Result from LASSO Final decision
IPTW IPCW (censor) IPTW
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Variable Numerator Numerator Denominator Denominator Numerator Denominator Numerator Denominator Numerator Denominator
TB X X 0 0 X X X 0 X X
Pneumothorax X X 0 0 X 0.32 X 0 X 0
Hemoptysis X X 1 0 X 0 X 1 X 1
Using any enzymes X X 1 1 X 0 X 1 X 1
ABPA X X 0 0 X 0.84 X 1 X 1
Aspergillus X X 0 0 X 1 X 1 X 1
B. cepacia X X 1 1 X 1 X 1 X 1
B. cenocepacia X X 0 0 X 0.2 X 0 X 0
Burkholderia species X X 0 0 X 0 X 0 X 0
Candida X X 1 1 X 0 X 1 X 1
Mycobacterium gordonae X X 0 0 X 0 X 0 X 0
MAI X X 1 1 X 0 X 1 X 1
MRSA X X 0 0 X 0 X 1 X 1
MSSA X X 0 0 X 1 X 1 X 1
Other gram-negative 
microorganisms X X 1 1 X 0 X 1 X 1
Serratia marcescens X X 0 0 X 0.4 X 0 X 0
Staphylococcus aureus X X 0 0 X 1 X 1 X 1
Stenotrophomonas/ 
Maltophilia X X 0 0 X 0 X 0 X 0
Non-mucoid Pa PI X X 0 0 X 0.16 X 1 X 1
Unknown type of mucoid 
Pa PI
X X 0 0 X 0.6 X 1 X 1
Smoking (baseline) 0 0 0 0 0 0 0 0 0 0
Transplant (baseline) 0 0 1 0 0 1 1 1 1 1
Arthropathy (baseline) 0 0 0 0 0 0 0 0 0 0
CFRD_status (baseline) 0 0 1 1 0 0 1 1 1 1
Probability of being selected
Result from LASSO Final decision
IPTW IPCW (censor) IPTW
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Variable Numerator Numerator Denominator Denominator Numerator Denominator Numerator Denominator Numerator Denominator
DIOS (baseline) 0 0 0 0 0 0 0 0 0 0
GERD (baseline) 0 0 1 1 0 0 1 1 1 1
Pancreatitis (baseline) 0 0 0 0 0 0 0 0 0 0
Hemoptysis (baseline) X X X X X X X X X X
Using any enzymes 
(baseline)
0 0 0 0 0 0 0 0 0 0
ABPA (baseline) 0 0 0 0 0 0 0 0 0 0
Aspergillus (baseline) 0 0 0 0 0 0 0 0 0 0
B. cepacia (baseline) 0 0 1 1 0 0 1 1 1 1
B. cenocepacia (baseline) X X 1 1 X X 0 0 X X
Burkholderia species 
(baseline)
0 0 0 0 0 0.04 0 0 0 0
Candida (baseline) 0 0 0 0 0 0 0 0 0 0
MAI (baseline) 0 0 0 0 0 0 0 0 0 0
MRSA (baseline) 0 0 1 1 0 0 1 1 1 1
MSSA (baseline) 0 0 0 0 0 0 0 0 0 0
Other gram-negative 
microorganisms (baseline)
0 0 1 1 0 0.28 1 1 1 1
Serratia marcescens 
(baseline)
0 0 0 0 0 0 0 0 0 0
Staphylococcus aureus 
(baseline)
0 0 0 1 0 0.04 0 0 0 0
Stenotrophomonas/ 
Maltophilia (baseline)
0 0 0 0 0 0.04 0 0 0 0
Non-mucoid Pa PI 
(baseline)
0 1 1 1 0 0 1 1 1 1
Probability of being selected
Result from LASSO Final decision
IPTW IPCW (censor) IPTW
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Variable Numerator Numerator Denominator Denominator Numerator Denominator Numerator Denominator Numerator Denominator
Unknown type of mucoid 
Pa PI (baseline)
0 0 0 0 0 0 0 0 0 0
Number of PEx in the past 
year in current visit 
(baseline) 
0 0 0 0 0.32 0.76 1 1 1 1
Number of PEx in the past 
year in current visit X X 0 0 X 1 X 1 X 1
Drug resistance of 
aminoglycosides in current 
visit (baseline) 
0 0 1 1 0 0.96 1 1 1 1
Drug resistance of beta 
lactams in current visit 
(baseline) 
0 0 0 1 0 0.6 1 1 1 1
Drug resistance of 
quinolones in current visit 
(baseline) 
0 0 0 0 0 1 1 1 1 1
Drug resistance of 
aminoglycosides in current 
visit
X X 0 0 X 1 X 1 X 1
Drug resistance of beta 
lactams in current visit X X 0 0 X 1 X 1 X 1
Drug resistance of 
quinolones in current visit X X 0 0 X 0.76 X 1 X 1
Mucolytics X X X X X 1 X X X 1
Inhaled antibiotics X X X X X 1 X X X 1
Anti-inflammatories X X X X X 1 X X X 1
Bronchodilators X X X X X 1 X X X 1
Mucolytics (baseline) X X X X 1 1 X X 1 1
Probability of being selected
Result from LASSO Final decision
IPTW IPCW (censor) IPTW
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Table 7.1. (continued). 
 
*Red font indicates that the change was made to match the baseline variable that was selected in this model; Pink font indicates that 
that the change was made to match the baseline variable in the denominator; Green font indicates that that the change was made to 
match the variable in the numerator; Blue font indicates that the change was made to match the variable in the IPCW; Orange font 







Variable Numerator Numerator Denominator Denominator Numerator Denominator Numerator Denominator Numerator Denominator
Inhaled antibiotics 
(baseline) 
X X X X 0.08 0 X X 0 0
Anti-inflammatories 
(baseline) 
X X X X 1 1 X X 1 1
Bronchodilators (baseline) X X X X 0 0 X X 0 0
Probability of being selected
Result from LASSO Final decision
IPTW IPCW (censor) IPTW
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Table 7.2. The estimate of variables in the numerator of the IPTW under three strategies using imputed dataset 2. 
 
Censor    <0.001 <0.001 >999.999 <0.001 <0.001 >999.999 <0.001 <0.001 >999.999
Age 0.982 0.952 1.012 0.979 0.949 1.010 0.984 0.953 1.015
Predicted FEV1 in current 
visit
0.993 0.991 0.995 0.993 0.991 0.995 0.993 0.991 0.995
Height 0.986 0.979 0.993 0.985 0.978 0.993 0.985 0.977 0.992
Weight 1.006 0.998 1.013 1.007 0.999 1.014 1.007 0.999 1.015
Mutation 2 class:
1 1.861 1.341 2.583 2.004 1.429 2.810 2.097 1.478 2.975
2 1.849 1.344 2.546 1.959 1.408 2.725 2.125 1.509 2.992
3 1.640 1.138 2.363 1.799 1.235 2.619 1.918 1.302 2.824
4 1.082 0.698 1.678 1.160 0.741 1.815 1.271 0.804 2.010
5
Doesn’t belong to any class 1.775 1.274 2.473 1.865 1.325 2.625 1.943 1.364 2.767
Missing 1.546 1.075 2.223 1.661 1.144 2.413 1.822 1.241 2.675
Race:
Caucasian 1.361 0.713 2.598 1.330 0.700 2.525 1.229 0.647 2.334
Black 1.421 0.724 2.788 1.264 0.646 2.470 1.185 0.606 2.319
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Will have 0.896 0.314 2.556 0.965 0.338 2.754 1.011 0.354 2.884
CFRD status:
No
Impaired glucose tolerance 1.060 0.647 1.738 1.159 0.707 1.901 1.289 0.785 2.116
CFRD with or without 
fasting hyperglycemia
1.181 0.968 1.440 1.174 0.959 1.436 1.213 0.991 1.485
GERD 0.967 0.863 1.083 0.993 0.886 1.114 1.029 0.917 1.156
B. cepacia 3.100 0.335 28.664 3.455 0.372 32.055 3.644 0.394 33.711
MRSA 1.022 0.909 1.150 1.048 0.931 1.180 1.067 0.946 1.202
Other gram-negative 
microorganisms
1.250 0.774 2.018 1.344 0.833 2.170 1.330 0.816 2.168
Non-mucoid Pa PI 1.127 0.932 1.362 1.168 0.963 1.417 1.124 0.928 1.362
Number of PEx in the past 
year in current visit:
0
1 1.070 0.962 1.190 1.115 1.001 1.241 1.129 1.013 1.259
2 1.168 0.954 1.431 1.208 0.985 1.482 1.227 1.000 1.505
3 1.685 1.217 2.331 1.635 1.181 2.262 1.562 1.124 2.172
4 1.120 0.613 2.045 1.202 0.660 2.189 0.973 0.528 1.794
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Table 7.2. (continued). 
 
 
Drug resistance of 
aminoglycosides in current 
visit:
No
Yes 1.792 1.214 2.647 1.784 1.209 2.633 1.802 1.219 2.663
Testing not done 0.785 0.145 4.266 0.963 0.193 4.808 0.993 0.191 5.155
Drug resistance of beta 
lactams in current visit:
No
Yes 0.533 0.282 1.010 0.578 0.306 1.089 0.572 0.302 1.085
Testing not done 0.417 0.047 3.688 0.822 0.099 6.802 0.729 0.082 6.442
Drug resistance of 
quinolones in current visit:
No
Yes 1.017 0.550 1.881 1.006 0.538 1.881 1.122 0.605 2.079
Testing not done 2.743 0.569 13.231 1.169 0.209 6.528 1.227 0.212 7.085
Mucolytics:
0
1 0.995 0.913 1.084 0.956 0.876 1.042 0.926 0.848 1.010
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Table 7.2. (continued). 
 












1 0.611 0.540 0.692 0.606 0.534 0.688 0.608 0.534 0.691
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Table 7.3. The estimate of variables in the numerator of the IPTW under three strategies using imputed dataset 8. 
 
Censor    <0.001 <0.001 >999.999 <0.001 <0.001 >999.999 <0.001 <0.001 >999.999
Age 0.992 0.962 1.023 0.992 0.961 1.023 0.990 0.959 1.021
Predicted FEV1 in current 
visit
0.993 0.991 0.995 0.993 0.991 0.995 0.994 0.992 0.996
Height 0.986 0.979 0.993 0.985 0.978 0.992 0.985 0.978 0.992
Weight 1.004 0.996 1.011 1.004 0.996 1.011 1.004 0.997 1.012
Mutation 2 class:
1 2.052 1.463 2.876 2.199 1.550 3.119 2.354 1.637 3.385
2 2.002 1.440 2.785 2.136 1.517 3.007 2.335 1.636 3.332
3 1.816 1.249 2.641 2.001 1.360 2.944 2.203 1.480 3.281
4 1.244 0.798 1.938 1.334 0.847 2.101 1.476 0.926 2.354
5
Doesn’t belong to any class 1.944 1.381 2.736 2.037 1.430 2.901 2.096 1.452 3.026
Missing 1.761 1.214 2.555 1.913 1.304 2.806 2.027 1.364 3.012
Race:
Caucasian 1.351 0.709 2.572 1.288 0.679 2.445 1.186 0.624 2.255
Black 1.344 0.686 2.633 1.177 0.602 2.300 1.090 0.557 2.134
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Will have 0.907 0.318 2.588 0.970 0.340 2.766 1.017 0.356 2.900
CFRD status:
No
Impaired glucose tolerance 1.071 0.653 1.755 1.093 0.659 1.815 1.207 0.726 2.006
CFRD with or without 
fasting hyperglycemia
1.146 0.938 1.399 1.141 0.932 1.396 1.191 0.972 1.458
GERD 0.983 0.877 1.101 1.006 0.896 1.128 1.041 0.927 1.169
B. cepacia 3.205 0.349 29.414 3.520 0.382 32.482 3.739 0.405 34.482
MRSA 1.009 0.897 1.136 1.055 0.937 1.189 1.076 0.954 1.213
Other gram-negative 
microorganisms
1.273 0.789 2.055 1.352 0.838 2.181 1.350 0.828 2.201
Non-mucoid Pa PI 1.192 0.985 1.441 1.205 0.992 1.464 1.156 0.951 1.404
Number of PEx in the past 
year in current visit:
0
1 1.067 0.959 1.187 1.108 0.995 1.234 1.130 1.013 1.259
2 1.174 0.958 1.439 1.162 0.946 1.428 1.200 0.977 1.475
3 1.683 1.215 2.332 1.756 1.269 2.430 1.688 1.215 2.346
4 1.145 0.627 2.089 1.197 0.657 2.178 1.234 0.678 2.246
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Table 7.3. (continued). 
 
 
Drug resistance of 
aminoglycosides in current 
visit:
No
Yes 1.807 1.223 2.671 1.766 1.195 2.609 1.794 1.212 2.656
Testing not done 0.814 0.150 4.423 0.973 0.194 4.881 1.025 0.197 5.340
Drug resistance of beta 
lactams in current visit:
No
Yes 0.579 0.309 1.086 0.645 0.344 1.208 0.643 0.341 1.212
Testing not done 0.414 0.047 3.678 0.812 0.097 6.802 0.741 0.083 6.593
Drug resistance of 
quinolones in current visit:
No
Yes 1.011 0.548 1.863 0.980 0.526 1.828 1.090 0.589 2.018
Testing not done 2.804 0.581 13.523 1.192 0.212 6.700 1.204 0.207 6.994
Mucolytics:
0
1 0.969 0.889 1.056 0.928 0.851 1.012 0.884 0.810 0.965
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Table 7.3. (continued). 
 












1 0.615 0.543 0.697 0.612 0.539 0.695 0.636 0.559 0.723
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Table 7.4. The estimate of variables in the denominator of the IPTW under three strategies using imputed dataset 2. 
 
Censor    <0.001 <0.001 >999.999 <0.001 <0.001 >999.999 <0.001 <0.001 >999.999
Age* 0.899 0.869 0.930 0.898 0.868 0.929 0.904 0.874 0.935
Predicted FEV1 in current 
visit* 1.018 1.014 1.021 1.018 1.015 1.021 1.018 1.015 1.021
Height* 1.020 1.005 1.035 1.019 1.005 1.034 1.013 0.999 1.028
Weight* 1.004 0.993 1.015 1.004 0.993 1.015 1.004 0.994 1.016
Mutation 2 class:
1 1.829 1.284 2.607 1.980 1.374 2.853 2.101 1.444 3.058
2 1.794 1.269 2.535 1.935 1.353 2.766 2.110 1.461 3.048
3 1.796 1.211 2.663 2.002 1.336 3.002 2.146 1.416 3.250
4 0.964 0.606 1.534 1.083 0.675 1.738 1.207 0.746 1.955
5
Doesn’t belong to any class 1.626 1.141 2.317 1.731 1.202 2.494 1.820 1.250 2.650
Missing 1.219 0.746 1.992 1.287 0.779 2.126 1.552 0.928 2.595
Race:
Caucasian 0.737 0.355 1.529 0.869 0.421 1.795 0.763 0.372 1.565
Black 0.557 0.261 1.190 0.599 0.282 1.273 0.539 0.255 1.139
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Table 7.4. (continued). 
 
Transplant status*:
Will have 0.666 0.189 2.341 0.849 0.240 3.002 0.893 0.253 3.156
CFRD status*:
No
Impaired glucose tolerance 0.927 0.516 1.666 0.982 0.546 1.768 1.039 0.574 1.882
CFRD with or without 
fasting hyperglycemia 0.821 0.596 1.131 0.833 0.604 1.149 0.842 0.610 1.161
GERD* 0.879 0.716 1.079 0.859 0.700 1.053 0.845 0.689 1.036
B. cepacia* 0.107 0.006 1.868 0.098 0.006 1.709 0.138 0.008 2.363
MRSA* 0.963 0.800 1.159 1.010 0.839 1.216 0.995 0.825 1.199
Other gram-negative 
microorganisms* 1.373 0.754 2.498 1.372 0.756 2.490 1.334 0.727 2.448
Non-mucoid Pa PI* 1.402 1.065 1.846 1.574 1.195 2.074 1.605 1.221 2.111
Number of PEx in the past 
year in current visit*:
0
1 0.655 0.574 0.746 0.693 0.607 0.790 0.698 0.611 0.796
2 0.542 0.422 0.696 0.572 0.445 0.735 0.582 0.453 0.748
3 0.488 0.318 0.748 0.478 0.314 0.729 0.441 0.288 0.674
4 0.503 0.240 1.054 0.617 0.294 1.295 0.495 0.237 1.036
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Table 7.4. (continued). 
 
Drug resistance of 
aminoglycosides in current 
visit*:
No
Yes 1.465 0.907 2.366 1.588 0.985 2.562 1.665 1.033 2.682
Testing not done 7.393 0.609 89.816 9.748 0.824 115.259 10.491 0.922 119.383
Drug resistance of beta 
lactams in current visit*:
No
Yes 0.525 0.244 1.131 0.543 0.253 1.166 0.522 0.244 1.117
Testing not done 1.979 0.072 54.655 3.150 0.110 90.239 2.944 0.103 84.061
Drug resistance of 
quinolones in current visit*:
No
Yes 1.003 0.483 2.082 0.932 0.447 1.944 0.990 0.477 2.054
Testing not done 0.145 0.008 2.778 0.077 0.004 1.664 0.080 0.004 1.713
Mucolytics*:
0
1 1.202 1.079 1.339 1.148 1.030 1.280 1.120 1.004 1.250
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1 1.012 0.853 1.200 0.963 0.811 1.144 0.993 0.835 1.183
2 0.706 0.332 1.499 0.965 0.451 2.067 0.733 0.338 1.589
Predicted FEV1 in current 
visit 0.959 0.956 0.962
0.959 0.955 0.962 0.959 0.956 0.963
Height 0.978 0.966 0.991 0.980 0.967 0.993 0.985 0.973 0.998
Weight 1.003 0.993 1.013 1.002 0.993 1.012 1.001 0.992 1.011
Number of visit (spline) 0.999 0.998 0.999 0.999 0.999 0.999 0.999 0.999 0.999
Number of visit 1.282 1.242 1.323 1.246 1.207 1.285 1.217 1.180 1.256
Smoking:
No 1.311 1.098 1.565 1.292 1.080 1.545 1.277 1.068 1.528
Yes 0.973 0.575 1.648 1.086 0.647 1.822 1.004 0.608 1.659
Unknown
Transplant status:
No 0.550 0.206 1.473 0.795 0.330 1.914 0.730 0.301 1.770
Had 1.064 0.221 5.130 1.119 0.260 4.813 1.007 0.232 4.370
Will have
CFRD status:
No 0.771 0.597 0.997 0.806 0.624 1.041 0.774 0.599 1.000
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Table 7.4. (continued). 
 
CFRD status:
CFRD with or without 
fasting hyperglycemia
GERD 1.108 0.927 1.323 1.172 0.982 1.399 1.249 1.048 1.489
Pancreatic insufficiency 0.881 0.631 1.229 0.859 0.613 1.204 0.930 0.662 1.307
Pancreatitis 0.434 0.238 0.790 0.418 0.230 0.762 0.443 0.243 0.806
Hemoptysis 0.902 0.189 4.312 0.779 0.171 3.549 0.848 0.185 3.881
Using any enzymes 1.164 0.963 1.406 1.186 0.980 1.436 1.162 0.959 1.408
ABPA 1.261 1.014 1.567 1.357 1.094 1.684 1.214 0.977 1.508
Aspergillus 1.266 1.114 1.440 1.320 1.160 1.501 1.347 1.183 1.533
B. cepacia 11.274 5.128 24.787 12.154 5.602 26.371 10.009 4.736 21.156
Candida 1.001 0.855 1.171 0.960 0.820 1.125 0.951 0.811 1.115
MAI 1.881 0.897 3.945 1.550 0.717 3.352 1.076 0.463 2.496
MRSA 0.994 0.857 1.152 1.002 0.864 1.162 0.991 0.853 1.151
MSSA 0.750 0.622 0.904 0.787 0.652 0.949 0.753 0.623 0.910
Other gram-negative 
microorganisms 1.002 0.735 1.367
1.064 0.785 1.443 1.048 0.771 1.424
Staphylococcus aureus 1.021 0.828 1.259 0.950 0.770 1.173 0.999 0.808 1.235
Non-mucoid Pa PI 0.662 0.522 0.838 0.604 0.478 0.763 0.548 0.435 0.690
Unknown type of mucoid 
Pa PI
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Number of PEx in the past 
year in current visit:
0
1 3.272 2.903 3.688 3.128 2.774 3.526 3.231 2.868 3.641
2 4.483 3.651 5.505 4.465 3.638 5.481 4.399 3.585 5.399
3 8.026 5.708 11.284 8.045 5.738 11.280 7.951 5.678 11.136
4 3.926 2.119 7.272 3.495 1.893 6.450 3.836 2.082 7.069
5 4.249 2.050 8.804 3.995 1.938 8.235 4.227 2.025 8.823
Drug resistance of 
aminoglycosides in current 
visit:
No
Yes 1.263 0.930 1.717 1.147 0.845 1.555 1.048 0.772 1.423
Testing not done 0.017 <0.001 0.423 0.023 <0.001 0.529 0.021 <0.001 0.504
Drug resistance of beta 
lactams in current visit:
No
Yes 0.625 0.377 1.037 0.644 0.385 1.074 0.708 0.427 1.172
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Table 7.4. (continued). 
 
*Variables were measured at the baseline 
Drug resistance of 
quinolones in current visit:
No
Yes 1.477 0.914 2.385 1.507 0.935 2.428 1.638 1.019 2.633
Testing not done 54.302 3.862 763.538 43.272 3.000 624.226 41.581 2.925 591.078
Mucolytics:
0
1 0.626 0.546 0.717 0.622 0.543 0.713 0.577 0.504 0.662
2 0.151 0.124 0.184 0.148 0.121 0.180 0.148 0.121 0.180
Inhaled antibiotics:
0
1 0.407 0.369 0.449 0.406 0.368 0.448 0.416 0.377 0.460
2 0.221 0.168 0.290 0.182 0.137 0.243 0.191 0.143 0.254
3 0.016 0.002 0.141 0.018 0.002 0.155 0.022 0.003 0.181
Anti-inflammatories:
0
1 0.419 0.368 0.477 0.441 0.388 0.503 0.428 0.376 0.488
2 0.624 0.384 1.014 0.515 0.313 0.848 0.568 0.349 0.924
Bronchodilators:
0
1 0.616 0.562 0.675 0.621 0.566 0.682 0.629 0.573 0.690
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Table 7.5. The estimate of variables in the denominator of the IPTW under three strategies using imputed dataset 8. 
 
Censor    <0.001 <0.001 >999.999 <0.001 <0.001 >999.999 <0.001 <0.001 >999.999
Age* 0.906 0.876 0.937 0.908 0.877 0.939 0.909 0.879 0.941
Predicted FEV1 in current 
visit*
1.017 1.014 1.020 1.017 1.014 1.021 1.017 1.014 1.021
Height* 1.022 1.007 1.038 1.021 1.006 1.036 1.014 1.000 1.028
Weight* 1.000 0.990 1.010 0.999 0.989 1.010 1.000 0.989 1.010
Mutation 2 class:
1 2.012 1.398 2.895 2.161 1.483 3.149 2.390 1.621 3.523
2 1.922 1.346 2.745 2.091 1.446 3.024 2.349 1.605 3.437
3 1.956 1.307 2.927 2.196 1.449 3.327 2.491 1.627 3.815
4 1.143 0.715 1.829 1.288 0.798 2.079 1.468 0.900 2.396
5
Doesn’t belong to any class 1.767 1.229 2.543 1.877 1.289 2.733 1.981 1.343 2.922
Missing 1.447 0.879 2.384 1.503 0.902 2.506 1.745 1.033 2.948
Race:
Caucasian 0.783 0.379 1.618 0.846 0.408 1.753 0.721 0.351 1.485
Black 0.580 0.273 1.233 0.578 0.271 1.234 0.496 0.234 1.052
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Table 7.5. (continued). 
 
Transplant status*:
Will have 0.909 0.264 3.133 0.980 0.281 3.411 1.015 0.289 3.568
CFRD status*:
No
Impaired glucose tolerance 0.966 0.537 1.738 0.952 0.521 1.739 1.020 0.556 1.871
CFRD with or without 
fasting hyperglycemia
0.845 0.613 1.165 0.846 0.613 1.169 0.896 0.649 1.236
GERD* 0.871 0.709 1.071 0.857 0.698 1.053 0.837 0.682 1.028
B. cepacia* 0.104 0.006 1.876 0.106 0.006 1.891 0.144 0.008 2.531
MRSA* 0.975 0.810 1.173 1.037 0.861 1.248 1.017 0.843 1.226
Other gram-negative 
microorganisms*
1.315 0.724 2.389 1.267 0.699 2.297 1.286 0.701 2.359
Non-mucoid Pa PI* 1.473 1.118 1.940 1.592 1.206 2.101 1.624 1.232 2.141
Number of PEx in the past 
year in current visit*:
0
1 0.647 0.568 0.738 0.681 0.597 0.777 0.700 0.613 0.799
2 0.537 0.418 0.690 0.563 0.437 0.725 0.591 0.459 0.760
3 0.465 0.302 0.717 0.494 0.322 0.759 0.462 0.300 0.713
4 0.529 0.251 1.116 0.619 0.292 1.313 0.622 0.295 1.312



















   
  
311 
Table 7.5. (continued). 
 
Drug resistance of 
aminoglycosides in current 
visit*:
No
Yes 1.489 0.922 2.404 1.590 0.984 2.569 1.689 1.047 2.726
Testing not done 6.757 0.546 83.696 8.727 0.729 104.464 9.872 0.853 114.307
Drug resistance of beta 
lactams in current visit*:
No
Yes 0.493 0.231 1.054 0.559 0.261 1.198 0.528 0.247 1.130
Testing not done 1.306 0.052 32.630 2.345 0.089 61.708 2.143 0.083 55.167
Drug resistance of 
quinolones in current visit*:
No
Yes 1.032 0.501 2.127 0.907 0.438 1.879 0.944 0.458 1.945
Testing not done 0.249 0.017 3.589 0.115 0.007 1.956 0.119 0.007 1.968
Mucolytics*:
0
1 1.177 1.056 1.311 1.121 1.005 1.249 1.076 0.965 1.200
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1 1.014 0.855 1.204 0.962 0.809 1.143 1.021 0.858 1.216
2 0.740 0.351 1.560 1.099 0.510 2.365 0.762 0.351 1.653
Predicted FEV1 in current 
visit
0.959 0.956 0.963 0.960 0.956 0.963 0.960 0.957 0.963
Height 0.976 0.963 0.989 0.978 0.965 0.991 0.985 0.973 0.998
Weight 1.005 0.996 1.015 1.004 0.995 1.014 1.004 0.995 1.014
Number of visit (spline) 0.999 0.998 0.999 0.999 0.999 0.999 0.999 0.999 0.999
Number of visit 1.283 1.243 1.324 1.247 1.209 1.287 1.214 1.177 1.252
Smoking:
No 1.220 1.024 1.454 1.205 1.009 1.438 1.232 1.031 1.472
Yes 0.762 0.453 1.281 0.873 0.525 1.453 0.833 0.507 1.367
Unknown
Transplant status:
No 0.882 0.310 2.515 0.798 0.329 1.932 0.723 0.296 1.768
Had 2.717 0.591 12.492 1.553 0.387 6.232 1.421 0.353 5.716
Will have
CFRD status:
No 0.801 0.620 1.035 0.828 0.640 1.071 0.824 0.638 1.066
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Table 7.5. (continued). 
 
CFRD status:
CFRD with or without 
fasting hyperglycemia
GERD 1.123 0.938 1.343 1.182 0.989 1.412 1.268 1.063 1.513
Pancreatic insufficiency 0.934 0.668 1.306 0.889 0.633 1.251 0.952 0.675 1.342
Pancreatitis 0.393 0.211 0.730 0.376 0.202 0.700 0.384 0.207 0.712
Hemoptysis 0.915 0.191 4.387 0.789 0.172 3.607 0.891 0.193 4.108
Using any enzymes 1.189 0.983 1.438 1.204 0.993 1.459 1.141 0.941 1.383
ABPA 1.226 0.985 1.527 1.319 1.062 1.639 1.228 0.988 1.526
Aspergillus 1.272 1.118 1.446 1.329 1.167 1.512 1.344 1.181 1.531
B. cepacia 12.637 5.585 28.593 12.278 5.548 27.171 9.954 4.613 21.483
Candida 0.987 0.844 1.155 0.947 0.809 1.109 0.935 0.798 1.096
MAI 1.789 0.855 3.744 1.467 0.680 3.166 1.036 0.448 2.400
MRSA 1.003 0.865 1.164 1.000 0.862 1.161 0.996 0.858 1.157
MSSA 0.772 0.640 0.930 0.798 0.661 0.962 0.750 0.621 0.906
Other gram-negative 
microorganisms
1.038 0.762 1.415 1.098 0.811 1.487 1.080 0.796 1.467
Staphylococcus aureus 0.973 0.789 1.200 0.925 0.750 1.141 0.975 0.789 1.205
Non-mucoid Pa PI 0.679 0.536 0.861 0.629 0.498 0.796 0.558 0.443 0.704
Unknown type of mucoid 
Pa PI
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Number of PEx in the past 
year in current visit:
0
1 3.326 2.950 3.750 3.226 2.861 3.637 3.212 2.850 3.619
2 4.486 3.653 5.510 4.466 3.636 5.485 4.339 3.537 5.322
3 9.116 6.502 12.782 8.489 6.056 11.899 8.353 5.972 11.684
4 3.925 2.110 7.301 3.491 1.879 6.484 3.646 1.961 6.779
5 3.803 1.730 8.361 4.106 1.905 8.853 4.015 1.819 8.861
Drug resistance of 
aminoglycosides in current 
visit:
No
Yes 1.274 0.938 1.729 1.164 0.859 1.578 1.061 0.782 1.440
Testing not done 0.023 <0.001 0.525 0.029 0.001 0.635 0.027 0.001 0.578
Drug resistance of beta 
lactams in current visit:
No
Yes 0.703 0.429 1.150 0.667 0.403 1.103 0.755 0.461 1.236
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Table 7.5. (continued). 
 
*Variables were measured at the baseline 
Drug resistance of 
quinolones in current visit:
No
Yes 1.473 0.918 2.364 1.611 1.009 2.574 1.773 1.115 2.819
Testing not done 30.683 3.206 293.669 27.957 2.750 284.246 26.952 2.727 266.350
Mucolytics:
0
1 0.639 0.558 0.732 0.637 0.556 0.730 0.602 0.526 0.690
2 0.155 0.128 0.189 0.157 0.129 0.192 0.156 0.128 0.190
Inhaled antibiotics:
0
1 0.400 0.363 0.441 0.402 0.365 0.444 0.411 0.372 0.454
2 0.210 0.159 0.276 0.167 0.125 0.223 0.170 0.127 0.228
3 0.009 <0.001 0.094 0.011 0.001 0.105 0.014 0.001 0.129
Anti-inflammatories:
0
1 0.418 0.367 0.476 0.446 0.391 0.507 0.436 0.382 0.497
2 0.619 0.384 0.998 0.475 0.286 0.790 0.571 0.350 0.932
Bronchodilators:
0
1 0.617 0.563 0.677 0.616 0.562 0.676 0.622 0.567 0.683






















   
  
316 
Table 7.6. The estimate of variables in the numerator of the IPCW under three strategies using imputed dataset 2. 
 
Age 1.009 0.965 1.056 1.013 0.969 1.059 1.005 0.962 1.049
Predicted FEV1 in current 
visit
1.005 1.002 1.008 1.005 1.002 1.007 1.004 1.001 1.007
Height 0.981 0.971 0.99 0.98 0.971 0.99 0.982 0.972 0.991
Weight 1.012 1.002 1.022 1.011 1.001 1.021 1.011 1.001 1.02
Mutation 2 class:
1 0.783 0.549 1.117 0.761 0.539 1.074 0.745 0.534 1.04
2 0.677 0.482 0.95 0.669 0.482 0.929 0.659 0.48 0.905
3 0.827 0.546 1.252 0.814 0.544 1.22 0.779 0.526 1.154
4 1.119 0.714 1.754 1.075 0.693 1.668 1.035 0.674 1.59
5
Doesn’t belong to any class 0.743 0.517 1.067 0.728 0.512 1.034 0.707 0.503 0.993
Missing 0.762 0.497 1.168 0.725 0.479 1.099 0.697 0.465 1.046
Race:
Caucasian 0.908 0.415 1.986 1.031 0.473 2.248 1.064 0.489 2.319
Black 0.932 0.405 2.143 1.068 0.468 2.437 1.059 0.464 2.414




Had 8.152 2.491 26.671 8.051 2.47 26.243 7.481 2.299 24.348
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Impaired glucose tolerance 2.457 1.494 4.042 2.414 1.468 3.968 2.496 1.517 4.107
CFRD with or without 
fasting hyperglycemia
0.906 0.645 1.274 0.958 0.692 1.326 0.953 0.691 1.314
GERD 1.22 1.041 1.431 1.215 1.039 1.42 1.242 1.066 1.447
B. cepacia 8.082 1.609 40.596 7.915 1.577 39.738 7.937 1.582 39.811
MRSA 1.154 0.972 1.371 1.146 0.967 1.357 1.138 0.964 1.343
Other gram-negative 
microorganisms
3.759 2.427 5.82 3.637 2.351 5.626 3.682 2.397 5.653
Non-mucoid Pa PI 1.61 1.225 2.117 1.575 1.204 2.059 1.594 1.23 2.065
Number of PEx in the past 
year in current visit:
0
1 1.066 0.908 1.252 1.066 0.911 1.248 1.07 0.917 1.249
2 0.989 0.706 1.384 0.943 0.674 1.319 0.919 0.66 1.279
3 0.815 0.419 1.587 0.754 0.389 1.462 0.852 0.466 1.56
4 0.845 0.263 2.715 0.793 0.247 2.549 0.931 0.337 2.57
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Table 7.6. (continued). 
 
* All variables were measured at the baseline 
 
 
Drug resistance of 
aminoglycosides in current 
visit:
No
Yes 0.829 0.43 1.599 0.754 0.391 1.453 0.764 0.4 1.458
Testing not done 0.387 0.052 2.86 0.216 0.032 1.456 0.224 0.033 1.503
Drug resistance of beta 
lactams in current visit:
No
Yes 0.559 0.21 1.488 0.517 0.197 1.361 0.548 0.209 1.433
Testing not done 5.244 0.805 34.167 3.051 0.445 20.933 3.03 0.452 20.321
Drug resistance of 
quinolones in current visit:
No
Yes 1.376 0.582 3.253 1.616 0.719 3.634 1.376 0.591 3.207
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Table 7.7. The estimate of variables in the numerator of the IPCW under three strategies using imputed dataset 8. 
 
Age 1.002 0.958 1.048 1.001 0.958 1.046 0.998 0.956 1.042
Predicted FEV1 in current 
visit
1.004 1.001 1.007 1.004 1.001 1.007 1.004 1.001 1.007
Height 0.981 0.972 0.991 0.982 0.973 0.991 0.982 0.973 0.991
Weight 1.012 1.003 1.021 1.011 1.002 1.020 1.011 1.002 1.020
Mutation 2 class:
1 0.733 0.519 1.034 0.716 0.512 1.001 0.697 0.504 0.965
2 0.644 0.464 0.893 0.638 0.464 0.877 0.629 0.462 0.857
3 0.777 0.518 1.166 0.770 0.519 1.144 0.733 0.498 1.080
4 1.065 0.685 1.656 1.026 0.667 1.580 1.008 0.661 1.539
5
Doesn’t belong to any class 0.699 0.491 0.994 0.687 0.488 0.967 0.672 0.483 0.936
Missing 0.700 0.459 1.067 0.681 0.452 1.026 0.681 0.458 1.013
Race
Caucasian 0.980 0.449 2.139 1.060 0.486 2.311 1.082 0.497 2.357
Black 1.009 0.441 2.310 1.100 0.483 2.505 1.086 0.478 2.469




Had 9.539 2.869 31.710 9.378 2.824 31.142 9.040 2.729 29.947
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Impaired glucose tolerance 2.426 1.475 3.989 2.518 1.550 4.090 2.614 1.607 4.251
CFRD with or without 
fasting hyperglycemia
0.934 0.667 1.309 0.971 0.704 1.341 0.946 0.686 1.305
GERD 1.219 1.041 1.429 1.216 1.041 1.420 1.252 1.075 1.457
B. cepacia 8.141 1.623 40.843 8.019 1.600 40.197 8.053 1.606 40.365
MRSA 1.171 0.988 1.388 1.160 0.981 1.372 1.157 0.981 1.365
Other gram-negative 
microorganisms
3.702 2.392 5.729 3.561 2.303 5.507 3.669 2.389 5.635
Non-mucoid Pa PI 1.542 1.176 2.022 1.525 1.167 1.992 1.576 1.214 2.047
Number of PEx in the past 
year in current visit:
0
1 1.079 0.921 1.265 1.102 0.943 1.287 1.100 0.944 1.281
2 0.971 0.694 1.360 1.005 0.726 1.391 0.959 0.693 1.327
3 0.847 0.439 1.632 0.812 0.423 1.562 0.910 0.500 1.654
4 0.826 0.257 2.656 0.788 0.245 2.530 0.748 0.233 2.403
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Table 7.7. (continued). 
 
* All variables were measured at the baseline 
 
 
Drug resistance of 
aminoglycosides in current 
visit:
No
Yes 0.789 0.403 1.543 0.713 0.364 1.394 0.726 0.375 1.408
Testing not done 0.376 0.050 2.851 0.209 0.031 1.437 0.221 0.033 1.497
Drug resistance of beta 
lactams in current visit:
No
Yes 0.540 0.193 1.511 0.498 0.179 1.385 0.539 0.195 1.489
Testing not done 5.165 0.792 33.683 3.032 0.446 20.590 2.971 0.445 19.841
Drug resistance of 
quinolones in current visit:
No
Yes 1.233 0.502 3.025 1.475 0.636 3.421 1.232 0.509 2.983
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Table 7.8. The estimate of variables in the denominator of IPCW under three strategies using imputed dataset 2. 
 
Age* 0.995 0.945 1.047 0.995 0.945 1.046 0.984 0.936 1.034
Predicted FEV1 in current 
visit*
1.003 0.999 1.007 1.004 1.000 1.008 1.003 1.000 1.007
Height* 0.989 0.974 1.004 0.990 0.975 1.004 0.991 0.977 1.006
Weight* 1.019 1.005 1.032 1.017 1.004 1.030 1.017 1.004 1.030
Mutation 2 class:
1 1.093 0.730 1.636 1.076 0.725 1.597 1.022 0.699 1.495
2 0.927 0.628 1.369 0.925 0.632 1.355 0.908 0.629 1.310
3 1.182 0.744 1.877 1.220 0.776 1.921 1.175 0.757 1.824
4 1.295 0.800 2.097 1.284 0.803 2.055 1.267 0.800 2.005
5
Doesn’t belong to any class 0.969 0.650 1.446 0.943 0.638 1.394 0.899 0.616 1.311
Missing 0.821 0.453 1.489 0.729 0.408 1.305 0.701 0.398 1.237
Race:
Caucasian 0.699 0.315 1.551 0.784 0.355 1.733 0.795 0.360 1.753
Black 0.720 0.307 1.689 0.799 0.344 1.854 0.791 0.341 1.833




Had 9.550 1.688 54.046 9.339 1.687 51.701 9.598 1.543 59.709
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Impaired glucose tolerance 3.211 1.829 5.638 3.052 1.748 5.328 3.086 1.767 5.389
CFRD with or without 
fasting hyperglycemia
1.304 0.823 2.067 1.231 0.790 1.919 1.158 0.752 1.784
GERD* 1.053 0.824 1.346 1.064 0.839 1.350 1.106 0.877 1.395
B. cepacia* 8.570 1.383 53.115 10.873 1.761 67.116 9.633 1.598 58.088
MRSA* 1.288 1.011 1.640 1.262 0.999 1.595 1.268 1.009 1.593
Other gram-negative 
microorganisms*
2.978 1.794 4.942 3.084 1.865 5.100 3.118 1.902 5.113
Non-mucoid Pa PI* 1.777 1.228 2.571 1.842 1.286 2.639 1.884 1.325 2.678
Number of PEx in the past 
year in current visit*:
0
1 1.024 0.857 1.223 1.051 0.883 1.250 1.053 0.887 1.248
2 0.968 0.669 1.401 0.963 0.667 1.390 0.962 0.670 1.383
3 0.675 0.323 1.409 0.698 0.339 1.436 0.737 0.377 1.439
4 0.910 0.265 3.125 0.918 0.267 3.160 0.905 0.310 2.643
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Table 7.8. (continued). 
 
Drug resistance of 
aminoglycosides in current 
visit*:
No
Yes 0.952 0.446 2.033 0.918 0.432 1.953 0.951 0.453 1.995
Testing not done 0.820 0.077 8.750 0.449 0.037 5.444 0.471 0.039 5.640
Drug resistance of beta 
lactams in current visit*:
No
Yes 0.510 0.152 1.710 0.443 0.135 1.448 0.520 0.158 1.707
Testing not done 11.029 0.692 175.899 3.962 0.288 54.438 4.069 0.299 55.435
Drug resistance of 
quinolones in current visit*:
No
Yes 1.177 0.411 3.374 1.485 0.555 3.973 1.146 0.410 3.207
Testing not done 0.067 0.004 1.189 0.355 0.034 3.681 0.336 0.033 3.455
Predicted FEV1 in current 
visit
1.003 0.999 1.008 1.003 0.999 1.007 1.003 0.999 1.007
Height 0.981 0.970 0.993 0.982 0.971 0.993 0.981 0.971 0.992
Weight 0.990 0.980 1.001 0.990 0.980 1.001 0.991 0.981 1.001
Number of visit (spline) 1.001 1.001 1.001 1.001 1.001 1.001 1.001 1.001 1.001
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Table 7.8. (continued). 
 
Smoking:
No 0.872 0.686 1.108 0.856 0.678 1.080 0.825 0.659 1.032
Yes 1.104 0.606 2.010 1.145 0.641 2.044 1.125 0.651 1.946
Unknown
Transplant status:
No 0.146 0.044 0.480 0.410 0.130 1.298 0.408 0.131 1.273
Had 0.189 0.036 0.999 0.542 0.108 2.730 0.502 0.088 2.857
Will have
CFRD status:
No 1.276 0.920 1.769 1.191 0.872 1.628 1.098 0.816 1.480
Impaired glucose tolerance 1.317 0.896 1.937 1.297 0.899 1.871 1.214 0.852 1.730
CFRD with or without 
fasting hyperglycemia
GERD 1.204 0.979 1.480 1.189 0.976 1.449 1.203 0.992 1.458
Pancreatic insufficiency 0.803 0.530 1.216 0.711 0.476 1.063 0.719 0.486 1.063
Pancreatitis 1.185 0.698 2.014 1.097 0.651 1.849 1.021 0.614 1.695
Hemoptysis 4.263 1.391 13.070 2.848 1.099 7.381 2.740 1.056 7.107
Using any enzymes 0.706 0.541 0.921 0.708 0.543 0.922 0.710 0.549 0.919
ABPA 0.887 0.639 1.230 0.895 0.651 1.231 0.928 0.689 1.250
Aspergillus 0.883 0.740 1.053 0.914 0.770 1.084 0.914 0.774 1.080
B. cepacia 1.550 0.754 3.189 1.208 0.588 2.479 1.363 0.697 2.665
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Table 7.8. (continued). 
 
MAI 1.560 0.874 2.783 1.631 0.943 2.821 1.688 0.997 2.856
MRSA 1.038 0.867 1.243 1.035 0.870 1.232 1.058 0.895 1.252
MSSA 1.339 1.035 1.732 1.259 0.982 1.614 1.286 1.007 1.641
Other gram-negative 
microorganisms
1.723 1.365 2.176 1.636 1.303 2.054 1.680 1.346 2.097
Staphylococcus aureus 0.921 0.680 1.248 0.976 0.727 1.310 0.966 0.723 1.290
Non-mucoid Pa PI 1.046 0.750 1.458 1.001 0.727 1.379 1.023 0.750 1.394
Unknown type of mucoid 
Pa PI
0.782 0.479 1.279 0.837 0.521 1.345 0.856 0.543 1.348
Number of PEx in the past 
year in current visit:
0
1 0.998 0.833 1.195 0.983 0.824 1.173 0.987 0.831 1.172
2 1.302 0.965 1.756 1.313 0.985 1.751 1.335 1.012 1.760
3 1.498 0.885 2.535 1.287 0.771 2.147 1.083 0.647 1.813
4 1.639 0.704 3.817 1.969 0.912 4.253 1.933 0.924 4.046
5 0.811 0.247 2.666 0.998 0.314 3.178 1.140 0.399 3.259
Drug resistance of 
aminoglycosides in current 
visit:
No
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Table 7.8. (continued). 
 




Drug resistance of 
aminoglycosides in current 
visit:
Testing not done 0.068 0.008 0.583 0.060 0.008 0.470 0.062 0.008 0.478
Drug resistance of beta 
lactams in current visit:
No
Yes 0.670 0.328 1.371 0.705 0.348 1.426 0.667 0.330 1.347
Testing not done 0.968 0.092 10.182 1.939 0.228 16.499 1.812 0.213 15.372
Drug resistance of 
quinolones in current visit:
No
Yes 1.259 0.707 2.241 1.277 0.738 2.209 1.338 0.779 2.298
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Table 7.9. The estimate of variables in the denominator of the IPCW under three strategies using imputed dataset 8. 
 
Age* 0.990 0.940 1.042 0.983 0.934 1.034 0.973 0.926 1.023
Predicted FEV1 in current 
visit*
1.003 0.999 1.007 1.004 1.000 1.008 1.004 1.000 1.007
Height* 0.992 0.978 1.007 0.993 0.979 1.008 0.994 0.980 1.008
Weight* 1.018 1.007 1.030 1.017 1.005 1.028 1.017 1.006 1.029
Mutation 2 class:
1 1.031 0.695 1.529 1.017 0.691 1.497 0.979 0.674 1.423
2 0.873 0.597 1.276 0.873 0.601 1.266 0.865 0.603 1.239
3 1.106 0.702 1.741 1.147 0.735 1.792 1.106 0.716 1.707
4 1.233 0.768 1.979 1.232 0.776 1.956 1.229 0.782 1.932
5
Doesn’t belong to any class 0.909 0.615 1.343 0.884 0.603 1.294 0.849 0.586 1.229
Missing 0.686 0.382 1.232 0.614 0.346 1.089 0.627 0.359 1.094
Race:
Caucasian 0.755 0.341 1.672 0.821 0.372 1.815 0.828 0.375 1.827
Black 0.749 0.321 1.749 0.812 0.350 1.885 0.796 0.344 1.844




Had 13.268 2.078 84.732 13.479 2.172 83.635 15.782 2.058 121.046
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Impaired glucose tolerance 3.302 1.885 5.784 3.317 1.922 5.723 3.445 1.995 5.948
CFRD with or without 
fasting hyperglycemia
1.322 0.840 2.083 1.175 0.758 1.823 1.140 0.739 1.759
GERD* 1.033 0.810 1.318 1.041 0.822 1.318 1.088 0.863 1.371
B. cepacia* 8.323 1.346 51.464 10.577 1.718 65.112 9.864 1.633 59.571
MRSA* 1.314 1.035 1.667 1.304 1.035 1.644 1.329 1.059 1.669
Other gram-negative 
microorganisms*
3.178 1.923 5.253 3.230 1.960 5.322 3.313 2.025 5.418
Non-mucoid Pa PI* 1.768 1.225 2.551 1.809 1.260 2.599 1.899 1.328 2.715
Number of PEx in the past 
year in current visit*:
0
1 1.025 0.860 1.223 1.073 0.903 1.274 1.073 0.906 1.270
2 0.915 0.632 1.325 0.961 0.671 1.378 0.947 0.662 1.356
3 0.663 0.319 1.377 0.657 0.320 1.350 0.716 0.367 1.397
4 0.831 0.243 2.842 0.782 0.227 2.693 0.779 0.227 2.674
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Table 7.9. (continued). 
 
Drug resistance of 
aminoglycosides in current 
visit*:
No
Yes 0.896 0.416 1.931 0.881 0.410 1.891 0.898 0.422 1.909
Testing not done 0.549 0.040 7.616 0.290 0.021 4.064 0.298 0.021 4.239
Drug resistance of beta 
lactams in current visit*:
No
Yes 0.506 0.143 1.783 0.396 0.115 1.360 0.475 0.138 1.644
Testing not done 6.192 0.383 100.039 2.745 0.200 37.710 2.892 0.208 40.136
Drug resistance of 
quinolones in current visit*:
No
Yes 1.119 0.378 3.312 1.473 0.535 4.058 1.134 0.389 3.303
Testing not done 0.188 0.011 3.351 0.811 0.099 6.647 0.777 0.095 6.345
Predicted FEV1 in current 
visit
1.003 0.998 1.007 1.003 0.999 1.007 1.002 0.998 1.007
Height 0.979 0.968 0.991 0.980 0.969 0.991 0.980 0.970 0.991
Weight 0.990 0.980 1.000 0.990 0.980 1.000 0.990 0.980 1.000
Number of visit (spline) 1.001 1.001 1.001 1.001 1.001 1.001 1.001 1.001 1.001
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Table 7.9. (continued). 
 
Smoking:
No 0.920 0.721 1.173 0.902 0.712 1.143 0.864 0.689 1.083
Yes 1.173 0.655 2.099 1.222 0.695 2.147 1.150 0.667 1.984
Unknown
Transplant status:
No 0.165 0.051 0.538 0.467 0.147 1.482 0.460 0.147 1.443
Had 0.174 0.030 1.014 0.493 0.088 2.775 0.403 0.057 2.833
Will have
CFRD status:
No 1.267 0.918 1.747 1.162 0.853 1.583 1.125 0.833 1.519
Impaired glucose tolerance 1.247 0.853 1.823 1.217 0.846 1.751 1.185 0.831 1.689
CFRD with or without 
fasting hyperglycemia
GERD 1.257 1.025 1.542 1.237 1.016 1.505 1.246 1.028 1.509
Pancreatic insufficiency 0.734 0.488 1.103 0.643 0.433 0.954 0.656 0.447 0.964
Pancreatitis 1.175 0.702 1.969 1.086 0.652 1.809 1.039 0.625 1.727
Hemoptysis 3.247 0.970 10.865 2.307 0.848 6.274 2.257 0.830 6.137
Using any enzymes 0.715 0.548 0.931 0.717 0.551 0.934 0.714 0.550 0.926
ABPA 0.891 0.645 1.232 0.899 0.657 1.230 0.924 0.686 1.245
Aspergillus 0.869 0.729 1.037 0.911 0.768 1.081 0.919 0.778 1.085
B. cepacia 1.621 0.784 3.353 1.228 0.595 2.533 1.409 0.716 2.774
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Table 7.9. (continued). 
 
MAI 1.715 0.972 3.026 1.736 1.012 2.975 1.799 1.072 3.021
MRSA 1.042 0.872 1.245 1.062 0.894 1.261 1.057 0.895 1.249
MSSA 1.336 1.036 1.724 1.322 1.033 1.693 1.333 1.044 1.701
Other gram-negative 
microorganisms
1.637 1.300 2.061 1.568 1.253 1.962 1.605 1.289 1.998
Staphylococcus aureus 0.913 0.676 1.233 0.932 0.695 1.250 0.935 0.699 1.249
Non-mucoid Pa PI 1.023 0.735 1.422 0.990 0.719 1.364 1.030 0.755 1.405
Unknown type of mucoid 
Pa PI
0.749 0.459 1.222 0.790 0.490 1.273 0.837 0.529 1.324
Number of PEx in the past 
year in current visit:
0
1 1.002 0.837 1.199 1.008 0.846 1.201 1.006 0.848 1.193
2 1.294 0.960 1.744 1.317 0.988 1.755 1.311 0.994 1.729
3 1.676 1.007 2.791 1.402 0.853 2.306 1.180 0.714 1.949
4 1.943 0.876 4.309 2.662 1.344 5.275 2.577 1.324 5.017
5 1.049 0.356 3.091 1.479 0.557 3.926 1.604 0.640 4.019
Drug resistance of 
aminoglycosides in current 
visit:
No
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Table 7.9. (continued). 
 
* Variables were measured at the baseline 
 
Drug resistance of 
aminoglycosides in current 
visit:
Testing not done 0.185 0.017 1.986 0.137 0.014 1.301 0.150 0.016 1.439
Drug resistance of beta 
lactams in current visit:
No
Yes 0.612 0.296 1.266 0.742 0.369 1.490 0.704 0.351 1.414
Testing not done 1.471 0.143 15.118 2.378 0.270 20.958 2.188 0.245 19.534
Drug resistance of 
quinolones in current visit:
No
Yes 1.181 0.663 2.107 1.164 0.664 2.039 1.217 0.699 2.122























Figure 7.1. The distribution of SICW under different strategies in different imputed datasets. The left and right columns represent the 
distributions in imputed datasets 2 and 8, respectively. From the top to bottom, the figures represent the distributions under strategies 
33 and 53, respectively.   




Figure 7.2. The distribution of unstabilized IPTW under different strategies in different imputed datasets. The left and right columns 
represent the distributions in imputed datasets 2 and 8, respectively. From the top to bottom, the figures represent the distributions 
under strategies 33 and 53, respectively.   




Figure 7.3. The distribution of SIPTW under different strategies in different imputed datasets. The left and right columns represent 
the distributions in imputed datasets 2 and 8, respectively. From the top to bottom, the figures represent the distributions under 
strategies 33 and 53, respectively.   




Figure 7.4. The distribution of UIPW under different strategies in different imputed datasets. The left and right columns represent the 
distributions in imputed datasets 2 and 8, respectively. From the top to bottom, the figures represent the distributions under strategies 
33 and 53, respectively.   




Figure 7.5. The distribution of SIPW under different strategies in different imputed datasets. The left and right columns represent the 
distributions in imputed datasets 2 and 8, respectively. From the top to bottom, the figures represent the distributions under strategies 
33 and 53, respectively.   
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UIPW 28976 1307.4200 0.0503 1.1292 1.4863 2.9119 14588668.3800
SIPW 28976 190.7774 0.0021 0.6192 0.8806 1.0539 1821157.9900
UIPW 31087 118.4806 0.0449 1.1126 1.4275 2.5948 1314319.5100
SIPW 31087 20.9848 0.0035 0.6303 0.8840 1.0481 196570.6600
UIPW 29083 148.4058 0.1070 1.1258 1.4791 2.8909 1520071.7200
SIPW 29083 25.9004 0.0024 0.6223 0.8807 1.0540 224189.8000
UIPW 31064 17.3635 0.1001 1.1088 1.4248 2.5991 140137.3300
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2 33 SIPW 28976 1.0173 0.0021 0.6192 0.8806 1.0539 10.0000
2 53 SIPW 31087 1.0177 0.0035 0.6303 0.8840 1.0481 10.0000
8 33 SIPW 29083 1.0148 0.0024 0.6223 0.8807 1.0540 10.0000
8 53 SIPW 31064 1.0155 0.0055 0.6344 0.8842 1.0465 10.0000
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Imputed dataset Strategy Number of visits in the dataset
Number of 
patients Number of visits
2 33 28976 51 175
2 53 31087 46 168
8 33 29083 51 161
8 53 31064 49 166




Figure 7.6. Non-parametric Kaplan Meier curve under different treatment strategies in different imputed datasets. The left and right 
columns represent the trends in imputed datasets 2 and 8, respectively. The figures represent the trends without any adjustment on 
weighting. 
 
   
       
   
       




Figure 7.7. Non-parametric Kaplan Meier curve under different treatment strategies in different imputed datasets. The left and right 
columns represent the trends in imputed datasets 2 and 8, respectively. The figures represent the trends after adjusting by UIPW. 
   
       
   
       




Figure 7.8. Non-parametric Kaplan Meier curve under different treatment strategies in different imputed datasets. The left and right 






   
       
   
       




Figure 7.9. Survival curve of dynamic logistic MSMs adjusting by UIPW between different treatment strategies in different imputed 
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Estimate Minimum Maximum Estimate Minimum Maximum
Intercept -5.4682 -6.4865 -5.0618 0.0042 0.0015 0.0063
No strategy 1.3840 0.9777 2.4023 3.9909 2.6583 11.0490
Strategy11 2.0193 0.9088 4.1264 7.5329 2.4814 61.9565
Strategy12 2.0595 0.9302 4.1269 7.8418 2.5351 61.9845
Strategy13 2.1146 1.1996 4.1051 8.2859 3.3187 60.6484
Strategy14 2.0609 1.1985 3.9828 7.8526 3.3150 53.6690
Strategy15 2.0384 1.1814 3.9759 7.6783 3.2590 53.2992
Strategy21 2.0542 1.0670 4.1404 7.8006 2.9065 62.8272
Strategy22 2.0838 1.0802 4.1291 8.0347 2.9452 62.1247
Strategy23 2.1311 1.2012 4.1030 8.4244 3.3242 60.5213
Strategy24 2.0710 1.1936 3.9681 7.9331 3.2990 52.8820
Strategy25 2.0367 1.1806 3.9372 7.6656 3.2563 51.2751
Strategy31 -2.5084 -4.5064 -0.7453 0.0814 0.0110 0.4746
Strategy32 -2.4096 -4.3299 -0.6732 0.0898 0.0132 0.5101
Strategy33 -2.3118 -4.1998 -0.9120 0.0991 0.0150 0.4017
Strategy34 -2.2181 -4.0913 -0.8988 0.1088 0.0167 0.4070
Strategy35 -2.3055 -4.1135 -1.1701 0.0997 0.0164 0.3103
Strategy41 -1.2354 -3.1517 0.0041 0.2907 0.0428 1.0041
Strategy42 -1.1545 -2.9983 0.0590 0.3152 0.0499 1.0607
Strategy43 -1.0059 -2.8351 -0.0935 0.3657 0.0587 0.9108
Strategy44 -0.8005 -2.4858 0.0037 0.4491 0.0833 1.0038
Strategy45 -0.8959 -2.5261 -0.1620 0.4082 0.0800 0.8504
Strategy51 -0.2447 -0.5807 -0.0219 0.7829 0.5595 0.9783
Strategy52 -0.1634 -0.4840 0.0450 0.8492 0.6163 1.0460
Strategy53 -0.0809 -0.3071 0.0023 0.9223 0.7356 1.0023






Table 7.14. Results of a fixed parameterization of dynamic logistic MSM with SIPW. 
 
Estimate MinimumMaximum Estimate MinimumMaximum Lower Upper
Intercept -3.6395 -3.8098 -3.4342 0.0263 0.0222 0.0323 0.0188 0.0366
No strategy 0.1592 0.1301 0.1862 1.1725 1.1389 1.2047 1.1294 1.2173
Strategy11 0.0285 0.0088 0.0467 1.0289 1.0088 1.0478 0.9630 1.0994
Strategy12 0.0428 0.0247 0.0581 1.0438 1.0250 1.0598 0.9770 1.1151
Strategy13 0.0619 0.0442 0.0762 1.0638 1.0451 1.0792 0.9957 1.1367
Strategy14 0.0478 0.0304 0.0616 1.0490 1.0308 1.0635 0.9811 1.1216
Strategy15 0.0462 0.0287 0.0594 1.0473 1.0291 1.0612 0.9790 1.1203
Strategy21 0.0358 0.0226 0.0469 1.0365 1.0229 1.0480 0.9839 1.0918
Strategy22 0.0489 0.0406 0.0584 1.0502 1.0415 1.0601 0.9975 1.1056
Strategy23 0.0678 0.0574 0.0790 1.0702 1.0591 1.0822 1.0138 1.1297
Strategy24 0.0529 0.0427 0.0640 1.0544 1.0436 1.0661 0.9988 1.1130
Strategy25 0.0522 0.0415 0.0624 1.0536 1.0424 1.0644 0.9992 1.1111
Strategy31 -0.0023 -0.0173 0.0288 0.9977 0.9828 1.0292 0.9404 1.0586
Strategy32 0.0083 -0.0067 0.0384 1.0083 0.9933 1.0391 0.9413 1.0801
Strategy33 0.0275 0.0144 0.0558 1.0279 1.0145 1.0574 0.9595 1.1011
Strategy34 0.0162 0.0033 0.0462 1.0163 1.0033 1.0473 0.9583 1.0779
Strategy35 0.0142 0.0045 0.0454 1.0143 1.0045 1.0464 0.9558 1.0765
Strategy41 0.0102 -0.0085 0.0340 1.0102 0.9916 1.0346 0.9559 1.0676
Strategy42 0.0206 0.0020 0.0445 1.0208 1.0020 1.0455 0.9693 1.0751
Strategy43 0.0422 0.0302 0.0642 1.0432 1.0306 1.0663 0.9905 1.0987
Strategy44 0.0300 0.0178 0.0536 1.0305 1.0180 1.0551 0.9774 1.0865
Strategy45 0.0260 0.0146 0.0502 1.0263 1.0148 1.0515 0.9724 1.0832
Strategy51 -0.0186 -0.0352 -0.0135 0.9816 0.9655 0.9866 0.9304 1.0355
Strategy52 -0.0058 -0.0220 -0.0009 0.9942 0.9783 0.9991 0.9414 1.0500
Strategy53 0.0163 0.0138 0.0198 1.0165 1.0139 1.0200 0.9675 1.0679
Strategy54 0.0038 0.0018 0.0058 1.0038 1.0018 1.0058 0.9485 1.0625
Strategy55
Predicted FEV1 in 
current visit -0.0047 -0.0057 -0.0033 0.9953 0.9943 0.9967 0.9945 0.9961
Age 0.0601 0.0541 0.0706 1.0620 1.0556 1.0732 1.0503 1.0738
Mutation 2 class:
1 0.1518 0.0539 0.2313 1.1639 1.0554 1.2603 0.9989 1.3561
2 0.0699 -0.0468 0.1544 1.0724 0.9543 1.1669 0.9286 1.2385
3 0.3554 0.2470 0.4416 1.4267 1.2802 1.5551 1.1975 1.6999
4 -1.5286 -1.9649 -1.1069 0.2168 0.1402 0.3306 0.1755 0.2679
5 -1.5894 -1.7338 -1.4392 0.2040 0.1766 0.2371 0.1645 0.2531
Doesn’t belong to 













Estimate MinimumMaximum Estimate MinimumMaximum Lower Upper
Race:
Caucasian -0.6068 -0.6449 -0.5636 0.5451 0.5247 0.5691 0.3954 0.7515
Black 0.2099 0.1651 0.3077 1.2336 1.1795 1.3603 0.8982 1.6941
Asian -0.1230 -0.1897 -0.0565 0.8842 0.8272 0.9451 0.6292 1.2426
Others
Gender (male) 0.0362 0.0193 0.0597 1.0368 1.0195 1.0615 0.9825 1.0942
Number of PEx in 
the past year in 
current visit :
0
1 0.1083 0.0572 0.1663 1.1144 1.0588 1.1809 1.0472 1.1860
2 0.1856 0.1585 0.2327 1.2040 1.1717 1.2620 1.0288 1.4090
3 0.2456 -0.4120 0.7440 1.2784 0.6624 2.1044 1.0285 1.5891
4 -1.3019 -1.3489 -1.2455 0.2720 0.2595 0.2878 0.2092 0.3536
5 -0.1541 -0.2387 0.0094 0.8572 0.7877 1.0094 0.6403 1.1475
Mucolytics :
0
1 -0.0608 -0.0865 -0.0432 0.9411 0.9172 0.9578 0.8973 0.9869




1 0.1344 0.0735 0.1803 1.1439 1.0762 1.1976 1.0644 1.2293
2 -0.2262 -0.2670 -0.1880 0.7976 0.7657 0.8286 0.6305 1.0090




Yes 0.8144 0.7716 0.8733 2.2579 2.1632 2.3948 1.8622 2.7377
Testing not done -0.5795 -0.6197 -0.5073 0.5602 0.5381 0.6021 0.4794 0.6546
Drug resistance of 
beta lactams in 
current visit:
No
Yes -0.1209 -0.2490 0.0160 0.8861 0.7796 1.0161 0.6256 1.2550












Table 7.14. (continued). 
 
* All variables were measured at the baseline 
Estimate MinimumMaximum Estimate MinimumMaximum Lower Upper




Yes -0.1171 -0.1707 -0.0559 0.8895 0.8431 0.9456 0.6241 1.2677
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Table 7.15. Results of a flexible parameterization of the dynamic logistic MSM with 
stabilized weighting.  
 
Estimate MinimumMaximum Estimate MinimumMaximum Lower Upper
Intercept -3.4801 -3.6181 -3.2847 0.0308 0.0268 0.0375 0.0219 0.0433
Effect in the 1st year -0.1185 -0.2133 0.0053 0.8883 0.8079 1.0053 0.6999 1.1273
Effect in the 2nd year 0.1100 -0.0371 0.2532 1.1162 0.9636 1.2881 0.8650 1.4404
Effect in the 3rd year -0.3929 -0.5221 -0.2747 0.6751 0.5933 0.7598 0.5272 0.8645
Effect in the 4th year 0.1990 0.0375 0.4587 1.2202 1.0382 1.5821 0.9242 1.6109
Effect in the 5th year 0.4178 0.3285 0.5558 1.5186 1.3888 1.7432 1.1692 1.9722
Effect in the 6th year
Strategy1 0.3476 0.2606 0.4602 1.4156 1.2976 1.5844 1.1221 1.7860
Strategy11 -0.5898 -0.7437 -0.4244 0.5545 0.4753 0.6541 0.3578 0.8591
Strategy12 -0.5814 -0.7194 -0.4245 0.5591 0.4871 0.6541 0.3617 0.8644
Strategy13 -0.6152 -0.7251 -0.4868 0.5405 0.4843 0.6146 0.3496 0.8357
Strategy14 -0.6154 -0.7274 -0.4819 0.5404 0.4832 0.6176 0.3485 0.8380
Strategy15 -0.6203 -0.7337 -0.4871 0.5378 0.4801 0.6144 0.3459 0.8361
Strategy21 0.0813 -0.1271 0.2778 1.0847 0.8807 1.3202 0.6739 1.7462
Strategy22 0.1084 -0.1055 0.3131 1.1144 0.8999 1.3677 0.6868 1.8084
Strategy23 0.1128 -0.1313 0.3458 1.1194 0.8770 1.4132 0.6900 1.8160
Strategy24 0.0919 -0.1462 0.3195 1.0962 0.8640 1.3765 0.6752 1.7797
Strategy25 0.0723 -0.1669 0.2989 1.0750 0.8463 1.3483 0.6620 1.7456
Strategy31 0.3195 0.2681 0.3778 1.3765 1.3075 1.4591 0.8528 2.2218
Strategy32 0.3236 0.3022 0.3446 1.3820 1.3529 1.4115 0.8538 2.2370
Strategy33 0.3071 0.2536 0.3346 1.3594 1.2886 1.3973 0.8375 2.2066
Strategy34 0.3041 0.2420 0.3365 1.3554 1.2738 1.4000 0.8336 2.2037
Strategy35 0.2818 0.2156 0.3082 1.3255 1.2406 1.3609 0.8140 2.1584
Strategy41 0.0490 0.0058 0.1710 1.0502 1.0058 1.1865 0.6904 1.5975
Strategy42 0.0553 0.0049 0.1385 1.0569 1.0049 1.1485 0.6722 1.6617
Strategy43 0.0961 0.0581 0.1359 1.1009 1.0598 1.1455 0.6975 1.7376
Strategy44 0.0789 0.0441 0.1078 1.0821 1.0451 1.1138 0.6833 1.7138
Strategy45 0.0856 0.0451 0.1124 1.0893 1.0462 1.1189 0.7303 1.6249
Strategy51 -0.0533 -0.0860 0.0448 0.9481 0.9176 1.0458 0.6349 1.4160
Strategy52 -0.0347 -0.0601 0.0286 0.9659 0.9416 1.0290 0.6204 1.5038
Strategy53 0.0070 -0.0071 0.0255 1.0070 0.9929 1.0258 0.6734 1.5059
Strategy54 -0.0103 -0.0240 0.0041 0.9898 0.9763 1.0041 0.6592 1.4862
Strategy55
Strategy1*1st year -0.2642 -0.3873 -0.1728 0.7678 0.6789 0.8413 0.6101 0.9663
Strategy11*1st year 0.6107 0.4504 0.7639 1.8418 1.5690 2.1466 1.1831 2.8672
Strategy12*1st year 0.6003 0.4484 0.7385 1.8226 1.5659 2.0927 1.1738 2.8300
Strategy13*1st year 0.6291 0.4988 0.7391 1.8760 1.6468 2.0940 1.2082 2.9128
Strategy14*1st year 0.6202 0.4854 0.7318 1.8593 1.6249 2.0789 1.1981 2.8855
Strategy15*1st year 0.6239 0.4882 0.7364 1.8663 1.6293 2.0884 1.1986 2.9059
Strategy21*1st year -0.0689 -0.2559 0.1323 0.9334 0.7743 1.1414 0.5807 1.5004






Table 7.15. (continued).  
 
Estimate MinimumMaximum Estimate MinimumMaximum Lower Upper
Strategy22*1st year -0.0972 -0.3100 0.1088 0.9073 0.7334 1.1150 0.5604 1.4690
Strategy23*1st year -0.1063 -0.3445 0.1408 0.8992 0.7086 1.1513 0.5553 1.4558
Strategy24*1st year -0.0931 -0.3251 0.1470 0.9111 0.7224 1.1583 0.5632 1.4740
Strategy25*1st year -0.0742 -0.3056 0.1672 0.9284 0.7367 1.1820 0.5738 1.5023
Strategy31*1st year -0.3149 -0.3727 -0.2695 0.7299 0.6889 0.7638 0.4490 1.1863
Strategy32*1st year -0.3203 -0.3431 -0.3046 0.7260 0.7096 0.7374 0.4453 1.1835
Strategy33*1st year -0.3100 -0.3407 -0.2523 0.7335 0.7113 0.7770 0.4500 1.1956
Strategy34*1st year -0.3154 -0.3508 -0.2502 0.7295 0.7041 0.7786 0.4454 1.1947
Strategy35*1st year -0.2936 -0.3234 -0.2240 0.7456 0.7237 0.7994 0.4557 1.2198
Strategy41*1st year -0.0364 -0.1556 0.0070 0.9643 0.8559 1.0071 0.6291 1.4782
Strategy42*1st year -0.0443 -0.1238 0.0074 0.9566 0.8835 1.0074 0.6049 1.5128
Strategy43*1st year -0.0892 -0.1247 -0.0511 0.9147 0.8827 0.9502 0.5760 1.4524
Strategy44*1st year -0.0799 -0.1087 -0.0450 0.9232 0.8970 0.9560 0.5797 1.4701
Strategy45*1st year -0.0884 -0.1130 -0.0483 0.9154 0.8931 0.9529 0.6115 1.3703
Strategy51*1st year 0.0664 -0.0303 0.0977 1.0687 0.9702 1.1027 0.7138 1.5999
Strategy52*1st year 0.0484 -0.0126 0.0733 1.0495 0.9875 1.0760 0.6683 1.6482
Strategy53*1st year 0.0027 -0.0159 0.0174 1.0027 0.9843 1.0176 0.6676 1.5060
Strategy54*1st year 0.0119 -0.0026 0.0264 1.0120 0.9974 1.0267 0.6713 1.5255
Strategy55*1st year
Strategy1*2nd year -0.2797 -0.4071 -0.1435 0.7560 0.6656 0.8663 0.5911 0.9669
Strategy11*2nd year 0.5058 0.3042 0.6898 1.6583 1.3555 1.9934 1.0569 2.6020
Strategy12*2nd year 0.5350 0.3414 0.7026 1.7075 1.4069 2.0189 1.1021 2.6453
Strategy13*2nd year 0.6754 0.5564 0.8043 1.9648 1.7444 2.2350 1.2620 3.0592
Strategy14*2nd year 0.6431 0.5213 0.7719 1.9024 1.6843 2.1640 1.2213 2.9634
Strategy15*2nd year 0.6594 0.5332 0.7916 1.9336 1.7044 2.2070 1.2359 3.0252
Strategy21*2nd year -0.1324 -0.3998 0.1422 0.8760 0.6705 1.1529 0.5426 1.4145
Strategy22*2nd year -0.1201 -0.3796 0.1455 0.8868 0.6841 1.1566 0.5437 1.4465
Strategy23*2nd year -0.0254 -0.2606 0.2162 0.9749 0.7706 1.2414 0.5998 1.5846
Strategy24*2nd year -0.0385 -0.2664 0.2050 0.9623 0.7661 1.2275 0.5924 1.5630
Strategy25*2nd year -0.0079 -0.2404 0.2424 0.9921 0.7863 1.2744 0.6108 1.6114
Strategy31*2nd year -0.3868 -0.4773 -0.2957 0.6792 0.6205 0.7440 0.4213 1.0952
Strategy32*2nd year -0.3584 -0.4377 -0.3081 0.6988 0.6455 0.7348 0.4314 1.1320
Strategy33*2nd year -0.2445 -0.2816 -0.2052 0.7831 0.7546 0.8145 0.4861 1.2616
Strategy34*2nd year -0.2682 -0.3107 -0.2210 0.7647 0.7330 0.8017 0.4699 1.2444
Strategy35*2nd year -0.2341 -0.2685 -0.1803 0.7912 0.7645 0.8350 0.4858 1.2887
Strategy41*2nd year -0.1132 -0.2394 -0.0585 0.8929 0.7871 0.9432 0.5645 1.4125
Strategy42*2nd year -0.0900 -0.1843 -0.0355 0.9139 0.8317 0.9651 0.5755 1.4513
Strategy43*2nd year -0.0370 -0.0787 0.0088 0.9636 0.9243 1.0089 0.6055 1.5336
Strategy44*2nd year -0.0448 -0.0883 -0.0058 0.9562 0.9155 0.9942 0.5979 1.5292
Strategy45*2nd year -0.0471 -0.0926 -0.0083 0.9540 0.9116 0.9918 0.6302 1.4442
Strategy51*2nd year -0.0484 -0.1485 0.0063 0.9527 0.8620 1.0064 0.6377 1.4234
Strategy52*2nd year -0.0322 -0.1157 0.0078 0.9683 0.8907 1.0078 0.6230 1.5051





Table 7.15. (continued).  
 
Estimate MinimumMaximum Estimate MinimumMaximum Lower Upper
Strategy53*2nd year 0.0186 0.0008 0.0326 1.0188 1.0008 1.0331 0.6675 1.5549
Strategy54*2nd year 0.0120 -0.0025 0.0254 1.0120 0.9975 1.0257 0.6739 1.5199
Strategy55*2nd year
Strategy1*3rd year 0.1182 0.0023 0.2507 1.1254 1.0023 1.2849 0.8855 1.4304
Strategy11*3rd year 0.8044 0.6497 0.9589 2.2353 1.9150 2.6089 1.3717 3.6425
Strategy12*3rd year 0.7765 0.6331 0.9284 2.1739 1.8833 2.5304 1.3439 3.5167
Strategy13*3rd year 0.8011 0.6887 0.9242 2.2281 1.9911 2.5198 1.3734 3.6147
Strategy14*3rd year 0.7732 0.6544 0.9047 2.1667 1.9239 2.4712 1.3352 3.5161
Strategy15*3rd year 0.7675 0.6374 0.8986 2.1544 1.8915 2.4561 1.3267 3.4985
Strategy21*3rd year 0.0841 -0.0899 0.3278 1.0878 0.9141 1.3879 0.6813 1.7369
Strategy22*3rd year 0.0308 -0.1691 0.2715 1.0313 0.8445 1.3119 0.6303 1.6873
Strategy23*3rd year 0.0143 -0.2075 0.2515 1.0144 0.8126 1.2859 0.6194 1.6614
Strategy24*3rd year 0.0004 -0.2179 0.2368 1.0004 0.8042 1.2671 0.6171 1.6218
Strategy25*3rd year 0.0116 -0.2194 0.2492 1.0117 0.8030 1.2830 0.6290 1.6271
Strategy31*3rd year -0.2396 -0.3129 -0.1723 0.7869 0.7313 0.8417 0.4672 1.3254
Strategy32*3rd year -0.2691 -0.3126 -0.2157 0.7640 0.7316 0.8060 0.4487 1.3011
Strategy33*3rd year -0.2612 -0.3095 -0.1549 0.7701 0.7338 0.8565 0.4573 1.2968
Strategy34*3rd year -0.2877 -0.3392 -0.1749 0.7500 0.7123 0.8396 0.4633 1.2139
Strategy35*3rd year -0.2714 -0.3341 -0.1519 0.7623 0.7160 0.8591 0.4657 1.2480
Strategy41*3rd year 0.0566 -0.0585 0.1095 1.0583 0.9432 1.1157 0.6675 1.6778
Strategy42*3rd year 0.0310 -0.0611 0.0820 1.0315 0.9407 1.0855 0.6076 1.7512
Strategy43*3rd year -0.0201 -0.1160 0.0209 0.9801 0.8904 1.0211 0.5863 1.6386
Strategy44*3rd year -0.0295 -0.1302 0.0071 0.9710 0.8779 1.0071 0.6038 1.5615
Strategy45*3rd year -0.0400 -0.1472 0.0104 0.9608 0.8631 1.0104 0.6228 1.4822
Strategy51*3rd year 0.1130 0.0124 0.1502 1.1197 1.0124 1.1620 0.6863 1.8268
Strategy52*3rd year 0.0775 0.0238 0.1034 1.0805 1.0241 1.1090 0.6565 1.7785
Strategy53*3rd year 0.0269 0.0035 0.0425 1.0272 1.0035 1.0434 0.6220 1.6965
Strategy54*3rd year 0.0134 -0.0087 0.0299 1.0135 0.9913 1.0303 0.6606 1.5548
Strategy55*3rd year
Strategy1*4th year -0.4131 -0.6739 -0.2497 0.6616 0.5097 0.7790 0.5074 0.8627
Strategy11*4th year 0.5618 0.3028 0.7459 1.7538 1.3537 2.1083 1.0786 2.8516
Strategy12*4th year 0.5302 0.2490 0.7138 1.6993 1.2828 2.0417 1.0453 2.7622
Strategy13*4th year 0.5667 0.2538 0.7202 1.7625 1.2889 2.0548 1.0860 2.8604
Strategy14*4th year 0.5707 0.2407 0.7323 1.7696 1.2721 2.0798 1.0898 2.8733
Strategy15*4th year 0.5156 0.1749 0.6797 1.6747 1.1911 1.9732 1.0308 2.7209
Strategy21*4th year -0.0283 -0.3888 0.2626 0.9721 0.6779 1.3003 0.5911 1.5988
Strategy22*4th year -0.0707 -0.4714 0.2270 0.9318 0.6241 1.2548 0.5605 1.5490
Strategy23*4th year -0.0707 -0.4932 0.2145 0.9317 0.6107 1.2392 0.5607 1.5483
Strategy24*4th year -0.0478 -0.4719 0.2362 0.9533 0.6238 1.2664 0.5732 1.5854
Strategy25*4th year -0.0743 -0.5083 0.2123 0.9284 0.6015 1.2365 0.5624 1.5325
Strategy31*4th year -0.3235 -0.5004 -0.0235 0.7236 0.6063 0.9768 0.4230 1.2378
Strategy32*4th year -0.3540 -0.5663 -0.0459 0.7019 0.5676 0.9552 0.4127 1.1937






Table 7.15. (continued).  
 
Estimate MinimumMaximum Estimate MinimumMaximum Lower Upper
Strategy33*4th year -0.3356 -0.5691 -0.0320 0.7149 0.5660 0.9685 0.4202 1.2165
Strategy34*4th year -0.3360 -0.5715 -0.0335 0.7146 0.5647 0.9670 0.4172 1.2240
Strategy35*4th year -0.3655 -0.6200 -0.0634 0.6938 0.5380 0.9386 0.4018 1.1982
Strategy41*4th year 0.1325 -0.0015 0.3500 1.1417 0.9985 1.4190 0.7295 1.7869
Strategy42*4th year 0.1135 0.0218 0.3397 1.1201 1.0221 1.4045 0.6933 1.8098
Strategy43*4th year 0.0715 -0.0069 0.2992 1.0741 0.9931 1.3488 0.6615 1.7440
Strategy44*4th year 0.0828 0.0033 0.3068 1.0864 1.0033 1.3590 0.6662 1.7715
Strategy45*4th year 0.0426 -0.0252 0.2642 1.0435 0.9751 1.3024 0.6879 1.5830
Strategy51*4th year 0.0937 0.0095 0.1307 1.0982 1.0095 1.1396 0.7081 1.7033
Strategy52*4th year 0.0670 0.0206 0.0944 1.0693 1.0208 1.0990 0.6633 1.7237
Strategy53*4th year 0.0233 0.0107 0.0390 1.0236 1.0107 1.0397 0.6590 1.5899
Strategy54*4th year 0.0365 0.0244 0.0434 1.0372 1.0246 1.0444 0.6654 1.6167
Strategy55*4th year
Strategy1*5th year -0.4436 -0.5813 -0.3553 0.6417 0.5592 0.7010 0.4995 0.8244
Strategy11*5th year 1.2211 1.0749 1.3970 3.3908 2.9297 4.0430 2.1001 5.4745
Strategy12*5th year 1.3098 1.1931 1.4762 3.7053 3.2973 4.3765 2.2885 5.9992
Strategy13*5th year 1.3307 1.2301 1.4546 3.7837 3.4217 4.2828 2.3387 6.1216
Strategy14*5th year 1.3267 1.2248 1.4638 3.7687 3.4034 4.3223 2.3296 6.0970
Strategy15*5th year 1.3375 1.2040 1.4802 3.8095 3.3333 4.3939 2.3487 6.1790
Strategy21*5th year 0.4198 0.2454 0.5984 1.5217 1.2782 1.8192 0.9124 2.5378
Strategy22*5th year 0.4739 0.3133 0.6672 1.6063 1.3679 1.9487 0.9573 2.6954
Strategy23*5th year 0.4496 0.2702 0.7596 1.5676 1.3102 2.1374 0.9346 2.6293
Strategy24*5th year 0.4713 0.2845 0.7927 1.6021 1.3291 2.2093 0.9562 2.6843
Strategy25*5th year 0.5051 0.3319 0.8207 1.6572 1.3936 2.2721 0.9982 2.7513
Strategy31*5th year -0.2353 -0.3677 0.0693 0.7903 0.6923 1.0717 0.4850 1.2879
Strategy32*5th year -0.1244 -0.2619 0.1001 0.8830 0.7696 1.1053 0.5408 1.4420
Strategy33*5th year -0.1131 -0.2345 0.0967 0.8930 0.7909 1.1016 0.5461 1.4604
Strategy34*5th year -0.0773 -0.2054 0.1326 0.9256 0.8143 1.1418 0.5666 1.5119
Strategy35*5th year -0.0541 -0.1886 0.1417 0.9473 0.8282 1.1522 0.5813 1.5438
Strategy41*5th year -0.1132 -0.2273 0.0342 0.8930 0.7967 1.0348 0.5497 1.4507
Strategy42*5th year -0.0097 -0.0964 0.0789 0.9904 0.9081 1.0821 0.5910 1.6596
Strategy43*5th year -0.0373 -0.1169 0.0563 0.9634 0.8897 1.0579 0.5716 1.6237
Strategy44*5th year -0.0092 -0.0930 0.0812 0.9909 0.9112 1.0846 0.5973 1.6438
Strategy45*5th year -0.0363 -0.1251 0.0511 0.9644 0.8824 1.0524 0.6025 1.5436
Strategy51*5th year -0.0671 -0.1988 -0.0033 0.9351 0.8197 0.9967 0.5696 1.5352
Strategy52*5th year 0.0097 -0.0636 0.0540 1.0098 0.9384 1.0555 0.6172 1.6521
Strategy53*5th year -0.0096 -0.0495 0.0101 0.9905 0.9517 1.0101 0.6050 1.6216
Strategy54*5th year 0.0153 0.0009 0.0338 1.0154 1.0009 1.0344 0.6188 1.6662
Strategy55*5th year
Predicted FEV1 in 
current visit -0.0052 -0.0063 -0.0038 0.9948 0.9938 0.9962 0.9939 0.9956
Age 0.0562 0.0495 0.0674 1.0578 1.0507 1.0697 1.0476 1.0681
Reference
Reference








Estimate MinimumMaximum Estimate MinimumMaximum Lower Upper
Mutation 2 class:
1 0.1839 0.0771 0.2693 1.2019 1.0801 1.3091 1.0355 1.3951
2 0.0950 -0.0258 0.1842 1.0997 0.9745 1.2022 0.9476 1.2761
3 0.3725 0.2634 0.4533 1.4513 1.3013 1.5735 1.2048 1.7483
4 -1.5434 -1.9834 -1.1032 0.2137 0.1376 0.3318 0.1729 0.2641
5 -1.6538 -1.8022 -1.5002 0.1913 0.1649 0.2231 0.1530 0.2393
Doesn’t belong to 
any class -0.1519 -0.2609 -0.0548 0.8590 0.7703 0.9467 0.7458 0.9894
Missing
Race:
Caucasian -0.6409 -0.6700 -0.5887 0.5268 0.5117 0.5551 0.3720 0.7461
Black 0.1862 0.1218 0.2949 1.2046 1.1295 1.3430 0.8704 1.6672
Asian -0.1268 -0.1829 -0.0465 0.8809 0.8329 0.9546 0.6202 1.2513
Others
Gender (male) 0.0300 0.0138 0.0535 1.0304 1.0139 1.0549 0.9775 1.0862
Number of PEx in the 
past year in current 
visit :
0
1 0.1252 0.0677 0.1825 1.1334 1.0701 1.2002 1.0622 1.2093
2 0.2070 0.1735 0.2564 1.2299 1.1894 1.2922 1.0528 1.4368
3 0.3012 -0.3689 0.7966 1.3515 0.6915 2.2180 1.0882 1.6783
4 -1.2707 -1.3163 -1.2187 0.2806 0.2681 0.2956 0.2103 0.3745
5 -0.2205 -0.3074 0.0084 0.8021 0.7354 1.0084 0.5936 1.0840
Mucolytics :
0
1 -0.0545 -0.0792 -0.0360 0.9470 0.9239 0.9647 0.9015 0.9948
2 0.1645 0.1021 0.2394 1.1788 1.1075 1.2705 1.0712 1.2971
Anti-inflammatories:
0
1 0.0960 0.0254 0.1456 1.1007 1.0257 1.1567 1.0243 1.1828
2 -0.2777 -0.3188 -0.2342 0.7575 0.7270 0.7912 0.5997 0.9568




Yes 0.8439 0.7994 0.9044 2.3254 2.2242 2.4705 1.8950 2.8536












Table 7.15. (continued).  
 














Estimate MinimumMaximum Estimate MinimumMaximum Lower Upper
Drug resistance of 
beta lactams in 
current visit:
No
Yes -0.1662 -0.2857 -0.0267 0.8469 0.7515 0.9737 0.5989 1.1977
Testing not done -0.7936 -0.8831 -0.6776 0.4522 0.4135 0.5078 0.2723 0.7512




Yes -0.1132 -0.1669 -0.0565 0.8930 0.8463 0.9451 0.6218 1.2825









Table 7.16. Using stepwise regression (AIC value) to select variable in the time-dependent cox regression. 
 
Excluded variables 1 2 3 4 5 6 7 8 9 10
AIC of included all variables 15136.28 15132.05 15133.41 15122.60 15137.29 15131.30 15136.35 15124.56 15137.39 15124.41
AIC after excluded above 
variables 15092.57 15088.12 15089.22 15078.40 15093.02 15086.90 15092.26 15080.32 15093.33 15080.10
Predicted FEV1 in current 
visit (baseline)
1 1 1 1 1 1 1 1 1 1
Race 1 1 1 1 1 1 1 1 1 1
Drug resistance of 
quinolones in current visit 
(baseline)
1 1 1 1 1 1 1 1 1 1
Mutation 2 class 1 1 1 1 1 1 1 1 1 1
CFRD status 1 1 1 1 1 1 1 1 1 1
Transplant 1 1 1 1 1 1 1 1 1 1
Drug resistance of 
quinolones in current visit 1 1 1 1 1 1 1 1 1 1
Drug resistance of 
aminoglycosides in current 
visit (baseline)
1 1 1 1 1 1 1 1 1 1
Predicted FEV1 in current 
visit 1 1 1 1 1 1 1 1 1 1
Other gram-negative 
microorganisms 1 1 1 1 1 1 1 1 1 1
Candida 1 1 1 1 1 1 1 1 1 1
MSSA 1 1 1 1 1 1 1 1 1 1
Imputed dataset 











Excluded variables 1 2 3 4 5 6 7 8 9 10
GERD 1 1 1 1 1 1 1 1 1 1
B. cepacia 1 1 1 1 1 1 1 1 1 1
Weight 1 1 1 1 1 1 1 1 1 1
Gender 1 1 1 1 1 1 1 1 1 1
Smoking 1 1 1 1 1 1 1 1 1 1
Number of mucolytics 
(baseline)
1 1 1 1 1 1 1 1 1 1
Drug resistance of beta 
lactams in current visit 1 1 1 1 1 1 1 1 1 1
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Table 7.17. Results of the time-dependent cox regression. 
 
Lower Upper
Not following any strategy 2.8441 1.0820 2.4371 3.3190 4%
Following strategy 33
Hispanic 1.2789 1.1240 1.0170 1.6082 0%
height 1.0062 1.0020 1.0022 1.0103 0%
Hemoptysis 2.9534 1.5721 1.2169 7.1679 0%
Using any enzymes 1.4442 1.2211 0.9763 2.1363 0%
MAI 2.1484 1.3026 1.2796 3.6068 0%
MRSA 0.8517 1.0718 0.7435 0.9758 0%
Predicted FEV1 in baseline visit 0.9953 1.0022 0.9911 0.9995 0%
Predicted FEV1 in current visit 0.9992 1.0022 0.9949 1.0035 1%
Drug resistance of beta lactams 
in current visit*:
No
Yes 0.6144 1.3833 0.3253 1.1606 0%
Testing not done 2.0052 1.0766 1.7350 2.3173 0%
Drug resistance of beta lactams 
in current visit:
No
Yes 1.3100 1.1779 0.9504 1.8056 0%
Testing not done 2.1768 2.0382 0.5392 8.7888 0%
Drug resistance of quinolones 
in current visit:
No
Yes 1.8089 1.1084 1.4785 2.2130 0%
Testing not done 0.0080 2.1008 0.0019 0.0344 0%
Number of PEx in the past year 
in current visit :
0
1 0.9603 1.0843 0.8195 1.1253 0%
2 0.8025 1.1411 0.6195 1.0395 0%
3 0.7996 1.2208 0.5408 1.1822 0%
4 0.9353 1.3838 0.4949 1.7677 0%
5 0.6177 1.4435 0.3008 1.2682 0%
Inhaled antibiotics*:
0
1 1.3561 1.0945 1.1360 1.6188 0%











Table 7.17. (continued). 




1 0.8106 1.1120 0.6583 0.9980 0%
2 1.1940 1.6040 0.4729 3.0142 0%
Bronchodilators*:
0
1 0.8784 1.0795 0.7561 1.0205 0%
2 1.3117 1.3334 0.7463 2.3055 0%
Mucolytics :
0
1 1.1449 1.1203 0.9164 1.4305 0%
2 1.3900 1.1304 1.0931 1.7675 0%
Inhaled antibiotics:
0
1 0.9647 1.0827 0.8257 1.1272 0%
2 1.1220 1.1467 0.8580 1.4673 0%
3 1.4709 1.3790 0.7836 2.7612 0%
Anti-inflammatories:
0
1 1.1745 1.0790 1.0118 1.3633 0%
2 0.9039 1.2578 0.5766 1.4169 0%
Bronchodilators:
0
1 2.4115 1.1086 1.9703 2.9515 0%














OVERALL CONCLUSIONS AND IMPACTS 
 
Even though several assumptions were made prior to this investigation, the 
chance of the results being biased by those assumptions is low since the majority of them 
were determined either based on well-accepted clinical evidence or were investigated and 
supported by preliminary tests. Due to the application of innovative methods and 
comprehensive considerations, the results of this analysis are reasonable, accurate, and 
stable. 
This study is the largest cohort of CF patients in the United States who were 
diagnosed with nonmucoid PaPI from 2006 to 2011and had not developed mucoid PaPI 
at the index date. Among the 4,970 unique patients, the majority were Caucasian and 
younger than 12 years old. Given the youth of this cohort, patients were healthy: at the 
baseline, they were barely affected by comorbidities other than pancreatic insufficiency 
and GERD; the majority of patients had only mildly impaired lung function, did not have 
PEx in the previous 1 year, and had almost no drug resistance. However, according to the 
result of genetic testing, more than three-quarters of those patients had dysfunction of the 
CFTR protein, which indicates more aggressive disease progression. Subgroup analyses 
indicated that the clinical signals were applied in prescription decisions, affecting at least 
the treatment class that a patient received at the baseline. 
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Because patients were young and healthy at baseline, they received few advanced 
treatment combinations; more than half of patients received either no treatment or one 
mucolytic. Whether considering only the first treatment change or all treatment changes 
in the cohort, physicians were prone to change treatment prudently by prescribing only 
one additional treatment from any of the three treatment classes. At the same time, the 
fewer treatment classes a patient received, the more potential treatment combinations he 
could switch to. Finally, the more treatments a patient received in the current treatment, 
the longer the patient was likely to stay on the same treatments.  
After reformatting all patients’ irregular visits into routine quarterly visits and 
successfully imputing missing values using a complex strategy based on the mechanism 
of missing data, 10 imputed datasets were generated. With the assistance of the machine-
learning method, together with the support of Rubin’s rules, the independent variables in 
the predictive model were selected, and related coefficients among 10 imputed datasets 
were combined. The independent variables included demographic characteristics, clinical 
signals, comorbidities, and treatment histories. With the coefficient of each independent 
variable, the predicted probability of rational treatment change and the relative change of 
predicted probability between previous and current visits were calculated accordingly. 
Given the different thresholds of predicted probability and relative change of predicted 
probability, 25 varied timing strategies for treatment change were created. The proportion 
of patients who followed any one of the strategies was high. In other words, the 
assumption of positivity was met. A patient received a rational treatment change at the 
treatment class level if and only if his predicted probability and relative change of 
predicted probability between previous and current visits was higher than the strategy’s 
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threshold, and vice versa. There is a grace period for the predicted probability of having 
rational treatment change, within which the prescribing behavior of either having or not 
having a rational treatment change is acceptable. Models with different grace-period 
lengths were also investigated. The current grace period was chosen after balancing the 
proportion of patients who followed the strategy and the proportion of patients who had 
treatment change caused by uncertain reason.  
At the end, the treatment effects of 25 dynamic rational treatment change 
strategies for chronic treatment of pediatric CF patients were investigated using the 
dynamic marginal structural model and inverse probability weighting. Several models 
were analyzed; the fixed parameterization of the dynamic logistic marginal structural 
model with stabilized inverse probability weighing was preferred. In summary, patients 
who did not follow a treatment change regime had worse outcomes than patients 
following any regime. Among patients who followed different DTRs, the hazard ratio of 
developing mucoid PaPI first increased, then decreased, when the threshold of relative 
change of predicted probability increased. The regime in which the threshold of relative 
change of predicted probability equaled 1.831% always had the worst outcomes among 
the regimes that shared the same threshold of predicted probability. An optimal strategy, 
identified from 25 strategies, maximized the time to mucoid PaPI. The optimal strategy 
includes the following guidelines: the physician should not provide a treatment change on 
the treatment class level if the predicted probability of having a rational treatment change 
between the current and previous visit is lower than 0.088 and the relative change of 
predicted probability is lower than 0.222%; if the probability is higher than 0.098 and the 
relative change of predicted probability is higher than 0.222%, then the physician should 
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change the treatment on the treatment class level. If the probability ranges from 0.088 to 
0.098, it is acceptable to either implement a treatment change or not. Generally speaking, 
these results are consistent with the concept of evidence-based medicine: treatment has to 
be changed if and only if it is supported by the clinical signals.  
With the identification of an optimal strategy, healthcare providers will be able to 
prescribe rationally without any uncertainty, supported by confirmed evidence rather than 
guessing whether a treatment change is needed. At the same time, the value-based 
formulary can be designed at the treatment class level: adding treatment or switching 
treatment will be reimbursed only if the prescription timing matches the threshold of the 
dynamic treatment regime. In such a value-based formulary, patients’ lung function will 
be optimized so as to avoid or delay the need for extremely expensive treatments such as 
ivacaftor and ivacafotr/lumacaftor unless the healthcare provider has already prescribed 
all other treatments step by step (step therapy) and the scenario of suboptimal treatment 
effects has already occurred (prior authorization). Therefore, the annual cost of the health 
plan for CF patients could be well maintained without sacrificing healthcare utilization.  
Currently, several guidelines governing prescribing practices for chronic lung 
health maintenance treatments exist. However, rather than suggesting the order of 
prescription, the guidelines only categorize all treatments by the certainty of net benefits. 
Additionally, those evidences are generated by existing RCTs with small sample sizes 
and extremely narrow characteristics that do not represent the whole patient population. 
With the identification of the optimal dynamic treatment regime, using the longitudinal 
data under the causal inference, physicians can use the results of this study in the future 
to make treatment changes at the right time by following the optimal strategy. At the 
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same time, physicians can make personalized treatment change decisions for each patient 
confidently given the unique demographic values, clinical variables, and treatment 
histories at the baseline visit and current visit, rather than guessing whether the 
demographic and clinical characteristics of each individual patient match the studies’ 
inclusion criteria from which the guidelines were generated. With the application of the 
optimal dynamic rational treatment change strategy, both healthcare providers and 
patients are supported with certain signs when a treatment change decision has to be 
made. Therefore, the clinical outcome—time to mucoid PaPI—will be maximally 
delayed at the CF patient population level. Even though the casualty of this study was 
generated by observational database, which emulated an RCT, this evidence still needs to 
be proved by RCT. The results of this study serve perfectly to design an RCT. The RCT 
would not have to investigate numerous DTRs; the results of this study have already 
narrowed down the randomized arms in the RCT to the targeted DTRs, which will 
investigate the causality between following each one of them and the delay in developing 
mucoid PaPI.  
At the same time, the study results could also support value-based formulary 
design by optimizing traditional treatment utilization—step therapy, tiered formulary, 
prior authorization, and other tools for managed care pharmacy—prior to reimbursement 
of extremely expensive medications. Insurance companies would reimburse only 
treatment changes that matched the optimal strategy. In this situation, this research can 
not only deliver the right therapy to the right patient at the right time but also at the right 
cost, indirectly controlling healthcare costs by optimizing traditional treatments and 
delaying the use of innovative yet expensive treatments.  
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Finally, the DTRs’ grace period was caused by the low accuracy of differentiating 
between the observed treatment change and no treatment change within a specific range 
of values of predicted probability. However, in several years, after the optimal strategy is 
successfully identified and well accepted by healthcare providers in clinical practice, the 
number of patients who follow the optimal strategy will increase and the uncertainty 
range will shrink, shortening the grace period. In other words, the more evidence we have 
and the more physicians prescribe rationally according to the strategy, the less 
uncertainty remains. Ideally, the optimal strategy will be reestimated every couple of 
years using the latest cohort. Eventually, after several iterations, the grace period will 
disappear, and an optimal strategy with a clear-cut of threshold will be generated. During 
that time, healthcare providers and insurance companies will adjust their clinical practices 














EXPLORATORY ANALYSIS OF INVESTIGATING THE QUALITY  




A.1 Test on the trend of treatment consistency by calendar year 



























A.2 Test the discordance between self-reported treatment and claims refills information 
Table A.5. Number of treatments in claims database 
CF variable Frequency Percent Cumulative Percent 
Vx770 791 1.02 1.02 
aztreonam 2969 3.84 4.87 
dornasealfa 61384 79.45 84.31 
tobi 11785 15.25 99.57 
tobi_pod 335 0.43 100 
Total 77264 100   
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Table A.6. Overall number of claims by calendar year 
claimsYR Frequency Percent 
Cumulative 
Percent 
2000 161 0.21 0.21 
2001 220 0.28 0.49 
2002 747 0.97 1.46 
2003 1028 1.33 2.79 
2004 1483 1.92 4.71 
2005 1584 2.05 6.76 
2006 2870 3.71 10.47 
2007 5995 7.76 18.23 
2008 9774 12.65 30.88 
2009 11584 14.99 45.88 
2010 10409 13.47 59.35 
2011 11049 14.3 73.65 
2012 11535 14.93 88.58 
2013 8019 10.38 98.96 
2014 806 1.04 100 

































N % N % N %
0 71019 25486 4953 3733 5.26 21753 30.63 1220 1.72
30 71019 25486 8779 6524 9.19 18962 26.70 2253 3.17
60 71019 25486 11098 8033 11.31 17453 24.58 3053 4.30
90 71019 25486 12968 9089 12.80 16397 23.09 3754 5.29










N % N % N %
0 71019 49563 25528 21236 29.90 28327 39.89 4292 6.04
30 71019 49563 33387 27696 39.00 21867 30.79 5691 8.01
60 71019 49563 37258 30866 43.46 18697 26.33 6392 9.00
90 71019 49563 39685 32820 46.21 16743 23.58 6865 9.67



















N % N % N %
0 71019 5555 1313 911 1.28 4644 6.54 402 0.57
30 71019 5555 2571 1812 2.55 3743 5.27 759 1.07
60 71019 5555 3359 2309 3.25 3246 4.57 1050 1.48
90 71019 5555 3954 2639 3.72 2916 4.11 1315 1.85








Grey period All Encounter=1 Claims=1
N % N % N %
0 71019 314 170 46 0.06 268 0.38 124 0.17
30 71019 314 275 74 0.10 240 0.34 201 0.28
60 71019 314 373 98 0.14 216 0.30 275 0.39
90 71019 314 454 115 0.16 199 0.28 339 0.48






















N % N % N %
0 71019 476 278 214 0.30 262 0.37 64 0.09
30 71019 476 340 260 0.37 216 0.30 80 0.11
60 71019 476 368 285 0.40 191 0.27 83 0.12
90 71019 476 395 298 0.42 178 0.25 97 0.14




















claimsYR all aztreonamp0 aztreonamp30 aztreonamp60 aztreonamp90 aztreonampdou
2003 1003 0 0 0 0 0
2004 1617 0 0 0 0 0
2005 2216 0 0 0 0 0
2006 3796 0 0 0 0 0
2007 6973 0 0 0 0 0
2008 8877 0 0 0 0 0
2009 9713 0 0 0 0 0
2010 9342 204 379 481 549 365
2011 9418 401 796 1024 1185 768
2012 9292 407 774 984 1117 754
2013 6777 259 519 706 840 500













claimsYR all aztreonamp0 aztreonamp30 aztreonamp60 aztreonamp90 aztreonampdou
2003 1003 0 0 0 0 0
2004 1617 0 0 0 0 0
2005 2216 0 0 0 0 0
2006 3796 0 0 0 0 0
2007 6973 0 0 0 0 0
2008 8877 0.0048 0.0048 0.0048 0.0048 0.0048
2009 9713 0.0165 0.0165 0.0165 0.0165 0.0165
2010 9342 0.0635 0.0599 0.0608 0.0621 0.0604
2011 9418 0.1369 0.1191 0.1140 0.1103 0.1217
2012 9292 0.1540 0.1345 0.1276 0.1252 0.1360
2013 6777 0.1687 0.1474 0.1337 0.1269 0.1493













claimsYR N aztreonamp0 aztreonamp30 aztreonamp60 aztreonamp90 aztreonampdou
2003 247 0 0 0 0 0
2004 365 0 0 0 0 0
2005 467 0 0 0 0 0
2006 789 0 0 0 0 0
2007 1522 0 0 0 0 0
2008 1883 0.0039 0.0039 0.0039 0.0039 0.0039
2009 2031 0.0132 0.0132 0.0132 0.0132 0.0132
2010 2053 0.0483 0.0452 0.0454 0.0460 0.0454
2011 1896 0.1226 0.1073 0.1035 0.0998 0.1093
2012 1881 0.1433 0.1236 0.1172 0.1143 0.1249
2013 1588 0.1520 0.1362 0.1207 0.1116 0.1377




Table A.12. Proportion of discordance when patient claimed not on treatment by calendar year (aztreonam) 
 
claimsYR all aztreonamp0 aztreonamp30 aztreonamp60 aztreonamp90 aztreonampdou
2003 1003 0 0 0 0 0
2004 1617 0 0 0 0 0
2005 2216 0 0 0 0 0
2006 3796 0 0 0 0 0
2007 6973 0 0 0 0 0
2008 8877 0 0 0 0 0
2009 9713 0 0 0 0 0
2010 9342 0.0094 0.0170 0.0229 0.0272 0.0165
2011 9418 0.0136 0.0257 0.0353 0.0419 0.0255
2012 9292 0.0108 0.0208 0.0286 0.0345 0.0204
2013 6777 0.0106 0.0192 0.0261 0.0326 0.0187
2014 1995 0.0070 0.0175 0.0306 0.0371 0.0165











EXPLORATORY ANALYSIS OF INVESTIGATING THE RELATIONSHIP 











































EXPLORATORY ANALYSIS OF INVESTIGATING THE IMPACT OF 
DIFFERENT MEASUREMENTS ON THE NUMBER OF VARIABLES  
THAT WOULD BE SELECTED BY ELASTIC NET 
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FEV1% predicted Mucolytics Inhaled antibiotics Anti-inflammatory Bronchodilators Loose Neutral Strict Loose Neutral Strict
1 0 75% 1 0 0 0 . . . . . .
1 1 52% 1 0 0 0 1 1 1 1 1 1
1 2 64% 1 1 0 2 1 1 1 0 0 0
1 3 66% 1 1 0 1 1 1 0 1 1 0
1 4 65% 1 1 1 1 1 0 0 0 0 0
1 5 64% 1 1 1 0 . . . . . .
ID Visit Treatment classes
Treatment change     
including BD
Treatment change not    
including BD
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Figure C.1. The cross-validation figures conditional on different types of measurement for rational treatment change with strict 
assumption in imputed dataset 1. 
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Table C.2. The minimum of mean cross-validated error using deviance as the measurement for treatment change that includes BD use 








1 2 3 4 5 6 7 8 9 10 Mean SD
0 0.879694 0.881423 0.880417 0.881174 0.880946 0.880628 0.880037 0.879907 0.880106 0.880290 0.880462 0.000541
0.1 0.850469 0.852424 0.851256 0.852553 0.851965 0.851430 0.851045 0.850671 0.851103 0.851290 0.851421 0.000659
0.2 0.850396 0.852333 0.851190 0.852461 0.851873 0.851351 0.850964 0.850597 0.851017 0.851204 0.851339 0.000652
0.3 0.850376 0.852300 0.851174 0.852432 0.851847 0.851321 0.850941 0.850572 0.850991 0.851180 0.851313 0.000649
0.4 0.850367 0.852286 0.851165 0.852418 0.851831 0.851311 0.850931 0.850562 0.850978 0.851168 0.851302 0.000648
0.5 0.850361 0.852279 0.851162 0.852414 0.851826 0.851303 0.850929 0.850557 0.850971 0.851163 0.851297 0.000648
0.6 0.850361 0.852274 0.851160 0.852410 0.851821 0.851300 0.850925 0.850554 0.850968 0.851158 0.851293 0.000647
0.7 0.850357 0.852271 0.851158 0.852407 0.851819 0.851299 0.850925 0.850553 0.850965 0.851155 0.851291 0.000646
0.8 0.850357 0.852270 0.851157 0.852406 0.851817 0.851298 0.850924 0.850552 0.850963 0.851153 0.851290 0.000646
0.9 0.850356 0.852268 0.851157 0.852405 0.851816 0.851297 0.850924 0.850550 0.850962 0.851152 0.851289 0.000646
1 0.850356 0.852266 0.851156 0.852404 0.851815 0.851294 0.850923 0.850548 0.850962 0.851151 0.851288 0.000646
Imputed dateset
Alpha
   
392 
Table C.3. The minimum of mean cross-validated error using deviance as the measurement for treatment change that not include BD 
use under strict definition. 
 
1 2 3 4 5 6 7 8 9 10 Mean SD
0 0.513712 0.513815 0.513591 0.514084 0.513882 0.513225 0.513310 0.513633 0.513643 0.513989 0.513688 0.000260
0.1 0.506486 0.506602 0.506285 0.506779 0.506607 0.505879 0.506029 0.506293 0.506276 0.506802 0.506404 0.000291
0.2 0.506439 0.506565 0.506239 0.506739 0.506555 0.505823 0.505977 0.506249 0.506230 0.506757 0.506357 0.000294
0.3 0.506416 0.506545 0.506218 0.506713 0.506529 0.505802 0.505957 0.506227 0.506213 0.506734 0.506335 0.000293
0.4 0.506404 0.506534 0.506204 0.506702 0.506511 0.505789 0.505946 0.506215 0.506203 0.506723 0.506323 0.000293
0.5 0.506395 0.506526 0.506195 0.506694 0.506501 0.505780 0.505941 0.506208 0.506195 0.506715 0.506315 0.000292
0.6 0.506386 0.506521 0.506190 0.506686 0.506496 0.505772 0.505934 0.506200 0.506189 0.506709 0.506308 0.000293
0.7 0.506380 0.506517 0.506189 0.506683 0.506492 0.505767 0.505939 0.506196 0.506185 0.506706 0.506306 0.000292
0.8 0.506375 0.506514 0.506186 0.506681 0.506489 0.505763 0.505936 0.506193 0.506182 0.506694 0.506301 0.000291
0.9 0.506370 0.506511 0.506184 0.506678 0.506485 0.505761 0.505934 0.506191 0.506179 0.506690 0.506298 0.000291















EXPLORATORY ANALYSIS OF INVESTIGATING THE RELATIONSHIP 
BETWEEN FREQUENCY OF VISIT AND DETERIORATION  
OF LUNG FUNCTION 
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Table D.1. The association between relative FEV1% predicted change and frequency of 



















Table D.2. The association between relative FEV1% predicted change and frequency of 



















EXPLORATORY ANALYSIS OF INVESTIGATING THE INFLUENCES  
OF USING DIFFERENT METHODS TO DEFINE INDEX DATE  
ON BASELINE VARIABLES AND CLINICAL OUTCOMES
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Table E.1. Baseline characteristics using the first visit as index date (continuous variables). 
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Table E.1. (continued) 
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations   
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Table E.1. (continued). 
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations        
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Table E.2. Baseline characteristics using the first visit as index date (categorical variables). 
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations  
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Table E.2. (continued) 
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations  
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Table E.2. (continued) 
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations  
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Table E.2. (continued) 
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations  
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Table E.2. (continued) 
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations  
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Table E.3. (continued) 
 




   
410 









   
411 
Table E.3. (continued) 
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations        
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Table E.4. Baseline characteristics using the first visit as index date (categorical variables).  
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations  
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Table E.4. (continued) 
  
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations  
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Table E.4. (continued) 
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations  
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Table E.4. (continued) 
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations  
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Table E.4. (continued) 
 
*Fisher Exact test was conducted if more than 25% of cells have less than 5 observations   
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DATA MANAGEMENT OF MISSING VALUES
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In this appendix, the procedures of handling missing values were described in 
detail. All missing values in time-independent variables, which were caused by artificial 
created quarterly visits, were calculated using the last observation carried forward method. 
The arithmetic mean was calculated for time-varying demographic variables, such as 
height and weight, using the relative change of those variables among all visits that 
occurred 1 year before and 1 year after the visit, which contains the missing information. 
After above procedures, the only variable that had missing values was FEV1. To better 
impute FEV1 by preventing the consecutive missing since index date, a new index date 
was identified for Aim 2 and 3. Moreover, four questions were investigated 
simultaneously using different outcomes among 12 models to identify the most 
appropriate model for multiple imputation. Those questions were: which method, MCMC 
or FCS, should be chosen; whether to include the indicator or not; whether to include 
preexisting lung function variables or not; and which assumption (strict, loose, or neutral) 
to choose.  
The cohort in Aim 1 was used as the foundation to reformat the visit data as each 
patient had a routine visit quarterly. Other than FEV1, the missing values for the rest of 
the variables were imputed in Aim 1. However, because of the reformatting, for some 
patients who did not have a visit during a 3-month interval a visit was artificially created. 
For those visits, comorbidities, treatment-related variables, and fixed demographic 
information, such as race and ethnicity, were captured using the last observation carried 
forward method. The rationale is that 3 months is not enough time to have any extreme 
changes in those variables. Considering the uncertainty of imputed FEV1 when the 
missing values occurred consecutively, a new index date was identified following the 
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conclusion of Assumption 4 (3.10.1.4) for the cohort in Aim 2 and 3. Patients who had 
more than a 6-month grace period between the original index date in Objective 1 and 
when FEV1 was first measured were excluded from the cohort. The first measured date 
was applied as the index date for the rest of the patients. The number of patients 
decreased to 4,760 in the new cohort for Aim 2 and 3, and included 79,724 visits. The 
index date was the same for a majority of patients (4,174/4,760 = 87.69%), the rest had a 
new index date which was delayed from 0 to 6 months from the original index date.  
After the above procedures, FEV1 was the only variable that had missing values 
in the dataset. Two characteristics made the traditional imputation technique inapplicable 
to imputing the FEV1 value. First, the changing trend of FEV1 is not linear. From a long-
term perspective, it changes gradually, deteriorating over time. But in the short term, it 
fluctuates drastically. Moreover, FEV1 is the key clinical signal in this study, serving as 
both exposure and outcome in different objectives. Any inappropriate imputation would 
bias the final result. Therefore, a more advanced methodology was applied to closely 
impute those missing values. 
Compared with traditional imputation techniques, multiple imputation (MI) is 
superior, since it restores some of the lost variability by adding a residual term to the 
predicted scores from the regression imputation. That residual term is randomly drawn 
from a normal distribution with a mean of zero and variance equal to the residual 
variance from the regression model. This method produces unbiased coefficient estimates 
under missing at random (MAR), even including standard errors, which are produced 
during a regression estimation. Therefore, the result of MI is less biased than the single 
imputation approach. However, it may still be attenuated compared with the real residual 
421 
  
for the missing values. So, while multiple imputation is the most advanced and accurate 
method to impute missing values, without appropriately identifying the missing 
mechanisms, it may still bias the imputed result. 
Rather than imputing FEV1 directly, the change of FEV1 (delFEV1) between 
current visit and future visit was imputed as the outcome. There are two rationales for this. 
First, the value of FEV1 is an accumulated clinical variable; it reflects the pulmonary 
damage that a patient has suffered from infancy. Therefore, the demographics, other 
clinical variables, and treatment information of the current visit only affect the change of 
FEV1 between current and future visits assuming those conditions are held between the 
two visits. Moreover, the predictive accuracy is better using the change of FEV1, since 
the range of variation is narrower compared with calculating FEV1 directly. The change 
of FEV1 is less likely to have larger random errors, which increases the accuracy of the 
prediction.  
There are a couple of issues associated with the imputation of delFEV1. The first 
issue is related to the time point of the missing values. A missing value for delFEV1 
could be caused by failing to capture FEV1 at either the current visit or future visit. 
Another one is related to the rationale of the missing values, which could be caused by 
either failing to capture the FEV1 in the routine visit or by artificial reformatting. As 
mentioned previously, if there was no visit during the 3-month interval, a visit was 
artificially created to represent the quarterly visit, and thus all the values for that visit 
were missing. These values were denoted as ‘missing values at artificial visit.’ Similarly, 
‘missing values at existing visit’ was applied to refer to the missing delFEV1s that failed 
to be captured at the real visit. In order to investigate whether the rationale of missing 
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values in future visits affects the imputation of delFEV1, three assumptions (loose, 
neutral, and strict) were made. For the loose assumption, all missing delFEV1 values 
were imputed regardless of the time point and rationale of missing values. Conversely, 
under the strict assumption, missing delFEV1 was only imputed if it was caused by 
failing to capture FEV1 at the current visit or if the current visit was artificially created. 
The other missing delFEV1s were set as 0. For the neutral assumption, the missing 
delFEV1 was calculated, as long as it was not caused by a missing value at an artificially 
created future visit. The rationale of those assumptions varied. Under the strict 
assumption, the patient was assumed to have a stable lung function, the delFEV1 was not 
changed as long as the missing value occurred in the next visit regardless of the rationale. 
Conversely, in the loose assumption, there was no assumption about the changing trend 
of lung function when the value was missed at the future visit. It was assumed that all 
missing values should be imputed, and the imputation could handle all missing delFEV1. 
The neutral assumption, in contrast, had the most reasonable rationale that the patient had 
a stable lung function if he did not have a routine future visit. However, the imputation of 
the rest of the missing values for delFEV1 was still needed. Table F.1 presents these 
assumptions. Each cell represents all missing values that shared the same mechanism. For 
example, A represents all missing delFEV1s that were caused by failing to capture the 
FEV1 at the current visit. For the strict assumption, the missing values that belonged to B 
and D were not imputed. Conversely, all missing values were imputed under the loose 
assumption. If a missing value belonged to cell D, it was not imputed under the neutral 
assumption. In the cohort, the missed FEV1 was imputed according to the delFEV1 and 
FEV1 that was measured in the consecutive visit. 
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Other than investigating whether the rationale for the missing values in the future 
visit affects the imputation of delFEV1, questions of whether the artificially created 
current visit affects the imputation, and whether including preexisting lung function 
variables could improve the imputation were also investigated. To answer the first 
question, an indicator was created for all missing values that belonged to cell C in Table 
F.1. The preexisting lung function variables, such as the change of FEV1 between the 
previous and current visit (predelFEV1), and FEV1 in the previous visit (preFEV1), were 
included in some models. Given that other variables that were included in the models 
were fixed, the comparisons of delFEV1 between models that included indicator and not, 
and between models that included preexisting lung function variables or not were 
conducted to solve the related questions.  
The multiple imputation was conducted in the following manner. First, 
demographic variables and comorbidities were included to impute the delFEV1. Other 
clinical variables and treatment-related variables were not included, as the delFEV1 was 
the signal to direct the decision-making of treatments. At the same time, considering that 
FEV1 was one of the main predictors of having a rational treatment change, if the 
missing delFEV1 was imputed by other clinical variables and treatment-related variables, 
it could introduce bias and affect the prediction for the treatment change. Therefore, the 
change of FEV1 between the current and future visits was imputed in varied models 
given different assumptions. To identify the imputation model that was associated with 
the best performance, other than assumptions, three questions mentioned above were also 
investigated. Moreover, two methods of multiple imputation (Markov Chain Monte Carlo 
[MCMC] and Fully Conditional Specification [FCS]) were applied in the study, since 
424 
  
they each entail different assumptions. Compared to MCMC, FCS doesn’t assume the 
joint normal distribution. Last, after choosing the model for MI, the missing delFEV1s in 
the original dataset were imputed 10 times, which is enough to capture the variance of 
imputed values, and 10 imputed datasets were created accordingly. The only differences 
between these datasets were in the FEV1 values, which were imputed through delFEV1s 
and FEV1s that were captured in the consecutive visits.  
According to whether the model included the indicator, whether it included 
preexisting lung function variables, and the three assumptions, 12 models were built for 
the study. The following variables that were measured in the current visit were included 
as independent variables in all models under different assumptions: age, height, weight, 
mutation class 1, mutation class 2, whether the patient had F508 mutation, gender, status 
of lung transplant, whether the patient was infected by aspergillus, an Burkholderia 
species, B. cepacia, Candida, MAI, MRSA, MSSA, other Gram-negative 
microorganisms, S. aureus; whether the patient had ABPA, CFRD, DIOS, GERD, 
hemoptysis, or TB. From Figure F.1 to Figure F.13, different outcomes, such as trace of 
delFEV1, autocorrelation of delFEV1, distribution of delFEV1, among those 12 models 
were compared to investigate the most appropriate model for multiple imputation.  
First, four trace plots of delFEV1 in different models are presented in Figure F.2. 
Compared with the right column, the left column doesn’t include preexisting lung 
function variables, and from the top to bottom, the figure represents the model under 
strict and loose assumptions. Figure F.1 depicts the trace plot of the model that does not 
include the indicator under the strict assumption. The x axis is the number of iterations 
and the y axis is the mean delFEV1 in each iteration. Figure F.1 indicates two 
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characteristics of better performance in the MI model, a stable posterior distribution and 
reaching a stationary phase quickly. The stable posterior distribution was supported by 
the mean, which remained relatively constant with no trend between the mean and the 
number of iteration. The stable phase was achieved immediately, much earlier than the 
burn-in stage (200 iterations). The trend only existed in four models in Figure F.2 and all 
of them included the indicator variable. Therefore, compared to the model that did not 
include the indicator to differentiate the mechanism of missingness, after including the 
indicator, the outcome was not converged (Figure F.2), at least under loose and strict 
assumptions.  
Figure F.4 supports the result from another perspective that it was highly likely to 
have autocorrelation among those iterations. Figures F.3 and F.4 summarize the result 
from the related model in Figures F.1 and F.2. The x axis represents the lag, each one unit 
covers 100 iterations, and the y axis represents the correlation between two iterations. 
The blue band indicates the 95% CI of not having the correlation between two iterations. 
The lower the chance of having autocorrelation between iterations, the better a model is. 
Figure F.3 indicates a low chance of having autocorrelation between iterations: the 
correlation decreases rapidly from 1 to 0 and then locates in the blue band. However, the 
chance of having autocorrelation between iterations was high for the other four models in 
Figure F.4. The correlation was not only out of the blue band, but also close to 1. 
Therefore, including the indicator decreased the performance of a model, at least under 
loose and strict assumptions, since there was a strong correlation between imputed values 
in adjacent imputed datasets.  
According to the rationale of missing values, Figure F.5 and Figure F.6 were 
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created, which indicated the distributions of imputed delFEV1 that were caused by 
artifical reformatting and failure to capture it respectively in 1 of the 10 imputed datasets 
(imputed1). The other imputed datasets shared the same trends. Compared to the right 
column, the left column doesn’t include preexisting lung function variables. From the top 
to the bottom, the figure represents the model under strict, neutral, and loose assumptions, 
respectively. The green histogram and black dotted line represent the distribution of 
imputed delFEV1 in the model that included the indicator, and the blue histogram and red 
dotted line represent the model that did not take the indicator into consideration. The x 
axis represents the predicted value of delFEV1, and the y axis represents the proportion 
of a predicted value in the specific range. In Figure F.5, if the neutral assumption was 
applied, there was barely any difference in the distribution of imputed delFEV1 between 
the model that included the indicator and the one that did not. However, the difference 
was huge if the strict assumption was followed, and the direction was even reversed. 
Under the strict assumption, models that did not include the preexisting lung function 
variables had higher imputed values of delFEV1 after including the indicator. Conversely, 
if the model included the preexisting lung function variables, after including the indicator, 
the imputed delFEV1 would be more likely to concentrate around 0. Similarly, under the 
loose assumption, for the model that included preexisting lung function variables, after 
including the indicator, the imputed delFEV1 would also be more likely to concentrate 
around 0. Generally speaking, the imputed values in the neutral assumption would not be 
affected by whether the model included the indicator. But, after including the indicator, 
the imputed delFEV1 would change quite a bit under both the loose and strict 
assumptions. Figure F.6 shows that the difference in imputed delFEV1 was trivial 
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regardless of whether the model included the indicator, if only considering the missing 
value that failed to be captured. The only exception occurred when preexisting lung 
function variables were included under the neutral assumption. After including the 
indicator, the imputed delFEV1 would increase.  
Figures F.7 and F.8 were created to better visualize the difference in imputed 
delFEV1 between the model that did not include the indicator and the model that did 
include the indicator. Generally speaking, all figures were normally distributed, using 0 
as mean. However, compared to the difference of imputed delFEV1 that occurred in the 
artificial visit, the one that occurred in the existing visit was more likely to concentrate on 
0, since the maximum value of percentage was higher in Figure F.8 compared to the 
related figure in Figure F.7. In other words, compared to an artificial visit, there was less 
difference of imputed delFEV1 between models that included and did not include the 
indicator in the existing visit.  
Similar procedures were also conducted using the FCS rather than the MCMC 
method. The conclusion was that those models were converged regardless of including 
the indicator or not. Unlike when using MCMC, including the indicator did not affect the 
result of the multiple imputation using the FCS method. Figures F.9, F.10, and F.11 
support the above conclusion. Rather than presenting the results of all the models, only 
the model that includes the indicator under the strict assumption is presented in Figure 
F.9. The other results in the different models shared the same characteristics. Unlike the 
trace plots of MCMC, which only presents the result of one imputation, the trace plot of 
FCS presents the results of all imputations at the same time. In Figure F.9, the median of 
imputed delFEV1 in each imputation chain is overlayed on top of each other; each color 
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represents the result of one imputation. All ten imputations were converged quickly. The 
distribution of delFEV1 in two models, including or not including the indicator under the 
strict assumption, was generated in Figures F.10 and F.11 for the missing values that 
occurred at the artificial visit and existing visit, respectively. There was no difference in 
imputed delFEV1, regardless of the rationale of missing values. Compared with MCMC, 
which provides reliable estimates, even the assumption of multivariate normal 
distribution is violated, as long as the sample size is large enough,164,166 the chance of 
providing reliable estimates is lower if any distribution of imputed variable is 
misspecified in FCS. Therefore, the MCMC method was applied. 
To compare the influence of different assumptions on the imputed delFEV1, 
Figures F.12 and F.13 were created. There are four subfigures in Figures F.12 and F.13, 
respectively. The left and right column represents the distribution of imputed delFEV1 if 
the missing value only occurred at an artificial visit, and at an existing visit, respectively. 
In Figure F.12, from the top to bottom, those figures represent the result of original 
models, and models that included the indicator. Similarly, in Figure F.13, from the top to 
bottom, those figures represent the result of models that included preexisting lung 
function variables, and models that included both the indicator and preexisting lung 
function variables. The blue, green, and purple histograms indicate the proportion of visit 
that had imputed delFEV1 within the specific range under strict, neutral, and loose 
assumptions, respectively. Red, brown, and yellow dotted lines were also assigned to 
those three assumptions, respectively. Generally speaking, all figures were normally 
distributed, and the mean was close to 0 but slightly to the right. At the same time, the 
difference of distribution in imputed delFEV1 between the strict and neutral assumptions 
429 
  
was trivial regardless of the model and rationale of missing values. The only exception 
existed in the model which included both the indicator and preexisting lung function 
variables, and only when the missing value occurred at an existing visit (right bottom 
corner in Figure F.13). In this figure, the neutral assumption was more likely to have 
small values on imputed delFEV1 than the strict assumption. The loose assumption 
always had different distributions compared with either the strict or neutral assumption. 
However, the direction of difference was not consistent. The majority of the time, the 
loose assumption had the highest chance of having small values on imputed delFEV1. 
But, if missing values only occurred at the artificial visit and the model included the 
indicator, the loose assumption was more likely to have large values on imputed delFEV1. 
When it comes to the model that included both the indicator and preexisting lung function 
variables, if the missing value only occurred at an existing visit, the chance of having a 
small value on imputed delFEV1 under the loose assumption was higher than the strict 
assumption, but lower than the neutral assumption. Moreover, there was only one 
scenario in which the distribution was not normally distributed. In the model that 
included both the indicator and preexisting lung function variables, the missing value that 
occurred at an artificial visit skewed to the left under the loose assumption. The upper 
boundary for the majority of the models was around 12.5%. However, when the missing 
value only occurred at an existing visit, for models that included preexisting lung 
function variables, or models that included both the indicator and preexisting lung 
function variables, the upper boundary was around 15%. 
Finally, in order to identify the model that was associated with the best 
performance, an analysis was conducted. In this study, the delFEV1 was imputed to 
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calculate the missing value on FEV1. The FEV1 value could be calculated from two 
different directions in the same visit. If a missing value of FEV1 occurred at the current 
visit, it could be calculated by forward calculation, adding the delFEV1 and FEV1, both 
of which were measured in previous visit; or backward calculation, by subtracting the 
delFEV1 in the current visit from the FEV1 in the next visit. Hypothetically, the result 
should be the same regardless of the type of calculation that was applied. The difference 
between forward and backward calculation quantifies the performance of the model for 
MI. Therefore, O1 and O2 were measured to quantify the performance of each model. O1 
and O2 were calculated using the same numerator, the sum of the square of difference 
between forward and backward calculation. However, the denominator for O1 was the 
number of difference in FEV1 between the forward and backward calculations. All 
numbers of visits in the cohort were applied as the denominator for O2. 
Table F.2 shows the results of the twelve models. Because of the increase in the 
denominator, the results of O1 were consistently larger than O2. Compared to the model 
that did not include preexisting lung function variables, the one that included those 
variables, the majority of time, had smaller values in O1 and O2. If the model included 
the indicator and was operating under the neutral assumption, after including the 
preexisting lung function variables, the result for both O1 and O2 would increase. The 
inclusion of preexisting lung function variables increased the chance of shrinking the 
range of imputed delFEV1. If a model did not include preexisting lung function variables, 
after including the indicator, the result would decrease for both strict and neutral 
assumptions. The direction of effect reversed for the loose assumption. However, if a 
model included preexisting lung function variables, after including the indicator, all the 
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effects mentioned above reversed for each assumption, respectively. Compared to the 
loose or strict assumptions, the neutral assumption consistently had the smallest values in 
both O1 and O2. Therefore, considering the results of this analysis together with the 
results in the above sections, the model that included preexisting lung function variables 
and did not include the indicator under the neutral assumption using the MCMC method 
to impute missing delFEV1 was chosen. All the missing FEV1s in the 10 imputed 
datasets were calculated using this model.  
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missing
   
433 
Table F.2. The difference in FEV1 between forward and backward calculations in the same visit. 
 
* O1 and O2 were calculated using the same numerator, the sum of square of difference between calculating the FEV1 in the same 
visit forward and backward. However, the denominator for O1 is the number of difference in FEV1 between the forward calculation 
and backward calculation. However, all number of visits in the cohort was applied for O2.





O1 0.372523 0.328909 0.315875 0.294333 0.400694 0.405471
O2 0.021767 0.019219 0.018457 0.017198 0.023413 0.023692
O1 0.300238 0.318509 0.277217 0.306027 0.394175 0.379669
O2 0.017543 0.018611 0.016198 0.017882 0.023032 0.022185









Figure F.1. Trace plots using delFEV1 as the outcome to investigate the performance of 








Figure F.2. Trace plots using delFEV1 as the outcome to investigate the performance of 
MI model (compared to the right column, the left column doesn’t include preexisting 
lung function variables; from the top to bottom, the figures represent models under strict 







Figure F.3. Autocorrelation plot using delFEV1 as the outcome to investigate the 
performance of MI model (the figures represents models that do not include the indicator 








Figure F.4. Autocorrelation plot using delFEV1 as the outcome to investigate the 
performance of the MI model (compared to the right column, the left column doesn’t 
include preexisting lung function variables; from the top to bottom, the figures represent 







Figure F.5. Distribution of delFEV1 in two models of MI (green represents the one with 
indicator, blue represents the one without indicator) when missing value occurred at 
artificial visits (compared to the right column, the left column doesn’t include preexisting 
lung function variables; from the top to bottom, the figure represents model under strict, 





Figure F.6. Distribution of delFEV1 in two models of MI (green represents the one with 
indicator, blue represents the one without indicator) when the missing value occurred at 
existing visits (compared with right column, the left column doesn’t include preexisting 
lung function variables; from the top to bottom, the figure represents model under strict, 





Figure F.7. Distribution of difference in imputed delFEV1 between the model that did not 
include the indicator and the one that included the indicator when the missing value 
occurred at artificial visits (compared to the right column, the left column doesn’t include 
preexisting lung function variables; from the top to bottom, the figure represents the 




Figure F.8. Distribution of difference on imputed delFEV1 between the model that did 
not include the indicator and the one that did include the indicator when the missing 
value occurred at existing visits (compared to the right column, the left column doesn’t 
include preexisting lung function variables; from the top to bottom, the figure represents 





Figure F.9. Trace plots of imputed delFEV1 in 10 imputations (the model that included 




Figure F.10. Distribution of delFEV1 in two models of MI (green represents the one with 
the indicator, blue represents the one without the indicator) when the missing value 
occurred at artificial visits (the model that included the indicator under the strict 
assumption). 
 




Figure F.11. Distribution of delFEV1 in two models of MI (green represents the one with 
the indicator, blue represents the one without the indicator) when the missing value 









Figure F.12. Distribution of delFEV1 in models of MI (blue: strict; green: neutral; purple: 
loose assumptions). The left and right column represents the distribution of imputed 
delFEV1 if the missing value only occurred at an artificial visit, and at an existing visit, 
respectively. From the top to bottom, those figures represent the result of original models, 
and models that included the indicator.  
 
 
                




Figure F.13. Distribution of delFEV1 in models of MI (blue: strict; green: neutral; purple: 
loose assumptions). The left and right column represent the distribution of imputed 
delFEV1 if the missing value only occurred at an artificial visit, and at an existing visit, 
respectively. From the top to bottom, those figures represent the result of models that 
included preexisting lung function variables, and models that included both the indicator 
and preexisting lung function variables. 
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